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Since its discovery in 1988, endothelin-1 (ET-1) has emerged as a potential
therapeutic target in the treatment of cardiovascular disease. The powerful
vasoconstrictor effects ofET-1 are primarily mediated via the vascular smooth muscle
cell, ET-1 selective ETA receptor, while die non-isopeptide selective ETB receptor,
situated on endothelial cells, mediates vasodilatation through generation of nitric oxide
and prostacyclin. ETB receptors have also been described on vascular smooth muscle
cells, although their contribution to ET-1 mediated vasoconstriction remains to be
confirmed.
The aims of this thesis were to assess the relative contribution of each receptor
subtype to ET-1 mediated vasoconstriction and, in particular, investigate the
endogenous effects of the ETB receptor on vascular tone. In a series of clinical studies
in healthy men, the effects of endothelin receptor agonists and antagonists on local and
systemic measures of vascular tone were assessed using standard techniques. All
studies were carried out with the approval of the local Research Ethics Committee and
with the written informed consent of each subject. Locally active doses of ET receptor
agonists were used in combination with locally and systemically active doses of ET
receptor antagonists. Responses in capacitance vessels were assessed by measurement
of changes in dorsal hand vein size by a standard displacement technique. Responses
in resistance vessels were assessed by measurement of changes in forearm blood flow
by venous occlusion plethysmography. Changes in cardiac function were measured
non-invasively by a standard bioimpedance method.
Constriction in capacitance and resistance vessels was demonstrated in
response to locally active infusion of the non-selective ET receptor agonist ET-1 and
the ETB receptor selective agonists sarafotoxin S6c (SFTX6c) and BQ-3020,
supporting a potential role for the ETB receptor in ET-1 mediated vasoconstriction. In
capacitance vessels, constriction to ET-1 but not SFTX6c was attenuated during
co-infusion of the ETA receptor selective antagonist BQ-123, in contrast constriction to
SFTX6c but not ET-1 was attenuated during co-infusion of the ETB receptor selective
antagonist BQ-788. In addition to the vasoconstriction described with low dose
infusion of ETB receptor selective agonists, vasodilatation, which appeared to be
mediated largely by nitric oxide through ETB receptor stimulation, was demonstrated
with high dose intra-arterial infusion of the ETB agonist SFTX6c. The repeatability of
the forearm blood flow response to intra-arterial infusion of ET-1 was assessed and,
using this response as a model, a pharmacologically active dose range of the ETA
receptor selective antagonist BMS-193884 and the non-selective ETA/ETB receptor
antagonist MSD L-753,037 was identified.
Although ETB receptor mediated pharmacological effects can be demonstrated
by administration of ETB receptor agonists, the endogenous physiological effects of
the ETB receptor are perhaps better demonstrated by ETB receptor selective
antagonists. Local and systemic vasoconstriction were demonstrated in response to
locally and systemically active infusion of the ETB receptor selective antagonist BQ-
788. Both ETA receptor selective and combined ETA/ETB receptor antagonism
resulted in significant forearm vasodilatation. However, the local vasodilator effects of
the ETA receptor selective antagonist BQ-123 were attenuated in the presence of the
selective ETB receptor antagonist BQ-788. These results confirm the importance of
ET-1 in the maintenance of vascular tone and indicate that, in healthy blood vessels at
least, the vasodilator effects of non-selective ETA/ETB receptor antagonism are less
than those of ETA receptor selective antagonism.
The results of these investigations have provided valuable information on the
relative contribution of the ETA and ETB receptors to the physiological effects of ET-1
in the vasculature. In addition they have developed and characterised a series of tools
for future clinical studies. Further investigation of the integrated cardiovascular effects
of selective and non-selective ET receptor antagonists is required to confirm which
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1.1 The maintenance of vascular tone
Vascular tone is an important determinant of peripheral vascular resistance and, in turn,
blood pressure. Blood pressure is controlled through the interaction of a number of
physiological mechanisms and is influenced primarily by changes in cardiac output and
peripheral vascular resistance. The regulation of peripheral vascular resistance is
important in maintaining blood pressure in situations where there are changes in
cardiac output, for example during exercise.
The radius of a vessel is an important determinant of the resistance within that vessel,
with vasodilatation acting to reduce the resistance and vasoconstriction acting to
increase resistance. Vascular resistance is abnormally increased in arterial hypertension
and in chronic heart failure. A number of therapeutic approaches in cardiovascular
disease, including ACE inhibition, act to reduce vascular resistance through
vasodilatation.
1.1.1 Circulating mediators of vascular tone
Short term regulation of vascular tone is achieved by neuronal regulation through
baroreflexes and autonomic reflexes via the sympathetic neurotransmitters, adrenaline
and noradrenaline (catecholamines) and the parasympathetic neurotransmitter,
acetylcholine. In addition, neurohumoral factors such as the renin-angiotensin system,
ADH or arginine vasopressin and ANP play a role in the longer term control of
vascular tone through regulation of blood volume and direct effects on blood vessels.
1.1.2 Local mediators of vascular tone
In addition to the central mediators described above, a number of local mediators are
involved in the regulation of vascular tone. A number of these mediators are released
by the endothelium, which was once thought to represent merely an inert lining to
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blood vessels. The importance of the endothelium in the regulation of vascular tone is
now widely recognised (Vane, et al., 1990).
Endothelial stimulation results in the immediate release of a number of vasodilator
mediators including prostacyclin (Moncada, et al., 1976); nitric oxide (Ignarro, et al.,
1987; Palmer, et al., 1987) and endothelium-derived hyperpolarising factor (EDHF).
The recognition of an endothelium-derived constrictor factor (EDCF) (Hickey, et al.,
1985), which has subsequently been identified as endothelin-1 (ET-1) (Yanagisawa, et
al., 1988), demonstrates the ability of the endothelium to provide a counter-regulatory
tonic action on the adjacent vascular smooth muscle.
Both nitric oxide and ET-1 are released continuously by the endothelium to regulate
basal vascular tone (Haynes and Webb, 1994; Vallance, et al., 1989). Thus, the
endothelium plays a crucial role in the local paracrine regulation of vascular tone, blood
flow and blood pressure. Disruption of normal endothelial function can, therefore,
have a marked influence on the local and systemic haemodynamic balance, and
ultimately tissue perfusion. Indeed, endothelial dysfunction is now recognised as an
important factor in the pathophysiology of cardiovascular disease (Casino, et al., 1995;
Luscher, 1992; Panza, et al., 1990) and the endothelium has been the target of recent
treatments in cardiovascular disease including aspirin, nitrates and angiotensin-
converting enzyme (ACE) inhibitors.
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1.2 Endothelin
Endothelin-1 (ET-1) is a potent vasoconstrictor peptide generated by the endothelium
(Yanagisawa, et al., 1988). It is one of a family of three related peptides; ET-1,
endothelin-2 (ET-2) and endothelin-3 (ET-3), encoded in three distinct genes (Inoue, et
al., 1989). As ET-1 is the predominant isoform produced by the endothelium, it is
likely to be the most important in the regulation of vascular tone. Endothelin-1 is
generated from its precursor, big endothelin-1, through the actions of an endothelin
converting enzyme (ECE). Generation of ET-1 is regulated at a transcriptional level
and is influenced by a number of factors (Figure 1.1).
The discovery of ET-1, originally described as EDCF (Hickey, et al., 1985), followed
closely on the identification of the endothelium-derived relaxing factor (EDRF) as nitric
oxide (Palmer, et al., 1987) and these two mediators appear to act in opposition to
regulate vascular tone and blood pressure. Even in their original Nature paper,
Yanagisawa and colleagues raised the possibility that ET-1 might be involved in the
maintenance of blood pressure and the genesis of hypertension (Yanagisawa, et al.,
1988). There are now considerable preclinical and clinical data to support this view.
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Figure 1.1 Factors that alter endothelin-1 (ET-1) synthesis and the pathway for
endothelin-1 generation: see text for details (Section 1.2.1). IL-l=interleukin-l;
TGFB=transforming growth factor B; LDL=low-density lipoprotein; ANP, BNP,
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Endothelin-1
1.2.1 Endothelin genes and regulation
Endothelin-1 was originally identified in the culture medium of porcine aortic
endothelial cells (Yanagisawa, et al., 1988). It is now recognised to be a member of a
family comprising three isoforms (Inoue, et al., 1989): ET-1, ET-2 and ET-3 [Figure
1.2]. Each isoform contains 21 amino-acids, two intra-chain disulphide bonds linking
paired cysteine residues, and a conserved C-terminal sequence necessary for biological
activity (Inoue, et al., 1989). This structure is unique among the mammalian peptides
but is shared by the sarafotoxins (Figure 1.2), snake venom peptides from the Israeli
burrowing asp, Actractaspis engaddensis. One of the sarafotoxins, sarafotoxin S6c
(Williams, et al., 1991), has proven particularly valuable as a pharmacological probe
with a high selectivity for the ETB receptor.
Within the human genome, the endothelins are each represented by a separate gene
encoding a specific precursor for the mature isoform (Inoue, et al., 1989). Currently,
regulation of endothelin synthesis is thought to be primarily at the level of gene
transcription, with de novo production and release occurring in response to endothelial
cell stimulation by a number of extracellular factors. Factors acting at this level to
stimulate ET-1 synthesis (Figure 1.1) include insulin, thrombin, low density
lipoprotein, angiotensin II, vasopressin and ET-1 (Benatti, et al., 1994; Boulanger, et
al., 1992; Emori, et al., 1992; Emori, et al., 1991). These factors are thought to act via
protein kinase C (PKC). In contrast, other factors, including nitric oxide (Boulanger
and Luscher, 1990), natriuretic peptides (Kohno, et al., 1992), dilator prostanoids
(Prins, et al., 1994) and thrombin (Boulanger and Luscher, 1990) inhibit ET-1
generation by promoting production of cyclic GMP (cGMP). Low levels of shear
stress (1.8 dyne/cm2) are thought to enhance endothelial ET-1 release by PKC
activation (Wang, et al., 1993) wherease high levels of shear stress (>6 dyne/cm2)
























The product of human ET-1 gene transcription is preproendothelin-1, a peptide of 212
amino acid residues. After removal of a short secretory sequence, preproendothelin-1
undergoes cleavage by a dibasic pair specific endoprotease to generate the 38 amino-
acid peptide, 'big endothelin-1' (Yanagisawa, et al., 1988). Subsequent conversion to
the mature, biologically active peptide, ET-1, occurs through the action of a specific
endothelin converting enzyme (ECE). The gene encoding ET-1 can be detected in a
wide variety of tissues, including the endothelial cells, heart, lung, brain, kidney,
pancreas and spleen. Big ET-1, ET-1 and ET-3 are normally present in plasma at
picomolar concentrations that are probably insufficient to exert a direct influence on
vascular tone. Indeed, ET-1 is generally thought to be a paracrine and autocrine
mediator rather than an endocrine hormone and its secretion by endothelial cells is
largely abluminal, towards the adjacent vascular smooth muscle (Wagner, et al.,
1992). As a result, plasma concentrations of ET-1 are not always an accurate reflection
of functional activity.
1.2.3 Endothelin converting enzymes
The physiologically relevant ECE is thought to be a membrane-bound, zinc containing
metalloprotease that is inhibited by the neutral endopeptidase (NEP 24.11) inhibitor
phosphoramidon (Ikegawa, et al., 1991) but not by selective NEP inhibitors such as
thiorphan or ketalorphan (Mattera, et al., 1993).
At least two ECE isoforms have been identified ECE-1 (Xu, et al., 1994) and ECE-2
(Emoto and Yanagisawa, 1995). ECE-1, has a neutral pH optimum and is inhibited by
phosphoramidon in micromolar concentrations. ECE-2, is also inhibited by
phosphoramidon, but in nanomolar concentrations, and, in contrast to ECE-1, has an
acidic pH optimum. The distribution of these enzymes also appears to be different.
ECE-1 is widely distributed, with abundant expression in endothelial cells (Xu, et al.,
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1994). ECE-2 is abundantly expressed in neural tissues, in contrast, ECE-1 is not
found in neural tissues, suggesting that ECE-2 may be the major ECE in neurons, glia
and selected neuroendocrine cells (Emoto and Yanagisawa, 1995). Both isoenzymes
convert big ET-1 in preference to big ET-2 or big ET-3 (Xu, et al., 1994). Although
further isoforms have subsequently been described (Turner, et al., 1998), it is not yet
clear which isoform is most important in the pathophysiology of cardiovascular
disease.
Although phosphoramidon effectively inhibits ET-1 formation (Emoto and
Yanagisawa, 1995; Mattera, et al., 1993; Plumpton, et al., 1995; Xu, et al., 1994), its
therapeutic potential is limited by its low potency and by its lack of selectivity for ECE.
As yet there are no selective ECE inhibitors available for clinical use but there are
currently several in preclinical development (Descombes, et al., 1995).
1.2.4 Endothelin clearance and degradation
Intravenously administered [125I]ET-1 has a plasma half-life of less than 1 min in
anaesthetised rats, most of the ET-1 being rapidly taken up by the lungs and kidneys
(Anggard, et al., 1989; DeNucci, et al., 1988). In humans, ET-1 is rapidly cleared
from the circulation by the renal, pulmonary and splanchnic circulation (Gasic, et al.,
1992; Weitzberg, et al., 1991). Extraction of ET-1 follows binding to cell surface
receptors, which are then internalised, allowing degradation to be carried out within the
cell (Anggard, et al., 1989). Soluble proteases found in endothelial and vascular
smooth muscle cells may be involved in intracellular ET-1 degradation (Jackman, et
al., 1992; Jackman, et al., 1993). The endothelins can also be degraded by NEPs
(NEP 24.11) on venous and arterial endothelial cell membranes (Llorens-Cortes, et al.,
1992).
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There is evidence to suggest that the ETB receptor is involved in clearance of ET-1
(Fukuroda, et al., 1994). Although low affinity ETB binding sites that might serve this
purpose have been found in arteries and veins (Gray, et ah, 1994; Teerlink, et ah,
1994) an exact site for this clearance receptor has not been confirmed.
1.3 Endothelin receptors
The endothelins act on two receptor subtypes in humans, ETA (Arai, et ah, 1990) and
ETg (Sakurai, et ah, 1990) receptors, which have been characterised on the basis of
their pharmacology (Table 1.1). The ETA receptor is characterised by its high
(subnanomolar) affinity for ET-1 and ET-2 and its 70 - 100 fold lower affinity for
ET-3, while the ETB receptor has a high and equal affinity for all 3 isopeptides.
1.3.1 Endothelin receptor subtypes
Shortly after its initial description (Yanagisawa, et al., 1988), specific binding sites for
endothelin were identifed (Kloog, et ah, 1989; Watanabe, et ah, 1989) and the genes
encoding the ETA and ETB receptor subtypes were cloned and characterised (Arai, et
ah, 1990; Sakurai, et ah, 1990). Although there may be further functional
hetrerogeneity (Bax and Saxena, 1994), analysis of human genomic DNA, with
probes specific for the human ETA and ETB receptors, reveals only two endothelin
receptor genes (Sakamoto, et ah, 1991). Therefore, any genes encoding other
endothelin receptors within the human genome must have low sequence similarities to
the known human endothelin receptor genes. There has been a recent tendency to sub-
classify the ETb receptor on the basis of responses to selective agonists and



































A putative ETC receptor subtype, relatively selective for ET-3, has been cloned from
Xenopus laevis dermal melanophores (Karne, et al., 1993). A novel ET-1 selective
receptor has also been described on follicular membranes of Xenopus laevis oocytes
(Kumar, et al., 1993) and from Xenopus laevis heart (Kumar, et al., 1994). This ETAX
receptor has a typically ETA type binding profile but no affinity for the ETA receptor
selective antagonist, BQ-123, therefore it may simply be the amphibian form of the
mammalian ETA receptor.
1.3.2 Endothelin receptor structure, binding and signalling
The ETa and ETb receptors are classical heptahelical G-protein coupled receptors
(Figure 1.3). They share a structure consisting of an extracellular N-terminal region,
seven helical transmembrane loops connected by hydrophilic domains, and a 60 amino
acid intracellular carboxy terminal region.
The hydrophobic transmembrane domains and the interconnecting cytoplasmic loops
are highly conserved, in contrast to the N-terminal region, which shows only 4%
sequence homology between the ETA and the ETB receptors (Elshourbagy, et al.,
1993). Investigation into the structural determinants of receptor function, using site
directed mutagenesis and receptor chimera techniques, has allowed identification of the
sructural requirements for ligand selectivity (Adachi, et al., 1994; Sakamoto, et al.,
1992).
Once bound to the receptor, a number of signal transduction mechanisms have been
suggested to be involved in ET-1 mediated vascular effects. These include an early
rapid rise in [Ca2+]j through its release from intracellular stores and opening of
membrane Ca2+ channels; G-protein activated phospholipase C (PLC) leading to IP3
formation and diacylglycerol (DAG) accumulation; activation of protein kinase C
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(PKC); activation of phospholipase A2 and D increasing production of arachidonic
acid, and hence of prostacyclin (PGI2) and thromboxane A2; an increase in the
intracellular pH through an effect on the sodium-hydrogen ion exchange membrane
pump (full review in Rubyani & Polokoff (Rubyani and Polokoff, 1994)).
The characteristically slow onset and sustained vasoconstrictor effects described with
ET-1 (Yanagisawa, et al., 1988) are thought to result from internalisation of the ligand-
receptor complex and relatively slow recycling of receptors. The delayed action of
ET-1 appears to result from the time required to activate the receptor-coupled second
messenger systems and the prolonged duration of action may be due to continued
receptor signalling following internalisation. The irreversible nature of endothelin
receptor binding is most likely explained by internalisation of the receptor-ligand
complex. However, binding at the cell surface receptors is more easily dissociated.
Indeed, slow reversal of ET-1 mediated vasoconstriction has been demonstrated
following exposure to ET receptor antagonists (Warner, et al., 1994). This may reflect
reversal of binding at the cell surface receptors or result from inhibition of ET-1
binding as receptors are recycled.
S3
Figure 1.3 The predicted structure of the human ETA receptor with its 7
transmembrane spanning domains. Adapted from Adachi et al (1993) (Adachi, et al.,
1993).
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1.3.3 Endothelin receptor agonists
Understanding of the function of endothelin receptors has been aided by the use of
specific pharmacological agonists and antagonists (Table 1.2). Endothelin-1 has a
similar binding affinity for ETA and ETb receptors - in the nanomolar range - but has a
much higher binding affinity for the ETA receptor than ET-3. In contrast, ET-1 and
ET-3 have equal affinity for the ETg receptor. Currently, there are unfortunately no
selective agonists at the ETA receptor, however ET-3, SFTX6c and BQ-3020 are
among a number of selective agonists at the ETb receptor.
The endothelin and sarafotoxin peptides possess four cysteinyl residues that form two
disulphide bridges, three polar charged side chains (residues 8-10) and a well-
conserved hydrophobic C-terminus (residues 16-21, Figure 1.2). Examination of the
binding characteristics of these peptides reveals that the ETA receptor has much more
rigid structural requirements for ligand binding than the ETB receptor (Adachi, et al.,
1994; Sakamoto, et al., 1992). Both the amino-terminal loop structure and the carboxy
terminal linear portion with Trp in position 21 are vital for high affinity ETA receptor
binding. In contrast, only the linear carboxy terminal and the Trp21 are essential for
high affinity binding to the ETB receptor (Adachi, et al., 1994; Sakamoto, et al.,
1992). ET-3 and SFTX6c are ETB selective ligands, ET-3 having -2000-fold and
SFTX6c -30 000-fold selectivity for binding to ETB rather than the ETA receptor
(Williams, et al., 1991). Although both of these ligands contain loop and linear
portions like ET-1, they have different amino acid sequences within the inner loop
portion, which might account for their lower affinity at the ETA receptor. BQ-3020
(Ihara, et al., 1992) is a linear analogue of ET-1 which acts as an ETB receptor agonist,





















































































































1.3.4 Endothelin receptor antagonists
Since the first description of compounds that could inhibit the binding or actions of
ET-1 in 1991 (Ihara, et al., 1991; Spinella, et al., 1991), a large number of endothelin
receptor antagonists, peptide and nonpeptide, selective and nonselective, have become
available (Table 1.2) (Warner, et al., 1994). BQ-123 (Ihara, et al., 1991) and BQ-788
(Ishikawa, et al., 1994) are selective peptide antagonists at ETA and ETg receptors
respectively. Non-selective antagonists include bosentan (Clozel, et al., 1994) and
TAK-044 (Watanabe, et al., 1995). However, non-selective antagonists may have
some degree of selectivity for the ETA receptor, with few antagonists truly balanced at
both receptors. Indeed, TAK-044 (Kikuchi, et al., 1994) and bosentan (Clozel, et al.,
1994) are both described as non-selective receptor antagonists but have a relative
degree of selectivity for the ETA receptor with ~20-fold higher affinity for the ETA
receptor than the ETB receptor.
Peptide antagonists have been obtained by chemical modification of ET-1 itself, or of
microbial products with endothelin receptor binding activity (Ihara, et al., 1991;
Spinella, et al., 1991). BQ-123 is a cyclic pentapeptide derived from microbial broth
that has relatively high potency for binding to the ETA receptor with approximately
2000 fold affinity for the ETA receptor than the ETB receptor (Ihara, et al., 1992).
BQ-788 is a peptide ETB receptor antagonist with 1000 fold selectivity for the ETB
receptor in human cell lines (Ishikawa, et al., 1994). Both of these compounds have
provided valuable pharmacological tools in the investigation of endothelin physiology
and pathophysiology.
Although useful as research tools, the potential of peptides as therapeutic agents may
be limited by their short duration of action, as well as by their lack of oral availability.
Potent nonpeptide antagonists have been developed through optimisation of
compounds isolated from plant extracts (Fujimoto, et al., 1992), and microbial broths
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(Ohashi, et al., 1992) or screened from chemical libraries (Clozel, et al., 1993; Clozel,
et al., 1994). These compounds can be administered orally, which is of obvious
advantage in the treatment of chronic disease.
1.3.5 Distribution of the ETA and ETB receptors
ETa receptor mRNA has been detected in many tissues, with the highest expression in
aorta, heart and kidney. The ETa receptor predominates on vascular smooth muscle
cells and is responsible for causing vasoconstriction in both large and small blood
vessels (Davenport and Maguire, 1994). It is also the major receptor subtype in the
heart (Molenaar, et al., 1993) and renal arterioles, bronchial smooth muscle and
glandular tissues have been shown to preferentially express ETA receptors (Arai, et al.,
1990). In contrast, ETA mRNA cannot be detected in the liver or endothelial cells
(Hosada, et al., 1991).
ETb receptor mRNA is most abundant in endothelial cells (Hosada, et al., 1991;
Molenaar, et al., 1993; Ogawa, et al., 1991) and can also be detected in vascular
smooth muscle cells (Davenport, et al., 1993) and is predominantly found in brain,
lung, kidney and aorta.
1.4 Cardiovascular effects of Endothelin
Endothelin-1 is an important mediator of vascular tone (Haynes and Webb, 1994).
Indeed, ET-1 is a more potent vasoconstrictor and pressor agent even than angiotensin
II (Yanagisawa, et al., 1988). In addition to its direct vasoconstrictor actions, ET-1 can
potentiate the vasoconstrictor effects of other constrictor substances including
noradrenaline and angiotensin II (Yang, et al., 1990). Endothelin-1 has co-mitogenic
effects (Wang, et al., 1994) and, so may play a role in pathophysiological vascular and
cardiac remodelling and cell proliferation. The direct and indirect effects of ET-1 on
vascular function indicate its potential importance in the cardiovascular physiology.
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1.4.1 Endothelin and vascular tone
In vascular tissue, ETA receptor mRNA is expressed predominantly in smooth muscle
(Arai, et al., 1990; Hori, et al., 1992), while ETB receptor mRNA is most abundant in
endothelial cells (Hosada, et al., 1991; Molenaar, et al., 1993; Ogawa, et al., 1991).
These findings are consistent with the view that ET-1 constriction of vascular smooth
muscle is mediated predominantly by ETA receptors and that constriction is modified
by release of relaxing factors from the endothelium, including prostacyclin (DeNucci,
et al., 1988) and nitric oxide (Tsukahara, et al., 1994), through stimulation of ETB
receptors (Figure 1.4). However, ETB receptor mRNA is detectable in vascular smooth
muscle cells (Davenport, et al., 1993) and ETB receptor selective agonists can mediate
constriction in vitro and pressor responses in vivo (Clozel, et al., 1992; Gray, et al.,
1994; Moreland, et al., 1992; Seo, et al., 1994). In addition, although ETA receptor
selective antagonists attenuate ET-1 mediated vasoconstriction, the response is not
completely abolished (Gardiner, et al., 1994; McMurdo, et al., 1993; Seo, et al.,
1994). These observations suggest the presence of ETB receptors that mediate
constriction of vascular smooth muscle cells (Figure 1.3). However, the physiological
relevance of this constrictor response remains to be confirmed. The contribution of
ETB receptors to ET-1 mediated vasoconstriction is variable, with in vitro studies
reporting that ETB receptors make either a minimal (Davenport and Maguire, 1994;
Fukuroda, et al., 1994; Godfraind, 1993; Maguire, et al., 1994; Riezebos, et al.,
1994) or, at most, a moderate contribution (Seo, et al., 1994; White, et al., 1994) to
vasoconstriction. Responses appear to depend markedly on species, vessel type and





























































The ETb receptor is also thought to be involved in clearance of endothelin from the
circulation (Fukuroda, et al., 1994). In support of this, plasma concentrations of ET-1
are dose dependently increased following administration of combined ETA/ETB
(Loffler, et al., 1991) and selective ETB (Fukuroda, et al., 1994) receptor antagonists
but not following administration of selective ETA receptor antagonists. It is possible
that the vasoconstrictor effects of selective ETB receptor antagonism result partly from
inhibition of ETB mediated clearance ofET-1, allowing the uncleared peptide to bind to
unoccupied constrictor ETA receptors.
The balance between the constrictor effects of ET-1, mediated by the vascular smooth
muscle ETa and ETB receptors, and the dilator effects mediated by the endothelial ETB
receptor is important in determining the value of combined ETA/ETB and selective
endothelin receptor antagonists. There may be alterations in endothelin receptor
function, distribution and sensitivity in disease states, which could lead to an
imbalance between the actions of ET-1 on the ETA and ETB receptors. For example,
ETb receptor expression is increased during the change of cultured vascular smooth
muscle cells from a contractile to synthetic phenotype (Eguchi, et al., 1994), in
hypertension (Batra, et al., 1993) and under the influence of angiotensin II (Kanno, et
al., 1993).
The importance of ET-1 in the maintenance of vascular tone in healthy blood vessels
has been highlighted in recent clinical studies, which have confirmed the constrictor
effects of ET-1 (Clarke, et al., 1989) and the vasodilator effects of ETA receptor
antagonism (Haynes and Webb, 1994) in vivo . Further investigation is now required
to identify the relative contribution of the endothelin receptor subtypes to the vascular
effects of ET-1.
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1.4.2 Endothelin and blood pressure
In the original description of ET-1 (Yanagisawa, et al., 1988), a sustained increase in
blood pressure was demonstrated following intravenous administration of a bolus dose
of ET-1 in denervated rats. Similar pressor responses have been demonstrated by other
investigators in other species. ET-2 and ET-3 have also been shown to increase blood
pressure although to a lesser degree than ET-1. The increase in blood pressure
following continuous infusion of ET-1 is thought to be mediated through an increase in
peripheral vascular resistance (Mortensen, et al., 1990) and has been prevented by salt
restriction (Mortensen and Fink, 1992). This could reflect increased vascular
sensitivity to ET-1 with a high salt diet or an interaction with the renin-angiotensin
system.
The sustained increase in arterial pressure occurs despite the rapid clearance of ET-1
from the circulation (Anggard, et al., 1989), consistent with slow dissociation of ET-1
from its receptors (Hirata, et al., 1988). Interestingly, both ETB receptor selective
agonists and ET-1 increase blood pressure in animal models (Clozel, et al., 1992;
Yanagisawa, et al., 1988). Some investigators have shown that the pressor response to
ET-1 is not completely blocked by ETA receptor selective antagonists (Gardiner, et al.,
1994) but can be blocked following administration of the non-selective ET receptor
antagonist bosentan (Gardiner, et al., 1994), indicating the potential contribution of the
ETB receptor in this pressor response. Intravenous infusion of ET-1 has also been
shown to increase blood pressure in humans (Vierhapper, et al., 1990) which is not
affected by nifedipine, a Ca2+ channel blocker or by indomethacin, a cyclo-oxygenase
inhibitor (Vierhapper, et al., 1992).
Transient hypotension, preceding the sustained pressor effects, has been noted
following bolus doses of the endothelin peptides. This effect is most noticable with
ET-3 (Inoue, et al., 1989) and is thought to be caused by generation of endothelium-
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derived dilators nitric oxide and prostacyclin, mediated by endothelial cell ETB
receptors. This depressor response has been attenuated by inhibition of nitric oxide
synthase (Fozard and Part, 1992) and cyclo-oxygenase (Filep, et ah, 1993). However,
the effects of cyclo-oxygenase inhibition described are not universal (DeNucci, et ah,
1988) and although likely to be mediated by the actions of the endothelial ETB receptor,
no single mediator of this transient depressor effect has been proposed. Given the
potent and well recognised constrictor effects of ET-1, this dilator response is more
likely to represent a pharmacological rather than a physiological response. However, it
provides important evidence of the dilator effects of endothelial ETB receptor
stimulation.
1.4.3 Cardiac effects
Synthesis of ET-1 has been detected in rat (Suzuki, et ah, 1993), porcine (Tonnessen,
et ah, 1995) and human cardiomyocytes (Giaid, et ah, 1995) and both ETA and ETB
receptor subtypes are present on cardiomyocytes (Molenaar, et ah, 1993; Ono, et ah,
1995). Antagonist studies have shown an alteration in coronary flow of isolated rat
hearts (Wang, et ah, 1994), suggesting that ETA and ETB receptors are present in the
coronary vasculature. Indeed marked coronary vasoconstriction has been described
following administration of ET-1 in animal models (Clozel and Clozel, 1989; Pernow,
et ah, 1989). The initial hypotension produced by ET-1 is associated with an increase
in heart rate and cardiac output, suggesting that it is secondary to systemic
vasodilatation. In contrast, the pressor response to ET-1 is associated with bradycardia
and a reduction in stroke volume, causing a marked reduction in cardiac index (Miller,
et ah, 1989). In addition, ET-1 tends to reduce cardiac output (Wagner, et ah, 1992)
and coronary blood flow (Pernow, et ah, 1996). In addition to these vasoconstrictor
effects, both anti- and pro-arrhythmic effects of ET-1 have been described and, in a rat
acute ischaemia model, the ETA receptor selective antagonist BQ-123 has been shown
to be anti-arrhythmic at low doses but pro-arrhythmic at higher, and possibly non-
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selective, doses (Garjani, et al., 1995). Further investigation of the arrhythmic effects
of ET-1 is required.
1.4.4 Renal effects
ET-1 has two main direct actions on the kidney, renal vasoconstriction and increased
tubular sodium and water loss. These effects probably reflect separately regulated ET
systems in the renal vasculature and renal tubules. Indeed, in the human kidney, the
ETb receptor predominates over the ETA receptor, with the ETA receptor largely
confined to the vasculature and the ETB receptor more abundantly expressed in the
mesangial cells (Karet, et al., 1993). In contrast, the ETA receptor predominates in the
rat kidney with renal vasoconstriction mediated mainly by ETB receptors (Clozel, et al.,
1992).
Administration of low dosages of ET-1 in humans produces sustained renal
vasoconstriction (Gasic, et al., 1992; Rabelink, et al., 1994; Weitzberg, et al., 1991)
and induces sodium retention (Rabelink, et al., 1994). In contrast, studies in animal
models have consistently shown a natriuretic effect of ET-1 adminstration (Garcia, et
al., 1990; Perico, et al., 1991), despite a fall in GFR and renal blood flow. These
findings suggest that the actions of endothelin on sodium excretion depend on a
balance between sodium retaining and natriuretic factors. In humans, it appears that the
predominant effect of small increases in plasma endothelin concentration is sodium
retention (Rabelink, et al., 1994). Given these inter-species variations, caution should
be taken when extrapolating the results from animal experiments to humans, further
clinical investigation of the renal effects of ET receptor antagonists is required.
1.5 The role of endothelin in cardiovascular disease
As previously discussed, ET-1 plays an important role in the regulation of vascular
tone and blood pressure in vivo (Haynes, et al., 1996) due to its powerful and
sustained vasoconstrictor effects (Clarke, et al., 1989). ET-1 has been implicated as a
mediator of the raised peripheral vascular resistance associated with a number of
cardiovascular diseases, including essential (or primary) hypertension, chronic heart
failure and chronic renal failure. In addition to its direct vasoconstrictor actions, ET-1
can potentiate the effects of other vasoconstrictor substances including noradrenaline
and angiotensin II (Yang, et al., 1990). Endothelin-1 has co-mitogenic effects (Wang,
et al., 1994) and, so may play a role in vascular modelling and cell proliferation.
Plasma concentrations of ET-1 are increased in a number of cardiovascular diseases
including, heart failure (Pacher, et al., 1993; Wei, et al., 1994), renal failure (Koyama,
et al., 1989; Warrens, et al., 1990), and myocardial infarction (Omland, et al., 1994)
and, in most cases, the increase in plasma ET concentrations correlates with markers of
disease progression. Although it is unclear whether the increase in plasma
concentrations of ET-1 is merely a marker of disease progression, the direct and
indirect effects of ET-1 on vascular function support a functional role for ET-1 in the
pathophysiology of a number of cardiovascular diseases.
1.5.1 Heart failure
Plasma concentrations of ET-1 and its precursor, big ET-1, are elevated in patients
with heart failure and correlate with mortality and with the need for cardiac
transplantation (Pacher, et al., 1993; Wei, et al., 1994). Although the increase in
plasma ET-1 may result from reduced renal clearance, the increase in big ET-1
concentrations suggests an increase in ET-1 generation. Given the potent vascular
effects of ET-1, the correlation between measures of mortality and morbidity and the
increase in plasma levels of ET-1 and big ET-1, the endothelin system is likely to be of
functional importance in the pathophysiology of heart failure. Early clinical studies
have demonstrated benefits of endothelin antagonists in the presence and absence of
existing treatment with an ACE inhibitor. Systemic administration of the non-selective
ET receptor antagonist bosentan in patients with heart failure produced significant
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systemic and pulmonary vasodilatation; reducing mean arterial pressure, pulmonary
arterial pressure, right atrial pressure and pulmonary artery wedged pressure
(Kiowski, et al., 1995). Cardiac index was also increased with no change in heart rate.
Further investigation of the systemic effects of combined ETA/ETB and selective
endothelin receptor antagonism in heart failure is required to confirm which approach
will be of more benefit in the clinical setting. Phase II and III trials investigating
selective and combined ETA/ETB endothelin antagonists in the treatment of heart failure
are currently in progress.
Given the increase in plasma concentrations of big ET-1 in heart failure (Pacher, et al.,
1993; Wei, et al., 1994) and the proposal that this indicates an increase in the
generation of ET-1, ECE inhibitors may also be of value in treating chronic heart
failure.
1.5.2 Hypertension
Plasma endothelin concentrations are not normally raised in essential hypertension but
have been described in patients with coexisting renal disease (Koyama, et al., 1989).
Nevertheless, the potent vasoconstrictor and vasopressor actions of ET-1 may play a
role in the development of increased blood pressure and in the pathophysiology of
disease progression. The co-mitogenic properties of ET-1 may be important in the
hypertrophic and atherosclerotic process, again associated with an increasing
cardiovascular risk. Early studies with endothelin receptor antagonists in hypertension
have been promising. Local vasodilatation has been demonstrated in response to the
ETa selective antagonist BQ-123 (Ihara, et al., 1992) in healthy volunteers (Haynes
and Webb, 1994). Interestingly, a single oral dose of the combined ETA/ETB
antagonist bosentan was effective in lowering blood pressure in patients with essential
hypertension (Schmitt, et al., 1995). In essential hypertension, endothelin antagonists
may provide additional blood pressure reduction in combination with existing therapies
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or may be useful in treating hypertension which has proven resistant to current
methods of treatment. The combined vasoconstrictor and co-mitogenic properties of
ET-1 provide an argument for the use of endothelin antagonists in this condition and
the results of further studies are awaited.
1.5.3 Chronic renal failure
Plasma concentrations of ET-1 are elevated in renal disease (Koyama, et al., 1989;
Warrens, et al., 1990) and are likely to result from a reduced renal clearance of ET-1
rather than increased production of the peptide. However, it is also likely that ET-1 is
involved in the progression of renal disease (Benigni, 1995). Indeed, in a rat model of
progressive renal disease, renal ET-1 gene expression correlated with disease
progression (Orisio, et al., 1993). From animal studies, there is increasing evidence
that ET-1 plays a role in the progression of renal disease. Investigation of the role of
ET-1 and the endothelin receptor subtypes in renal function and the progression of
renal disease in humans is ongoing.
Although the ETB receptor subtype predominates in the human kidney (Karet, et al.,
1993), a greater proportion of ETA receptors are localised to the vasculature and the
ETa subtype is likely to be important in mediating renal vasoconstriction to ET-1
(Davenport, et al., 1994). The selective ETA receptor antagonist FR139317 appeared to
be successful in preventing disease progression in a rat model of chronic renal disease
by reducing proteinuria, markers of cell proliferation and providing evidence of
protection against glomerular structural injury (Benigni, et al., 1993). It is possible that
tubular ETB receptors offer renoprotection in ischaemic conditions through sodium and
water excretion. Theoretically, it would therefore be appropriate to block the ETA
receptor selectively and preserve ETB mediated diuresis and natriuresis. However, it is
important to interpret the results of studies in animal models with caution, due to
species differences in renal physiology (Becker, et al., 1994) and in endothelin
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receptor distribution. Early clinical trials with endothelin antagonists are being
conducted in patients with chronic renal failure. The results of such studies will help
identify the potential of endothelin antagonists in a clinical context.
1.5.4 Acute renal failure
Acute renal failure develops over a period of hours to days and can result from tubular
ischaemia, obstruction or toxic insult, or from a marked reduction in renal perfusion. It
is associated with a high mortality and is a recognised complication of cardiac surgery
and administration of radio-opaque contrast agents. Renal vasoconstriction is thought
to be important in the pathophysiology of radiocontrast nephropathy, and this may be
mediated by ET-1 (Cantley, et al., 1993). Indeed, plasma endothelin concentrations
have been shown to increase following intravascular administration of radiocontrast
agent in rats (Heyman, et al., 1992). The potent vasoconstrictor effects of ET-1,
combined with its effects on renal blood flow and glomerular fdtration, suggest a role
for endothelin in the pathophysiology of ischaemic acute renal failure (Clozel, et al.,
1993; Pollock and Opgenorth, 1994). In addition to the beneficial effects described in
chronic renal failure, selective and combined ETA/ETB endothelin antagonists have also
been shown to limit disease progression in acute models of renal failure (Benigni,
1995; Brooks, et al., 1994; Clozel, et al., 1993; Mino, et al., 1992). Interestingly,
administration of the ECE/NEP inhibitor phosphoramidon (Ikegawa, et al., 1991) was
more effective in restoring renal function and in minimising structural changes than
selective ETA antagonism with BMS-182874 in an animal model of ischaemic renal
failure (Bird, et al., 1995). Again, further studies and direct comparison of selective
and combined ETA/ETB antagonists are required to confirm the potential of these
compounds in the clinical setting.
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1.5.5 Myocardial infarction
Plasma ET-1 concentrations are increased following myocardial infarction and are
strongly related to mortality (Omland, et al., 1994). The vascular effects of ET-1
indicate a potential role in the progression of myocardial damage to heart failure.
However, it is not clear whether ET-1 plays a role in infarct development. The
potential of endothelin antagonists in the treatment of myocardial infarction and the
prevention of the progression of cardiovascular disease remain to be confirmed.
1.5.6 Subarachnoid haemorrhage
Subarachnoid haemorrhage carries a risk of rebleeding and of cerebral ischaemia
associated with cerebral vasospasm. Although the mechanism involved in cerebral
vasospasm is unclear, ET-1 is a likely mediator of this effect (Roux, et al., 1995). In
support of this, combined ETA/ETB antagonism with bosentan was effective in
reversing (Roux, et al., 1995) cerebral vasospasm in a rabbit model of subarachnoid
haemorrhage. Selective ETA receptor antagonism, with BQ-485 (Itoh, et al., 1993) is
also effective in limiting cerebral vasospasm in a dog model of subarachnoid
haemorrhage. Endothelin-1 may also be involved in the development of cerebral
ischaemia through cerebral vasoconstriction. Further investigation of selective and
combined ETA/ETB endothelin antagonists in the treatment of subarachnoid
haemorrhage will reveal the true potential of these compounds in this context.
1.5.7 Potential therapeutic benefits of endothelin receptor antagonists
and endothelin converting enzyme inhibitors
The therapeutic potential of a number of endothelin receptor antagonists is currently
under investigation in phase II and phase III clinical trials in heart failure and in
hypertension. Demonstration of a vasodilator response to these compounds, especially
in the presence of existing therapies, is vital if endothelin antagonists are to be
indicated as complimentary treatments in cardiovascular disease. Orally active
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compounds are of particular importance in the treatment of chronic disease. Once initial
benefits have been demonstrated, long term trials will be necessary to confirm their
benefits in terms of prevention of disease progression. Phase II and III clinical trials
investigating the long term administration of orally active compounds in the treatment
of patients with heart failure are in progress. Intravenous compounds are currently
being investigated as potential treatments in acute renal failure. Studies in animal
models have proven promising and clinical trials are now required to confirm the
potential of these compounds.
The question of whether combined ETA/ETB or selective receptor antagonism will be of
more benefit as vasodilator treatments depends on the balance between the ETB
receptor mediated effects of vasodilatation, vasoconstriction and clearance. Further
investigation of the actions mediated by the ETB receptor in health and in specific
disease states is necessary to answer this question. This issue is of particular relevance
in cardiovascular diseases where there is associated endothelial dysfunction and there
may be a reduced capacity for ETB receptor mediated dilatation.
ECE inhibition may be a useful approach in limiting the vascular effects of ET-1 in
conditions where its generation is increased. ECE inhibitors are likely to have systemic
vasodilator effects by directly inhibiting the generation of ET-1 and indirectly by
removal of the inhibitory effects of ET-1 on nitric oxide generation (Boulanger and
Luscher, 1990). Indeed, local vasodilatation was demonstrated following local
administration of the non-selective ECE/NEP inhibitor, phosphoramidon in humans in
vivo (Haynes and Webb, 1994). However, the development of ECE-inhibitors as
potential therapeutic agents is at least several years behind the development of
endothelin receptor antagonists. Furthermore, even if selective and potent ECE-
inhibitors were to be discovered, they would still have to overcome the problem of
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accessability should the intracellular ECE prove to be of more importance
physiologically.
Although much of the research interest is focused on the potential of endothelin
receptor antagonists in cardiovascular disease, endothelin receptor antagonists may
also be of value in the treatment of a number of conditions as diverse as bronchospasm
(Fukuroda, et al., 1996), prostate cancer (Nelson, et al., 1996), portal hypertension
(Gunal, et al., 1996), and gram positive infection (Uosaki, et al., 1996).
1.6 Aims and Hypotheses
Vasoconstriction to ET-1 has previously been demonstrated in a number of animal
models and in humans in vivo. Two human ET receptors have been described, the ETA
and the ETB receptors. Endothelin receptor agonists and antagonists have subsequently
been described and provide valuable pharmacological tools in the investigation of the
endothelin system. The constrictor effects of ET-1 are largely mediated by the ETA
receptor. However, the contribution of the ETB receptor to ET-1 mediated
vasoconstriction and the overall balance of effects at the endothelial cell and vascular
smooth muscle cell ETB receptors remain to be confirmed.
In a series of clinical studies in healthy volunteers, the following hypotheses will be
addressed:
• ETb receptor stimulation causes vasoconstriction in resistance and capacitance
vessels (Chapter 3, 4, and 5);
• the ETb receptor contributes to ET-1 mediated vascular tone (Chapter 4);
• the vasoconstrictor and vasodilator effects of ETB receptor stimulation are
modulated by the endothelium-derived dilators, nitric oxide and prostacyclin
(Chapter 4 and 5);
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• ETB receptor antagonism will affect the response to selective ETA receptor blockade
and will demonstrate the endogenous effects of the ETB receptor (Chapter 6).
• intra-arterial infusion of ET-1 at locally active doses, with assessment of local
forearm vasoconstriction by venous occlusion plethysmography, provides a
reproducible and valuable model for proof of concept studies with endothelin
receptor antagonists (Chapter 7);
• selective ETA and non-selective ETA/ETB receptor antagonists will block the effects
of exogenously administered ET-1 and provide evidence of blockade of the
endogenous effects of ET-1 (Chapter 8 and 9);
• systemic ETB receptor antagonism will demonstrate the endogenous effects of the
ETb receptor in the maintenance of vascular tone (Chapter 10).
These hypotheses will be addressed by assessment of the effects of endothelin receptor






As a first step in understanding the mechanisms involved in the role of the endothelin
system in the maintenance of vascular tone in vivo, the initial studies involved the
assessment of the effects of locally active doses of vasoactive agents on local measures
of vascular tone. The vasoactive compounds were infused either intra-venously, to
assess effects in capacitance vessels, or intra-arterially, to assess effects in the
resistance vessels. The use of locally active, subsystemic doses allows assessment of
the direct vascular effects of these compounds in intact vessels exposed to normal
physiological conditions (Webb, 1995), without the confounding effects on other
organs such as the brain, heart and kidneys and consequent neurohumoral reflexes,
associated with systemic drug administration.
In subsequent studies, the effects of systemically active doses of endothelin receptor
antagonists were assessed alone and in combination with local infusions, to further
investigate the role of endothelin receptor subtypes in the maintenance of vascular tone
in vivo.
All studies were conducted with the approval of the Lothian Medicine and Clinical
Oncology Ethics of Medical Research Sub-Committee and the written informed
consent of each subject. The investigations conformed with the principles outlined in
the Declaration of Helsinki. No subject received vasoactive or non-steroidal
anti-inflammatory drugs in the week before each phase of the study, and all abstained
from alcohol for 24 hours, and from food, caffeine containing drinks and cigarettes for
at least 3 hours before any measurements were made. All studies were performed in a
quiet room maintained at a constant temperature between 23 and 25°C.
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2.1 Drug administration
2.1.1 Locally active doses - intra-venous administration
A vein on the dorsum of the hand of the non-dominant arm was cannulated in the
direction of flow with a 23 SWG butterfly needle (Abbott, Sligo, Republic of Ireland)
attached to a 16G epidural catheter, without use of local anaesthesia (Figure 2.1). The
same vein was used in each subject for each individual study. Patency was maintained
by infusion of 0.9% physiologic saline via a syringe pump (Welmed P1000: Welmed
Clinical Care Systems, Bramley, Hampshire, UK; Chapter 3, Study 1 or IVAC
P1000: IVAC Ltd, Basingstoke UK; all other studies). In each study, saline was
infused for 30 min prior to the infusion of the study agent. The total rate of infusion
was maintained constant throughout all studies at 0.25 ml/min.
2.1.2 Locally active doses - intra-arterial administration
The hrachial artery of the non-dominant arm was cannulated under local anaesthesia
(1% lignocaine; Astra Pharmaceuticals, Kings Langley, UK) with a 27 SWG steel
needle (Coopers Needle Works, Birmingham, UK) attached to a 16G epidural catheter
(Portex Ltd, Hythe, Kent, UK) (Figure 2.2). Patency was maintained by infusion of
0.9% physiologic saline via a syringe pump (IVAC P1000). In each study, saline was
infused for 30 min prior to the infusion of the study agent. The total rate of
intra-arterial infusion was maintained constant throughout all intra-arterial studies at 1
ml/min.
Cannulation sites were examined for any adverse effects following studies and
volunteers were contacted 24 hours after the study to monitor for any symptoms
resulting from the cannulation procedure.
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Figure 2.1 A selected dorsal hand vein cannulated with a 23 SWG butterfly
needle for local intra-venous infusion of study compounds. The diameter of the vein
is measured by displacement of a magnetic rod supported within the linear variable
differential transformer by means of a tripod.
Figure 2.2 The brachial artery of the non-dominant arm cannulated with a
27 SWG steel cannula for local intra-arterial infusion of study compounds.
o
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2.1.3 Systemically active doses - intravenous administration
In Chapter 8 and Chapter 10, study drugs were infused intravenously, at systemically
active doses, via an 18 SWG cannula sited in an antecubital vein, at a constant rate for
60 minutes (Chapter 8) and 15 minutes (Chapter 10).
2.2 Drugs
A single dose of each endothelin receptor agonist or antagonist was used in individual
studies because the slow onset and long lasting action of the endothelin isopeptides
precludes the use of repeated doses in a single study to examine conventional dose-
response relationships (Clarke, et al., 1989). Exact concentrations of drug are not
easily obtainable in this setting. However, approximate estimation of concentrations
can be made, based on a flow of ~5 ml/min in the capacitance vessels and -50 ml/min
in the resistance vessels.
All dilutions, with the exception of L-753,037 (Section 2.2.8 and Chapter 8), were
prepared in 0.9% saline (Baxter Healthcare Ltd) from sterile stock solutions on the day
of the study. L-753,037 was prepared under standard aseptic conditions within the
hospital pharmacy department.
2.2.1 Endothelin-1
Endothelin-1 (Clinalfa, NovaBiochem, Nottingham, UK) was administered as a
non-selective ET receptor agonist and infused at a locally active dose of 5 pmol/min via
the dorsal hand vein (Chapters 3 & 4) and brachial artery (Chapters 7, 8 & 9) as
described above. The choice of this dose was based on previous work showing, in
vivo, that ET-1 at 5 pmol/min causes slow onset venoconstriction of -60% in human
skin capacitance vessels (Haynes and Webb, 1993) and -40% in human resistance
vessels (Haynes and Webb, 1994).
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2.2.2 Sarafotoxin S6c
As discussed in Chapter 1, sarafotoxin S6c (SFTX6c) is an ETB receptor selective
agonist with 30,000 fold selectivity for the ETB receptor over the ETA receptor
(Williams, et al., 1991). Sarafotoxin S6c (Sigma Chemical Co Ltd, Nottingham, UK:
Chapter 3, Study 1; Chapter 4, Study 3 & 4, and Calbiochem-Novabiochem,
Nottingham, UK: Chapter 3, Study 2 & 3; Chapter 5, Study 1 & 2) was administered
at locally active doses via the dorsal hand vein (Chapter 3 and Chapter 4) and the
brachial artery (Chapter 5) as described above.
Sarafotoxin S6c has affinity for the ETB receptor in the nanomolar range (B^ETb
0.25±0.07nM, K;ETA >7300nM; human hippocampus (Williams, et al., 1991)).
Although it is not possible to quantify exact tissue concentrations during local infusion,
the doses of SFTX6c used in studies in Chapter 3, Chapter 4, and Chapter 5 are
estimated to be within a range selective for the ETB receptor (Table 2.1).
Table 2.1 Estimated tissue concentrations during infusion of SFTX6c in the doses
administered in Chapter 3, Chapter 4, and Chapter 5.
SFTX6c Estimated tissue
infusion rate concentration
Vein Artery Chapter Study
5 pmol/min 1 nM 3 1, 2, 3
4 3,4
0.1 nM 5 1
50 pmol/min 10 nM 3 2
60 pmol/min 1.2 nM 5 2
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2.2.3 BQ-3020
BQ-3020 is an ETB receptor selective agonist with 4700 fold selectivity for the ETB
receptor over the ETA receptor (Ihara, et al., 1992). It is a linear analogue of ET-1 and
differs from ET-1 by 2 amino acids, over a limited stretch of peptide (Figure 2.3).
BQ-3020 has a closer structural similarity to ET-1 than SFTX6c, therefore, it may be
more representative of endogenous ET-1 binding than SFTX6c.
Figure 2.3 Diagramatic representation of the structures of endothelin-1, BQ-3020
and sarafotoxin S6c; asterisks denote positions of amino acids in BQ-3020 and




* amino acids which differ from ET-1
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BQ-3020 (Calbiochem-Novabiochem, Nottingham, UK) was administered by
continuous infusion for 90 min (Chapter 3, Study 3; Chapter 5, Study 1) at an infusion
rate of 50 pmol/min. This dose of BQ-3020 was chosen from a dose ranging (1-50
pmol/min) pilot study, in 3 volunteers. The dose selected from the pilot study (50
pmol/min) was the lowest dose at which constrictor effects were seen in the hand
veins, and was not intended to be directly comparable with the dose of SFTX6c used
in Chapter 3 (Study 3) and Chapter 5 (Study 1). In human tissues BQ-3020 has
affinity for the ETB receptor in the nanomolar range (KDETB 1.38±0.72nM, KDETA
1040±210nM; human heart (Peter and Davenport, 1996)). Although it is not possible
to quantify exact tissue concentrations during local infusion, this dose of BQ-3020 is
within a range selective for the ETB receptor (arteries ~1 nM, veins -10 nM).
2.2.4 BQ-123
BQ-123 is a selective ETA receptor antagonist with 2000 fold selectivity for the ETA
over the ETB receptor (Ihara, et al., 1992). BQ-123 (Clinalfa AG, Laufelfingen,
Switzerland) was infused in dorsal hand vein studies at doses of 0.3 nmol/min
(Chapter 4, Study 1) and 1 nmol/min (Chapter 4, Study 2) to assess the contribution of
the ETa receptor to the effects of exogenously applied ET-1 and SFTX6c. In Chapter
6, BQ-123 (10 nmol/min) was infused intra-arterially, as described previously (Ferro,
et ah, 1996).
In human tissues BQ-123 has affinity for the ETA receptor in the nanomolar range
(KdETa 0.73±0.22nM, KDETB 24.3±2.0pM; human heart (Peter and Davenport,
1996). The doses of BQ-123 used in studies in Chapter 4 & 6 are estimated to be
within a range selective for the ETA receptor (Table 2.2).
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Table 2.2 Estimated tissue concentrations during infusion of BQ-123 in the doses
administered in Chapter 4, and Chapter 6.
BQ-123 Estimated tissue
infusion rate concentration
Vein Artery Chapter Study
0.3 nmol/min 60 nM 4 1
1 nmol/min 200 nM 4 2
10 nmol/min 200 nM 6
2.2.5 BQ-788
BQ-788 is a selective ETB receptor antagonist, with 1000 fold selectivity for the ETB
receptor, in the nanomolar range, in human cell lines (Ishikawa, et al., 1994) and on
inhibition ofET-3 binding to recombinant human ETB receptors expressed in Chinese
Hamster ovary cells, also in the nanomolar range (Reynolds, et al., 1995).
Locally active administration - Intra-venous infusion
BQ-788 (American Peptide Company, Sunnyvale, CA, USA) was administered at
locally active doses via the dorsal hand vein, as described above, to assess the
contribution of the ETB receptor to the effects of exogenously applied ET-1 (Chapter 4,
Study 2), and SFTX6c (Chapter 4, Study 3).
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Locally active administration - Intra-arterial infusion
BQ-788 (American Peptide Company) was also administered at a dose level of 1
nmol/min via the brachial artery, as described above, to assess the contribution of the
ETb receptor to the response to bolus dose of SFTX6c (Chapter 5, Study 2) and to the
response to the ETA antagonist BQ-123 (Chapter 6). Administration of BQ-788 alone
allowed assessment of the endogenous effects of the ETB receptor in the resistance
vessels (Chapter 6).
Systemically active administration - Intravenous infusion
BQ-788 (Clinalfa AG, Laufelfingen, Switzerland: Chapter 10) was administered at
systemically active doses (3-300 nmol/min) intravenously, as described above. The
dose range used in the Chapter 10 was selected from studies investigating the local
effects of BQ-788 in the forearm circulation (Chapter 5 and Chapter 6) and from a dose
ranging pilot study in which 2 volunteers were studied at each dose level (data not
shown). Selected doses (1-300 nmol/min) were administered in the pilot study to
identify a no effect dose and select an appropriate maximum dose for the main study.
In Chapter 10, saline (0.9%; Baxter Healthcare, Ltd) was administered as placebo.
2.2.6 L-NMMA
L-A^-monomethyl-arginine (L-NMMA) is a specific substrate analogue that acts as a
competitive inhibitor of nitric oxide synthase in humans (Vallance, et al., 1989).
L-NMMA (NovaBiochem, Nottingham, UK) was administered in locally active doses
in dorsal hand veins (100 nmol/min (Vallance, et al., 1989); Chapter 4, Study 3) and
forearm resistance vessels (4 pmol/min (Vallance, et al., 1989); Chapter 5, Study 2),
as described above. The dose used in dorsal hand vein studies (100 nmol/min) has no
effect on basal hand vein size (Vallance, et al., 1989). In contrast, in forearm
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resistance vessels blockade of nitric oxide synthesis results in significant local
vasoconstriction (Vallance, et al., 1989).
2.2.7 Aspirin
Aspirin (600 mg, soluble; Reckitt & Coleman, Hull, UK) was dissolved in 200 ml
water and administered 30 min before local peptide infusions (Chapter 4, Study 3 and
Chapter 5, Study 2). Aspirin irreversibly inhibits cyclo-oxygenase (EC 1.14.99.1)
and, when given at this dose, inhibits bradykinin-stimulated endothelial production of
prostacyclin by at least 85% with recovery developing over the next 6 hours (Heavey,
et al., 1985).
2.2.8 L-753,037
L753,037 (Merck Sharpe and Dohme, Terlings Park, Middlesex, UK) is a potent
nonpeptide, nonselective endothelin receptor antagonist (Zhao, et al., 1999) available
in intravenous formulation. L-753,037 has almost balanced ETA/ETB selectivity;
L-753,037 has threefold ETA selectivity in cloned human endothelin receptors (K;ETA
0.12 ± 0.01 nM, KjETg 0.17 ± 0.02 nM).
In Chapter 8, on separate occasions, L-753,037 (0.25 or 0.375 mg/kg) or matching
placebo was administered by IV infusion for 30 min. L-753,037 was prepared under
standard aseptic conditions within the hospital pharmacy department on the evening
before administration and stored overnight at 4°C.
2.2.9 BMS-193884
BMS-193884 (Bristol-Myers Squibb Pharmaceutical Research Institute, Moreton,
Wirral, UK) is a selective ETA receptor antagonist available in orally active and
intravenous formulation. BMS-193884 inhibits [125I|ET-1 binding to recombinant
human ETA receptors in the nanomolar and ETB receptors in the micromolar range
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(K]ETa 1.4 ± 0.1 nM, KjETB 18.8 ± 2 pM) (Unpublished data: Murugesan N et al.
Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4'-Oxazolyl
biphenylsulfonamides as a new class of potent, highly selective ETA antagonists.
Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 085343-5400,
submitted for publication at time of submission of thesis).
Locally active administration - Intra-arterial infusion
BMS-193884 was prepared as a crystalline free acid and supplied as a 5 mg/ml
aqueous solution for infusion. In Study 1, Chapter 9, placebo (0.9% saline, Baxter
Healthcare Ltd, Therford, UK) or BMS-193884 (5 and 50 nmol/min) was
administered double blind by continuous intra-arterial infusion for 60 min, according
to the study randomisation schedule.
Although it is not possible to quantify exact tissue concentrations during local intra¬
arterial infusion, both doses of BMS-193884 were estimated to be within a range
selective for the ETA receptor (5 nmol/min -100 nM, 50 nmol/min -1 pM, assuming
arterial blood flow =50 ml/min).
Systemically active administration - Oral administration
BMS-193884 was prepared as a crystalline free acid and supplied as a capsule dosage
form for oral administration. BMS-193884 (50, 100 or 200 mg) or matching placebo
capsules (Bristol-Myers Squibb Pharmaceutical Research Institute) were administered
orally in Studies 2 and 3, Chapter 9, according to the study randomisation schedule,
administration was double blind.
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2.3 Haemodynamic measurements
2.3.1 Dorsal hand vein diameter
Subjects rested semi-recumbent throughout. The left hand was supported above the
level of the heart by means of an arm rest. Internal diameter of the dorsal hand vein,
distended by inflation of an upper arm cuff to 30 mmHg, was measured by the
technique of Aellig (Aellig, 1981) (Figure 2.4).
In brief, a magnetised lightweight rod rested on the summit of the infused vein
approximately 1 cm downstream from the tip of the infusion cannula. This rod passed
through the core of a linear variable differential transformer (LVDT; Model 025 MHR,
Lucas Schaevitz Inc, Pennsauken, NJ, LISA) supported above the hand by a small
tripod, the legs of which rested on areas of the dorsum of the hand free of veins. If
venoconstriction occurred while this cuff was inflated, or if the cuff was deflated with
consequent emptying of the vein, there was a downward displacement of the
lightweight rod which caused a linear change in the voltage generated by the LVDT.
The voltage output from the LVDT was transferred to a Macintosh personal computer
using a MacLab analogue-digital converter and Chart software (Figure 2.5).
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Figure 2.4 The experimental set up for dorsal hand vein studies. The volunteer
sits semi-recumbent in the bed, the hand is supported above the level of the heart.
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Figure 2.5 Typical tracing obtained during a vein diameter recording. A denotes
the voltage recorded during cuff inflation, B denotes the voltage recorded when the
cuff is deflated, indicating subsequent emptying of the vein.
Time
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2.3.2 Forearm blood flow
Subjects rested recumbent throughout each study. Blood flow was measured in the
infused and non-infused forearms by venous occlusion plethysmography (Webb,
1995) using mercury-in-silastic strain gauges which were securely applied to the
widest part of each forearm (Figure 2.6).
The hands were excluded from the circulation during each measurement period by
inflation of a wrist cuff to 220 mmHg. Upper arm cuffs were intermittently inflated to
40 mmHg for 10 sec in every 15 sec to temporarily prevent venous outflow from the
forearm and thus obtain plethysmographic recordings. Recordings of forearm blood
flow were made repeatedly over 3 min periods unless otherwise stated. Venous
occlusion plethysmography was performed using a dual channel strain gauge
plethysmograph (Hokanson, USA) and calibration was achieved using the internal
standard of the Hokanson plethysmography unit. The voltage output was transferred
from the plethysmograph to a Macintosh personal computer (Classic II, Apple
Computer Inc, Cupertino, CA) using a MacLab analogue-to-digital converter and Chart
software (v. 3.2.8; both from AD Instruments, Castle Hill, NSW, Australia) (Figure
2.7).
The repeatability of the forearm blood flow response to intra-arterial infusion of ET-1
is described in full in Chapter 7.
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Figure 2.6 The experimental set up for forearm blood flow studies. The volunteer
lies recumbent in the bed, forearm blood flow is measured in both arms.
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2.3.3 Blood pressure and heart rate
Blood pressure and heart rate were measured in the non-infused arm using a well-
validated semi-automated non-invasive oscillometric sphygmomanometer (Takeda
UA 751, Takeda Medical Inc, Tokyo, Japan) (Wiinberg, et al., 1988).
Blood pressure was measured immediately after forearm blood flow or hand vein
recordings to avoid any effect of the venous congestion caused by this procedure on
these measurements (Patterson and Shepherd, 1954).
2.3.4 Cardiac function
Cardiac output and stroke volume were recorded by a well validated non-invasive
bioimpedance technique (NCCOM3; BoMed Medical Manufacturer Ltd, Irvine,
California, USA) (Thomas, 1992). The Bomed NCCOM3 (Bomed) is a non-invasive
method of measuring cardiac function parameters by transthoracic bioimpedance. A
constant sinusoidal current is applied through electrodes situated on the neck and
trunk, to enable detection of changes in bioimpedance related to the cardiac cycle and
blood flow. The Bomed has the facility to record cardiac output, stroke volume,
ejection fraction, heart rate, peak blood flow, end-diastolic volume and ejection ratio.
Cardiac output (CO, 1/min) and stroke volume (SV, ml) are estimated from the
measures of bioimpedance by the Sramek-Bernstein formula, adapted from the original
formula of Kubicek (Thomas, 1992). These recordings can be corrected for body
surface area and described as cardiac index (CI, 1/min/m2) and stroke index (SI, ml/m2)
(Haynes, et ah, 1996). Total peripheral vascular resistance (TPVR) or total peripheral
vascular index (TPVRI) can then be calculated as MAP divided by CO or CI,
respectively, and expressed in arbitrary units (AU). Responses can be measured
continuously or at specified timepoints following drug administration.
The Bomed provides a valuable tool for the assessment of within-subject changes in
cardiac function in healthy volunteers, especially in acute interventional studies with
drugs (de Mey and Belz, 1989). A number of studies have compared measurement of
cardiac function by the Bomed technique with other non-invasive and invasive
techniques, there is generally greater agreement between methods when the Bomed
results are expressed as percentage change from baseline (Thomas, 1992).
2.4 Plasma assays
2.4.1 Plasma ET-1 and Big ET-1
In Chapters 8, 9 & 10, blood samples were obtained via an 18 SWG cannula sited in
the non-infused arm. In brief, 10 ml samples were collected into sterile EDTA tubes
(K3 EDTA, Vacutainer, Becton Dickinson Vacutainer Systems, Europe) centrifuged
immediately at 2000 g for 20 min and stored in plain tubes at -80°C prior to assay.
Endothelin-1 and big ET-1 (Peninsula Laboratories Europe) were determined by
standard radioimmunoassay, as described previously (Hand, et al., 1999; Newby, et
al„ 1998).
2.4.2 Plasma BMS-193884
In Chapter 9, Study 2 and Study 3, blood samples for assay of BMS-193884 and its
metabolites were obtained, via an 18 SWG cannula sited in the non-infused arm. In
brief, 10 ml samples were collected into sterile EDTA tubes (K3 EDTA, Vacutainer,
Becton Dickinson Vacutainer Systems, Europe) centrifuged immediately at 1000 g for
15 min (BMS-193884 assay) and stored in plain tubes at -80°C prior to assay.
Concentrations of BMS-193884 and its metabolites, BMS-205868 and BMS-212442,
were determined by a well validated standard liquid chromatography/mass
spectrometry method (unpublished data2: Eades DM. To develop an LC/MS/MS
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method for the quantitative determination of BMS-193884 and two of its metabolites in
various matrices. AAPS Proceedings, 1997. AAPS Meeting, November 1, 1997).
2,5 Statistical analysis
2.5.1 Dorsal hand vein diameter
Baseline vein diameter was calculated as the mean of the last 3 measurements during
the saline infusion, before the start of the active drug infusion, and is expressed in
arbitrary units. In order to minimise the effects of any inter-subject and inter-study
variability in hand vein diameter, responses following infusion of peptides are
expressed as percentage change in vein diameter from baseline (Haynes, et al., 1994).
2.5.2 Forearm blood flow
Plethysmography data listings were extracted from data files and forearm blood flows
calculated for individual venous occlusion cuff inflations using a template spreadsheet
(Excel 5.0; Microsoft Ltd, Wokingham, UK). Recordings made in the first 60 sec after
wrist cuff inflation were not used for analysis because of the transient instability in
blood flow that this causes (Kerslake, 1949). Blood flow in both forearms was
obtained from the mean of the last 5 consecutive recordings of each measurement
period. Baseline blood flow was taken as the last measurement during the saline
infusion, before the start of the active drug infusion. Forearm blood flow results are
expressed as the % change from baseline in the ratio of blood flow between the infused
and non-infused arms (Webb, 1995).
An investigation of the repeatability of the assessment of forearm blood flow response
to intra-arterial infusion of ET-1 and comparison of methods of data presentation are
discussed in more detail in Chapter 7.
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2.5.3 General
Statistical analysis methods for blood pressure and heart rate, cardiac function and
plasma concentrations of ET-1 and BMS-193884 are described in future chapters.
All results are expressed as mean ± standard error of the mean (SEM). Blood pressure,
heart rate and baseline measurements during local infusion studies were compared
using the Student's paired f-test. The forearm blood flow and vein diameter responses
were examined by repeated-measures analysis of variance (ANOVA) using StatView
512+ software (Brainpower Inc, Calabasas, CA, USA or Excel 5.0 (Microsoft Ltd,
Wokingham, UK). Statistical significance was accepted at the 5% level.
Footnote
Unpublished data1: Murugesan N et al. Biphenylsulfonamide endothelin receptor
antagonists. 2. Discovery of 4'-Oxazolyl biphenylsulfonamides as a new class of
potent, highly selective ETA antagonists. Bristol-Myers Squibb Pharmaceutical
Research Institute, Princeton, NJ 085343-5400, submitted for publication at time of
submission of current manuscript.
Unpublished data2: Eades DM. To develop an LC/MS/MS method for the quantitative
determination of BMS-193884 and two of its metabolites in various matrices. AAPS
Proceedings, 1997. AAPS Meeting, November 1, 1997.
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Chapter 3
The local constrictor effects of endothelin receptor agonists in
capacitance vessels in vivo.
Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels
in vivo. Haynes WG, Strachan FE, Webb DJ. Circulation 1995;92:357-63.
Constriction to ETB receptor agonists, BQ-3020 and sarafotoxin S6c, in human resistance and




As discussed in Chapter 1, the powerful vasoconstrictor and vasopressor effects of
endothelin-1 (ET-1) (Clarke, et al., 1989; Yanagisawa, et al., 1988) are predominantly
mediated via the ET-1 selective, vascular smooth muscle cell ETA receptor (Arai, et al.,
1990). ETb receptors have also been described on vascular smooth muscle cells
(Davenport, et al., 1993) and may contribute to the vasoconstrictor effects of ET-1
(Clozel, et al., 1992). Indeed, in animals and in humans there is functional evidence
for ETb mediated vasoconstriction in vitro, particularly in veins (Moreland, et al.,
1994; Seo, et al., 1994; Sumner, et al., 1992).
The contribution of ETB receptors to vasoconstriction is variable and appears to depend
markedly on species, vessel type and vessel size (Davenport and Maguire, 1994).
Furthermore, the functional significance of the vascular smooth muscle ETB receptor in
humans is unclear; with in vitro studies reporting that ETB receptors make either a
minimal (Davenport and Maguire, 1994; Fukuroda, et al., 1994; Godfraind, 1993;
Maguire, et al., 1994; Riezebos, et al., 1994) or, at most, a moderate contribution
(Seo, et al., 1994; White, et al., 1994) to vasoconstriction, depending on the types of
vessel studied. Given that species differences in ETB responses exist (Reynolds, et al.,
1995), it is important to investigate the function of endothelin ETA and ETB receptors in
blood vessels in vivo in humans. As a first step in this investigation, a series of studies
assessing the responses to infusion of locally active doses of endothelin receptor
agonists in human hand veins in vivo were performed. Investigation of locally active
doses allows early and safe investigation of the effects of these peptides in humans in
vivo with the distinct advantage of studying these effects in intact vessels, under
physiological conditions, without the confounding haemodynamic effects of
systemically active doses.
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The vascular effects of the ETA and ETB receptor were investigated using ET-1 as a
non-selective ET receptor agonist and SFTX6c and BQ-3020 as ETB receptor selective
agonists (for structures see Figure 1.2 and 2.3).
3.2 Methods
3.2.1 Subjects
Six healthy male subjects within the age range of 18-60 years were recmited to Study
1, six were recruited to Study 2 and eight were recruited to Study 3, under the standard
conditions listed in Chapter 2.
3.2.2 Drugs
Study 1
Endothelin-1 (5 pmol/min) and SFTX6c (5 pmol/min) were administered by
continuous infusion for 60 min.
Study 2
Sarafotoxin S6c was administered by continuous infusion for 90 min at an infusion
rate of 5 or 50 pmol/min.
Study 3
Sarafotoxin S6c (5 pmol/min) and BQ-3020 (50 pmol/min) were administered by
continuous infusion for 90 min.
In each of the studies, saline was infused for 30 min before infusion of the study
agent, the total infusion rate was kept constant at 0.25ml/min.
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3.2.3 Measurements
Dorsal hand vein diameter was measured in each study at 5 min intervals throughout,
as described in Chapter 2.3.1.
Blood pressure was measured at 30 min intervals in each study, as described in
Chapter 2.3.3.
3.2.4 Study design
Studies were performed single blind, with the experimental subjects, but not the
investigators, blinded to the peptide and dose administered in each study.
Study 1 Intra-venous endothelin-1 and sarafotoxin S6c
The local effects of intra-venous ET-1 and SFTX6c were investigated in six healthy
men in a single-blind, randomised, 2 way crossover study. Subjects were studied on 2
separate occasions, in random, balanced order. Endothelin-1 or SFTX6c was infused
at 5 pmol/min for 60 min.
Study 2 Intra-venous sarafotoxin S6c
The local effects of intra-venous SFTX6c were investigated in six healthy men in a
single-blind, randomised, 2 way crossover study. Subjects were studied on 2 separate
occasions, in random, balanced order. Sarafotoxin S6c was infused at 5 or 50
pmol/min for 90 min.
Study 3 Intra-venous sarafotoxin S6c and BQ-3020
The local effects of intra-venous and intra-arterial (see Chapter 5, Study 1) infusion of
BQ-3020 and SFTX6c were investigated in eight healthy male subjects in a
single-blind, randomised, 4 way crossover study. Subjects attended for 4 visits, each
separated by at least one week. On separate occasions, in a random order, each subject
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received either intra-venous infusion of SFTX6c (5 pmol/min) or BQ-3020 (50
pmol/min) for 90 min, or intra-arterial infusion of SFTX6c (5 pmol/min) or BQ-3020
(50 pmol/min), the intra-arterial studies are discussed in Chapter 5.
3.2.5 Data analysis and statistics
Baseline vein diameter was calculated as the mean of the last 3 measurements during
the saline infusion, before the start of the active drug infusion. Hand vein diameter
results are expressed as the percentage change in vein diameter from baseline (see
Chapter 2.5.1).
All results are expressed as mean ± standard error of the mean (SEM) at the end of the
infusion: 60 min for Study 1 and 90 min for Study 2 & 3. Vein diameter responses
were examined by repeated-measures analysis of variance (ANOVA). Statistical
significance was accepted at the 5% level.
3.3 Results
Six healthy male subjects (age range 22 - 39 years) completed Study 1, six (age range
19-22 years) completed Study 2 and eight (age range 20 - 28 years) completed Study
3. There was no significant difference between baseline measurements on each of the
study visits. There was no significant change in blood pressure and heart rate in the
non-infused arm at the end of each infusion, confirming that any drug effects were

























































































































Study 1 Intra-venous endothelin-1 and sarafotoxin S6c
Endothelin-1 caused a marked decrease in hand vein diameter (-68+6%, p=0.001)
[Figure 3.1] which was slow in onset. Sarafotoxin S6c also caused venoconstriction,
although the decrease in hand vein diameter (-19+4%, p=0.003) [Figure 3.1] was
significantly less than that to ET-1 (p=0.002).
Figure 3.1 Response of hand vein diameter to local intravenous infusion of ET-1 (5
pmol/min; closed circles) and SFTX6c (5 pmol/min; open circles). Responses are
expressed as mean % change in blood flow ratio ± SEM.
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Study 2 Intra-venous sarafotoxin S6c, at 2 dose levels
Sarafotoxin S6c caused venoconstriction at both doses (-13±6%, p=0.03; 5 pmol/min
and -7±2%, p<0.01; 50 pmol/min) [Figure 3.2]. There was no significant difference
between the responses to 5 and 50 pmol/min (p=0.5), although the response to
SFTX6c (5 pmol/min) appeared to be greater than SFTX6c (50 pmol/min) after the
first 15 min of the infusion.
Figure 3.2 Response of hand vein diameter to local intravenous infusion of
SFTX6c (5 pmol/min, closed circles; and 50 pmol/min, open circles). Responses are
expressed as mean % change in blood flow ratio ± SEM.
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Study 3 Intra-venous sarafotoxin S6c and BQ-3020
Sarafotoxin S6c (5pmol/min) caused a significant reduction in vein diameter (-30+8%,
p<0.001). BQ-3020 (50 pmol/min) also caused a small, but significant,
venoconstriction (-16+7%; p<0.001) [Figure 3.3]. For both agonists, the response
reached a maximum after -30 min and was sustained for the rest of the infusion. There
was a small but significant difference between the hand vein responses to SFTX6c and
BQ-3020 (p=0.001).
Figure 3.3 Response of hand vein diameter to local intravenous infusion of
SFTX6c (5 pmol/min; closed circles) and BQ-3020 (50 pmol/min; open circles),













These results show that the non-selective ET receptor agonist ET-1 constricts hand
capacitance vessels in vivo, consistent with earlier reports of vasoconstrictor effects of
ET-1 in forearm resistance vessels in vivo (Clarke, et al., 1989). In addition, the
demonstration of local constrictor effects of the ETB receptor selective agonists
SFTX6c and BQ-3020, in capacitance vessels, support the hypothesis that ETB
receptors can, under some circumstances, mediate vasoconstriction and may contribute
to the vasoconstrictor effects of endothelin-1 (Clozel, et al., 1992).
Interestingly, there was no significant difference between the responses to the two
dose levels of SFTX6c. Indeed, in Study 2, the constrictor response to SFTX6c
tended to be less with the higher dose level (50 pmol/min) than the response to the
lower dose level (5 pmol/min). This may be due to tachyphylaxis of the ETB receptor
following exposure to the higher concentration of SFTX6c. Tachyphylaxis of the ETB
receptor has been described in in vitro studies (Sudjarwo, et al., 1994) at
concentrations of -100 nM. Based on venous blood flow of 1-5 ml/min, the expected
tissue concentrations during the 50 pmol/min infusion, would be 10 - 50 nM,
therefore, there may be some degree of tachyphylaxis at this dose level. It is also
possible that the higher dose infusion in the current study mediates release of
endothelium-derived dilators nitric oxide (Tsukahara, et al., 1994) and prostacyclin
(DeNucci, et al., 1988) which could offset the constrictor effects of SFTX6c.
There has been some uncertainty over the use of SFTX6c as an agonist in the
investigation of the endogenous effects of the ETB receptor in vivo (Flynn, et al.,
1995; Shraga-Levine, et al., 1994;Sokolovsky, 1995). The exceptionally high degree
of selectivity of SFTX6c for the ETB receptor may result in effects not likely to be seen
with binding of the non-selective endogenous ligand, ET-1. Additional concerns have
arisen as a result of the finding that while SFTX6c, binds to the same receptors as the
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endogenous ligands, ET-1 and ET-3, its actions are achieved via a different signalling
pathway (Shraga-Levine, et al., 1994). In Study 3, constrictor effects were observed
with SFTX6c and a structurally distinct ETB receptor selective agonist, BQ-3020. The
fact that constriction also occurs in response to BQ-3020 provides evidence that the
effects of SFTX6c are not idiosyncratic to this peptide and may be representative of
endogenous binding of ET-1 to the ETB receptor. Indeed, constrictor effects of the
endogenous ETB selective agonist ET-3, have also been described in the hand vein
(Ferro, et al., 2000). Therefore, concerns over signalling pathway differences between
SFTX6c and endothelin peptide binding (Shraga-Levine, et al., 1994;Sokolovsky,
1995) may not be functionally important.
In study 3, the response to BQ-3020 was less than that to SFTX6c. Although, the
reason for this difference is unclear, it is important to note that the doses of agonists
selected for the study were not intended to be directly comparable in terms of activity at
the receptor site. It is unlikely that this difference is functionally significant.
An informal observation noted from Study 2 and 3 is that there is a higher degree of
variability in the response to ETB receptor agonists between subjects than with the
response to ET-1, with some subjects demonstrating little or no response and others
demonstrating >40% constriction. This variability has also been discussed following
review of the distribution and function of ETA and ETB receptors (Davenport and
Maguire, 1994). It could be that there is more variation in the distribution of vascular
smooth muscle cell ETB receptors within the population and therefore, that ETB
mediated constriction is more important in some individuals or patient groups than
others. Indeed, upregulation of the ETB receptor has been suggested in some patient
groups (Kanno, et al., 1993).
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The constrictor effects described with ETB receptor agonists are likely to be caused by
stimulation of vascular smooth muscle ETB receptors. However, there are a number of
possible alternative explanations, ETB receptors may cause late onset vasoconstriction
through stimulation of the generation of endothelium-derived vasoconstrictor agents.
These substances might include constrictor prostanoids or even endothelin-1, because
endothelin-3 is known to stimulate production of endothelin-1 in vitro (Yokokawa, et
al., 1991). It is also possible that ETB agonists might prevent local clearance of ET-1,
resulting in increased circulating ET-1 which could then act on unopposed ETA
receptors to cause vasoconstriction. However, this possibility is unlikely, given that
ETa antagonists do not appear to influence vasoconstriction to SFTX6c in vitro (Gray,
et al., 1994; Moreland, et al., 1992; Seo, et al., 1994; Sudjarwo, et al., 1994; Warner,
et al., 1993) and that a proportion of the response to ET-1 appears to be resistant to
ETa receptor selective antagonists (Seo, et al., 1994; Sudjarwo, et al., 1994).
It could also be postulated that some of the effects of ETB receptor agonists are
mediated by a putative ETC (ET-3 selective) receptor. However, although there is
evidence from binding (Yokokawa, et al., 1991) and functional studies (Harrison, et
al., 1992) to support the existence of an endothelin-3 selective receptor in the
vasculature, and a potential candidate has been identified in Xenopus laevis
melanophores (Karne, et al., 1993), this receptor has not been identified in humans.
Any contribution from the putative ETC receptor will depend on its isolation and
pharmacological characterization.
The results of the current studies confirm the vasoconstrictor effects of ET-1 in vivo
and indicate a potential role for the ETB receptor in the mediation of this constriction.
Although vasoconstriction to the ETB agonists has been described, the effects of ETB
receptor agonists may not give a true reflection of the overall balance of the
endogenous effects of ET-1 mediated by ETB receptors. Studies with selective ETB
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receptor antagonists should help to clarify this issue further, although, such agents
may potentiate responses to ET-1, through reduced clearance of ET-1 and subsequent
increases in circulating ET-1.
In future chapters, I will discuss the results of studies investigating the haemodynamic
effects of endothelin antagonists in vivo and discuss how these results contribute to




The role of the endothelium-derived dilators and endothelin receptors in
the local constrictor effects of endothelin receptor agonists in
capacitance vessels in vivo
Endothelium-dependent modulation of venoconstriction to sarafotoxin S6c in human hand veins in
vivo. Strachan FE, Haynes WG, Webb DJ. J Cardiovasc Pharmacol 1995;26:S 180-S182.
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4.1 Introduction
The constrictor effects of ET0 receptor selective agonists in hand veins in vivo are
described in Chapter 3 (Haynes, et al., 1995;Strachan, et al., 2000). However, the
functional significance of the vascular effects of ETB receptor selective agonists and the
contribution of ETB receptors to ET-1 mediated vasoconstriction remains unclear.
Vasoconstriction to ET-1 is attenuated but not completely abolished following
administration of the ETA receptor antagonists BQ-123 (McMurdo, et al., 1993) and
FR139317 (Gardiner, et al., 1994; Seo, et al., 1994). However, the attenuation of the
ET-1 response with FR139317 was greater following desensitisation of the ETB
receptors with preincubation with SFTX6c (Seo, et al., 1994). These results indicate a
potential contribution from the ETB receptor to ET-1 mediated constriction.
In addition to the proposed constrictor effects of the vascular smooth muscle ETB
receptor, the endothelial ETB receptor stimulates generation of nitric oxide and dilator
prostaglandins (DeNucci, et al., 1988;Tsukahara, et al., 1994) to mediate
vasodilatation to modulate the contrictor effects of ET-1. Indeed the constrictor effects
of the ETb receptor selective agonists IRL 1620 and ET-3 were greater in endothelium
denuded vessels than in endothelium intact (Shetty, et al., 1993). In addition, in
human hand veins, venoconstriction to ET-1 is attenuated by dilator prostanoids but
not by nitric oxide (Haynes and Webb, 1993).
In order to identify the relative contribution of each receptor subtype to ET-1 mediated
vascular tone, the responses to the non-selective agonist ET-1, and the ETB receptor
selective agonist SFTX6c were assessed in the current series of studies (Study 1, 2
and 3), in the presence and absence of locally active doses of the ETA receptor selective
antagonist BQ-123 and the ETB receptor selective antagonist BQ-788, in the dorsal
hand vein in vivo.
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In addition, the effect of the endothelium-derived dilators, nitric oxide and
prostacyclin, on ETB receptor mediated constriction was investigated in a further study
(Study 4), using the ETB receptor agonist SFTX6c, the cyclo-oxygenase inhibitor,
aspirin, and the nitric oxide synthase inhibitor, L-NMMA.
4.2 Methods
4.2.1 Subjects
Six healthy male subjects within the age range of 18-60 years were recruited to each
study, under the standard conditions listed in chapter 2.
4.2.2 Drugs
Study 1
Endothelin-1 (5 pmol/min), SFTX6c (5 pmol/min) and BQ-123 (0.3 nmol/min) were
administered by continuous infusion for 60 min, as described in Chapter 2.
Study 2
Endothelin-1 (5 pmol/min), BQ-123 (1 nmol/min) and BQ-788 (1 nmol/min) were
administered by continuous infusion for 90 min, as described in Chapter 2.
Study 3
Sarafotoxin S6c (5 pmol/min) and BQ-788 (1 nmol/min) were administered by
continuous infusion for 60 min, as described in Chapter 2.
Study 4
Sarafotoxin S6c (5 pmol/min) and L-NMMA (100 nmol/min) were administered by
continuous infusion for 60 min. Aspirin (600 mg) was administered orally 30 min
before the SFTX6c infusion, as described in Chapter 2.
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In each of the studies, saline was infused for 30 min before infusion of the active
infusion, the total infusion rate was kept constant at 0.25ml/min.
4.2.3 Measurements
Dorsal hand vein diameter was measured in each study at 5 min intervals throughout,
as described in Chapter 2.3.1.
Blood pressure was measured at 30 min intervals in each study, as described in
Chapter 2.3.3.
4.2.4 Study design
Studies were performed single blind, with the experimental subjects, but not the
investigators, blinded to the peptide and dose administered in each study. Oral
administration of Aspirin was unblinded.
Study 1 Intra-venous endothelin-1, sarafotoxin S6c and BQ-123
The local effects of intra-venous ET-1, SFTX6c and BQ-123 were investigated in six
healthy men in a single-blind, randomised, 5 way crossover study. On separate
occasions, ET-1 or SFTX6c was infused at 5 pmol/min for 60 min either alone or in
combination with BQ-123 (0.3 nmol/min), in addition, BQ-123 was infused alone.
Subjects were studied on 5 separate occasions, in random, balanced order, each study
period was separated by at least one week.
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Study 2 Intra-venous endothelin-1, BQ-123 and BQ-788
The local effects of intra-venous ET-1, BQ-123 and BQ-788 were investigated in six
healthy men in a single-blind, randomised, 3 way crossover study. On separate
occasions, ET-1 was infused at 5 pmol/min for 90 min either alone or in combination
with BQ-123 (1 nmol/min) or BQ-788 (1 nmol/min). Subjects were studied on 3
separate occasions, in random, balanced order, each study period was separated by at
least one week.
Study 3 Intra-venous sarafotoxin S6c and BQ-788
The local effects of intra-venous SFTX6c and BQ-788 were investigated in six healthy
men in a single-blind, randomised, 3 way crossover study. On separate occasions,
SFTX6c (5 pmol/min) or BQ-788 (1 nmol/min) were infused for 60 min either alone
or in combination. Subjects were studied on 3 separate occasions, in random, balanced
order, each study period was separated by at least one week.
Study 4 Intra-venous sarafotoxin S6c and L-NMMA with Aspirin
The local effects of intra-venous SFTX6c were investigated during co-infusion of
L-NMMA or following oral administration of Aspirin, in a single-blind, 4 way
crossover study. Subjects were studied on 4 separate occasions, each study period was
separated by at least one week. The order of the study periods was randomised, with
the exception of the final study period in which the effects of SFTX6c were
investigated in the presence of both L-NMMA and Aspirin.
72
4.2.5 Data analysis and statistics
Baseline vein diameter was calculated as the mean of the last 3 measurements during
the saline infusion, before the start of the active drug infusion. Hand vein diameter
results are expressed as the percentage change in vein diameter from baseline (see
Chapter 2).
All results are expressed as mean ± standard error of the mean (SEM) at the end of the
infusion: 60 min for Study 1, 3 & 4 and 90 min for Study 2. Statistical significance
was accepted at the 5% level.
4.3 Results
Six subjects (age range 26 - 39 years) completed Study 1, six (age range 19-22 years)
completed Study 2, six (age range 20 - 28 years) completed Study 3 and six (age range
22-39 years) completed Study 4. There was no significant difference between baseline
measurements on each of the study visits. There was no significant change in blood
pressure and heart rate in the non-infused arm at the end of each infusion, confirming


















































































































































































































































































































Study 1 Intra-venous endothelin-1, sarafotoxin S6c and BQ-123
Endothelin-1 caused a slow-onset and marked decrease in hand vein diameter
(-61±12%, p=0.0008) which was significantly attenuated in the presence of BQ-123
(pcO.OOl vs ET-1) (Figure 4.1a), although there was still a reduction in vein diameter
in the presence of BQ-123 (-20+7%, pcO.OOl vs basal). Sarafotoxin S6c also reduced
hand vein diameter (-14+5%, pcO.OOl vs basal), similarity, there was a reduction in
vein diameter during co-infusion of SFTX6c and BQ-123 (-19+10%, pcO.OOl)
(Figure 4.1b) which did not differ significantly from the response to SFTX6c alone
(p=0.2). Interestingly the response to ET-1 in the presence of BQ-123 was not
significantly different from the response to SFTX6c alone (-20+7% vs -14±5%,
respectively; p=0.4) (Figure 4.1c). There was a small reduction in vein size following
infusion of BQ-123 alone (-7+3%), although small, this change was found to be
significant (p=0.03 vs basal).
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Figure 4.1a Response of hand vein diameter to local intravenous infusion of ET-1
(5 pmol/min) alone (closed circles) and during co-infusion with BQ-123 (0.3
nmol/min; open circles). Responses are expressed as mean % change in blood flow
ratio ± SEM.
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Figure 4.1b Response of hand vein diameter to local intravenous infusion of
SFTX6c (5 pmol/min) alone (closed squares) and during co-infusion with BQ-123
(0.3 nmol/min; open squares). Responses are expressed as mean % change in blood
flow ratio ± SEM.
Time (min)
Figure 4.1c Response of hand vein diameter to local intravenous infusion of ET-1
(5 pmol/min) during co-infusion with BQ-123 (0.3 nmol/min; open circles) and
SFTX6c (5 pmol/min) alone (closed squares). Responses are expressed as mean %
change in blood flow ratio + SEM.
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Study 2 Intra-venous endothelin-1, BQ-123 and BQ-788
Endothelin-1 caused a slow-onset and marked decrease in hand vein diameter
(-52+19%, pcO.OOl) which was attenuated in the presence of BQ-123 (-14+22%;
p<0.001 vs ET-1, p=0.04 vs basal) (Figure 4.2). In contrast, BQ-788 had no effect on
the response to ET-1, causing a significant reduction in hand vein diameter (-49±18%,
p<0.001) which was not significantly different from the response to infusion of ET-1
alone (p=0.8).
Figure 4.2 Response of hand vein diameter to local intravenous infusion of ET-1
(5 pmol/min) alone (closed circles) and during co-infusion with BQ-123 (1 nmol/min;
open circles) or BQ-788 (1 nmol/min; open squares). Responses are expressed as









Study 3 Intra-venous sarafotoxin S6c and BQ-788
Hand vein diameter was significantly reduced following infusion of SFTX6c (13±4%,
pcO.OOl). This constriction was abolished in the presence of BQ-788 (0±4%, p=0.03
vs SFTX6c alone, p=0.9 vs basal) (Figure 4.3). There was no significant change in
vein size in response to BQ-788 alone (-3+2%, p=0.9 vs basal).
Figure 4.3 Response of hand vein diameter to local intravenous infusion of
SFTX6c (5 pmol/min) alone (closed squares), BQ-788 (1 nmol/min) alone (Closed
circles) and during co-infusion of SFTX6c and BQ-123 (open squares). Responses are







Study 4 Intra-venous sarafotoxin S6c and L-NMMA with Aspirin
SFTX6c caused significant venoconstriction (19±4%, p=0.003) which tended to
increase after administration of aspirin (25+7%) and during co-infusion of L-NMMA
(24±10%), but was not significantly different from sarafotoxin S6c alone (Figure 4.4).
Venoconstriction to SFTX6c was substantially and significantly increased in the
presence of aspirin and L-NMMA together (46±9%, p=0.0001; p=0.01 vs. S6c).
Figure 4.4 Response of hand vein diameter to local intravenous infusion of
SFTX6c (5 pmol/min) alone (closed squares), during co-infusion of L-NMMA (100
nmol/min; open squares), following oral administration of Aspirin (600 mg; open
circles) and during combined treatment with L-NMMA and Aspirin (closed squares).
























The results from this series of studies have confirmed the constrictor effects of the
endothelin receptor agonists ET-1 and SFTX6c in dorsal hand veins in vivo (Haynes,
et al., 1995; Strachan, et al., 2000). Venoconstriction to ET-1 was attenuated in the
presence of the ETA receptor selective antagonist BQ-123, but was not affected by co-
infusion of the ETb receptor selective antagonist BQ-788, suggesting that the ETA
receptor is more important in mediating the constrictor effects of ET-1 than the ETB
receptor in healthy blood vessels.
Interestingly, the constriction to ET-1 was not completely blocked by BQ-123 at two
dose levels. This could be simply due to incomplete blockade of the ETA receptor with
the doses chosen, however the concentrations achieved are estimated to be within the
range sufficient to block the actions of ET-1 at the ETA receptor. Inhibition of the
response to ET-1 was greater with the higher dose of BQ-123, this could indicate that
the higher dose was more effective producing a more complete blockade of the effects
of the ETa receptor or may result from non-selective effects of BQ-123 with the higher
dose level. More importantly, incomplete blockade of the effects of ET-1 by BQ-123
could indicate a role for the ETB receptor in the ET-1 response, either directly through
ETB mediated constriction or indirectly by a cross talk mechanism (Mickley, et al.,
1997; Seo, et al., 1994).
Venoconstriction to ET-1 was not affected by the selective ETB receptor antagonist
BQ-788, similar effects have been described in animal studies (Mickley, et al., 1997;
Seo, et al., 1994) and would seem to dispute a direct role for ETB receptor mediated
constriction in ET-1 mediated venoconstriction. Interestingly, BQ-788 did not
potentiate the response to ET-1 indicating that any increase in ET-1 concentrations
caused by infusion of BQ-788, as a result of reduction in ETB receptor clearance of
ET-1, did not lead to additional vasoconstriction mediated by unoccupied ETA
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receptors. This lack of potentiation could reflect a lack of available binding sites for
increased circulating ET-1 following pseudo-irreversible binding of ET-1 to the ETA
receptor.
Selective ETA receptor antagonism did not appear to affect the constriction mediated by
SFTX6c, which contradicts the suggestion that the constrictor effects of ETB receptor
agonists result solely from displacement of ET-1, through reduced ETB receptor
mediated clearance, onto unoccupied ETA receptors.
In Study 3 the selective ETB receptor antagonist BQ-788 completely blocked the effects
of SFTX6c showing that the current dose level of BQ-788 is sufficient to block the
effects of the ETB receptor in vivo. The fact that BQ-788 inhibits the response to
SFTX6c in vivo further supports the use of SFTX6c as an ETB receptor selective
agonist (Strachan, et al., 2000). These data highlight the potential for both agents as
tools for use in the investigation of ETB mediated actions in health and cardiovascular
disease.
BQ-788 had no effect on hand vein diameter when infused alone. In contrast, there
was a small but significant reduction in vein diameter following infusion of BQ-123.
This reduction in vein size could result from the actions of ET-1 at the unoccupied
vascular smooth muscle ETB receptors. It is unlikely, although possible, that this small
reduction in vein size with BQ-123 infusion would have a significant effect on the
results during co-infusion with the endothelin receptor agonists described. Combined
administration of BQ-123 and BQ-788 alone and during co-infusion of ET-1 would
help clarify further the functional significance of ETB receptor mediated constriction.
In Study 4 the role of the endothelium-derived dilators nitric oxide and prostacyclin in
the venoconstrictor effects of SFTX6c were investigated. The constrictor effects of
SFTX6c were confirmed, and, as seen previously, were substantially less than those
of ET-1 shown in earlier studies. These findings support the hypothesis that ETB
receptors contribute to, but do not wholly account for, ET-1 mediated
venoconstriction. In addition, venoconstriction to sarafotoxin S6c is significantly and
substantially increased when generation of both nitric oxide and dilator prostanoids,
most likely prostacyclin, are blocked. Combined inhibition of nitric oxide and
prostacyclin appeared to produce a greater effect on venoconstriction to sarafotoxin
S6c than the addition of the individual effects of inhibition of generation of either nitric
oxide or prostacyclin alone. This may reflect a capacity for the endothelium to
compensate for inhibition of one dilator mediator by increased production of another.
Earlier studies have shown that responses to ET-1 are potentiated by aspirin
administration but not by co-infusion of L-NMMA (Haynes and Webb, 1993). It
would appear from these results with SFTX6c that the endothelial ETB receptor
modulates the constrictor effects produced by stimulation of the vascular smooth
muscle ETB receptors, through generation of vasodilator substances by the
endothelium. However, in these experiments, the vasoconstrictor action predominates.
In diseases such as chronic heart failure, where endothelium-dependent vasodilatation
is impaired, venoconstrictor effects of ET-1 may be enhanced as a result of unopposed
vasoconstrictor effects mediated by both ETA and ETB receptors on vascular smooth
muscle. Indeed local vasoconstriction to SFTX6c is enhanced in heart failure patients
(Love, et al., 1996) and may indicate upregulation of ETB receptor mediated
constriction in heart failure.
Given that the overall effect of combined stimulation of the vascular smooth muscle
and endothelial cell ETB receptors is venoconstriction, and incomplete attenuation of
ET-1 mediated constriction following ETA receptor antagonism in the hand vein, it may
be necessary to block both ETA and ETB receptors, in order to completely block
venoconstriction to ET-1. Drugs which would act specifically on the vascular smooth
86
muscle receptors (Warner, et al., 1993) may be more effective vasodilators, since they
would fully block ET-1 mediated vasoconstriction, while allowing the potentially
desirable effects of the endothelial ETB receptors to be preserved.
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Chapter 5
Local vasoconstrictor and vasodilator effects of endothelin-B receptor
agonists in forearm resistance vessels in vivo.
Constriction to ETB receptor agonists, BQ-3020 and sarafotoxin S6c, in human resistance and




As previously discussed, the powerful vasoconstrictor and vasopressor effects of
endothelin-1 (ET-1) (Clarke, et al., 1989; Yanagisawa, et al., 1988) are predominantly
mediated via the ET-1 selective, vascular smooth muscle cell ETA receptor (Arai, et al.,
1990). ETB receptors have also been described on vascular smooth muscle cells
(Davenport, et al., 1993) and may contribute to the vasoconstrictor effects of ET-1
(Clozel, et al., 1992). In addition to the vasoconstrictor effects of endothelin receptor
agonists, transient hypotension, preceding sustained pressor effects, has been noted
following bolus doses of the endothelin peptides. This effect is most noticable with
ET-3 (Inoue, et al., 1989) and is thought to be caused by generation of endothelium-
derived dilators nitric oxide and prostacyclin, mediated by endothelial cell ETB
receptors. However, although likely to be mediated by the actions of the endothelial
ETB receptor, no single mediator of this transient depressor effect has been proposed.
Inhibition of nitric oxide synthase (Fozard and Part, 1992) and cyclo-oxygenase
(Filep, et al., 1993) have been shown to attenuate this depressor response, although
the effects of cyclo-oxygenase were not found to be significant by other investigators
(DeNucci, et al., 1988).
Chapter 3 and Chapter 4 describe the local constrictor effects of ETB receptor selective
agonists in hand veins in vivo (Haynes, et al., 1995; Strachan, et al., 2000).
Similarily, local vasoconstriction in response to intra-arterial infusion of the non¬
selective endothelin receptor agonist ET-1 (Clarke, et al., 1989; Haynes, et al., 1995)
and the ETB receptor selective agonist ET-3 (Haynes, et al., 1995) has also been
described in the forearm resistance vessels. As in the hand vein studies, the response
to ET-3, although significant, was less than that to ET-1. Transient vasodilatation
followed by local vasoconstriction has previously been demonstrated in the forearm
resistance vessels in vivo in response to high dose infusion of the endogenous ETB
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receptor agonist ET-3 (Haynes, et al., 1995). In contrast, this effect is not evident with
low dose infusion of ET-1 in the forearm resistance vessels (Haynes, et al., 1995). In
view of the relatively high doses required to effect this vasodilator effect it is likely that
vasodilatation to endothelin receptor agonists represents a pharmacological rather than
a physiological phenomenon. However, using this response to demonstrate
vasodilatation in vivo allows investigation of the mechanisms involved in mediating
this dilator effect.
In order to investigate the effects of ETB receptor stimulation in the arterial circulation
further the effects of low dose intra-arterial infusion of two structurally distinct ETB
receptor agonists, SFTX6c and BQ-3020, on forearm blood flow was assessed in
Study 1. In Study 2, ETB receptor mediated vasodilatation was investigated following
high dose infusion of SFTX6c. The role of endothelium-derived dilators in this
response was investigated using aspirin as an inhibitor of dilator prostaglandins
(Heavey, et al., 1985) and L-NMMA to inhibit generation of nitric oxide (Vallance, et
al., 1989) and BQ-788 was used as a selective ETB antagonist.
5.2 Methods
5.2.1 Subjects
Eight healthy male subjects within the age range of 18 - 60 years, were recruited to




Sarafotoxin S6c (5 pmol/min) and BQ-3020 (50 pmol/min) were administered by
continuous infusion for 90 min.
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Study 2
Sarafotoxin S6c (60 pmol/min) was administered by continuous infusion for 5 min.
BQ-788 (1 nmol/min), L-NMMA (4 (imol/min) or saline was administered for 60 min
prior to and for 30 min following SFTX6c infusion. Aspirin (600mg) was
administered orally 30 min before infusion of SFTX6c.
Study 2 was extended, in 3 subjects, to include assessment of the response to SFTX6c
in the presence of noradrenaline. Sarafotoxin S6c (60 pmol/min) was administered by
continuous infusion for 5 min. Noradrenaline (160 pmol/min) or saline was
administered for 60 min prior to and for 30 min following SFTX6c infusion.
In all studies, saline was infused for 30 min before infusion of the study agent, the
total infusion rate was kept constant at 1 ml/min.
Intra-arterial Administration
The brachial artery of the non-dominant arm was cannulated under local anaesthetic
(1% Lignocaine; Astra Pharmaceuticals, Kings Langley, England) with a 27 SWG
steel cannula (Cooper's Needle Works, Birmingham, England).
5.2.3 Measurements
Forearm Blood Flow
The response to intra-arterial infusion was assessed by measurement of forearm blood
flow in the infused and non-infused forearm by venous occlusion plethysmography as
described in Chapter 2.
In Study 1, forearm blood flow recordings were made at 10 min intervals throughout
the intra-arterial infusion. In Study 2, forearm blood flow was recorded continuously
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for 13 min from the 3 min before the start of the SFTX6c infusion, until 5 min after the
end of the SFTX6c infusion. At all other times during the intra-arterial infusions,
forearm blood flow recordings were made at 10 min intervals.
Blood Pressure and Heart Rate
Blood pressure and heart rate were measured in the non-infused arm using a
well-validated semiautomated non-invasive method at 30 min intervals throughout the
infusions as described in Chapter 2.
5.2.4 Study Design
Studies were performed single blind, with the experimental subjects, but not the
investigators, blinded to the peptide and dose administered in each study. Oral
administration of aspirin was unblinded.
Study 1 Intra-arterial sarafotoxin S6c and BQ-3020
The local effects of intra-venous (see Chapter 3) and intra-arterial infusion of BQ-3020
and SFTX6c were investigated in eight healthy male subjects in a single-blind,
randomised, 4 way crossover study. Subjects attended for 4 visits, each separated by
at least one week. On separate occasions, in a random order, each subject received
either intra-venous infusion of SFTX6c (5 pmol/min) or BQ-3020 (50 pmol/min) for
90 min, or intra-arterial infusion of SFTX6c (5 pmol/min) or BQ-3020 (50 pmol/min),
the intra-venous studies are discussed in Chapter 3.
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Study 2 High dose infusion of sarafotoxin S6c and the effects of
BQ-788, L-NMMA and Aspirin
The local effects of intra-arterial infusion of SFTX6c were investigated in six healthy
male subjects in a single-blind, randomised, 5 way crossover study. Subjects attended
for 5 visits, each separated by at least one week. On separate occasions, in a random
order, SFTX6c (60 pmol/min) for 5 min was administered by intra-arterial infusion,
during co-infusion with either BQ-788 (1 nmol/min), L-NMMA (4 pmol/min) or
saline, or following oral administration of aspirin (600 mg). BQ-788, L-NMMA and
saline were infused for 60 min before and for 30 min after the start of infusion of
SFTX6c according to the study randomisation (Figure 5.1). On one of the visits in
random order, BQ-788 (1 nmol/min) was administered alone by intra-arterial infusion
for 90 min. On this visit, saline was administered for 5 min, in the same manner as
SFTX6c on all other studies, in order to provide a control for the method of bolus
administration and the measurement technique.
In order to investigate the response to SFTX6c in the presence of a constrictor agent
acting by a different mechanism than BQ-788 or L-NMMA, study 2 was extended to
investigate the response to intra-arterial infusion of SFTX6c during co-infusion of
noradrenaline, in three healthy male subjects in a single-blind, randomised, 2 way
crossover study. On separate occasions, each separated by at least one week, in a
random order, SFTX6c (60 pmol/min) for 5 min was administered by intra-arterial
infusion, during co-infusion with either noradrenaline (160 pmol/min) or saline.
Noradrenaline and saline were infused for 60 min before and for 30 min after the start
of infusion of SFTX6c according to the study randomisation.
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Figure 5.1 Schematic representation of the study protocol for Study 2: BQ-788
(1 nmol/min), L-NMMA (4 pmol/min), noradrenaline (160 pmol/min) or saline were
administered as study treatments, SFTX6c (60 pmol/min) or saline was administered
for 5 min as a bolus infusion 60 min after the start of the study treatment infusion. On











Plethysmographic data listings were extracted from data files and forearm blood flows
calculated for individual venous occlusion cuff inflations using a template spreadsheet
(Excel 5.0; Microsoft Ltd, Wokingham, UK), as described in Chapter 2. Forearm
blood flow results are expressed as the percentage change from baseline in the ratio of
blood flow between the infused and non-infused arms.
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Study 1
All results are expressed as mean ± standard error of the mean (SEM) at 90 min.
Responses were examined by repeated-measures analysis of variance (ANOVA) (Excel
5.0, Microsoft Ltd, Wokingham, UK).
Study 2
The response to the bolus infusion is expressed as the % change from blood flow
measured immediately before the start of the SFTX6c infusion. Results are expressed
as mean ± standard error of the mean (SEM) at 2 min and 30 min after SFTX6c
infusion. The forearm blood flow responses, from 0-5 min and 6-30 min, were
examined by repeated-measures analysis of variance (ANOVA) (Excel 5.0, Microsoft
Ltd, Wokingham, UK).
In both studies, heart rate and baseline measurements were compared using the
Student's paired r-test (Excel 5.0, Microsoft Ltd, Wokingham, UK). For all
comparisons, statistical significance was accepted at the 5% level.
5.3 Results
Eight healthy male subjects (age range 20 - 28 years) completed Study 1 and six
healthy male subjects (age range 20 - 43 years) completed Study 2. There was no
significant difference between baseline measurements on each of the study visits.
There was no significant change in forearm blood flow in the non-infused arm at the
end of the intra-arterial infusion, or in blood pressure and heart rate in the non-infused
arm at the end of each infusion, confirming that any drug effects were confined to the
infused arm (Table 5.1, Study 1; Table 5.2, Study 2).
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Table 5.1 Mean arterial pressure (MAP), heart rate (HR), forearm blood flow













90 min 5.011.4 5.211.0
Infused Arm
Basal 4.611.0 3.910.7







































































Study 1 Intra-arterial sarafotoxin S6c and BQ-3020
Sarafotoxin S6c (5 pmol/min) caused a significant reduction in the ratio of forearm
blood flow (-25±7%; p<0.001), indicating vasoconstriction in the infused arm (Figure
5.2). Similarly, BQ-3020 (50 pmol/min) caused significant vasoconstriction (-27±7%;
p<0.001) (Figure 5.1). The response to both SFTX6c and BQ-3020 was slow in onset
and reached a maximum after -60 min. There was no significant difference between
the forearm blood flow responses to SFTX6c and BQ-3020 (p=0.5).
Figure 5.2 Response of forearm blood flow to local intra-arterial infusion of
SFTX6c (5 pmol/min; open circles) and BQ-3020 (50 pmol/min; closed circles).
Responses are expressed as mean % change in blood flow ratio ± SEM. There was no
significant difference (p = 0.3) between the responses to SFTX6c and BQ-3020, n=8.
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Study 2 High dose infusion of sarafotoxin S6c and the effects of
BQ-788, L-NMMA and Aspirin
SFTX6c alone caused a transient vasodilatation (22±8%; pcO.OOl vs basal), with
vasoconstriction developing after 5 min and continuing until 30 min after the start of
the SFTX6c infusion (-20±4%, pcO.OOl vs basal) (Figure 5.3). L-NMMA and
BQ-788 completely abolished the vasodilatation at 2 min (-4±4%; -8±4%, respectively;
pcO.OOl vs SFTX6c for both) (Figure 5.4 and 5.5, respectively). In contrast, aspirin
did not affect the vasodilator response (18±9%; p=0.6 vs SFTX6c) (Figure 5.5).
The vasoconstriction to SFTX6c at 30 min (-20±4%) was evident with all treatments
(Aspirin, -21±3%; BQ-788, -26±6%; L-NMMA, -13±4%; pcO.OOl for all). Although
there was no significant difference in the response to SFTX6c between 6-30 min in the
presence of Aspirin or L-NMMA (p=0.8 vs SFTX6c for both), there was a significant
difference in the presence of BQ-788 (pcO.OOl, 6-30 min; p=0.05, 10-30 min vs
SFTX6c).
As expected L-NMMA caused significant vasoconstriction before infusion of SFTX6c
(L-NMMA: -47±2%, pcO.OOl) (Figure 5.6). Infusion of BQ-788 alone also caused
vasoconstriction (-15±3%, pcO.OOl at 60 min) (Figure 5.6). Saline was infused
during the BQ-788 alone visit in the same manner as the SFTX6c infusion in all other
treatments, when the data were represented relative to the timing of the 'bolus' infusion
there was no dilatation evident at 2 min (0.1±1.4%, p=0.2 vs basal) or constriction at
30 min (-5±5%, p=0.4 vs basal) (Figure 5.3).
In the extension of Study 2, noradrenaline caused vasoconstriction prior to infusion of
SFTX6c (-46±14% at 60 min). SFTX6c caused a transient dilatation in the presence of
noradrenaline (15±3% at 2 min after bolus infusion) with constriction developing after
3 min (-18±8% at 30 min) (Figure 5.7).
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Figure 5.3 Response of forearm blood flow to local intra-arterial infusion of
SFTX6c (60 pmol/min for 5 min; closed circles) and BQ-788 (1 nmol/min; open
circles, saline was infused for 5 min in the same manner as SFTX6c). SFTX6c caused
transient vasodilatation followed by vasoconstriction. Bolus infusion of saline had no
effect on forearm blood flow. Responses are expressed as mean % change, from pre-
bolus infusion, in blood flow ratio ± SEM.
Time (min)
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Figure 5.4 Response of forearm blood flow to local intra-arterial infusion of
SFTX6c (60 pmol/min for 5 min; closed circles) alone and during co-infusion of
BQ-788 (1 nmol/min; open circles). SFTX6c caused transient vasodilatation followed
by vasoconstriction. BQ-788 completely blocked the vasodilator response to SFTX6c
and potentiated the development of the vasoconstrictor response. Responses are
expressed as mean % change, from pre-bolus infusion, in blood flow ratio ± SEM.
Time (min)
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Figure 5.5 Response of forearm blood flow to local intra-arterial infusion of
SFTX6c (60 pmol/min for 5 min; closed circles) alone, during co-infusion of
L-NMMA (4 |iimol/min; open circles) and following oral administration of Aspirin
(600 mg; open squares). SFTX6c caused transient vasodilatation followed by
vasoconstriction. L-NMMA completely blocked the vasodilator response to SFTX6c
but had no effect on the vasoconstrictor response. Oral administration of aspirin had no
effect on the vasodilat or vasoconstrictor response to SFTX6c. Responses are
expressed as mean % change, from pre-bolus infusion, in blood flow ratio ± SEM.
Time (min)
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Figure 5.6 Response of forearm blood flow to local intra-arterial infusion of
BQ-788 (1 nmol/min; open circles) and L-NMMA (4 pmol/min; closed circles) in the
60 min before the bolus infusion. Responses are expressed as mean % change, from
pre-bolus infusion, in blood flow ratio ± SEM.
Time (min)
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Figure 5.7 Response of forearm blood flow to local intra-arterial infusion of
SFTX6c (60 pmol/min for 5 min) during co-infusion of noradrenaline (160 pmol/min)
in 3 subjects. SFTX6c caused transient vasodilatation followed by vasoconstriction
during co-infusion of noradrenaline. Responses are expressed as mean % change,



















The results of Study 1 have confirmed that infusion of a locally active dose of the ETB
receptor agonist SFTX6c causes vasoconstriction (Haynes, et al., 1995) in healthy
blood vessels in vivo. We have also extended these observations to show, for the first
time, that similar effects are seen with a structurally distinct ETB receptor selective
agonist, BQ-3020, with close homology to ET-1. The fact that constriction also occurs
in response to BQ-3020 provides evidence that the effects previously described with
SFTX6c are not idiosyncratic to this peptide and may be representative of endogenous
binding of ET-1 to the ETB receptor. Therefore, concerns over signalling pathway
differences between SFTX6c and endothelin peptide binding (Shraga-Levine, et al.,
1994; Sokolovsky, 1995) may not be functionally important. In contrast to the results
in the hand veins, described in Chapter 3, there was no difference in the response to
SFTX6c and BQ-3020 in the forearm resistance vessels.
The results from Study 2 demonstrate that a bolus dose of the selective ETB agonist
SFTX6c causes transient vasodilatation followed by vasoconstriction in vivo in human
forearm resistance vessels, consistent with previous results with the endogenous ETB
receptor agonist ET-3 (Haynes, et al., 1995). Inhibition of the vasodilator response by
both BQ-788 and L-NMMA, but not aspirin, suggests that this vasodilatation is
mediated by the ETB receptor through increased NO generation. Interestingly, the
constriction to SFTX6c was still evident with each of the study treatments. However,
there was a significant difference between the constriction with SFTX6c alone and in
the presence of BQ-788. Although the constriction was still evident in the presence of
BQ-788, the difference appeared to be in the development of the response, perhaps due
to inhibition of the dilator effects of the endothelial ETB receptor potentiating the
constrictor effects of the vascular smooth muscle receptors. Infusion of BQ-788 alone
caused vasoconstriction, which could indicate that the balance of effects at the ETB
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receptor favour vasodilatation, this response is discussed in more detail in Chapters 6
and 10.
Although the vasodilator response to SFTX6c was completely blocked in the presence
of the selective ETB receptor antagonist BQ-788, the constrictor response was not
reduced, in fact it seemed to develop more quickly during co-infusion with BQ-788.
These results could indicate that the constrictor response following the transient
vasodilatation is not directly mediated by the vascular smooth muscle cell ETB receptor.
It is possible that this constrictor response is mediated by the ETA receptor either
through reduced clearance of ET-1 via ETB receptors following SFTX6c infusion or as
a result of ETB receptor desensitisation following the high dose infusion of SFTX6c.
Alternatively, although SFTX6c mediated constriction in the hand vein was completely
blocked by the same dose of BQ-788 (Chapter 4, Study 3), the dose of BQ-788 may
not have been sufficient to block effects of SFTX6c at the endothelial and vascular
smooth muscle cell ETB receptors in the forearm resistance vessels in the current study.
It has also been suggested that some ETB receptor antagonists, including BQ-788, act
preferentially at the endothelial ETB receptors and are less potent at the vascular smooth
muscle ETb receptors (Schroeder, et al., 1998), this could account for the lack of effect
of BQ-788 on SFTX6c mediated vasoconstriction in the current study. It is possible
that the predominant effects of intra-luminal infusion of BQ-788 selectively affect the
endothelial ETB receptor because the drug has better access to the endothelial than to
the smooth muscle receptors.
It is important to recognise that infusion of BQ-788 alone causes significant
vasoconstriction and so it may not be possible to demonstrate attenuation of the
constriction to SFTX6c on the background of the BQ-788 effect. Interpretation of the
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results of co-infusion studies is difficult due to the individual effects of each agent on
vascular tone.
Intra-arterial infusion of L-NMMA also causes significant vasoconstriction due to
blockade of endogenous nitric oxide generation (Vallance, et al., 1989). Therefore,
vasodilatation to SFTX6c may be difficult to demonstrate on the background of this
substantial forearm vasoconstriction. In order to investigate whether the lack of effect
was due to the inhibition of nitric oxide generation caused by L-NMMA or simply due
to the vasoconstriction present in the forearm a follow-on study in 3 subjects assessing
the response to SFTX6c infusion following preconstriction with noradrenaline was
performed. The results of this small study demonstrate vasodilatation following
administration of SFTX6c in the presence of noradrenaline mediated vasoconstriction,
supporting the hypothesis that the blockade of the dilator response in the presence of
L-NMMA results from nitric oxide inhibition and not merely as an additive effect of the
L-NMMA and the SFTX6c response. The apparent lack of involvement of dilator
prostaglandins in the vasodilator response to SFTX6c is consistent with previous
studies (DeNucci, et al., 1988) but in contrast with others (Filep, et al., 1993).
We have demonstrated local vasoconstriction in healthy blood vessels in vivo in
response to locally active infusions of two structurally distinct ETB receptor selective
agonists. In addition we have confirmed that high dose infusion of ETB receptor
selective agonists causes vasodilatation and demonstrated that this vasodilatation is
mediated via the ETB receptor through increased nitric oxide generation. The
importance of ETB mediated vasodilatation was demonstrated by the vasoconstrictor
response to administration of the ETB receptor selective antagonist BQ-788. This
response will be discussed in future chapters and the relative benefits of selective and
non-selective ET receptor antagonists investigated.
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Chapter 6
The local vasodilator effects of selective ETA and
combined ETA/ET„ receptor antagonism in healthy volunteers
Endothelin-A receptor antagonist mediated vasodilatation is attenuated by inhibition of nitric oxide
synthesis and by endothelin-B receptor blockade. Verhaar MC, Strachan FE, Newby DE, Cruden NL,
Koomans HA, Rabelink TJ, Webb DJ. Circulation 1998;97:752-756.
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6.1 Introduction
As discussed in earlier chapters, the contribution of the vascular ETB receptor to the
recognised endogenous ET-1 mediated constrictor tone depends on the balance
between the ETB receptor mediated effects of vasodilatation, vasoconstriction and ET-1
clearance. The contribution of the ETA and ETB receptors to ET-1 mediated vascular
tone is of mechanistic importance and, potentially, of major therapeutic relevance in the
development of endothelin receptor antagonists. A number of selective ETA and
non-selective ETA/ETB receptor antagonists are currently in clinical development as
vasodilator agents (Strachan and Webb, 1998; Weber, et al., 1996). Although both
selective and non-selective endothelin receptor antagonists have demonstrated
vasodilator effects in healthy subjects (Haynes, et al., 1996) in patients with heart
failure (Kiowski, et al., 1995) and in patients with hypertension (Cardillo, et al., 1999;
Ferro, et al., 1996; Taddei, et al., 1999), the question of whether selective ETA or
combined ETA/ETB receptor antagonism will be of more benefit as vasodilator therapy
remains to be clarified.
Chapter 5 describes local vasoconstriction in response to infusion of the ETB receptor
selective antagonist BQ-788. In order to investigate the role of the ETA and ETB
receptor subtypes and their possible interactions in mediating the vasodilator response
to selective ETA receptor antagonism (Haynes and Webb, 1994), the effects of locally
active doses of the ETA receptor selective antagonist BQ-123, the ETB receptor
selective antagonist BQ-788 and their combined effects in forearm resistance vessels




Sixteen healthy male subjects within the age range of 18-60 years were recruited to the
study, under the standard conditions listed in chapter 2.
6.2.2 Drugs
BQ-123 (10 nmol/min) and BQ-788 (1 nmol/min) were administered by continuous
infusion for 120 min. Saline was infused for 30 min before infusion of the study
agent. The total infusion rate was kept constant at 1 ml/min.
Local forearm vasodilatation to intra-arterial infusion of BQ-123 (100 nmol/min) has
been demonstrated previously (Haynes and Webb, 1994). A ten-fold lower dose of
BQ-123 (10 nmol/min) was used in the current study because it has been shown more
recently that this dose causes vasodilatation of equal magnitude to that seen with the
higher dose (Ferro, et al., 1996).
6.2.3 Measurements
Forearm Blood Flow
The response to intra-arterial infusion was assessed by measurement of forearm blood
flow in the infused and non-infused forearm by venous occlusion plethysmography as
described in Chapter 2.
Blood Pressure and Heart Rate
Blood pressure and heart rate were measured in the non-infused arm using a well-
validated semi-automated non-invasive method at 30 min intervals throughout the
infusions as described in Chapter 2.
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6.2.4 Study design
The study was performed single blind, with the experimental subjects, but not the
investigators, blinded to the peptide and dose administered in each study.
On 2 separate study days in random order, in eight subjects, the ETA receptor
antagonist, BQ-123, was infused for 120 min alone, or during co-infusion of BQ-788,
also for 120 min. On a separate occasion, BQ-788 was infused alone in eight subjects
(two of whom also participated in the earlier parts of the study). Each study day was
separated by at least a week.
6.2.5 Analysis
Forearm blood flow
Plethysmographic data listings were extracted from data files and forearm blood flows
calculated for individual venous occlusion cuff inflations using a template spreadsheet
(Excel 5.0; Microsoft Ltd, Wokingham, UK), as described in Chapter 2. Forearm
blood flow results are expressed as the percentage change from baseline in the ratio of
blood flow between the infused and non-infused arms.
All results are expressed as mean ± standard error of the mean (SEM) at 120 min.
Blood pressure, heart rate and baseline measurements were compared using the
Student's paired r-test.
Responses were examined by repeated measures analysis of variance (ANOVA).
Statistical significance was taken at the 5% level and analysis was performed using an
Excel data analysis package (Excel 5.0; Microsoft Ltd, Wokingham, UK).
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6.3 Results
Fourteen healthy men (age range 20-43 years) completed the study, 2 subjects
participated in the first (BQ-123 alone or in combination with BQ-788) and the second
(BQ-788 alone) part of the study. There were no significant changes in baseline
hemodynamics between phases of each study (Table 6.1), and no change in blood
pressure, or blood flow in the non-infused forearm, during the course of the studies.
Forearm blood flow
Both BQ-123 alone and co-administration of BQ-123 and BQ-788 caused progressive
vasodilatation (p<0.001) which appeared to plateau at 60 min (Figure 6.1). The
vasodilatation to BQ-123 alone was significantly greater than during co-infusion with
BQ-788 (76+13% vs. 47+14% at 120 min, p<0.001). BQ-788 alone caused a small
but consistent reduction in forearm blood flow (20±3% at 120 min, p<0.001)
(Figure 6.1).
Table 6.1 Mean arterial pressure (MAP) and forearm blood flow (FBF) predose
and at 120 min afterintra-arterial infusion of BQ-123, BQ-788 or co-infusion of
BQ-123 and BQ-788. Values are mean 1 SEM.
BQ-123 BQ-123 BQ-788
(lOnmol/min) +BQ-788 (1 nmol/min)
Forearm Blood Flow
(ml/lOOml/min)
Infused arm 3.6±0.6 4.5±1.0 4.5+0.7





Figure 6.1 Eight subjects received brachial artery infusion of BQ-123
(lOnmol/min) alone, closed circles; BQ-788 (1 nmol/min) alone, closed triangles;
BQ-123 (10 nmol/min) co-infused with BQ-788 (1 nmol/min), open circles. Slow
onset vasodilatation occurred in response to BQ-123, this response was attenuated




Earlier results demonstrating the importance of endogenous ET-1 in the mediation of
vascular tone (Ferro, et al., 1996; Haynes and Webb, 1994) have been confirmed by
the demonstration of slow onset forearm vasodilatation to local arterial infusion of the
selective ETA receptor antagonist BQ-123. The observation that the vasodilator
response to combined ETA and ETB receptor antagonism was significantly less than to
selective ETA receptor antagonism alone could reflect the presence of an endogenous
ETB mediated vasodilator tone. This is further supported by the local vasoconstrictor
effect of ETB receptor antagonism in the forearm resistance vessels. The attenuation of
BQ-123 mediated vasodilatation by BQ-788 could simply be an additive effect of
BQ-788 mediated constriction on the BQ-123 mediated vasodilatation. However, in the
current study, it reflects the combined effects of ETA and ETB receptor blockade,
indicating the potential for ETA receptor antagonists may offer more benefit in terms of
vasodilatation than combined ETA/ETB receptor antagonists.
The vasoconstrictor effects of ETB receptor antagonism may result directly from
blockade of the vasodilator effects of the endothelial ETB receptor or indirectly from
displacement of endogenously generated ET-1 from ETB receptors to unoccupied ETA
receptors. Clearly, the indirect effects of ET-1 on ETA receptors are more relevant with
administration of selective ETB antagonists than with non-selective ETA/ETB receptor
antagonists, because in this latter situation the constrictor ETA receptor is also blocked.
Indeed, vasodilator effects have been demonstrated with both selective (Ferro, et al.,
1996; Haynes and Webb, 1994) and non-selective (Ferro, et al., 1997; Haynes, et al.,
1996) endothelin receptor antagonists in humans and the non-selective ETA/ETB
antagonist bosentan has recently been shown to effectively lower blood pressure in
patients with hypertension (Krum, et al., 1998). In the current study, the vasodilator
effects of BQ-123 are attenuated in the presence of BQ-788, suggesting that the overall
effect of vascular ETB receptor stimulation by endogenous ET-1 is vasodilatation. This
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attenuation of BQ-123 mediated vasodilatation by BQ-788 suggests that the
vasoconstrictor effect of ETB receptor blockade is not mediated by displacement of ET-
1 onto the ETA receptor, but is due to direct blockade of ETB mediated vasodilator tone.
Results from previous local studies, using a 'nitric oxide clamp technique'(Stroes, et
al., 1995), suggest that the vasodilator response to BQ-123 is in part due to blockade
of ETA constrictor tone, and in part mediated by nitric oxide (Verhaar, et al., 1998)
probably mediated by the endothelial ETB receptor. Indeed in Chapter 5, the dilator
effect of high dose infusion of the ETB receptor agonist SFTX6c was shown to be
mediated by the ETB receptor through increased generation of nitric oxide, and not
prostacyclin. These data highlight the importance of nitric oxide in ETB receptor
mediated dilatation. Loss of endothelial cell ETB mediated vasodilator tone may occur
in cardiovascular diseases, such as essential hypertension and hypercholesterolaemia,
in which there is associated endothelial dysfunction (Casino, et al., 1995; Panza, et al.,
1995). Here, because of a reduced capacity for ETB receptor mediated, nitric oxide
dependent dilatation, selective ETA receptor antagonists may be less effective.
Local vasoconstriction in response to infusion of BQ-788 alone was demonstrated in
the current study, suggesting that the balance of effects of ET-1 at the vascular ETB
receptors favours vasodilatation. This is further supported by the fact that co-infusion
of the ETB receptor antagonist, BQ-788, reduces the vasodilator response to BQ-123,
and by the suggestion that the degree of vasodilatation to the combined ETA/ETB
endothelin receptor antagonist, TAK-044 (Haynes, et al., 1996) appears to be less than
that to the ETa selective agent, BQ-123 (Haynes and Webb, 1994). It is possible that
the predominant effects of intra-luminal infusion of BQ-788 selectively affects the
endothelial ETB receptor because the drug has better access to the endothelial than to
the smooth muscle receptors. However, this is unlikely because ET-1 and BQ-123 find
ready access to the smooth muscle. The response to BQ-788 may indicate either
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displacement of ET-1 from, or failure of clearance of ET-1 by, ETB receptors
(Plumpton, et al., 1996). However, the present study cannot distinguish between these
effects. Unfortunately, there are currently no pharmacological tools available that have
been shown clearly to distinguish between the endothelial and vascular smooth muscle
ETB receptors.
Although the balance of effects of endogenous ET-1 at ETB receptors would appear to
be vasodilatation, partly mediated by nitric oxide, earlier studies describe
venoconstriction and vasoconstriction in response to exogenous administration of
selective ETB receptor agonists (Chapter 3, Chapter 4 and Chapter 5; Strachan, et al.,
2000; Haynes, et al., 1995; Strachan, et al., 1995). This constriction may be of
functional importance, especially in cardiovascular disease. Interestingly, in ischaemic
heart disease there appears to be upregulation of human coronary ETB receptors
(Dagassan, et al., 1996) and this is associated, in heart failure, with enhanced
vasoconstrictor responses to sarafotoxin S6c in both the forearm (Love, et al., 1996)
and coronary circulation (Cannan, et al., 1996). The endothelial ETB receptor,
however, appears still to be functionally active because infusion of BQ-788 has been
shown to cause forearm vasoconstriction in patients with heart failure (Love, et al.,
2000).
In diseases associated with endothelial dysfunction, such as hypercholesterolemia and
hypertension (Casino, et al., 1995; Panza, et al., 1995), while selective ETA receptor
blockade should allow antagonism of direct ETA receptor mediated constriction, the
beneficial effects of ETB mediated vasodilator tone may be reduced or absent and the
constrictor effects of the vascular smooth muscle ETB receptor more important.
Therefore, the response to ETA receptor blockade may be decreased in such conditions.
In contrast, there is evidence to support upregulation of non-constrictor ETB receptors
in renal disease [see (Rabelink, et al., 1996) for discussion] which again has important
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implications in the use of endothelin antagonists as treatments in cardiovascular
disease. Clearly, at some stage, it will be necessary to examine the integrated
physiology of systemic ETA and ETB blockade in order to fully understand the relative
importance of these receptor subtypes in physiological control of the circulation.
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Chapter 7
The repeatability of local forearm vasoconstriction to endothelin-1
measured by venous occlusion plethysmography
Repeatability of local forearm vasoconstriction to endothelin-1 measured by venous occlusion




The importance of ET-1 as an endogenous mediator of vascular tone has been
confirmed by forearm (Haynes, et al., 1996; Haynes and Webb, 1994) and systemic
(Haynes, et al., 1996; Spratt, et al., 1999) vasodilatation in response to local and
systemic administration of endothelin receptor antagonists, respectively. As a
consequence of its potent vasoconstrictor and growth promoting properties, ET-1 has
been implicated in the pathophysiology of diseases such as hypertension, heart failure
and renal failure (Battistini, et al., 1993; Haynes and Webb, 1993), leading to the rapid
development of endothelin receptor antagonists as potential vasodilator treatments for
cardiovascular disease (Strachan and Webb, 1998). Some of these compounds are
currently being investigated in clinical trials (Freed, et al., 1999; Haynes, et al., 1996;
Weber, et al., 1996).
Venous occlusion plethysmography coupled with brachial artery infusion provides a
valuable method for the assessment of pharmacological and physiological vasoactive
properties of locally active doses of potentially vasoactive compounds (Webb, 1995).
Indeed, vasoconstriction of the forearm vascular bed to local intra-arterial infusion of
ET-1 has previously been demonstrated by venous occlusion plethysmography
(Clarke, et al., 1989; Haynes, et al., 1995; Haynes and Webb, 1994) and inhibition of
this response has been used to assess the efficacy of endothelin receptor antagonists in
early clinical trials (Ferro, et al., 1997; Haynes, et al., 1996). However, although there
are published data describing the repeatability of this technique with other vasoactive
agents or stimuli in forearm resistance vessels in vivo (Newby, et al., 1997; Petrie, et
al., 1998; Roberts, et al., 1986; Walker, et al., 1999), there are currently no data
specifically with ET-1.
119
In order to assess the repeatability of the forearm blood flow response to intra-arterial
infusion of ET-1 in vivo, we compared the response to infusion of two locally active
doses of ET-1, administered on separate occasions, in the forearm resistance vessels of
healthy men. Each dose level was administered twice, on consecutive visits, and the
dose order was randomised. We also compared methods of data presentation of the
forearm blood flow data to assess which method is more reliable in this setting.
7.2 Methods
7.2.1 Subjects
Eight healthy men (aged between 18-60 years), were recruited to the study, under the
standard conditions described in Chapter 2.
7.2.2 Drugs
Endothelin-1 was administered by continuous infusion, via the brachial artery, for 120
min at a rate of 2.5 or 10 pmol/min according to the study randomisation. The infusion
rate was kept constant at 1 ml/min for both dose levels. We have previously assessed
the effects of ET-1 at a non-systemic dose of 5 pmol/min for 60 - 90 min (Ferro, et al.,
1997; Haynes, et al., 1996; Haynes and Webb, 1994). The doses selected for the
current study allowed assessment of the repeatability of the response to ET-1 at a lower
(2.5 pmol/min) and a higher (10 pmol/min) dose than previously used, to provide
further information on the threshold of effect, the dose response and tolerability.
All dilutions were prepared in 0.9% saline (Baxter Healthcare Ltd, Thetford, UK)
from sterile stock solutions on the day of the study.
Intra-arterial infusion
The brachial artery of the non-dominant arm was cannulated under local anaesthetic
(1% lignocaine; Astra Pharmaceuticals, Kings Langley, England) with a 27 SWG steel
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cannula (Cooper's Needle Works, Birmingham, UK). The infusion rate was kept
constant at 1 ml/min throughout.
7.2.3 Measurements
Forearm Blood Flow
The response to intra-arterial infusion was assessed by measurement of forearm blood
flow in both the infused and non-infused forearms by venous occlusion
plethysmography as described in Chapter 2.
Blood Pressure and Heart Rate
Blood pressure and heart rate were measured in the non-infused arm using a well-
validated semi-automated non-invasive method (Wiinberg, et al., 1988). Blood
pressure was measured immediately after forearm blood flow to avoid any effect on
these measurements of the venous congestion caused by this procedure.
7.2.4 Study Design
In a single-blind, randomised, 2 way crossover study, the local effects of two dose
levels of ET-1 were investigated in eight healthy men. On separate occasions, each
separated by at least one week, subjects received an intra-arterial infusion of ET-1 (2.5
pmol/min or 10 pmol/min) for 120 min. Each dose level was administered twice, on
consecutive visits and the dose order randomised. Subjects were blinded to the dose
administered.
Saline (0.9%) was infused for at least 30 min, during which 3 measurements of
forearm blood flow were made. ET-1 was then infused for 120 min. Forearm blood




Plethysmographic data listings were extracted from data files and forearm blood flows
calculated as described in Chapter 2. Baseline blood flow was taken as the last
measurement during the saline infusion, before the start of the ET-1 infusion. Forearm
blood flow results are expressed as the % change from baseline in the ratio of blood
flow between the infused and non-infused arms (Webb, 1995). We also expressed the
results as % change in forearm blood flow in the infused arm alone, to compare this
with our standard method of data presentation. The area under the curve (AUC) was
calculated for both methods to present a summary statistic for the overall response.
The repeatability of each method was assessed by the method of Bland and Altman
(Bland and Altman, 1986) using Student's t distribution. In brief, the mean response
and the mean difference between the responses on each visit are compared and the
repeatability coefficient calculated according to the recommendations of the British
Standards Institution (Bland and Altman, 1986). Power calculations were performed
using the standard deviation and the mean response, as a % change, for visit 1 for each
dose, to estimate the sample sizes required to detect a shift in the response at 60, 90
and 120 min; and the AUC for (0 - 60 min), (30 - 60 min), (0 - 90 min), (60 - 90
min), (0 - 120 min) and (90 - 120); for each dose for 80 or 90% power to detect a
predetermined difference (of 10 - 100%) with significance accepted at the 5% level.
All results are expressed as mean ± standard error of the mean (SEM). Blood pressure,
heart rate and baseline measurements were compared using the Student's paired r-test.
Forearm blood flow data were examined by repeated-measures analysis of variance
(ANOVA) (Excel 5.0, Microsoft Ltd, Wokingham, UK). Statistical significance was
accepted at the 5% level.
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7.3 Results
All eight subjects successfully completed the study (age range: 18-50 years, mean 33 ±
3 years). There were no significant differences between baseline measurements on
each of the study visits. There was no significant change in blood pressure or heart rate
at the end of each infusion (Table 1). There was a trend for the blood flow in the non-
infused arm to increase with time (Figure 1). Although this trend reached significance
over 120 min (p=0.02) for one of the visits (10 pmol/min, visit 1) when the data were
expressed as % change in blood flow, there was no significant change in forearm
blood flow (absolute values) in the non-infused arm at the end of each infusion (Table
1).
Although there were no reported adverse events with either dose of ET-1, some skin
blanching was noted in some volunteers with the higher dose of ET-1 (10 pmol/min).
These effects were not formally evaluated and did not cause symptoms at the end of the
study or thereafter.
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Table 7.1 Mean arterial pressure (MAP), heart rate (HR) and forearm blood flow
(FBF) at baseline and 120 min after the start of each infusion. Values are mean ±
SEM.
Endothelin-1 infusion
2.5 pmol/min 10 pmol/min
visit 1 visit 2 visit 1 visit 2
MAP (mmHg)
Basal 94 ±2 92 ±3 91 ±3 90 ±2
120 Mins 94 ±3 98 + 4 93 ±4 94 ±3
HR (bpm)
Basal 62 + 4 64 ±5 61 ±5 63 + 4




Basal 3.4 1 0.3 3.3 + 0.4 3.1 10.3 3.5 1 0.3
120 min 3.7 1 0.5 3.9 1 0.3 4.1 1 0.3 4.4 1 0.5
Infused Arm
Basal 4.01 0.4 3.9 1 0.7 3.-6 10.4 3.8 1 0.5
120 min 2.5 10.3 3.2 10.1 1.6 10.1 1.7 10.2
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Forearm blood flow
(i) Forearm blood flow ratio (FBFR)
Forearm vasoconstriction was indicated by a reduction in the ratio of forearm blood
flow in response to both doses of ET-1 at each visit (p<0.0001, all visits) (Figure
7.1). The response to ET-1 was slow in onset and appeared to plateau at around 60
min. There was no significant difference between the responses on visit 1 and visit 2
for either dose. The repeatability coefficient for 10 pmol/min was lower than that for
2.5 pmol/min (Table 7.2), indicating that the response to 10 pmol/min was the more
repeatable.
The AUC was calculated for each dose and each visit (p<0.0001, all visits) (Table
7.2). There was no significant difference between the responses on visit 1 and visit 2
for either dose. Again, the repeatability coefficient for 10 pmol/min was lower than for
2.5 pmol/min (Table 7.2).
(ii) Infused arm only (FBFj)
There was a significant reduction in blood flow in the infused arm in response to both
doses of ET-1 at each visit (p<0.0001, all visits) (Figure 7.1). Although there was no
significant difference between the response to ET-1 (10 pmol/min) on visit 1 and visit
2 (p=0.7), the difference between the response to ET-1 (2.5 pmol/min) on visit 1 and
visit 2 was significant (p=0.03). The repeatability coefficient for 10 pmol/min was
lower than that for 2.5 pmol/min (Table 7.2).
The AUC was calculated for each dose and each visit (p<0.0001, all visits) (Figure
7.1). There was no significant difference between the responses on visit 1 and visit 2
for either dose. Again, the repeatability coefficient for 10 pmol/min was lower than
that for 2.5 pmol/min (Table 7.2).
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(iii) Non-infused arm only(FBFNI)
Although there was no significant change in forearm blood flow (absolute values) at
the end of the infusion (Table 7.1), when expressed as a % change from baseline, the
change on visit 1 for the 10 pmol/min dose was significant over 120 min (p=0.02;
ANOVA, one way). This change was not significant up to and including the 90 min
timepoint for this visit (p>0.1; ANOVA, one way), or for the other visits over 120
min.
There was no significant difference between the % change in the non-infused arm on
visit 1 and visit 2 for the 10 pmol/min dose. However the difference between the %
change on visit 1 and visit 2 for the 2.5 pmol/min dose reached statistical significance
(p=0.047).
(iv) Power calculations
The sample sizes estimated from the power calculations were smaller when data were
represented as a % change in the ratio of forearm blood flow rather than as % change
in the infused arm alone (Tables 7.3 & 7.4).
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Figure 7.1 Response of forearm blood flow to local intra-arterial infusion of ET-1;
% change in forearm blood flow ratio; infused arm:non-infused arm (2.5 pmol/min;
visit 1, open circles; visit 2, closed circles and lOpmol/min; visit 1, open squares; visit
2, closed squares). Responses are expressed as mean % change in forearm blood
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Table 7.3 Power calculations estimating the sample sizes required to detect a 10,
25, 33, 50, 75 and 100% shift in the response, as % change (i) at 120 min, (ii) AUC
(0 - 120 min), (iii) AUC (90 - 120) min; for each dose with a power of 90% and 80%
and significance accepted at 5%.
(i)
FBF - ratio FBF - Infused arm
ET-1 % shift 90% 80% 90% 80%
(pmol/min) (120 min) power power power power
10 132 99 389 293
25 22 16 63 47
33 13 10 36 27
50 6 >5 16 12
75 >5 >5 7 6
100 >5 > 5 >5 >5
10 38 29 122 92
25 6 >5 20 15
33 >5 >5 12 9
50 >5 >5 >5 > 5
75 >5 >5 >5 >5
100 >5 >5 >5 >5
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FBF - ratio FBF - Infused arm
ET-1 % shift 90% 80% 90% 80%
(pmol/min) (AUC power power power power
0-120 min)
10 180 136 1093 823
25 29 22 175 132
33 17 13 101 76
50 8 6 44 33
75 >5 >5 20 15
100 >5 >5 11 9
10 33 25 144 108
25 6 >5 23 18
33 >5 >5 14 10
50 >5 >5 6 >5
75 >5 >5 >5 >5









FBF - Infused arm
90% 80%
power power
2.5 10 83 63 368 277
25 13 10 59 45
33 8 6 34 26
50 >5 >5 15 12
75 >5 >5 7 >5
100 >5 >5 >5 >5
10 50 38 130 98
25 8 6 21 16
33 > 5 >5 12 9
50 >5 >5 6 >5
75 >5 >5 >5 >5













































































































































































































These results describe dose-dependent vasoconstriction in the forearm vascular bed of
healthy men in response to infusion of locally active doses of ET-1 (2.5 and 10
pmol/min), consistent in evolution and magnitude with previous responses to ET-1 (1
and 5 pmol/min) (Clarke, et al., 1989; Haynes, et al., 1996; Haynes, et al., 1995).
The response to each dose of ET-1 was investigated on two separate occasions and
found to be similar on both visits.
Forearm blood flow can be measured in both arms and it has been suggested that data
from studies with locally active doses of drugs are best represented as % change in the
ratio of forearm blood flow in the infused and non-infused arm (Benjamin, et al.,
1995; Chin-Dusting, et al., 1999; Petrie, et al., 1998; Webb, 1995). However, some
investigators prefer to report the effects in the infused arm without including blood
flow data from the non-infused arm (Panza, et al., 1990; Walker, et al., 1999). It is
likely that, where the responses are relatively small, and particularity in the case of
constrictors, the response is more accurately expressed as a % change in the ratio of
forearm blood flow. On the other hand, when responses are potentially of a greater
magnitude, particularity with vasodilator effects (Walker, et al., 1999), it may be more
useful to express the response as a % change in the infused arm and use the effects in
the non-infused arm only to confirm that there are no systemic drug effects.
We examined the response to ET-1 when expressed as % change in the ratio of
forearm blood flow and as % change in the infused arm alone, to identify which is
better suited for future studies investigating this response. Although both methods
demonstrated significant reduction in blood flow for all visits (Figure 1), the
repeatability coefficients were consistently lower for the blood flow ratio than for
blood flow in the infused arm (Table 2) indicating that the data are less variable when
presented as % change in forearm blood flow ratio. This translates into a need for a
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lower sample size to achieve the same power, using blood flow ratios rather than
changes in the infused arm alone (Table 3), suggesting that, at least in the case of
responses to ET-1, presentation of the response as a ratio is more robust.
Summarising the forearm blood flow responses as areas under the curve (AUCs)
allows presentation of responses as single values and may reduce the effect of single
unexpected variations in blood flow on an overall assessment of the response. Again,
the AUC data for the blood flow ratio appeared more robust than the AUC for the
infused arm only with the response more repeatable and with consistently smaller
sample sizes needed for future studies investigating this response. Interestingly, the
sample sizes were smaller for AUC for the last 30 min of the response than for the
AUC for the entire infusion period, for both the ratio and infused arm data (Table 4),
probably because the response is more completely developed by this time.
In the current study there was a trend for the blood flow to increase in the non-infused
arm, with significant change detected over 120 min on one of the study visits (10
pmol/min, visit 1). It is important to note that, although changes were observed in the
non-infused arm, these changes were not significant up to 90 min. Therefore, limiting
the duration of the intra-arterial infusion to 90 min or less might help avoid this
problem. This increase in blood flow may simply be a time-dependent effect.
However, as these effects were more pronounced with the higher dose level of ET-1
(10 pmol/min), it is possible that the changes described in the non-infused arm are a
breakthrough of systemic effects. Previous investigations of forearm blood flow
responses to ET-1 have demonstrated vasodilatation in response to low dose (-0.05 -
0.2 pmol/min) infusion of ET-1 (Dahlof, et al., 1990; Kiowski, et al., 1991).
Therefore the small increase in blood flow observed in the non-infused arm during
infusion of ET-1 (10 pmol/min) in the current study may have resulted from a small
increase in ET-1 concentrations in the non-infused arm. Alternatively, this increase in
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forearm blood flow could reflect splanchnic vasoconstriction with the higher dose of
ET-1. Although no changes were seen in blood pressure in the non-infused arm during
infusion of ET-1, the increase in blood flow in the non-infused arm could result from
an increase in blood flow to the forearm vascular bed in response to a degree of
systemic vasoconstriction in more important vascular beds. Indeed, similar effects
have been described in studies with systemic infusion of angiotensin n, where forearm
vasodilatation was demonstrated in response to high dose infusion of angiotensin II
(Motwani and Struthers, 1992).
We have shown that the forearm blood flow response to ptra-arterial infusion of ET-1,
at two dose levels, is repeatable in between-day comparisons in healthy volunteers.
These data support the use of the forearm blood flow response to ET-1 as a model to
assess the effects of antagonists and inhibitors of the endothelin system in early clinical
trials (Ferro, et al., 1997; Haynes, et al., 1996; Haynes and Webb, 1994). From our
experience this model is most powerful when the response to intra-arterial infusion is
assessed in a within-subject, placebo-controlled design, allowing the shift in individual
dose responses to be assessed with each study subject acting as his own control. The
method described is generally well tolerated and repeat studies can be scheduled 5-7
days apart, allowing the effects of study drug to be investigated using a crossover
design. This model is also useful in assessing any differences in responses to ET-1
between patients and healthy matched controls (Hand, et al., 1999; Love, et al., 1996;
Newby, et al., 1998).
The characteristically slow onset of and sustained vasoconstriction to ET-1 (Clarke, et
al., 1989; Haynes, et al., 1995) precludes the construction of a full dose response
curve on a single visit. There is also the possibility of an accumulation of effect with
subsequent increases in dose level. Indeed, early studies with ET-1 demonstrated
significant adverse events including vomiting, sensation of heat and deep muscular
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pain following intra-arterial infusion of ET-1 in stepwise increases in dose from 5 x 10
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to 5 x lO"8 mol/min with effects still evident 10 hours following infusion (Dahlof, et
al., 1990). In the current study, we observed skin blanching in the infused arm
following infusion of ET-1, but only at the higher dose level. These effects have not
been noted in our studies with ET-1 (5 pmol/min) (Ferro, et al., 1997; Hand, et al.,
1999; Haynes, et al., 1996; Haynes and Webb, 1994; Love, et al., 1996). In addition,
a small but significant increase in forearm blood flow was noted in the non-infused
arm following infusion of ET-1 (10 pmol/min), which could indicate threshold
systemic effects at this dose level. Given these observations with ET-1 (10 pmol/min),
and our previous results with ET-1 (5 pmol/min), we would suggest that the forearm
blood flow response to intra-arterial infusion of ET-1 at 5 pmol/min for 90 min
provides the most useful model for the assessment of effects of receptor antagonists or
the responsiveness to ET-1 in patients. Based on power calculations from the current
data, a sample size of 8 should be sufficient to detect a 50% shift in AUC (60 - 90 min)
for ET-1 (10 pmol/min) and a 33% shift in AUC (60 - 90 min) for ET-1 (2.5
pmol/min), with 90% power, when responses are expressed as a % change in the
forearm blood flow ratio. Therefore, we would expect that a sample size of 8 should
be sufficient to detect a 33 - 50% shift in AUC (60 - 90 min) for 5 pmol/min, with
90% power, when responses are expressed as a % change in the forearm blood flow
ratio.
In summary, the assessment of the forearm blood flow response to intra-arterial
infusion of ET-1 provides a well tolerated and reliable model for the pharmacodynamic
assessment of endothelin receptor antagonists at an early stage in drug development in
a relatively small number of patients or controls (Ferro, et al., 1997; Hand, et al.,
1999; Haynes, et al., 1996; Love, et al., 1996; Newby, et al., 1998) enabling
identification of a pharmacologically effective dose range for use in early patient trials.
The data from the current study should provide a valuable basis for protocol design in
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The effect of the non-selective endothelin receptor antagonist
L-753,037 on forearm vasoconstriction to endothelin-1
138
8.1 Introduction
As discussed previously, the importance of endothelin-1 (ET-1) as a physiological
mediator of basal vascular tone in vivo in man has been demonstrated by local
(Haynes, et al., 1996; Haynes, et al., 1994; Verhaar, et al., 1998) and systemic
(Freed, et al., 1999; Haynes, et al., 1996; Spratt, et al., 1999; Weber, et al., 1996)
vasodilatation in response to endothelin receptor antagonism in healthy subjects. The
potent vasoconstrictor effects of ET-1 (Clarke, et al., 1989; Yanagisawa, et al., 1988),
combined with the increased plasma concentrations of ET-1 in patients with
cardiovascular disease, including cardiac (Pacher, et al., 1993) and renal failure
(Koyama, et al., 1989), provide strong evidence to support a functional role for ET-1
in the development and maintenance of the increased peripheral vascular resistance
associated with these conditions. Indeed, vasodilator effects of endothelin antagonists
have been described in patients with heart failure (Cowburn, et al., 1998; Kiowski, et
al., 1995; Love, et al., 1996) and hypertension (Cardillo, et al., 1999; Ferro, et al.,
1996; Taddei, et al., 1999).
The recognition of the endothelin system as a therapeutic target in the treatment of
cardiovascular disease has led to the rapid development of endothelin receptor
antagonists as potential vasodilator treatments (Strachan and Webb, 1998), with a
number of these compounds, both ETA receptor selective and mixed ETA/ETB receptor
antagonists, currently being investigated in clinical trials. L-753,037 is a potent,
non-peptide, mixed ETA/ETB receptor antagonist (Zhao, et al., 1999) which,
unusually, is almost equipotent at both receptors.
Following validation of the forearm blood flow response to ET-1 as a model for the
assessment of endothelin receptor antagonists in early clinical trials (Chapter 7), the
effect of L-753,037 on forearm vasoconstriction to ET-1 in healthy volunteers was
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investigated. In addition the effect of L-753,037 on blood pressure, heart rate and
plasma concentration of ET-1 was assessed.
8.2 Methods
8.2.1 Subjects
Eight healthy men, aged between 18 and 60 years, were recruited to the study which
was performed in the Clinical Research Centre at the Western General Hospital,
Edinburgh under the standard conditions listed in Chapter 2. All subjects attended for a
pre-trial screening visit for full assessment of medical history and a physical
examination. All subjects tested negative for HBsAg and for drugs of abuse. No
subject received any medication, including over the counter medications, in the 2
weeks before each treatment period. All subjects abstained from alcohol for 48 hours
and from food, caffeine containing drinks and tobacco for at least 7 hours before L-
753,037 and ET-1 administration. All studies were performed in a quiet room kept at a
controlled temperature between 22-24°C.
8.2.2 Drugs
Intra-arterial administration ofET-1
Endothelin-1 (Calbiochem, Nottingham, UK) was administered by continuous
intra-arterial infusion for 90 min at an infusion rate of 5 pmol/min, as described
previously (Ferro, et al., 1997; Haynes, et al., 1996, and Chapter 7; Haynes and
Webb, 1994), ET-1 administration was unblinded. Saline (0.9%) was infused for at
least 30 min before ET-1 infusion.
Intravenous infusion of L-753,037
On separate occasions, L-753,037 (0.25 or 0.375 mg/kg) or matching placebo was
administered by IV infusion for 30 min.
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Endothelin-1 was prepared in 0.9% saline (Baxter Healthcare Ltd) from sterile stock
solutions on the day of the study. L-753,037 was prepared under standard aseptic




The response to brachial artery infusion was assessed in both forearms by
measurement of blood flow using venous occlusion plethysmography, as described in
Chapter 2. Recordings of forearm blood flow were made over 3 min periods at 10 min
intervals throughout the intra-arterial infusion.
Bloodpressure and heart rate
Blood pressure and heart rate were measured in the non-infused arm as described in
Chapter 2. During intra-arterial infusions, blood pressure was measured immediately
after forearm blood flow measurements to avoid any effect of the venous congestion
caused by this procedure on these measurements.
Plasma ET-1
Blood samples for assay of ET-1 were obtained, via an 18 SWG cannula sited in the
opposite arm from the intra-arterial infusion. In brief, 10 ml samples were collected
into sterile EDTA tubes (K3 EDTA, Vacutainer, Becton Dickinson Vacutainer
Systems, Europe) centrifuged immediately at 1000 g for 20 min (ET-1 assay) and
stored in plain tubes at -80 C prior to assay. Endothelin-1 concentrations were
determined by standard radioimmunoassay (Peninsula Laboratories Europe), as
described previously (Hand, et al., 1999).
14)
Additional blood samples were taken at screening, on admission, prior to discharge
and at the post trial physical examination for standard biochemistry and haematology
assays. Routine urinalysis was carried out at screening and after the trial.
8.2.4 Study design
In a 3 way, placebo controlled, crossover study, the effects of L-753,037 (0.25 or
0.375 mg/kg) or placebo on the local vasoconstrictor response to intra-arterial infusion
of ET-1 and systemic haemodynamics were investigated, in 8 healthy male subjects.
On separate occasions, each separated by at least one week, L-753,037 or matching
placebo was administered by IV infusion for 30 min.
Blood pressure and heart rate were measured on 3 occasions in the 30 min before and
at 30 min intervals until 60 min after the start of the infusion of L-753,037, thereafter
recordings were made at 10 min intervals until the end of the intra-arterial infusion
(150 min after the start of L-753,037 infusion) (Figure 8.1). Blood samples for
assessment of plasma concentrations of ET-1 were collected immediately before and at
30 min intervals until 180 min after the start of the L-753,037 infusion.
Figure 8.1 Schematic representation of the study design: L-753,037 or placebo
was infused intravenously for 30 min, ET-1 was infused intra-arterially for 90 min
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Subjects attended the research centre on the morning of each study day and were
discharged the following day, 24 hours after L-753,037 infusion. Blood pressure and
heart rate were measured and a 12 lead ECG, physical examination, safety blood
sample and adverse event check were performed before discharge.
8.2.5 Analysis
Forearm bloodflow
Plethysmography data listings were extracted from data files and forearm blood flows
calculated for individual venous occlusion cuff inflations using a template spreadsheet
(Excel 5.0; Microsoft Ltd, Wokingham, UK), as described in Chapter 2. Forearm
blood flow results are expressed as the percentage change from baseline in the ratio of
blood flow between the infused and non-infused arms (Webb, 1995; Benjamin, 1995;
and Chapter 7). Data were examined by repeated-measures analysis of variance
(ANOVA).
Bloodpressure and heart rate
Blood pressure is presented as mean arterial pressure (MAP; diastolic blood pressure +
1/3 pulse pressure). Blood pressure and heart rate are expressed as placebo corrected
percentage changes from baseline at 150 min after the start of the L-753,037 infusion
(Haynes, et al., 1996). Statistical analysis was performed on untransformed data and
data examined by repeated-measures analysis of variance (ANOVA).
Plasma ET-1
Plasma concentrations of ET-1 (pg/ml) are presented as absolute values at 150 min
after the start of the L-753,037 infusion with data examined by repeated-measures
analysis of variance (ANOVA).
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All results are expressed as mean ± standard error of the mean (SEM). Data analysis
was performed using an Excel data analysis package (Excel 5.0; Microsoft Ltd,
Wokingham, UK). For ANOVA comparisons, treatment and subject were the factors
and the p values are for treatment comparisons over all timepoints. Statistical
significance was taken at the 5% level.
8.3 Results
Eight subjects (aged 20-42 years) completed the study. There were no serious or
unexpected adverse events and no significant changes in safety evaluations. The most
commonly reported event, on active treatment, was headache and abdominal rash.
Other events reported included a fainting episode on placebo treatment and four events
directly related to the intra-arterial infusion, which included blanching of skin and local
swelling at the cannula site.
There was no significant change in blood pressure and heart rate, or in blood flow
measured in the non-infused arm during the intra-arterial infusions, confirming that
any effects of the intra-arterial infusion were confined to the infused arm (Table 8.1).
Forearm bloodflow
There was significant local vasoconstriction, indicated by a reduction in the ratio of
forearm blood flow, in response to intra-arterial infusion of ET-1 following placebo
infusion (-40±6%, p<0.0001; Figure 8.2). Forearm vasoconstriction was significantly
attenuated (-14±8%, p<0.0001 vs placebo) following infusion of L-753,037 (0.25
mg/kg) and completely abolished (3±10%, p<0.0001 vs placebo) following infusion
of L-753,037 (0.375 mg/kg). The attenuation of the response to ET-1 was
significantly greater with L-753,037 at 0.375 mg/kg than at 0.25 mg/kg (p=0.0004).
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Table 8.1 Mean arterial pressure (MAP), heart rate (HR), plasma ET-1 and
forearm blood flow (FBF) predose 60 min and 150 min after the start of the L-753,037






Predose 88±2 93+2 86+3
60 min 90±1 89+3 84+3
150 min 93+2 93+4 83+3
HR (bpm)
Predose 62+3 58+2 62+2
60 min 61±3 62+2 65+1
150 min 60±2 65+3 63+2
Plasma ET-1 (pg/ml)
Predose 2.2+0.3 2.4+0.2 2.1+0.2
60 min 2.5+0.3 18.9+2.7 14.9+1.1
150 min 3.8+0.4 17.5+2.5 21.0+2.1
FBF (ml/lOOml/min)
Control Arm
Predose - - -
60 min 2.2+0.3 2.7+0.5 2.2+0.2
150 min 2.8+0.3 3.0+0.3 2.7+0.3
Infused Arm
Predose - - -
60 min 2.8+0.4 3.2+0.5 2.6+0.2
150 min 2.1+0.4 3.0+0.3 3.2+0.4
145
Figure 8.2 Response of forearm blood flow to local intra-arterial infusion of ET-1
(5 pmol/min) after iv administration of L-753,037 (0.25 mg/kg, open squares or 0.375
mg/kg, closed squares) or placebo, closed circles. Responses are expressed as mean %
change in forearm blood flow ratio ± SEM.
-20 -10 0 10 20 30 40 50 60 70 80 90
Time (min)
Bloodpressure and heart rate
There were no significant changes in blood pressure or heart rate after placebo
administration (Table 8.1). However blood pressure was reduced following
administration of L-753,037 (0.25 mg/kg: -6±3%; 0.375 mg/kg: -9+2%; p<0.0001 vs
placebo) (Figure 8.3). There was no significant difference in the blood pressure
response to either dose level. Heart rate was increased following administration of
L-753,037 (0.25 mg/kg: 12±4%; 0.375 mg/kg: 4+3%; p<0.0001 vs placebo) (Figure







Figure 8.3 Mean arterial pressure and heart rate after iv administration of
L-753,037 (0.25 mg/kg, open squares or 0.375 mg/kg, closed squares). Responses
are expressed as placebo corrected mean % change + SEM.
147
Plasma ET-1
Administration of placebo had no effect on plasma concentrations of ET-1 (Table 8.1),
confirming that intra-arterial infusion of ET-1 had no effect on plasma concentrations
of ET-1 measured in the opposite arm. In contrast, there was a significant increase in
plasma concentrations of ET-1 150 min following administration of L-753,037 at both
dose levels (0.25 mg/kg: 18+2 pg/mi; 0.375 mg/kg: 21+2 pg/ml; p<0.0001 for both)
(Figure 8.4). There was no significant difference between the increase in plasma ET-1
to either dose of L-753,037.
Figure 8.4 Mean plasma concentrations of ET-1 (pg/ml) after iv administration of
L-753,037 (0.25 mg/kg, open squares or 0.375 mg/kg, closed squares) or placebo,





In the current study, vasoconstriction in the forearm vascular bed in response to
intra-arterial infusion of a locally active dose of ET-1 (5 pmol/min) was demonstrated,
consistent with previous results (Ferro, et al., 1997; Haynes, et al., 1996; Haynes and
Webb, 1994; Strachan, et al., 1998). Systemic administration of the mixed ETA/ETB
receptor antagonist L-753,037 significantly attenuated the response to ET-1 in the
forearm vascular bed at two dose levels, completely blocking the response with the
higher dose.
In addition to attenuating exogenous ET-1 mediated increases in forearm vascular tone,
intravenous infusion of L-753,037 caused modest but significant reduction in blood
pressure in healthy volunteers, indicating systemic vasodilatation. Unlike the
attenuation of the forearm blood flow response, the reduction in blood pressure did not
appear to be dose-dependent. There was also a significant increase in heart rate
following infusion of L-753,037, most likely in response to systemic vasodilatation.
Like the blood pressure effects, the change in heart rate did not appear to be dose
dependent. The current design did not include measurement of cardiac index or stroke
index, therefore it is not possible to calculate changes in peripheral vascular resistance
in response to L-753,037 administration. However, the changes in blood pressure and
heart rate are comparable to the effects seen previously with the non-selective ET
receptor antagonist TAK-044 (Haynes, et al., 1996). The blood pressure changes
demonstrated with TAK-044 were associated with a reduction in total peripheral
vascular resistance. Therefore it is likely that blood pressure changes in the current
study indicate systemic vasodilatation in response to L-753,037 administration.
Plasma concentrations of ET-1 have been shown to increase after administration of
ETB receptor selective antagonists (Cowburn, et al., 1998; Fukuroda, et al., 1994;
Gratton, et al., 1997) and mixed ETA/ETB receptor antagonists (Haynes, et al., 1996;
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Weber, et al., 1996) but not after adminstration of ETA receptor selective antagonists
(Ohnishi, et al., 1998; Spratt, et al., 1999), consistent with clearance of ET-1 mediated
by the ETB receptor. In the current study we found plasma ET-1 concentrations were
increased after administration of L-753,037 at both dose levels, suggesting that the
current dose range is active at the ETB receptor. Interestingly, the increase in plasma
concentrations of ET-1 did not appear to affect blood pressure or forearm blood flow
responses.
The current dose range and method of administration appeared to be well tolerated as
there were no serious or unexpected adverse events and few adverse events reported
after administration of L-753,037. Headache is commonly reported with endothelin
receptor antagonists, however, in the current study there was only one reported event
of headache.
A number of ETA receptor selective and mixed ETA/ETB receptor antagonists are
currently being investigated in clinical trials (Strachan and Webb, 1998). It is unclear at
present whether ETA receptor selective or mixed ETA/ETB receptor antagonists will
offer greater therapeutic benefit. In healthy volunteers (Verhaar, et al., 1998, Chapter
6) and from results in animal models (Gratton, et al., 1997), it would appear that the
balance of effects at the vascular ETB receptors favours vasodilatation. Therefore,
selective ETA receptor antagonists may provide greater vasodilatation in some
circumstances by allowing blockade of the constrictor effects of the ETA receptor while
preserving the vasodilator effects of the ETB receptor. Indeed, in heart failure patients,
selective ETB receptor antagonism results in both local (Love, et al., 1996) and
systemic vasoconstriction (Cowburn, et al., 1998). Therefore, in heart failure selective
ETa receptor antagonists may offer greater therapeutic benefit. In contrast, in patients
with hypertension, where endothelial function is likely to be impaired, vasodilatation
has been described in response to selective ETB receptor antagonism (Cardillo, et al.,
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1999). This may reflect a reduced capacity for ETB mediated vasodilatation through
generation of nitric oxide (Taddei, et al., 1999). Therefore, in patient groups with
endothelial dysfunction, mixed ETA/ETB receptor antagonists may be more effective
vasodilator treatments. Further investigation in patient groups is required to assess the
acute and chronic effects of selective ETA receptor antagonists and mixed ETA/ETB
receptor antagonists and to assess which of these approaches offers the greater
therapeutic advantage in the clinical setting.
In summary, these results demonstrate that the combined ETA/ETB receptor antagonist
L-753,037 is effective in blocking ET-1 mediated increase in vascular tone in healthy
volunteers. In addition the reduction in blood pressure in comparison with placebo
demonstrates the potential of L-753,037 as a vasodilator treatment. This study has
allowed identification of a pharmacologically active, and apparently well tolerated,
dose range for L-753,037 in healthy volunteers, this information may be of value in
the design of future trials in patient groups.
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Chapter 9
Vasodilator effects of the endothelin-A selective antagonist
BMS-193884 in healthy men
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9.1 Introduction
As discussed in Chapter 8, the recognition of the endothelin system as a new
therapeutic target in the treatment of cardiovascular disease, has led to the rapid
development of endothelin receptor antagonists as potential vasodilator treatments
(Strachan and Webb, 1998), with a number of these compounds, both ETA receptor
selective and mixed ETA/ETB receptor antagonists, currently being investigated in
clinical trials. Further investigation of the integrated cardiovascular effects in patient
groups is required to address whether selective ETA receptor antagonists would
provide greater therapeutic benefit than mixed ETA/ETB receptor antagonists.
The forearm blood flow response to ET-1 provides a well validated model for the
assessment of endothelin receptor antagonists in early clinical trials (Chapter 7). Indeed
the study described in Chapter 8 demonstrates the value of this model in providing
important information on the pharmacologically active dose range of a combined
ETa/ETb receptor antagonist, L-753,037, in vivo at an early stage in its clinical
development. BMS-193884 is an orally available biphenylsulfonamide derivative that
selectively binds to recombinant human ETA receptors with > 10 000 fold selectivity
for human recombinant ETA receptors over ETB receptors (unpublished data1:
Murugesan N et al. Biphenylsulfonamide endothelin receptor antagonists. 2.
Discovery of 4'-Oxazolyl biphenylsulfonamides as a new class of potent, highly
selective ETA antagonists. Bristol-Myers Squibb Pharmaceutical Research Institute,
Princeton, NJ 085343-5400, submitted for publication at time of submission of current
manuscript).
We investigated the effects of BMS-193884 on the local vasoconstrictor response to
ET-1 in healthy volunteers (Haynes, et al., 1996; Strachan, et al., 1998). In addition




28 healthy men, aged between 18 and 60 years, and within 15% of ideal body weight,
were recruited to the study which was performed in the Clinical Research Centre at the
Western General Hospital, Edinburgh with the approval of the local research ethics
committee and the written informed consent of each subject. The investigations
conformed with the principles outlined in the Declaration of Helsinki. All subjects
attended for a pre-trial screening visit for full assessment of medical history and a
physical examination. All subjects tested negative for HBsAg and for drugs of abuse.
No subject received any medication, including over the counter medications, in the 2
weeks before each treatment period. All subjects abstained from alcohol for 48 hours
and from food, caffeine containing drinks and tobacco for at least 7 hours before
BMS-193884 and ET-1 administration. All studies were performed in a quiet room
kept at a controlled temperature between 22-24°C.
9.2.2 Drugs
Intra-arterial administration
Endothelin-1 (Calbiochem, Nottingham, UK) was administered by continuous intra¬
arterial infusion for 60 min (Protocol 1) and 120 min (Protocol 2 & 3) at an infusion
rate of 5 pmol/min, as described previously (Ferro, et al., 1997; Haynes, et al., 1996;
Haynes and Webb, 1994), ET-1 administration was double-blind in Protocol 1 and
single-blind in Protocols 2 & 3.
BMS-193884 (Bristol-Myers Squibb Pharmaceutical Research Institute, Moreton,
Wirral, UK) was prepared as a crystalline free acid and suplied as a 5 mg/ml aqueous
solution for infusion. In protocol 1, placebo (0.9% saline, Baxter Healthcare Ltd,
Thetford, UK) or BMS-193884 (5 and 50 nmol/min) was administered double-blind
by continuous intra-arterial infusion for 60 min, according to the study randomisation
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schedule. Active intra-arterial infusion was followed by a 30 min washout infusion of
saline 0.9%.
BMS-193884 inhibits [1251!ET-1 binding to recombinant human ETA receptors in the
nanomolar and ETB receptors in the micromolar range (K,ETA 1.4 ± 0.1 nM, KjETg
18.8 ± 2 |iM) (Unpublished data1: Murugesan N et al. Biphenylsulfonamide
endothelin receptor antagonists. 2. Discovery of 4'-Oxazolyl biphenylsulfonamides as
a new class of potent, highly selective ETA antagonists. Bristol-Myers Squibb
Pharmaceutical Research Institute, Princeton, NJ 085343-5400, submitted for
publication at time of submission of current manuscript). Although it is not possible to
quantify exact tissue concentrations during local intra-arterial infusion, both doses of
BMS-193884 were estimated to be within a range selective for the ETA receptor (5
nmol/min -100 nM, 50 nmol/min -1 (iM, assuming arterial blood flow =50 ml/min).
All dilutions were prepared in 0.9% saline (Baxter Healthcare Ltd) from sterile stock
solutions on the day of the study.
Intra-arterial infusion
The brachial artery of the non-dominant arm was cannulated under local anesthesia
(1% lidocaine; Astra Pharmaceuticals, Kings Langley, England) with a 27 SWG steel
cannula (Cooper's Needle Works, Birmingham, UK) attached to a 16-gauge epidural
catheter (Portex Ltd, Hythe, UK). Patency was maintained by infusion of saline via an
IVAC PI000 syringe pump (IVAC Ltd, Basingstoke, UK). The total rate of intra¬
arterial infusions was kept constant at 1 ml/min throughout all studies. During co-
infusion in Protocol 1 each agent was, therefore, infused at a rate of 0.5 ml/min.
Oral administration
BMS-193884 (Bristol-Myers Squibb Pharmaceutical Research Institute) was prepared
as a crystalline free acid and supplied as a capsule dosage form for oral administration.
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BMS-193884 (50, 100 or 200 mg) or matching placebo capsules (Bristol-Myers
Squibb Pharmaceutical Research Institute) were administered orally in Protocols 2 and
3, according to the study randomisation schedule, administration was double-blind.
9.2.3 Measurements
Forearm Blood Flow
The response to brachial artery infusion was assessed in both forearms by
measurement of blood flow using venous occlusion plethysmography, as described
previously (Strachan, et al., 1998; Webb, 1995). Venous occlusion plethysmography
was performed using a dual channel strain gauge plethysmograph (DE Hokanson Inc,
Bellevue, WA, USA). Recordings of forearm blood flow were made over 3 min
periods at 10 min intervals throughout intra-arterial infusions.
Systemic Hemodynamics
Hemodynamic recordings were made before (Protocols 2 & 3) and at 2 and 4 hours
after (Protocol 3) oral drug administration, and then at regular intervals throughout the
intra-arterial infusions (Protocols 1, 2 & 3).
Blood pressure and heart rate were measured in the non-infused arm using a well-
validated semiautomated non-invasive method (Takeda UA 751 sphygmomanometer,
Takeda Medical Inc., Tokyo, Japan.) (Wiinberg, et al., 1988). Blood pressure is
presented as mean arterial pressure (MAP; diastolic blood pressure + 1/3 pulse
pressure). During intra-arterial infusions, blood pressure was measured immediately
after forearm blood flow measurements to avoid any effect of the venous congestion
caused by this procedure on these measurements.
Cardiac output (CO) and stroke volume (SV) were recorded by a well validated non¬
invasive bioimpedance technique (NCCOM3; BoMed Medical Manufacturer Ltd,
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Irvine, California, USA) (Thomas, 1992). Total peripheral vascular resistance (TPVR)
was calculated as MAP divided by CO and expressed in arbitrary units.
Blood Sampling
Blood samples for assay of ET-1 and BMS-193884 and its metabolites were obtained,
within 30 min of the start and at the end of the ET-1 infusion, via an 18 SWG cannula
sited in the non-infused arm (Protocols 2 & 3). In brief, 10 ml samples were collected
into sterile EDTA tubes (K3 EDTA, Vacutainer, Becton Dickinson Vacutainer
Systems, Europe) centrifuged immediately at 1000 g for 15 min (BMS-193884 assay)
or 20 min (ET-1 assay) and stored in plain tubes at -80°C prior to assay.
Endothelin-1 and big ET-1 were determined by standard radioimmunoassay (Peninsula
Laboratories Europe), as described previously (Hand, et al., 1999). Concentrations of
BMS-193884 and its metabolites, BMS-205868 and BMS-212442, were determined
by a well validated standard liquid chromatography/mass spectrometry method
(Unpublished data2: Eades DM. To develop an LC/MS/MS method for the quantitative
determination of BMS-193884 and two of its metabolites in various matrices. AAPS
Proceedings, 1997. AAPS Meeting, November 1, 1997).
Additional blood samples were taken at screening, on admission, prior to discharge
and at the post trial physical examination for standard biochemistry and haematology
assays. Routine urinalysis was carried out at screening and after the trial.
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9.2.4 Study design
Protocol 1 - The local effects of intra-arterial infusion ofET-1 & BMS-193884
Twelve subjects were recruited to a double-blind, randomised 3 way crossover study.
Subjects attended for 3 visits, each separated by 7 days. On separate occasions, in a
random order, subjects received a 60 min intra-arterial infusion of ET-1 alone,
BMS-193884 alone or co-infusion of ET-1 and BMS-193884. BMS-193884 was
administered at a dose level of 5 nmol/min to 6 subjects in the first part of the study
(Part A) and at a dose level of 50 nmol/min to 6 subjects in the second part of the study
(Part B).
Blood pressure, heart rate, cardiac output and stroke volume were measured
immediately before and at 15, 30 and 60 min during the intra-arterial infusions.
Subjects attended the research centre on the morning of each study day and were
discharged at least 5 hours after intra-arterial infusion.
Protocol 2 - The effect oforal administration ofBMS-193884 systemic hemodynamics
and the response to intra-arterial infusion ofET-1 at 12 hours
Eight subjects were recruited to a double-blind, randomised 4 way crossover study.
All subjects attended for 4 visits, each separated by 7 days. The effect of intra-arterial
infusion ofET-1 (5 pmol/min for 120 min) was assessed on separate occasions, 12
hours after oral administration of BMS-193884 (50, 100 or 200 mg) or matched
placebo.
Blood pressure, heart rate, cardiac output and stroke volume were measured
immediately before oral drug administration, 30 min before and immediately before
intra-arterial infusion of ET-1, and at 30, 60 and 120 min after the start of the ET-1
infusion. Blood samples were taken from the non-dominant arm for ET-1 assay
immediately before and 1 hour after the start of the ET-1 infusion and for
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pharmacokinetic assay immediately before, and at the end of, the ET-1 infusion.
Subjects attended the research centre at 4 pm on the evening before oral drug
administration, stayed overnight and were discharged at least 5 hours after intra-arterial
infusion the following day. BMS-193884 or placebo was administered at around 11
pm on the evening of admission. Intra-arterial infusion of ET-1 was timed to start at 10
hours after oral drug administration.
Protocol 3 - The effect oforal administration ofBMS-193884 systemic hemodynamics
and the response to intra-arterial infusion ofET-1 at 24 hours
Eight subjects were recruited to a double-blind, randomised 2 way crossover study.
All subjects attended for 2 visits, each separated by 7 days. The effect of intra-arterial
infusion of ET-1 (5 pmol/min for 120 min) was assessed on separate occasions, 24
hours after oral administration ofBMS-193884 (200 mg) or matched placebo.
Blood pressure, heart rate, cardiac output and stroke volume were measured
immediately before, 2 and 4 hours after oral drug administration, at 30 min before and
immediately before intra-arterial infusion ofET-1, and at 30, 60 and 120 min after the
start of the ET-1 infusion. Blood samples were taken from the non-dominant arm for
ET-1 assay at 2 and 4 hours after oral dosing and immediately before and 1 hour after
the start of the ET-1 infusion and for pharmacokinetic assay immediately before, and at
the end of, the ET-1 infusion. Subjects attended the research centre at 9 pm on the
evening before oral drug administration, were resident for 2 days and nights and were
discharged at least 5 hours after intra-arterial infusion on day 2. BMS-193884 or
placebo was administered at approximately 11 am on the morning after admission.
Intra-arterial infusion of ET-1 was timed to start at 22 hours after oral drug
administration.
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Forearm bloodflow studies (Protocols 1,2 & 3)
Subjects rested recumbent throughout each forearm blood flow study in a quiet
temperature-controlled room (23-25°C). Strain gauges and arm cuffs were applied and
the brachial artery cannula was sited in the non-dominant arm. Saline (0.9%) was
infused for at least 30 min, during which 3 measurements of forearm blood flow were
made before the active intra-arterial infusion. Forearm blood flow recordings were
made at 10 min intervals throughout.
9.2.5 Analysis
Forearm bloodflow
Plethysmographic data listings were extracted from data files and forearm blood flows
calculated for individual venous occlusion cuff inflations using a template spreadsheet
(Excel 5.0; Microsoft Ltd, Wokingham, UK). Because wrist cuff inflation results in a
transient forearm vasoconstriction, recordings made in the first 60 sec after wrist cuff
inflation were not used for analysis. Blood flow in both forearms was obtained from
the mean of the last 5 consecutive recordings of each measurement period. Baseline
blood flow was taken as the last measurement during the saline infusion, before the
start of the ET-1 infusion.
Forearm blood flow results are expressed as the percentage change from baseline in the
ratio of blood flow between the infused and non-infused arms (Benjamin, et al., 1995;
Strachan, et al., 1998; Webb, 1995). Data from the active intra-arterial infusion were
examined by repeated-measures analysis of variance (ANOVA).
Systemic hemodynamics
Hemodynamic results are expressed as maximum placebo corrected percentage
changes from baseline (Haynes, et al., 1996). Statistical analysis was performed on
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untransformed data with cardiac function (bioimpedance method), heart rate and blood
pressure data examined by repeated-measures analysis of variance (ANOVA).
Plasma ET-1
Plasma concentrations of ET-1 are represented as absolute change from predose
(pg/ml) with statistical significance assessed by paired f-test.
Pharmacokinetic assay ofBMS-193884 & metabolites
Plasma concentrations of BMS-193884, BMS-205868 and BMS-212442 are
represented as absolute change from predose (ng/ml). No statistical analysis was
performed on the data.
All results are expressed as mean ± standard error of the mean (SEM). Data analysis
was performed using an Excel data analysis package (Excel 5.0; Microsoft Ltd,
Wokingham, UK). For ANOVA comparisons, treatment and subject were the factors
and the p values are for treatment comparisons over all timepoints. Statistical
significance was taken at the 5% level.
9.3 Results
Twenty two subjects (mean age 37 ± 2 yrs), completed the study; 12 subjects
completed Protocol 1, 7 subjects completed Protocol 2, and 8 subjects completed
Protocol 3. Five subjects participated in both Protocol 1, in which they received only
locally active doses of study drugs, and Protocol 3, with 6-12 weeks between then-
last study visit for Protocol 1 and their first dosing day for Protocol 3. Four subjects
were withdrawn from Protocol 2; 1 subject was withdrawn as a result of adverse
events judged to be unrelated to study drug administration, 3 subjects were withdrawn
because of technical difficulties with arterial cannulation. Three of the subjects
withdrawn from Protocol 2 were replaced.
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There were no serious or unexpected adverse events and no significant changes in
safety evaluations. Headache was the most commonly reported adverse event thought
to be related to study drug administration with 23 reported events (from 16 subjects)
on active treatment and 2 (from 2 subjects) on placebo treatment. Other events possibly
related to active drug administration, but less frequently reported, were facial flushing
(3 events, 3 subjects: 2 on active treatment), drowsiness (2 events, 2 subjects: 2 on
active treatment) and nausea and vomiting (4 events, 3 subjects: 2 on active treatment).
Protocol 1 - The local effects of intra-arterial infusion of ET-1 & BMS-
193884
There was no significant change in blood pressure and heart rate, or in blood flow
measured in the non-infused arm, at the end of intra-arterial infusions, confirming that
any drug effects were confined to the infused arm (Table 9.1).
Forearm bloodflow
There was significant local vasoconstriction, indicated by a reduction in the ratio of
forearm blood flow, in response to intra-arterial infusion of ET-1 in both Part A and
Part B of the study (p<0.0001 both parts) (Figure 9.1). Intra-arterial infusion of BMS-
193884 (5 nmol/min) attenuated the constrictor response to ET-1 (p<0.0001) and had
no significant vasodilator effect when infused alone (p=0.7) (Figure 9.1A). At the
higher dose of 50 nmol/min, BMS-193884 abolished the constrictor response to ET-1
(pcO.OOOl) and caused vasodilatation when infused alone (p=0.02) (Figure 9. IB).
162
Figure 9.1 Response of forearm blood flow to local intra-arterial infusion of
ET-1(5 pmol/min) alone, ET-1 co-infused with BMS-193884 (5 nmol/min, Part A; 50
nmol/min, partB) and BMS-193884 alone: ET-1, closed circles; BMS-193884 alone,
closed squares; ET-1 + BMS-193884, open circles. Part A results shown in Figure
1A, Part B results shown in Figure IB. Responses are expressed as mean % change in
forearm blood flow ratio ± SEM. ET-1 caused significant forearm vasoconstriction,
which was attenuated during co-infusion with BMS-193884 (5 nmol/min; p<, n=6 and
50 nmol/min; p<0.0001, n=6). BMS-193884 (50 nmol/min) caused local
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Protocol 2 - The effect of oral administration of BMS-193884 systemic
hemodynamics and the response to intra-arterial infusion of ET-1 at 12
hours
There was no significant change in blood pressure and heart rate, or in blood flow
measured in the non-infused arm, at the end of intra-arterial infusions, confirming that
any drug effects were confined to the infused arm (Table 9.2).
Forearm bloodflow
Forearm vasoconstriction to intra-arterial infusion of ET-1 was slightly attenuated after
oral administration of BMS-193884 (200 mg) (p<0.01; Figure 9.2A). In contrast,
there was no significant effect on ET-1 vasoconstriction after administration of
BMS-193884 (50 or 100 mg; Table 9.2).
Systemic hemodynamics
Mean arterial pressure did not alter significantly after administration of BMS-193884 at
any dose, with the exception of BMS-193884 50 mg (5 ± 6%, p=0.02; Table 9.3).
There were small, changes in cardiac function, indicative of systemic vasodilatation,
after administration of BMS-193884 (200 mg) when compared with placebo. Although
there was no significant change in stroke volume (1 ± 7%, p=0.3), cardiac output
increased (11 ± 7%, p=0.01) and there was a reduction in total peripheral vascular
resistance (-14 ± 9%, p=0.03) up until 12 hours after oral dosing with BMS-193884
(200 mg) (Figure 9.3). There was no significant change in any of the systemic
hemodynamic parameters after administration of BMS-193884 100 mg (Table 9.3). In
contrast, there were systemic changes after administration of BMS-193884 50 mg
(stroke volume: -10 ± 4%, p=0.03; cardiac output: -8 ± 6%, p=0.003; total peripheral
vascular resistance: 16 ± 9%, p=0.0004; Table 9.3). There were no significant
systemic hemodynamic changes after placebo administration (Table 9.3).
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Plasma ET-1
There was no significant change in plasma ET-1 concentrations for any of the
treatments compared with placebo (p>0.3, at 10 and 11 hours; Table 9.4).
Pharmacokinetic assay ofBMS-193884 & metabolites
Plasma concentrations of BMS-193884 and its metabolites, BMS-205868 and BMS-
212442, increased dose dependently, were higher at 10 than 12 hours after
administration (Table 9.5) and were not detected after placebo administration.
Protocol 3 - The effect of oral administration of BMS-193884 systemic
hemodynamics and the response to intra-arterial infusion of ET-1 at 24
hours
There was no significant change in blood pressure and heart rate or in blood flow,
measured in the non-infused arm, during intra-arterial infusion, confirming that any
effects of intra-arterial infusion were confined to the infused arm (Table 9.2).
Forearm bloodflow
There was significant vasoconstriction in response to intra-arterial infusion of ET-1
after placebo administration (-42 ± 5%, p<0.0001). The response to intra-arterial
infusion of ET-1 was significantly attenuated after oral administration of BMS-193884






































































































































































































Figure 9.2 Response of forearm blood flow to local intra-arterial infusion of ET-1
(5 pmol/min) 10-12 hours after oral administration of BMS-193884 (200 mg) or
placebo, Protocol 2: placebo, closed circles; BMS-193884 (200mg), open circles; and
22 - 24 hours after oral administration of BMS-193884 (200 mg) or placebo, Protocol
3: placebo, closed circles; BMS-193884 (200 mg) open circles. Protocol 2 results
shown in Figure 2A, Protocol 3 results shown in Figure 2B. Responses are expressed
as mean % change in forearm blood flow ratio ± SEM. ET-1 caused significant
forearm vasoconstriction, which was attenuated after oral dosing with BMS-193884
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Mean arterial pressure did not alter significantly after administration of BMS-193884
(Figure 9.3). There were small changes in cardiac function, indicative of systemic
vasodilatation, after administration of BMS-193884 (200 mg) when compared with
placebo: stroke volume and cardiac output increased (6 ± 7%, p<0.001 and 14 + 7%,
p<0.0001 respectively) and there was a reduction in total peripheral vascular resistance
(-12 ± 7%, p<0.0001) 24 hours after oral dosing with BMS-193884 (200 mg) (Figure
9.3). There were no significant changes in systemic hemodynamics after placebo
administration (Table 9.3).
Plasma ET-1
There was no significant change in plasma ET-1 concentrations after treatment with
BMS-193884 compared with placebo (p>0.1, at 22 and 23 hours; Table 9.4).
Pharmacokinetic assay ofBMS-193884 & metabolites
Plasma concentrations of BMS-193884, BMS-205868 and BMS-212442 were barely
detectable (<10 ng/ml) at 24 hours and were not detected after placebo administration.
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Figure 9.3 Systemic hemodynamic response (mean arterial pressure, heart rate,
stroke volume, cardiac output, total peripheral vascular resistance) after oral
administration of BMS-193884 (200 mg): Protocol 2, open circles; Protocol 3, closed
circles. Responses are expressed as placebo corrected mean % change ± SEM. Oral
administration of BMS-193884 (200 mg) caused systemic vasodilatation, indicated by
a reduction in total peripheral vascular resistance at 12 (-14 ± 9%, p=0.03; n=7) and
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We have demonstrated vasoconstriction in the forearm vascular bed in response to
infusion of locally active doses of ET-1 (5 pmol/min), consistent with previous results
(Ferro, et al., 1997; Haynes, et al., 1996; Haynes and Webb, 1994; Strachan, et al.,
1998). Using this model to assess the efficacy of endothelin receptor antagonists, we
have shown that the ETA receptor selective antagonist BMS-193884 attenuates ET-1
mediated constriction in the forearm vascular bed, when given locally or systemically,
with the oral formulation demonstrating small effects for up to 24 hours.
Consistent with previous results with the ETA receptor selective antagonist BQ-123
(Haynes and Webb, 1994), local forearm vasodilatation was demonstrated following
intra-arterial infusion of BMS-193884 alone and, to a lesser degree, during co-infusion
with ET-1, confirming the importance of endogenous ET-1 in the maintenace of
vascular tone and indicating the therapeutic potential of these compounds as vasodilator
treatments. Similarity, in addition to attenuating exogenous ET-1 mediated increases in
forearm vascular tone, oral administration of BMS-193884 (200 mg) caused modest
but significant systemic vasodilatation in healthy volunteers, similar to previous results
with the mixed ETA/ETB receptor antagonist TAK-044 (Haynes, et al., 1996). This
vasodilatation appeared to be dose-dependent and was clearer with observation over 24
rather than 12 hours. This may be related to the difference in the study design and the
timing of drug administration and, therefore the difference in timing of predose and
post dose assessments between protocols.
Plasma concentrations of ET-1 have been shown to increase after administration of
ETB receptor selective antagonists (Cowburn, et al., 1998; Fukuroda, et al., 1994;
Gratton, et al., 1997; Strachan, et al., 1999) and mixed ETA/ETB receptor antagonists
(Haynes, et al., 1996; Weber, et al., 1996) but not after adminstration of ETA receptor
selective antagonists (Ohnishi, et al., 1998; Spratt, et al., 1999), consistent with
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clearance of ET-1 mediated by the ETB receptor. In the current study we found no
increase in plasma ET-1 concentrations after administration of BMS-193884,
suggesting that its actions are predominantly mediated via the ETA receptor in the
current dose range.
As expected, plasma concentrations of BMS-193884 and its metabolites increased dose
dependently and were higher at 12 hours than at 24 hours after oral drug
administration, with levels at 24 hours barely detectable. Interestingly, although BMS-
193884 and metabolite concentrations were almost undetectable at 23 hours post
administration, attenuation of the vasoconstrictor response to ET-1 was still detected.
This apparent dissociation between pharmacokinetic levels and pharmacodynamic
effects has been described with other endothelin antagonist compounds (Haynes, et
al., 1996). However, although reported plasma levels of BMS-193884 were less than
10 ng/ml (2 ± 1 ng/ml), the IC50 binding for human recombinant ETA receptors is 1.4
nmol/L or 0.6 ng/ml. Therefore, although the plasma levels of the compound were
reduced at 23 hours, the drug concentrations reached appeared to be active in terms of
receptor blockade.
There were no serious or unexpected adverse events after administration of
BMS-193884 in the current study. Headache, generally mild to moderate, was the
most commonly reported event, and was effectively treated with paracetamol.
Headaches are common with acute administration of endothelin receptor antagonists to
healthy volunteers and most likely due to their vasodilator effects, perhaps through
increased nitric oxide generation (Verhaar, et al., 1998).
A number of ETA receptor selective and mixed ETA/ETB receptor antagonists are
currently being investigated in clinical trials. It is unclear at present whether ETA
receptor selective or mixed ETA/ETB receptor antagonists will offer greater therapeutic
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benefit. However, from our results in healthy volunteers (Strachan, et al., 1999;
Verhaar, et al., 1998) and from results in animal models (Gratton, et al., 1997), it
would appear that selective ETA receptor antagonists may provide greater vasodilatation
in some circumstances by allowing blockade of the constrictor effects of the ETA
receptor while preserving the vasodilator effects of the ETB receptor. Indeed, in heart
failure patients, selective ETB receptor antagonism results in both local (Love, et al.,
1996) and systemic vasoconstriction (Cowburn, et al., 1998). In contrast, in patients
with hypertension vasodilatation has been described in response to selective ETB
receptor antagonism (Cardillo, et al., 1999). Therefore, in this case, mixed ETA/ETB
receptor antagonists may be more effective. Further investigation in patient groups is
required to assess the acute and chronic effects of selective ETA receptor antagonists
and mixed ETA/ETB receptor antagonists and to assess which of these approaches
offers the greater therapeutic advantage in the clinical setting.
In summary, using the forearm vasoconstrictor response to exogenously applied ET-1
as a model (Ferro, et al., 1997; Haynes, et al., 1996; Haynes and Webb, 1994;
Strachan, et al., 1998) we have shown that the ETA receptor selective antagonist BMS-
193884 is effective in blocking ET-1 mediated increase in vascular tone in healthy
volunteers, with small effects evident 24 hours after oral adminstration. We have also
shown modest systemic vasodilator effects after oral administration of BMS-193884,
again evident 24 hours after oral adminstration of 200 mg, indicating its potential as a
vasodilator treatment for further investigation in clinical trials. More pronounced
effects may have been evident with higher dose levels. The current study provides
further information on the in vivo activity and duration of effect of BMS-193884, this




Unpublished data1: Murugesan N et al. Biphenylsulfonamide endothelin receptor
antagonists. 2. Discovery of 4'-Oxazolyl biphenylsulfonamides as a new class of
potent, highly selective ETA antagonists. Bristol-Myers Squibb Pharmaceutical
Research Institute, Princeton, NJ 085343-5400, submitted for publication at time of
submission of current manuscript.
Unpublished data2: Eades DM. To develop an LC/MS/MS method for the quantitative
determination of BMS-193884 and two of its metabolites in various matrices. AAPS
Proceedings, 1997. AAPS Meeting, November 1, 1997.
177
Chapter 10
Systemic blockade of the ETB receptor increases peripheral vascular
resistance in healthy men.
Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men.




The importance of endothelin-1 (ET-1) as a mediator of basal vascular tone in vivo in
man has been described in earlier chapters, by demonstration of local (Haynes, et al.,
1996; Haynes and Webb, 1994; Verhaar, et al., 1998 and Chapter 6) and systemic
(Haynes, et al., 1996, and Chapter 8 and Chapter 9) vasodilatation in response to
endothelin receptor antagonism. The potent vasoconstrictor effects of ET-1 (Clarke, et
al., 1989; Yanagisawa, et al., 1988), combined with the increased plasma
concentrations of ET-1 associated with cardiovascular diseases including heart failure
(Pacher, et al., 1993) and renal failure (Koyama, et al., 1989), provide strong
evidence to support a functional role for ET-1 in the development and maintenance of
the increased peripheral vascular resistance associated with these conditions.
Local vasoconstriction to ETB receptor agonists has been described in healthy
volunteers (Hand, et al., 1999; Strachan, et al., 2000; Strachan, et al., 1995; and
Chapter 3 and Chapter 4) and in patients with heart failure (Love, et al., 1996).
However, more recently, vasoconstriction following local administration of the
selective ETB receptor antagonist BQ-788 (Ishikawa, et al., 1994) has been described
in healthy volunteers (Verhaar, et al., 1998; Chapter 6) and in patients with heart
failure (Love, et al., 2000). The results with antagonists are particularly important as
they indicate that the endogenous effect of vascular ETB receptor stimulation in vivo
favours vasodilatation. Indeed, hypertension has been described following
administration of systemic doses of the selective ETB receptor antagonists A192621 in
rats and BQ-788 in rabbits in vivo, as well as in rescued ETB knockout mice (Gratton,
et al., 1997; Webb, et al., 1998). The vasoconstrictor effects of ETB antagonism may
result from direct blockade of an endothelial ETB receptor mediated dilator tone or
indirectly from displacement of endogenously generated ET-1 to vasoconstrictor ETA
receptors, or as a result of reduced clearance of ET-1 by vascular ETB receptors.
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Confirmation of the balance of the vascular effects mediated by the ETB receptor in
different circumstances is important in understanding the physiology of the endothelin
system, and in determining whether selective ETA receptor antagonists or combined
ETa/ETb receptor antagonists are likely to be more effective vasodilator agents in the
clinical setting.
As a further step in understanding the contribution of the ETB receptor to the
maintenance of vascular tone in vivo, the systemic hemodynamic effects of BQ-788 in
healthy male volunteers were investigated.
10.2 Methods
10.2.1 Subjects
Five healthy male subjects between 18 and 50 years of age were recruited to the study,
under the standard conditions listed in Chapter 2.
10.2.2 Drugs
BQ-788 (Clinalfa AG, Laufelfingen, Switzerland) was used as a selective ETB receptor
antagonist, the dose range (3-300 nmol/min) used in the current study was selected
from previous work investigating the local effects of BQ-788 in the forearm circulation
(Chapter 10) and from a dose ranging pilot study in which 2 volunteers were studied
at each dose level (data not shown), see Chapter 2.
BQ-788 was dissolved in physiological saline (0.9%; Baxter Healthcare, Ltd). Saline
(0.9%; Baxter Healthcare, Ltd) was administered as placebo. BQ-788 and placebo
were administered single blind and infused intravenously via an 18 SWG cannula sited
in the left antecubital vein at a constant rate for 15 minutes. All solutions were prepared




Hemodynamic recordings were made at 10 minute intervals from 30 minutes predose
until 1 hour following the start of the infusion, with an additional blood pressure
measurement at 15 minutes corresponding with the end of the infusion, and then at 30
minute intervals until 2 hours and hourly until 4 hours following the start of the
infusion.
Blood pressure and heart rate were recorded in duplicate at each timepoint, as
described in Chapter 2, and averaged for each timepoint. Cardiac output and stroke
volume were recorded by a well validated non-invasive bioimpedance technique
(NCCOM3; BoMed Medical Manufacturer Ltd, Irvine, California, USA). As described
in Chapter 2, parameters were corrected for body surface area and described as cardiac
index (CI, 1/min/m2) and stroke index (SI, ml/m2) (Haynes, et al., 1996).
Plasma ET-1 and Big ET-1
Blood samples were obtained for assay of ET-1 and big ET-1; predose and at 5, 15, 60
and 240 minutes post dose, via an 18 SWG cannula sited in the non-infused arm, as
described in Chapter 2.
Blood samples were also taken on admission and prior to discharge for safety tests
(sodium, potassium, creatinine, urea, alkaline phosphatase, gamma-glutamyl
transpeptidase, hemoglobin and white cell count).
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Table 10.1 Mean arterial pressure (MAP), heart rate (HR), cardiac output (CO),
stroke volume (SV), total peripheral vascular resistance (TPVR) predose and at 60 min





Predose 80±3 81±2 79±2 80+2
60 min 80±3 81±2 79+2 82±1
HR (bpm)
Predose 53±2 55±2 51±2 54±3
60 min 51+3 52±1 48±1 53±4
CI (1/min/m2)
Predose 2.6+0.2 2.8+0.2 2.7+0.2 2.9+0.3
60 min 2.6+0.2 2.8+0.2 2.5+0.2 2.5+0.4
SI (ml/min/m2)
Predose 49+3 51+3 52+4 53+3
60 min 48+2 51+3 51+4 49+5
TPVRI
(Arbitrary units)
Predose 31+2 30+2 29+2 29+2
60 min 32+1 30+2 32+2 35+4
1 O A
1 O-T
Figure 10.1 Placebo corrected mean percentage change in hemodynamic
parameters; mean arterial pressure (MAP), heart rate (HR), cardiac index (CI), stroke
index (SI), total peripheral vascular resistance (TPVRI) following a 15 minute
intravenous infusion of BQ-788 or saline placebo in five subjects: closed circles,
BQ-788 (300 nmol/min); open circles, BQ-788 (30 nmol/min); shaded diamonds,
BQ-788 (3 nmol/min). There was no change in MAP, but there was a reduction in HR,
CI and SI, and an increase in TPVRI following administration of BQ-788 (300
nmol/min).
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Plasma ET-1 and Big ET-1
There was no significant difference between predose plasma ET-1 concentrations for
any of the treatments (range of baseline mean values 4.4-4.9 pg/ml). Plasma ET-1
concentration increased significantly following administration of BQ-788 (from
4.6±0.8 to 8.4±1.8 pg/ml at 15 minutes with 300 nmol/min, p=0.02) (Figure 10.2) but
not during treatment with the lower doses of BQ-788 or placebo (Table 10.2). In
contrast, concentrations of big ET-1 did not change significantly with treatment.
Figure 10.2 The change in plasma ET-1 concentrations (pg/ml) following a 15
minute intravenous infusion of BQ-788 or saline placebo in five subjects: solid
columns, BQ-788 (300 nmol/min); shaded columns, BQ-788 (30 nmol/min); hatched
columns, BQ-788 (3 nmol/min); open columns, placebo. Plasma ET-1 concentrations




5 min 15 min 60 min 240 min
Time (min)
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Table 10.2 Mean plasma concentrations of ET-1 (pg/ml), predose and at 60 min








Predose 4.4±1.0 4.8±0.8 5.2±1.0 4.6±0.8
60 min 4.4±0.5 4.4±0.7 4.8±1.0 6.3±1.4
10.4 Discussion
Substantial systemic vasoconstriction, associated with a reduction in heart rate and
cardiac index but no change in blood pressure, has been demonstrated in the current
study in response to administration of the selective ETB receptor antagonist BQ-788 in
healthy men. Consistent with earlier work in the forearm circulation (Verhaar, et al.,
1998; Chapter 6) these observations are highly suggestive of the overall effect of
endogenous ETB receptor mediated vascular tone favouring vasodilatation. An
alternative explanation for the hemodynamic effects is that BQ-788 is directly
negatively chronotropic and that peripheral effects are indirect. However, this is
unlikely given the local vasoconstriction following local infusion of BQ-788 (Verhaar,
et al., 1998; Chapter 6), and the lack of evidence of an important positive chronotropic
and inotropic role of the cardiac ETB receptor (Zhu, et al., 1997). Although peripheral
resistance was substantially increased, blood pressure was unaffected because of a
decrease in heart rate which was probably reflex in origin. Increases in plasma ET-1,
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but not big ET-1, concentrations were also demonstrated following ETB receptor
blockade, consistent with reduced clearance of ET-1 by the ETB receptor (Fukuroda, et
al., 1994). All of these effects were prominent with BQ-788 at the highest dose but
were not clearly seen at lower doses.
The vasoconstrictor effects of ETB receptor antagonism may result directly from
blockade of the vasodilator effects of the endothelial ETB receptor or indirectly from
displacement of endogenously generated ET-1 from ETB receptors to unoccupied ETA
receptors. It is unlikely that these effects are mediated by non-selective ETA/ETB
receptor blockade because they are the opposite of those found with selective ETA
receptor antagonists in healthy subjects (Spratt, et al., 1999) and patients with heart
failure (Cowburn, et al., 1998), and of those found with combined ETA/ETB receptor
antagonists in healthy subjects (Haynes, et al., 1996). Clearly, the indirect effects of
ET-1 on ETa receptors are more relevant with administration of selective ETB
antagonists than with non-selective ETA/ETB receptor antagonists, because in this latter
situation the constrictor ETA receptor is also blocked. Indeed, vasodilator effects have
been demonstrated with both selective (Cowburn, et al., 1998; Haynes and Webb,
1994; Verhaar, et al., 1998) and non-selective (Haynes, et al., 1996; Kiowski, et al.,
1995) endothelin receptor antagonists in humans and the non-selective ETA/ETB
antagonist, bosentan, has also been shown to effectively lower blood pressure in
patients with hypertension (Krum, et al., 1998). However, direct comparison of the
effects of selective and non-selective endothelin receptor antagonism will be important
in assessing the relative contribution of each receptor subtype to the vascular effects of
ET-1.
Forearm vasodilatation in response to local ETA receptor antagonism with BQ-123 has
been demonstrated previously (Haynes, et al., 1994; Verhaar, et al., 1998;
Berrazueta, et al., 1997; Chapter 6]. In the presence of BQ-788 in healthy volunteers
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this effect was attenuated (Verhaar, et al., 1998; Chapter 6), suggesting that the
overall effect of vascular ETB receptor stimulation by endogenous ET-1 is
vasodilatation. This attenuation of BQ-123 mediated vasodilatation by BQ-788
suggests that the vasoconstrictor effect of ETB receptor blockade is not mediated by
displacement of ET-1 onto the ETA receptor, but is due to direct blockade of ETB
mediated vasodilator tone. Using a 'nitric oxide clamp' technique, it has also been
shown that the vasodilator response to BQ-123 is in part mediated by nitric oxide
(Verhaar, et al., 1998) and, therefore, probably mediated by the endothelial ETB
receptor. The dilator response to high dose infusion of ETB receptor selective agonist
also appears to be mediated through generation of nitric oxide (Chapter 5). Loss of
endothelial cell ETB mediated vasodilator tone may occur in cardiovascular diseases,
such as essential hypertension and hypercholesterolaemia, in which there is associated
endothelial dysfunction (Casino, et al., 1995; Panza, et al., 1995). Here, because of a
reduced capacity for ETB receptor mediated, nitric oxide dependent dilatation, selective
ETa receptor antagonists may be less effective. Indeed, vasodilatation has been
described in response to BQ-788 in patients with hypertension (Cardillo, et al., 1999),
indicating that in this patient group, the dilator effects of the ETB receptor may be less
important than the constrictor effects.
In summary, the results of the current study demonstrate systemic vasoconstriction in
response to acute ETB receptor blockade with the selective ETB receptor antagonist
BQ-788 in healthy men in vivo, indicating that the predominant endogenous effect of
stimulating vascular ETB receptors is vasodilatation. One exciting possibility is that
tonic endogenous ET-1 release, acting via the endothelial ETB receptor, is responsible
for the physiological basal release of nitric oxide. This now needs to be addressed in
clinical studies. Further investigation of the influence of ETB receptor antagonism on
the sympathetic nervous system and renal function are also warranted. In addition,
direct comparison of the effects of chronic administration of selective ETA and
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combined ETA/ETB receptor antagonists are required in patients with cardiovascular
disease, with and without endothelial dysfunction, in order to confirm which of these






The role of the endothelin system in the maintenance of vascular tone has been
investigated in the current series of clinical studies, using local and systemic measures
of vascular tone. In particular, the relative contribution of the ETA and ETB receptor
towards ET-1 mediated vascular tone was investigated.
11.1.1 ETb mediated constriction in capacitance vessels
Constriction in capacitance and resistance vessels was demonstrated in response to
locally active infusion of the non-selective ET receptor agonist ET-1 and the ETB
receptor selective agonists SFTX6c and BQ-3020, supporting a potential role for the
ETb receptor in ET-1 mediated vasoconstriction. In addition, the demonstration of
vasoconstriction in response to SFTX6c and the structurally distinct agonist BQ-3020
addressed concerns over the validity of SFTX6c as a pharmacological probe for the
ETb receptor in clinical studies.
Constriction to ET-1 but not SFTX6c was attenuated during co-infusion of the ETA
receptor selective antagonist BQ-123 in the hand vein. In contrast, constriction to
SFTX6c but not ET-1 was attenuated during co-infusion of the ETB receptor selective
antagonist BQ-788. These results suggest that while the constrictor effects of ETB
receptor agonists are mediated through the ETB receptor, the ETB receptor does not
play a direct role in ET-1 mediated vasoconstriction.
11.1.2 ETb mediated vasoconstriction and vasodilatation in
resisitance vessels
Consistent with the effects described in the hand vein, local vasoconstriction in
response to locally active infusion of the non-selective ET receptor agonist ET-1 and
the ETB receptor selective agonists SFTX6c and BQ-3020 was demonstrated in
forearm resistance vessels. In addition to the vasoconstrictor effects of ETB receptor
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agonists, the vasodilator response to high dose infusion of the ETB agonist SFTX6c
was investigated. The vasodilator effect was blocked by infusion of the ETB receptor
selective antagonist BQ-788 and the nitric oxide synthase inhibitor L-NMMA, but not
by aspirin or noradrenaline. These results indicate that this vasodilatation was mediated
by the ETB receptor, largely through nitric oxide, but not by prostacyclin, generation.
In this study, the constrictor response to SFTX6c was not affected by infusion of BQ-
788.
11.1.3 Local effects of endothelin receptor antagonists on vascular
tone
Local vasoconstriction was demonstrated in response to locally active infusion of the
ETb receptor selective antagonist BQ-788. Interestingly, both ETA receptor selective
and combined ETA/ETB receptor antagonism resulted in significant forearm
vasodilatation. However, the local vasodilator effects of the ETA receptor selective
antagonist BQ-123 were attenuated in the presence of the selective ETB receptor
antagonist BQ-788. These results confirm the importance of ET-1 in the maintenance
of vascular tone and indicate that, in healthy blood vessels at least, the vasodilator
effects of non-selective ETA/ETB receptor antagonism are less than those of ETA
receptor selective antagonism.
11.1.4 Systemic effects of endothelin receptor antagonists
The forearm vasoconstrictor response to intra-aiterial infusion of ET-1 was assessed in
detail and, using this response as a model, a pharmacologically active dose range for
the non-selective ETA/ETB receptor antagonist MSD L-753,037 and the ETA receptor
selective antagonist BMS-193884 was identified. Both antagonists were effective in
blocking ET-1 mediated vasoconstriction and also demonstrated modest but significant
systemic vasodilator effects.
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In a final evaluation of ETB receptor function, the systemic effects of the ETB receptor
selective antagonist BQ-788 were assessed and significant systemic vasoconstriction
demonstrated, with an increase in peripheral vascular resistance, and a reduction in
cardiac index and stroke index. These results, in the systemic circulation, confirm the
effects of locally active infusion of BQ-788, and provide further evidence that the
balance of effects at the ETB receptor in healthy blood vessels favours vasodilatation.
Administration of the non-selective ETA/ETB receptor antagonist MSD L-753,037 or
the ETb receptor selective antagonist BQ-788 resulted in significant increases in plasma
concentrations of ET-1, suggesting activity at the ETB clearance receptor. In contrast,
there was no increase in plasma concentrations of ET-1 following administration of the
ETA receptor antagonist BMS 193884.
The results of these investigations have provided valuable information on the relative
contribution of the ETA and ETB receptors to the physiological effects of ET-1 in the
vasculature. Despite demonstration of vasoconstriction in response to ETB receptor
agonists, the predominant effect of the vascular ETB receptors in healthy human blood
vessels appears to be vasodilatation. However, it is important to acknowledge the
potential constrictor effects of the increased plasma ET-1 concentrations associated
with ETb receptor antagonism. Further assessment is required both in healthy
volunteers and in patients with cardiovascular disease.
In addition to the assessement of the relative contribution of the ET receptors in the
mediation of vascular tone, the series of studies described in this thesis has developed
and characterised a series of tools for future clinical studies.
11.2 Current research
Many endothelin receptor antagonists have progressed to clinical studies in healthy
volunteers and in patient groups. However, as yet, none have been licensed for clinical
use. Much of the current clinical research has focussed on cardiovascular disease.
11.2.1 Endothelin and vascular tone
The vasodilator effects of endothelin receptor antagonists have been confirmed by a
number of investigators in healthy volunteers (Haynes, et al., 1996; Spratt, et al.,
1999; Strachan, et al., 2000; Verhaar, et al., 2000) and in patients with cardiovascular
disease (Cardillo, et al., 1999; Cowburn, et al., 1998; Love, et al., 2000). In addition
assessment of the forearm blood flow response to intra-arterial infusion of ET-1, as
described in Chapter 7, has allowed identification of pharmacologically active dose
ranges and duration of effect for endothelin receptor antagonists in early phase I
clinical trials (Haynes, et al., 1996; Verhaar, et al., 2000).
The constrictor effects of ETB receptor selective agonists have been confirmed
following local infusion of the endogenous ETB receptor selective agonist, ET-3, in the
dorsal hand vein and forearm resistance vessels of healthy volunteers (Ferro, et al.,
2000). In addition, systemic vasoconstriction has been described following infusion of
ET-3 in patients with heart failure (Cowburn, et al., 1999). However, local (Love, et
al., 2000) and systemic (Cowburn, et al., 1998) vasoconstriction have also been
described in patients with heart failure following infusion of the ETB receptor selective
antagonist BQ-788. These results suggest that, although the ETB receptor may mediate
vasoconstriction directly, the endogenous effects of the ETB receptor in patients with
heart failure appear to favour vasodilatation. In contrast, in patients with hypertension,
vasodilatation has been described in response to infusion of BQ-788 (Cardillo, et al.,
1999), indicating that, in this patient group, the endogenous effects of the ETB receptor
favour vasoconstriction. The effects described in hypertension may be due to the
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recognised endothelial dysfunction in patients with hypertension and consequent
reduction in capacity for endothelial ETB receptor mediated vasodilatation. However,
the dose used in this study (50 nmol/min) is higher than those used in the studies
described in Chapters 4, 5 and 6(1 nmol/min) and vasodilatation could result from
non-selective effects at the ETA receptor in this dose range. It is also important to
recognise that the vasoconstrictor effects of ETB receptor antagonism could result from
increased plasma ET-1, as a result of reduced clearance at the ETB receptor, acting at
the unopposed ETA receptors.
11.2.2 Endothelin: cardiac effects
Endothelin-1 is synthesized, stored and released in the human heart and exerts both
indirect effects, through changes in coronary vascular tone, and direct effects on
cardiac muscle (Russell, et al., 2000; for review ). In contrast to results in rat models
previously described (Garjani, et al., 1995), ET-1 induced arrhythmias in isolated
human cardiac tissue were reduced in the presence of combined ETA/ETB receptor
blockade and not in the presence of ETA receptor selective blockade (Burrell, et al.,
2000). A positive inotropic role for the ETA receptor has been suggested (MacCarthy,
et al., 2000). Further investigation of the endogenous effects of ET-1 on the
contractility of the heart is required.
11.2.3 Endothelin and renal function
The potential therapeutic benefits of endothelin receptor antagonists and the
endogenous effects of ET-1 have been investigated in healthy volunteers using
selective and combined endothelin receptor antagonists. Following administration of
the non-selective ETA/ETB receptor antagonist SB 209670, there was a modest increase
ineffective renal plasma flow (ERPF) indicating that endogenous ET-1 contributes to
resting vascular tone within the kidney. In contrast, selective ETB receptor antagonism
with BQ-788 resulted in an increase in renal vascular resistance in healthy volunteers
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and in patients with renal disease, indicating that the ETB receptor in the renal
vasculature favours vasodilatation (Goddard, et al., 2000) consistent with studies in
systemic circulation (Strachan, et al., 1999).
In contrast to animal models, there were no changes in urinary sodium excretion
following combined or selective ET receptor blockade (Freed, et al., 1999), indicating
that ET-1 does not contribute significantly to sodium transport in resting conditions in
healthy volunteers.
11.2.4 Endothelin receptor antagonists: clinical results
Endothelin receptor antagonists are currently in clinical development, and have shown
potential therapeutic benefits. Although long term clinical studies are ongoing, the
results of these studies are not currently available
Heartfailure
Previous studies have demonstrated additional vasodilator benefits of endothelin
receptor antagonists in patients with heart failure in the presence of existing treatment
with ACE inhibitors (Kiowski, et al., 1995). Recent clinical studies confirmed the
potential of ET receptor antagonists as vasodilator treatments in heart failure
(Cowburn, et al., 1998; Givertz, et al., 2000; Love, et al., 2000; Miyauchi and Goto,
1999; Spieker, et al., 2000). The relative benefits of combined ETA/ETB and ETA
receptor selective antagonists are currently being investigated (Bauersachs, et al.,
2000; Mulder, et al., 2000; Ohnishi, et al., 1998). Although systemic vasoconstriction
has been described in response to the ETB receptor selective agonist ET-3 (Cowburn,
et al., 1999), the overall balance of effects at the ETB receptor appears to favour
vasodilatation (Cowburn, et al., 1998; Love, et al., 2000), indicating that ETA receptor
selective antagonists may offer greater therapeutic benefit as vasodilators. Indeed,
upregulation of ETA receptors in failing human myocardium has been described (Zolk,
197
et al., 1999) and, in a rat model, ETA receptor selective antagonism shows greater
improvement in endothelial vasomotor dysfunction than combined ETA/ETB receptor
antagonism (Bauersachs, et al., 2000). In a dog model of heart failure, both combined
ETa/ETb and ETA receptor selective antagonism offered similar haemodynamic benefits
but the ETa receptor selective antagonist showed greater benefits in renal function
(Ohnishi, et al., 1998), in this case, providing an additional benefit over combined
ETa/ETb receptor antagonism. Interestingly, in the same study, plasma aldosterone
concentrations were reduced following combined ETa/ETb receptor antagonism. This
may be of benefit in long term treatment of heart failure by preventing volume retention
by suppressing aldosterone secretion. Despite the differences described between
combined and selective receptor antagonism, a recent long term study in a coronary
ligation rat model, chronic administration of both ETA receptor selective and combined
ETa/ETb receptor antagonists improved systemic haemodynamics to a similar degree
(Mulder, et al., 2000). However, combined ETa/ETb receptor blockade reduced heart
rate, which may be of benefit in long term treatment of heart failure.
These data support the use of ET receptor antagonism in the treatment of heart failure.
Further investigation of the long term benefits of ET receptor antagonism and
comparison of the relative benefits of combined and selective ET receptor antagonists
is required.
Hypertension
Endothelin receptor antagonism may also be of benefit in the treatment of
hypertension. Treatment with the combined ETA/ETB receptor antagonist bosentan has
been shown to lower blood pressure in patients with essential hypertension (Krum, et
al., 1998) and local vasodilatation has been described, in patients with hypertension,
following acute infusion of the ETA receptor selective antagonist BQ-123 and
co-infuson of BQ-123 and the ETB receptor selective antagonist BQ-788 (Cardillo, et
i no
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al., 1999). Interestingly, local vasodilatation was described in patients with
hypertension following infusion of BQ-788 alone (Cardillo, et al., 1999) and contrasts
with the vasoconstriction described in healthy volunteers (Cardillo, et al., 1999;
Strachan, et al., 1999; Verhaar, et al., 1998) and in patients with heart failure (Love, et
al., 2000). This seems to indicate that, in patients with hypertension, the balance of
effects of the ETB receptor favours vasoconstriction. This may result from the
endothelial dysfunction described in this patient group and their reduced capacity for
nitric oxide dilatation (Panza, et al., 1995). However, it may result from non-selective
effects of BQ-788 in the dose range used.
Interestingly, vascular smooth muscle cell ETB receptors have been shown to be more
abundant in human atherosclerotic lesions (Fan, et al., 2000), indicating that here ETB
receptor mediated vasoconstriction may be more important.
Renalfailure
ET receptor antagonists have demonstrated potential clinical benefits in the treatment of
renal failure (Strachan and Webb, 1998). Recent studies have confirmed this potential
in healthy volunteers (Freed, et al., 1999), and in patients with renal disease
(Goddard, et al., 2000). However, despite evidence to suggest involvement of ET-1
in the pathophysiology of radiocontrast nephrotoxicity and potential therapeutic
benefits ofET receptor antagonism in an animal model (Cantley, et al., 1993), a recent
study described exacerbation of radiocontrast nephrotoxicity following combined
ETa/ETb receptor antagonism in patients undergoing cardiac angiography (Wang, et
al., 2000). Selective ETA receptor antagonists may be of benefit for this indication as
ETB mediated vasodilatation and ET-1 clearance would be preserved. Further




Plasma ET-1 concentrations are increased following myocardial infarction and are
strongly related to mortality (Omland, et al., 1994) and endothelin receptor antagonists
have been shown to reduce expression of molecular markers of failing myocardial
function (Sakai, et al., 2000). Upregulation of smooth muscle ETB receptors that
modulate ETA mediated constriction have been described following myocardial
infarction in a rat model (Gray, et al., 2000). Therefore, it is possible that
administration of ETA receptor selective antagonists may be ofmore benefit in reducing
constriction to increased plasma concentrations of ET-1 if myocardial infarction
progresses to heart failure (Gray, et al., 2000).
Subarachnoid haemorrhage
A therapeutic role for ETB receptor selective antagonism has been described in reducing
cerebral vasospasm in a rabbit subarachnoid haemorrage model (Zucarello, et al.,
1998). However, the systemic haemodynamic effects of ETB receptor selective
antagonists (Cowburn, et al., 1998; Strachan, et al., 1999) must also be considered if
this approach were to be considered in a clinical setting.
11.3 Future directions
11.3.1 The role of the ETB receptor in ET-1 mediated vascular
tone
Although the results of the studies described in Chapter 3, Chapter 4 and Chapter 5
indicate that the ETB receptor mediates constriction under direct stimulation from ETB
receptor agonists, the functional significance of this constriction remains unclear.
Indeed, the vasoconstrictor effects of ETB receptor antagonists in healthy volunteers
appear to contradict a direct role for ETB mediated constriction in ET-1 mediated
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vascular tone. These studies require co-infusion of agonists and antagonists and then-
results can be difficult to interpret due to the additive effects of each agent on vascular
tone and possible local increases in ET concentration following antagonism at the ETB
receptor. Therefore, the relative contribution of the ETA and the ETB receptor to the
constrictor and dilator effects of ET receptor agonists described in Chapter 3 and
Chapter 5, may be clearer if systemic administration of ET receptor antagonists was
combined with local infusion of ET receptor agonists, similar to the studies described
in Chapter 8 and Chapter 9.
Future studies investigating the dilator and constrictor effects of local infusion of ETB
receptor selective agonists following systemically active selective and combined
ETa/ETb receptor antagonism would help address these difficulties, and also provide a
cleaner model with which to assess the role of each receptor in the constrictor effects
described with ETB receptor agonists.
11.3.2 Combined ETA/ETB versus selective ETA receptor
antagonism in cardiovascular disease
Recent research has focussed on the potential clinical benefits of endothelin receptor
antagonists in animal models of cardiovascular disease and, latterly, in patient groups.
However, few studies have compared directly the effects of selective ETA and
combined ETA/ETB receptor antagonists. Further investigation of the integrated
cardiovascular effects of selective and non-selective ET receptor antagonists is required
to confirm which approach will be the more effective in the clinical setting.
The results of the studies described in this thesis, in particular in Chapter 10, have
assisted the development of models with which to assess the effects of ET receptor
antagonists in humans in vivo. Indeed, using this methodology, studies investigating
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the acute effects of ET receptor antagonists in patients with heart failure and in patients
with renal disease are ongoing in our research group. Direct comparison of the
integrated effects of endothelin receptor antagonists in cardiovascular disease, both
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A novel S-nitrosothiol (RIG200) causes
prolonged relaxation in dorsal hand veins
with damaged endothelium
Background: Reduced nitric oxide bioavailability caused by endothelial dysfunction or damage is a
contributory factor in the initiation and progression of a number of cardiovascular diseases. Delivery of
exogenous nitric oxide is an attractive therapeutic option, but current agents lack selectivity for areas of
endothelial damage. We tested the hypothesis that a novel nitric oxide donor drug, 2V-(S-nitroso-N-
acetylpenicillamine)-2-amino-2-deoxy-l,3,4,6-tetra-0-acetyl-p-glucopyranose [RIG200], which has selec¬
tive effects in endothelium-denuded isolated arteries in vitro, would exert similar effects in dorsal hand
veins with experimentally damaged endothelium in vivo.
Methods: Venodilator responses to sodium nitroprusside and RIG200 were compared in two groups of
healthy volunteers (age range, 18 to 63 years; n = 7 for each group) in norepinephrine 70% maximum
effective concentration (EC70) preconstricted hand veins with use of the Aellig technique. In this double-
blind study, subjects were randomly assigned to receive either sodium nitroprusside or RIG200 (infusions
of 0.06 and 6 nmol/min into the hand vein) before and 2 days after 15 minutes of local venous irriga¬
tion with distilled water. Endothelial function was assessed in all subjects on both visits with use of the
endothelium-dependent vasodilator acetylcholine (1 nmol/min).
Results: Irrigation of hand veins with distilled water abolished endothelium-dependent dilatation in
response to acetylcholine in both study groups (n = 14) but did not affect the amplitude or duration of
responses to the conventional nitric oxide donor sodium nitroprusside (P = .87; n = 7). However, responses
to RIG200 were significantly prolonged during the washout phase (30 minutes) in veins after water irri¬
gation (P = .02; n = 7).
Conclusion: These studies confirm that RIG200 has prolonged effects in veins with damaged endothelium,
a characteristic that might be exploited therapeutically to target nitric oxide delivery to damaged blood
vessels. (Clin Pharmacol Ther 2000;68:75-81.)
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The vascular endothelium plays a pivotal role in reg¬
ulating blood vessel structure and function through
release of a number of vasoactive mediators. One of
these mediators is nitric oxide, which dilates blood ves¬
sels' 3 and inhibits platelet aggregation,45 platelet
adhesion,6'7 smooth muscle proliferation,8 and mono¬
cyte adhesion.9 Reduced nitric oxide production from
vessels with damaged or dysfunctional endothelium
causes a predisposition to vasospasm and thrombosis10
and has been implicated as an early step in atherogen-
esis.11 Morphologic studies have also indicated that
small areas of endothelial cell erosion are common over
established coronary plaques.12-15 Focal endothelial
denudation associated with atheromatous plaques may
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Fig 1. Structural formulas and full generic names for sodium
nitroprusside (A) and /V-(S-nitroso-/V-acetylpenicillamine)-2-
amino-2-deoxy-l ,3,4,6-tetra-0-acetyl-|3-glucopyranose
(RIG200; B).
stimulate smooth muscle proliferation, alter vasomotor
responses, and facilitate infiltration of activated
macrophages. Although microthrombi are often associ¬
ated with such focal erosion, they are believed to be too
small to directly cause symptoms. However, more gen¬
eralized plaque erosion is now recognized as a frequent
cause of coronary thrombosis.14-15 Delivery of exoge¬
nous nitric oxide is an attractive therapeutic option to
supplement or replace endogenous nitric oxide both in
established atherosclerosis and after percutaneous
transluminal angioplasty for which unavoidable
endothelial damage is a contributory factor in throm¬
bosis and restenosis after the procedure.16 Indeed, sev¬
eral nitric oxide donors have been shown to prevent the
development of thrombosis and hyperplasia in balloon-
injured models,17 and S-nitrosoglutathione inhibits
platelet activation after coronary balloon angioplasty
in humans.18
A number of nitric oxide donor drugs, including
sodium nitroprusside (Fig 1, A) and the organic nitrates,
are already in widespread clinical use, but the value of
these drugs is limited by several factors. Besides the
weak antiplatelet effect of these agents at therapeutic
concentrations,19 prolonged administration of sodium
nitroprusside can lead to cyanide poisoning, and
organic nitrates engender vascular tolerance.20-21 Fur¬
thermore, current drugs cannot be targeted at areas of
endothelial damage and their use can be associated with
systemic hypotension.
Recently, S-nitrosothiols have been recognized as novel
nitric oxide donor drugs that do not appear to engender
vascular tolerance.22-23 We have demonstrated previously
that a novel S-nitrosated glycoamino acid, A-(S-nitroso-
A-acetylpenicillamine)-2-amino-2-deoxy-1,3,4,6-tetra-
O-acetyl-P-glucopyranose (RIG200; Fig 1, B), causes
prolonged, nitric oxide-mediated vasodilatation in rat
femoral arteries only when the endothelium has been
removed, suggesting a selective action of RIG200 in ves¬
sels with damaged endothelium.24 These data suggest that
RIG200 may be a valuable therapeutic agent but, to date,
its clinical pharmacology is unknown.
We tested the hypothesis that RIG200 would cause
sustained relaxation in human hand veins with damaged
endothelium in vivo and that the effect would not be
observed with sodium nitroprusside or with RIG200 in
endothelium-intact hand veins. Selectivity for blood ves¬
sels with damaged endothelium would support the in
vitro data24 and would indicate the potential of com¬
pounds such as RIG200 to protect coronary blood ves¬
sels against spasm after coronary balloon angioplasty.
METHODS
Studies were performed to investigate the effect of
endothelial damage induced by irrigation with distilled
water on the duration of action of brief infusions of
sodium nitroprusside and RIG200 (0.06 and 6
nmol/min for both drugs).
Subjects
Fourteen healthy nonsmoking men (age range, 18 to
65 years) were recruited for the study, which was con¬
ducted with the approval of the local research ethics
committee and with the written informed consent of
each subject. All subjects abstained from vasoactive
medication in the 2 weeks before the study and from
alcohol and caffeine-containing drinks for at least 12
hours before each study. Each subject fasted for at least
3 hours before any measurements were made. All stud¬
ies were performed in a quiet room maintained at a con¬
trolled temperature between 24°C and 26°C.
Drugs
Drugs, with the exception of aspirin, were dissolved
in physiologic saline solution (0.9%; Baxter Healthcare
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Ltd, Norfolk, UK) supplemented with 1 mg/mL ascor¬
bic acid to prevent oxidation of norepinephrine
(Abbott Laboratories Ltd, Kent, England), and infused
at locally active concentrations into the hand vein of
each subject. The concentrations of sodium nitroprus-
side (David Bull Laboratories, Warwick, England) and
RIG200 were approximately 50% maximum effective
concentration (~EC50) and maximal concentrations,
as determined in preliminary studies.25 Acetylcholine
was obtained from CIBA Vision Ophthalmics
(Southampton, England). All solutions were prepared
aseptically from sterile vials or ampules on the day of
the study. Three hundred milligrams of aspirin
(Approved Pharmaceutical Services Limited, Leeds,
England) was administered orally 30 minutes before
the start of measurements on the first day of the study
and 75 mg aspirin was given on each of the following
2 days to prevent thrombosis in the endothelium-
damaged hand vein.26 RIG200 was synthesized by a
published method.24 Although large-scale toxicologic
studies of RIG200 have not yet been performed, data
from our preclinical studies24 and from systemic
administration of relatively high doses (2 nmol/kg) to
rabbits suggested that the locally active infusions of
RIG200 in this study would not have toxic effects.
Indeed, no adverse effects were observed with other
S-nitrosothiols in clinical studies in hand veins,27 in
the forearm circulation,27-28 in the coronary circula¬
tion after balloon angioplasty,18 or in microvessels in
the skin after topical application.29 Similarly, pilot
studies with R1G200 in hand veins did not cause
adverse effects.25
Intravenous administration
A 23-gauge butterfly needle was sited in a selected
dorsal hand vein of the nondominant arm of each sub¬
ject, in the direction of blood flow without the use of
local anesthetic. The same vein was cannulated for each
study in that individual. The infusion rate was kept con¬
stant throughout at 0.25 mL/min.
Endothelial damage
At the end of the first study visit, the endothelium
was damaged by means of a published technique.25-26'30
In brief, a "withdrawal" needle was placed 3 to 4 cm
downstream from the tip of the "infusion" needle, and
the segment of the vein was temporarily isolated with
use of occluding wedges. For removal of the endothe¬
lium, distilled water was perfused through the segment
at 5 mL/min for 15 minutes with use of a constant rate
infusion-withdraw pump (Harvard Apparatus Inc,
South Natick, Mass). The results of a preliminary study
(not shown), consistent with earlier work,25-26-30 indi¬
cated that a 15-minute perfusion of distilled water com¬
pletely abolishes relaxation and causes constriction in
response to acetycholine infusion. It has been reported
previously that endothelial function remains impaired
2 days after perfusion of distilled water but returns to
normal within 14 days 26
Measurements
Dorsal hand vein diameter. The response to local
intravenous infusion of vasoactive drugs was assessed
by measurement of the diameter of the cannulated dor¬
sal hand vein.31 The nondominant arm was supported
above the level of the heart by an arm rest. The diame¬
ter of the selected vein, distended by the inflation of an
upper arm cuff to 30 mm Hg, was measured by use of
a standard displacement technique.32 In brief, a magne¬
tized lightweight rod rested on the summit of the infused
vein ~1 cm downstream from the tip of the infusion can¬
nula. This rod passed through the core of a linear vari¬
able differential transformer (model 025 MHR, Lucas
Schaevitz Inc, Pennsauken, NJ) supported above the
hand by a small tripod, the legs of which rested on areas
of the dorsum of the hand free of veins. If venoconstric-
tion occurred while the upper arm cuff was inflated or
if the cuff were deflated, with a consequent emptying
of the vein, there was a downward displacement of the
rod, causing a linear change in the voltage generated by
the linear variable differential transformer. The voltage
output from the transformer was transferred by a
MacLab analog-to-digital converter and Chart software
(ADInstruments, Castle Hill, Australia) to a Macintosh
personal computer (Apple Computer, Inc, Cupertino,
Calif).
Blood pressure. Blood pressure was measured in the
noninfused arm with use of a well-validated semiauto-
mated noninvasive method33 at 30-minute intervals
throughout the studies.
Study design
In this double-blind parallel-group study, 14 subjects
were randomly assigned to receive either sodium nitro-
prusside or RIG200 (seven in each group). Each sub¬
ject was studied on two occasions separated by 2 days.
On both study days, saline solution was infused into
the hand vein for at least 30 minutes before the admin¬
istration of drugs to obtain baseline measurements.
Increasing doses of norepinephrine (1 to 128 ng/min)
were infused sequentially (5 minutes each) until -70%
venoconstriction was achieved. This concentration of
norepinephrine (N70) was infused continuously for the
remainder of the study. In some volunteers, particularly
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Table I. Comparison of baseline parameters between groups before and 2 days after irrigation with distilled water
Sodium nitroprusside* RIG200f
Before water After water Before water After water
irrigation irrigation irrigation irrigation
Norepinephrine dose (ng/min) 6 ± 2 13 ± 5 11 ±2 37 ± 15
Venoconstriction to norepinephrine (%) 69 ±5 60 ± 5 69 ±4 64 ±7
Reversal of norepinephrine constriction by acetylcholine (%) 27 ± 5 -27 ± 13 30 ± 3 -4 ± 6
Only the response to acetylcholine was significantly affected after irrigation with water in both the sodium nitroprusside (P = .009; paired Student / test; n = 7) and
RIG200 (P = .006) groups. None of the parameters were significantly different between groups (P > .05). Negative values indicate a further constriction.
*Age of subjects, 39 ± 5 years.
fAge of subjects, 40 ± 5 years.
on the second visit, venous tone was unstable at N70,
and a lower norepinephrine concentration had to be
used to ensure a stable baseline. In one volunteer, veno-
constriction in response to norepinephrine after the
removal of endothelium did not reach 70% constric¬
tion within the dose range used in this study. In this
case, the highest dose of norepinephrine (128 ng/min;
41% constriction) was used for the study. The
endothelium-dependent vasodilator, acetylcholine (1
nmol/min), was then co-infused for 5 minutes and
venous responses to acetylcholine were recorded to
assess the functional integrity of the endothelium.
Acetylcholine was then washed out of the vein and two
doses (0.06 and 6 nmol/min) of either RIG200 or
sodium nitroprusside were sequentially infused for 10
minutes. The infusion of each dose was followed by a
30-minute washout period. Vein diameter measurements
were made at 5-minute intervals throughout the study.
Irrigation of the vein with distilled water to cause
endothelial damage was performed at the end of the first
visit. The subject returned 2 days later, and the same
vein was preconstricted and infused with acetylcholine
to test endothelial function and then with the same nitric
oxide donor drug as that used in the first visit.
Analysis
Baseline vein diameter was calculated as the mean
of the last three measurements during the saline infu¬
sion, before the start of the active drug infusion. Veno-
dilatation during the infusion of acetylcholine or study
drug was expressed as the percentage reversal of N70
norepinephrine-induced venoconstriction. Recovery
during washout of nitric oxide donor drugs was com¬
pared before and after water irrigation in each study
group by calculating the area under the curve (AUC).
Data were expressed as mean values ± SEM. Unpaired
or paired Student t tests were used to analyze differ¬
ences in mean values between groups (as indicated in
the text). A value of P < .05 was considered to be sta¬
tistically significant.
RESULTS
There was no significant difference in the age of sub¬
jects or the norepinephrine concentration (N70) between
RIG200 and sodium nitroprusside study groups (Table
I). There was also no significant change in the blood
pressure during the course of the study in subjects
receiving either sodium nitroprusside or RIG200, indi¬
cating that the effects of the study drugs were confined
to the infused arm.
Responses to acetylcholine in intact and water-
irrigated hand veins
Before irrigation with water, N70-contracted hand
veins of both study groups dilated during perfusion with
acetylcholine (Table I). Acetylcholine infusions into the
hand veins of subjects 2 days after irrigation with water
failed to dilate or even caused further contraction of the
veins (Table I). The effect of water irrigation on acetyl¬
choline responses was significant in both study groups
(P = .009 for sodium nitroprusside and P = .006 for
RIG200), but there was no significant difference
between the effect in the two groups (P = . 17).
Effect of sodium nitroprusside in hand veins before
and after water irrigation
Before irrigation with water, hand veins of subjects
in the sodium nitroprusside study group dilated during
infusion with low doses (0.06 nmol/min; 78% ± 12%)
and high doses (6 nmol/min; 105% ± 1 1%) of sodium
nitroprusside (Fig 2, A). Dilatation to both concentra¬
tions recovered to around baseline levels (-5% ± 5%
and 21% ± 7%, respectively) during the 30-minute
washout period.
Similar responses were obtained 2 days after water irri¬
gation, with dilatations of 82% ± 17% and 113% ± 11%
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for low and high sodium nitroprusside concentrations,
respectively (Fig 2, A). Again, dilatation reversed rapidly
during washout; the AUC values for the washout periods
were not significantly different from those obtained
before irrigation (P = .58 and P = .87, respectively).
Effect of RIG200 in hand veins before and after
water irrigation
Before irrigation with water, hand veins of subjects
in the R1G200 study group dilated on infusion with
low doses (0.06 nmol/min; 59% ± 4%) and high doses
(6 nmol/min; 98% ± 5%) of RIG200 (Fig 2, B). Dilata¬
tion to both concentrations recovered to around base¬
line levels (-6% ± 10% and 13% ± 11% for low and
high concentrations, respectively) during the 30-
minute washout period.
Responses of similar amplitude were obtained 2 days
after water irrigation, with dilatations of 64% ± 10.2%
and 97% ± 7% for the two concentrations, respectively.
However, unlike responses to sodium nitroprusside, the
responses to RIG200 showed slower recovery on
washout, with veins still 48% ± 12% relaxed 30 min¬
utes after washout of the high RIG200 concentration
began (Fig 2, B). The AUC for the washout period after
the low concentration of RIG200 was not significantly
different before water irrigation compared with 2 days
after water irrigation (P = .16; AUC, paired Student
t test). However, responses to the higher concentration
of RIG200 were significantly prolonged after water irri¬
gation (P = .02; AUC, paired Student t test).
DISCUSSION
Our results show that the novel S-nitrosothiol
RIG200 is a powerful venodilator in vivo in humans,
with a similar efficacy to sodium nitroprusside. Fur¬
thermore, we clearly show that responses to RIG200
are prolonged in hand veins that no longer relax to the
endothelium-dependent dilator acetylcholine after irri¬
gation with water. This sustained effect is not observed
with RIG200 before irrigation with water or with
sodium nitroprusside, either before or after water irri¬
gation. The results support earlier findings in rat arter¬
ies in vitro24 and suggest that RIG200 may offer a clin¬
ical approach to targeted delivery of nitric oxide to
blood vessels with damaged endothelium.
Functional endothelial integrity was assessed in the
dorsal hand vein of each subject before and 2 days after
irrigation with distilled water with use of the endothe-
lium-dependent dilator acetylcholine. Endothelium-
dependent venodilatation was inhibited in both study
groups. Indeed, consistent with previous data,2(1 acetyl¬





HMj saline washout MB saline washout
Fig 2. Percentage of reversal of norepinephrine-induced tone
by 0.06 and 6.0 nmol/min sodium nitroprusside infusion (A)
and 0.06 and 6 nmol/min R1G200 infusion (B) in hand veins
of subjects before and 2 days after 15 minutes of water irri¬
gation to produce endothelial denudation. Negative values
indicate further constriction. Area under the curve (AUC) was
calculated for responses during washout of each drug con¬
centration. AUC was significantly different after high-dose
R1G200 after water irrigation compared with before water
irrigation (P = .02; paired Student 1 test; n = 7), but not tor
low-dose R1G200 (P = .16) or either of the sodium nitroprus¬
side doses (P = .58 and P = .87, respectively).
is likely that this endothelial dysfunction is a reflection
of cellular damage, and possibly endothelial denuda¬
tion, induced by irrigation with water. In contrast to ear¬
lier reports,26 hand veins in this study were not more
sensitive to norepinephrine after water irrigation.
Endothelial damage alone would be expected to
increase sensitivity to norepinephrine attributable to
abolition of basal nitric oxide generation.44 However,
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our results suggest either that nitric oxide generation in
hand veins after stimulation with norepinephrine is rel¬
atively low, as suggested previously,35 or that hyper¬
sensitivity of hand veins caused by endothelial damage
is compensated for by some smooth muscle damage.
Neither the amplitude nor the duration of responses
to sodium nitroprusside was affected by endothelial
denudation. In the absence of endothelium-derived
nitric oxide, it might be expected that responses to
sodium nitroprusside would have been accentuated
after endothelial denudation. However, given that basal
nitric oxide production in veins is regarded to be low,35
supersensitivity to exogenous nitric oxide might not be
as pronounced as it is in arteries. The amplitude of
responses to RIG200 was also unaffected by endothe¬
lial denudation, but responses to 6 nmol/min RIG200
were significantly more sustained in veins after irriga¬
tion than before. The effect lasted for at least 30 min¬
utes, at which time veins were still ~50% relaxed. Sub¬
jects are generally unable to tolerate studies for more
than ~3 hours, limiting the washout period we were able
to study and preventing determination of the durability
of sustained RIG200-induced dilatation of veins with
damaged endothelium. However, in vitro studies in rat
femoral arteries24 and human internal mammary arter¬
ies have indicated that the effect lasts >4 hours; similar
studies in human saphenous veins show sustained activ¬
ity for ~2 hours.36
The mechanism by which RIG200 induces sustained
venodilatation is unclear. Our in vitro data show that
sustained responses to much higher (1 mmol/L) con¬
centrations of RIG200 are reversed by the nitric oxide
scavenger hemoglobin.24 This result indicates that the
sustained action is nitric oxide-mediated and is unlikely
to be caused by any cytotoxic effect of RIG200 or nitric
oxide. However, the persistence of nitric oxide derived
from RIG200 during infusion is highly unlikely in view
of the short half-life of nitric oxide in biological envi¬
ronments (3 to 30 seconds). Further in vitro studies
have shown that this property of sustained activity is
shared by other lipid-soluble S-nitrosothiols but not by
water soluble compounds.37 We therefore suggest that
damage to the endothelium exposes lipophilic regions
in the subendothelial layers that retain RIG200 and
other compounds with similar chemical characteristics.
Slow release of nitric oxide from the retained com¬
pound is sufficient to maintain dilatation after washout
of the drug from the lumen.
Drugs such as RIG200 present a promising therapeu¬
tic alternative to conventional nitric oxide donors both
in established cardiovascular disease and after invasive
vascular procedures that cause endothelial damage. In
particular, S-nitrosothiols with sustained action in areas
of endothelial damage may be of benefit in established
atherosclerotic plaques in which the endothelium has
been eroded, predisposing arteries to microthrombi,12
and after percutaneous transluminal angioplasty. Our
results suggest that R1G200 could prevent local
vasospasm immediately after the procedure and, in
view of the powerful antiplatelet activity of S-nitroso-
thiols,18 27 may also help to prevent postprocedural
thrombosis. We believe that further experiments are
now merited to determine the duration of sustained
activity in blood vessels with damaged endothelium and
to examine the potential impact of these compounds on
plaque stability and restenosis in vessels undergoing
angioplasty. In addition, further research is required to
determine whether RIG200 is orally active or, like other
S-nitrosothiols,29 it can be delivered transdermally.
We gratefully acknowledge supply of RIG200 from Ms F. A.
Mazzei and Dr A. R. Butler, University of St Andrews, St Andrews,
Scotland.
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PHARMACODYNAMICS AND
DRUG ACTION
Big endothelin-3 constricts forearm resistance
vessels but not hand veins in humans
Background: EndotheIin-3 (ET-3) and its inactive precursor, big endothelin-3 (big ET-3), are both found
in human plasma. We investigated whether big ET-3 is converted to ET-3 in the human forearm resis¬
tance vessels and dorsal hand veins in vivo.
Methods: In a 4-phase study, 6 subjects received 90 minute intrabrachial artery infusions of big ET-3
(50 and 100 pmol • min-1) and ET-3 (5 and 10 pmol • min-1) in random order. Forearm blood flow was
measured by venous occlusion plethysmography. In a second 3-phase study, 6 subjects received 90-minute
dorsal hand vein infusions of saline solution, big ET-3 (50 pmol • min-1) and ET-3 (5 pmol • min-1) in
random order. In a third 2-phase study, 6 subjects received 90-minute dorsal hand vein infusions of big
ET-3 (100 pmol • min-1) and ET-3 (10 pmol • min-1). In the dorsal hand vein studies, vessel diameter
was measured by the Aellig technique.
Results: Intra-arterial ET-3 caused local forearm vasoconstriction of 20% ± 9% (P = .009) at 5 pmol • min-1
and 20% ± 10% (P = .001) at 10 pmol • min-1 after 90 minutes, with no difference between doses (P =
.69). Intra-arterial big ET-3 also caused local forearm vasoconstriction of 22% + 6% at 50 pmol • min-1
(P = .004) and 18% + 3% at 100 pmol • min-1 (P < .0001) after 90 minutes, with no difference between
doses (P = .44). There were no significant differences between the responses to intra-arterial big ET-3
and ET-3 at these doses. Local intravenous ET-3 caused a constriction of 9% ± 2% at 5 pmol • min-1 (P =
.04) and 22% ± 8% at 10 pmol • min-1 (P = .002) after 90 minutes. Big ET-3 at 50 pmol • min-1 and 100
pmol • min-1 did not affect hand vein tone. All responses were slowly progressive.
Conclusions: Based on vasoconstriction, measurable conversion of big ET-3 to ET-3 occurs in forearm
resistance vessels but not in dorsal hand veins in vivo. An endothelin-converting enzyme, capable of con¬
verting exogenously administered big ET-3 to ET-3, appears to be present in upper limb resistance arter¬
ies but not in capacitance vessels in humans. (Clin Pharmacol Ther 2000;68:67-74.)
Charles J. Ferro, MD, MRCP, Fiona E. Strachan, BN, RGN, Ewan Shepherd, BSc,
William G. Haynes, MD, FRCP,a and David J. Webb, MD, FRCP Edinburgh, Scotland
The endothelins (ET-1, ET-2. and ET-3) are a family of
21-amino acid peptides.1-2 They are extremely potent vaso¬
constrictor and vasopressor agents, with a characteristi¬
cally sustained action, and have been shown to contribute
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to the maintenance of basal vascular tone and blood pres¬
sure in humans.2-4 ET-1 is the predominant isoform in the
vascular endothelium2 and is, therefore, likely to be the
isoform of most importance in cardiovascular regulation.
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Two human endothelin receptor subtypes, ETA and
ETb, have been characterized and cloned.5 6 The ETA
receptor has a high affinity for ET-1, with an inhibition
constant of 0.6 nmol/L4 compared with 140 nmol/I/1 for
ET-3.7 In blood vessels, the ETA receptor is expressed
solely on vascular smooth muscle cells where it mediates
vasoconstriction.8 The ETB receptor has equal affinity for
all 3 endothelins, with inhibition constants for ET-1 and
ET-3 of 0.12 and 0.06 nmol/L1, respectively.7 The ETB
receptor is expressed on endothelial cells,5 where it medi¬
ates vasodilatation,9 and on vascular smooth muscle
cells,10 where it can contribute to vasoconstriction.n42
The balance of responses to endogenous ET-1 at the
vascular endothelial and smooth muscle ETB receptor
appears to favor vasodilatation in forearm resistance ves¬
sels13 and in the systemic circulation14 in vivo in humans.
ET-1 is produced from an inactive 38-amino acid
intermediate form, big endothelin-1 (big ET-1), by
selective cleavage of the Trp21-Val22 bond in the car-
boxy-terminal of big ET-1 catalyzed by an endothelin-
converting enzyme (ECE).15 In humans, ET-2 and ET-3
are also formed from corresponding intermediates, big
ET-2 and big ET-3.15 Along with ET-1 and big ET-1,16
immunoreactive big ET-2, ET-3, and big ET-3 have been
detected in human plasma17-18 and preproET-3 mRNA
has been detected in blood vessels,19 suggesting that
they might generate and respond to other endothelin
isopeptides in addition to ET-1.
Two ECEs have so far been cloned in humans;
ECE-120 and ECE-2.21 Both convert big ET-1 in pref¬
erence to big ET-2 and big ET-3.2 O22 This substrate
specificity suggests that there may be yet-undiscovered
ECEs selective for big ET-2 or big ET-3. Previous work
in our department has demonstrated that exogenously
administered big ET-1 constricts human forearm resis¬
tance vessels3 but not human hand veins23 in vivo.
Because circulating blood contains no significant ECE
activity24 and because big endothelins are considered to
be inactive without conversion to the mature peptide,15
these findings suggest that forearm resistance vessels,
but not hand veins, contain an ECE able to cleave lumi-
nally presented big ET-1 to the mature peptide.
Endogenously generated ET-3 acts mainly at the ETB
receptor, and the balance of actions appears to favor
vasodilatation. It would, therefore, be potentially
advantageous for a clinically useful ECE inhibitor to
inhibit ET-1, but not ET-3 synthesis. However, it is not
currently known whether human resistance or capaci¬
tance vessels contain an ECE able to generate ET-3
from big ET-3. Therefore, we aimed to determine the
existence of such an ECE by infusing big ET-3 into the
brachial artery and dorsal hand vein of healthy volun¬
teers and assessing responses by measuring forearm
blood flow and dorsal hand vein diameter.
METHODS
Subjects
Eighteen healthy white male subjects between 18 and
60 years of age were recruited to these studies, which
were conducted with the approval of the local research
ethics committee and with the written informed consent
of each subject. All studies were performed in a quiet
room, maintained at a constant temperature between
24°C and 26°C. As a further measure of standardization,
no subject received vasoactive or nonsteroidal anti¬
inflammatory drugs in the week before each phase of the
study, and all abstained from food for 4 hours, and from
alcohol, caffeine-containing drinks and cigarettes for at
least 12 hours before any measurements were made.25
Drugs
Pharmaceutical grade ET-3 (Peninsula Laboratories,
Belmont, Calif) and big ET-3 (Peninsula Laboratories)
were administered. A single dose of each peptide was
used in individual studies because the slowly progres¬
sive and sustained actions of the endothelin isopeptides
preclude the use of repeated doses in a single study to
examine conventional dose relationships.26 The pep¬
tides were dissolved in physiologic saline solution
(0.9%; Baxter Healthcare Ltd, Thetford, UK).
Local intra-arterial administration. The left brachial
artery was cannulated with the patient under local anes¬
thesia (1% lidocaine; Astra Pharmaceuticals Ltd, Kings
Langley, Herts, UK) with a 27-standard wire gauge nee¬
dle (Cooper's Needle Works, Birmingham, UK)
attached to a 16-gauge epidural catheter (Portex Ltd,
Hythe, Kent, UK). Patency was maintained by infusion
of saline solution through a Welmed PI000 pump
(Welmed Clinical Care Systems, Bramley, Hampshire,
UK). The total rate of intra-arterial infusion was main¬
tained constant at 1 mL • mim4.
Local intravenous administration. A 23-gauge but¬
terfly needle (Abbott, Sligo, Republic of Ireland)
attached to a 16-gauge epidural catheter was sited in a
selected dorsal hand vein, without the use of local anes¬
thesia, in the direction of Bow. Patency was maintained
by infusion of saline solution through a Welmed PI000
syringe pump. The total rate of intravenous infusion
was maintained constant at 0.25 mL • min-1.
Measurements
Forearm bloodflow. Blood flow was measured in both
forearms by venous occlusion plethysmography25 by
using mercury-in-silicone elastomer strain gauges27 that
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were securely applied to the widest part of each forearm.
The hands were excluded from the circulation during each
measurement period by inflation of a wrist cuff to 220
mm Hg. Upper arm cuffs were intermittently inflated to
40 mm Hg for 10 seconds out of every 15 seconds to tem¬
porarily prevent venous outflow from the forearm and thus
allow us to obtain plethysmography recordings. Record¬
ings of forearm blood flow were made repeatedly over
3-minute periods. Voltage output from 2 single-channel
Hokanson EC 4 strain-gauge plethysmographs (DE
Hokanson Inc, Bellevue, Wash) was transferred to a Mac¬
intosh personal computer (LCIII, Apple Computer Inc,
Cupertino, Calif) with a MacLab analogue-to-digital con¬
verter and Chart software (v3.2.8: both from AD Instru¬
ments Ltd, Castle Hill, Australia). Calibration was achieved
by use of the internal standard of the plethysmography unit.
Dorsal hand vein diameter. The left hand was sup¬
ported above the level of the heart by means of an arm
rest. The internal diameter of the dorsal hand vein, dis¬
tended by inflation of an upper arm cuff to 30 mm Hg,
was measured by the Aellig technique.28 In brief, a
magnetized lightweight rod rested on the summit of the
infused vein approximately 1 cm downstream from
the tip of the infusion cannula. This rod passed through
the core of a linear variable differential transformer
(LVDT; model 025 MHR, Lucas Schaevitz Inc,
Pennsauken, NJ) supported above the hand by a small
tripod, the legs of which rested on areas of the dorsum
of the hand free of veins. If venoconstriction occurred
while this cuff was inflated, or if the cuff was deflated
with consequent emptying of the vein, there was a
downward displacement of the lightweight rod that
caused a linear change in the voltage generated by the
LVDT. The voltage output from the LVDT was trans¬
ferred to a Macintosh personal computer by use of a
MacLab analogue-to-digital converter and Chart soft¬
ware. Standard displacements were used to calibrate the
LVDT to determine the internal diameter of the vein.
Blood pressure. A well-validated semi-automated non¬
invasive oscillometry sphygmomanometer (Takeda UA
751, Takeda Medical Inc, Tokyo, Japan) was used to make
duplicate measurements of blood pressure in the non-
infused arm.29
Study design
Forearm blood flow protocol. Subjects were studied
on 4 separate occasions and rested recumbent through¬
out each study. Strain gauges and upper arm cuffs were
applied, and the left brachial cannula was sited. Saline
solution was infused for 30 minutes, during which 3
measurements of lorearm blood flow were made after
5, 15, and 25 minutes, the last measurement being taken
as the baseline value. Blood pressure was measured
immediately after each forearm blood flow measure¬
ment, thereby avoiding any effect on forearm blood
flow measurements of the venous congestion caused by
this procedure.30 In random order, and on 4 occasions
separated by at least 7 days, subjects received 90-
minute brachial artery infusions of ET-3 at 5 and 10
pmol • min-1 and big ET-3 at 50 and 100 pmol • min-1.
The lower dose of ET-3 was chosen based on previous
work showing in vivo that 5 pmol • min-1 of ET-3
causes slow-onset vasoconstriction in human forearm
resistance vessels, reducing blood flow by approxi¬
mately 20%.12 The higher dose of ET-3 (10 pmol •
min-1) was chosen with the intention of causing a
greater forearm vasoconstriction and reducing blood
flow to a similar extent to ET-1 (approximately
40%).3-26 The doses of big ET-3 were chosen with the
intention of producing a measurable forearm vasocon¬
striction even with only 5% to 10% conversion to ET-3.
Although no in vivo studies in human resistance vessels
with big ET-3 have been reported, previous work with
big ET-1 has shown that 50 pmol • min-1 of big ET-1
produces a vasoconstriction comparable to 5 pmol ■
min-1 of ET-1.3 Forearm blood flow was measured at
5-minute intervals during the infusion of the study
agents. Blood pressure was measured at 30, 60, and 90
minutes after the start of the infusion.
Dorsal hand vein protocol. In the first set of stud¬
ies, subjects were studied on 3 separate occasions sep¬
arated by at least 7 days, in random order. Subjects
rested semirecumbent throughout each study. The dor¬
sal hand vein cannula and the LVDT were sited. Saline
solution was infused for 30 minutes, during which vein
diameter was measured every 5 minutes. Then, on 3
separate occasions, saline solution, ET-3, or big ET-3
was infused for 90 minutes, with measurement of vein
diameter every 5 minutes. The choice of dose of ET-3
was based on previous work showing, in vivo, that 5
pmol • min-1 ET-3 causes slow-onset venoconstriction
of approximately 5% to 10%.31 As in the forearm blood
How protocol, the choice of dose of big ET-3 was based
on previous work with big ET-1 23
Based on the responses obtained to the intravenous
infusion of ET-3 (5 pmol ■ min-1) and big ET-3 (50
pmol ■ min-1), a further 6 subjects were studied on 2
separate occasions separated by at least 7 days, in ran¬
dom order, by using a higher dose of both ET-3 (10
pmol min-1) and big ET-3 (100 pmol • min ').
Data analysis and statistics
Plethysmography data listings were extracted from
the Chart data files, and forearm blood flows were cal-
Time (min) Time (min)
Fig 1. Changes in forearm blood flow after infusion of ET-3 (open circles, 5 pmol • min-1; solid
circles, 10 pmol • min~') and big ET-3 (open squares, 50 pmol • min~>; solid squares, 100 pmol •
min ')• Significant vasoconstriction occurred after infusion of both peptides at both doses.
Table I. Mean arterial pressure and heart rate before and after 90-minute infusion of sodium chloride, big ET-3,
and ET-3
Saline Big ET-3 Big ET-3 ET-3 ET-3
Parameter Time solution (50 pmol ■ min'1) (100 pmol ■ mim1) (5 pmol-min1) (10 pmol • min'1)
Intra-arterial protocol
MAP (mm Hg) Basal —- 85 + 3 86 + 4 84 + 2 87+4
90 min — 86 + 3 90 + 3 89 + 3 91+3
Heart rate (beats/min) Basal — 60 + 3 63 + 5 59 + 4 60 + 5
90 min — 59 + 4 58 + 5 58 + 3 61+4
Infused FBF Basal — 4.8 ± 1.1 4.1 ± 1.2 4.3 + 0.8 5.0+ 1.5
(mL • 100 mL • min1) 90 min — 4.1 ±2.0 3.5 ± 1.6 3.6+ 1.2 4.4 ± 1.5
Intravenous protocol
MAP (mm Hg) Basal 85 ±4 86 + 3 95 + 3 85 + 3 94 + 2
90 min 88 + 3 88 + 4 98 + 3 88 + 5 96 + 3
Heart rate (beats/min) Basal 64 + 5 63 + 4 72 + 4 63 + 4 68 + 3
90 min 63 + 5 65 + 6 68 + 3 65 + 5 69 + 3
Hand vein size (mm) Basal 2.4 ± 0.4 2.2 ± 0.2 2.7 ± 0.3 2.2 ± 0.3 2.6 + 0.3
90 min 2.5 ± 0.5 2.1 ±0.2 2.4 ± 0.3 1.9 + 0.4 2.0 ± 0.4
MAP, Mean arterial pressure; big ET-3, big endothelin-3; ET-3, endothelin-3; FBF, forearm blood flow.
culated for individual venous occlusion cuff inflations
by use of a template spreadsheet (Excel 4.0; Microsoft
Corp, Redmond, Wash). Because wrist cuff inflation
results in a transient alteration of forearm blood flow,32
recordings made in the first 60 seconds after wrist cuff
inflation were not used for analysis. Usually, the last 5
flow recordings in each 3-minute measurement period
were calculated and averaged for the infused and non-
infused arms. To reduce the variability of blood flow
data, the ratio of flows in the 2 arms was calculated for
each timepoint, in effect by using the noninfused arm
as a contemporaneous control for the infused arm.25
Forearm blood flow results are shown as a percentage
change from basal in the ratio of blood flow between
infused and noninfused arms.25
Basal vein diameter was calculated as the mean of
the last 3 measurements before the start of the study
infusion, expressed in millimeters.28 All 3 baseline
measurements had to be within 5% of each other before
the study infusion was started. To further reduce the
already small temporal variability in baseline, the mean
of these 3 measurements was used as the baseline value
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Fig 3. Changes in hand vein diameter after infusion of ET-3
{circles, 10 pmol • min-1) and big ET-3 (squares, 100 pmol •
min-1). Significant venoconstriction occurred only during
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Fig 2. Changes in hand vein diameter after inusion of sodium
chloride {open circles, 0.9% wt/vol), ET-3 {solid circles,
5 pmol • min-1), and big ET-3 {solid squares, 50 pmol ■
min-1). Significant venoconstriction occurred only during
infusion of ET-3 {P = .04).
for calculations. Because basal vein size varies between
subjects, responses are expressed as a percentage
change in vein size from basal in order to reduce the
intersubject variability.25
From previous studies that used intrabrachial ET-3
infusions,12 studying 6 subjects would have an 80%
power to detect a 10% vasoconstriction and 95% power
to detect a 20% vasoconstriction produced by ET-3 at the
5% level. Our group has not previously infused big ET-3
intra-arterially, but from previous work with intra-arterial
big ET-13 it was estimated that studying 6 subjects would
have a 95% power to detect a vasoconstriction of 20%.
Similarly, although our group has no experience with
intravenous ET-3 or big ET-3, from previous work with
dorsal hand vein infusion of ET-153 and big ET-1,23 it was
estimated that studying 6 subjects would have a 90%
power to detect a 10% venoconstriction produced by each
agent at the 5% level. All power calculations were per¬
formed by using GraphPad Instat software (GraphPad
Software, San Diego, Calif).
Data are shown as mean values, with 95% CI shown
in the text and SEM in the figures. Data were examined
by a repeated measures ANOVA with statistical testing
of overall significance by Scheffe F test (ANOVA) with
Statview 512+ software (Brainpower Inc, Calabasas,
Calif) for the Apple Macintosh personal computer.
RESULTS
A total of 14 subjects completed the study, age range
22 to 60 years (mean age, 37 years). Six subjects were
included in the forearm blood flow protocol, 12 in the
dorsal hand vein protocol, and 4 subjects participated
in both the forearm blood (low and the dorsal hand vein
protocols. None of the subjects were overweight (mean
body mass index, 19) and only 3 were regular smokers.
Basal blood pressure, heart rate, forearm blood flow,
and vein diameter were similar on the different study
days (Table I). Blood pressure, heart rate, and blood
flow in the noninfused arm did not change significantly
after infusion of any study agent, confirming that drug
effects were confined to the infused arm.
Forearm blood flow protocol
ET-3 at 5 pmol • min-1 caused a significant forearm
vasoconstriction, with a 20% ± 9% reduction in fore¬
arm blood flow at 90 minutes (CI, -1% to -40%; P =
.009 versus baseline; Fig 1). ET-3 at 10 pmol ■ min 1
also reduced forearm blood flow by 20% ± 10% after
90 minutes (CI, -8% to -33%; P = .001 versus base¬
line; Fig 1). There was no difference in the vasocon¬
strictor responses between doses (P = .69).
Big ET-3 at 50 pmol • min 1 caused forearm vaso¬
constriction, with a 22% ± 6% reduction in forearm
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blood flow at 90 minutes (CI, -5% to -38%; P = .009
versus baseline; Fig 1). Big ET-3 at 100 pmol • min-1
also reduced forearm blood flow by 18% ± 3% after 90
minutes (CI, -8% to -29%; P = .001 versus baseline;
Fig 1). There were no significant differences between
the vasoconstriction produced by the 2 doses of big
ET-3 (P = .44) or between the vasoconstrictor responses
to big ET-3 and ET-3.
Dorsal hand vein protocol
There was no significant change in vein diameter
with the placebo treatment, with a change from basal
after infusion of saline solution for 90 minutes of
+2% ± 3% (CI, -6% to +10%; P = .66; Fig 2). Intra¬
venous infusion of big ET-3, at a rate of 50 pmol ■
min-1, did not affect vein size, with a change at 90 min¬
utes of -2% ± 2% (CI, -12% to +8%; P = .43; Fig 2).
In contrast, a 10-fold lower dose of ET-3 (5 pmol •
min-1) caused progressive venoconstriction of 9% ± 2%
at 90 minutes (CI, -6 to -12%; P - .04), which was sig¬
nificantly different from the response to saline solution
(.P = .001) and big ET-3 (P = .008).
The higher dose of big ET-3 (100 pmol • min-1) also
did not affect vein size, with a change at 90 minutes of
-7% ± 6% (CI, -22% to +9%; P = .83; Fig 3). In con¬
trast, a 10-fold lower dose of ET-3 (10 pmol • min-1)
caused a significant venoconstriction of-22% ± 10%
at 90 minutes (CI, -46% to -3%; P = .002; Fig 3). The
difference between the venous responses to these higher
doses of ET-3 and big ET-3 was significant (P = .03).
DISCUSSION
In these clinical studies, we have shown that both
ET-3 and its precursor big ET-3 cause forearm vaso¬
constriction. We have also shown that ET-3 constricts
human hand veins, whereas big ET-3 does not. These
findings have important implications for the existence
and distribution of an ECE capable of converting big
ET-3 to the mature peptide and are consistent with pre¬
vious findings obtained for big ET-1.
We have shown that intra-arterial infusion of ET-3
causes vasoconstriction of forearm resistance vessels,
suggesting the presence of constrictor ETB receptors
and confirming the results of an earlier report.12 How¬
ever, the vasoconstriction to ET-3 (5 pmol • min1) was
considerably less than that seen with the nonselective
ETa and ETB agonist ET-1 (5 pmol • min-1).3'4'27 This
held true even when the concentration of ET-3 infused
was increased to 10 pmol ■ min-1. However, it is diffi¬
cult to extrapolate these results to quantify the relative
contribution of each receptor subtype in mediating the
vasoconstrictor effects of endogenous endothelin. Fur¬
ther comparative studies with selective ETA and ETB
antagonists may help clarify this issue.
Recent reports by our group have provided evidence
suggesting that the balance of actions of endogenously
generated endothelin acting on ETB receptors favors
vasodilatation.13'14 These observations may appear to
be at odds with the findings presented here. However,
in this study the infusions of ET-3 and big ET-3 would
have produced much higher local concentrations of
ET-3 than normally found physiologically and may
either have had direct actions on the vasoconstrictor
ETa receptors or have shifted the balance of ETB recep¬
tor activation away from vasodilatation and toward vaso¬
constriction. Furthermore, given the role for the ETB
receptor as a clearance receptor,34 the vasoconstrictor
actions of ET-3 may be mediated by ET-1 displaced from
ETb receptors onto unoccupied ETA receptors. These
possibilities could be further explored by coinfusing
ET-3 with selective ETA and ETB receptor antagonists.
It is highly unlikely that big ET-3 had a direct vaso¬
constrictor action given its very low affinity for
endothelin receptors.15 Therefore, the vasoconstriction
caused by big ET-3 is likely to have resulted from con¬
version to ET-3. Our studies are consistent with the
existence of an ECE capable of converting big ET-3 to
ET-3. As both ECE-1 and ECE-2 convert big ET-1 in
preference to big ET-3,35 our study also suggests the
possible existence of another ECE in forearm resistance
arteries. The slow onset and sustained actions of the
endothelin isopeptides precluded us from using
repeated doses in a single study to examine conven¬
tional dose-relationships. Therefore, the proportion of
exogenously administered big ET-3 converted to ET-3
cannot be determined from this study.
It is unlikely that any significant ECE activity is pre¬
sent in human hand veins, because we found no veno¬
constriction to high doses of big ET-3. However, it is
possible that an ECE may be present in these vessels,
but not in a location capable of converting exogenous
(intraluminal) big ET-3. Hand vein size did not alter
during saline solution infusion, confirming that vein
size in these experiments is not influenced by repeated
measurement or diurnal variation.
The lack of effect of big ET-3 in human hand veins
contrasts with the forearm vasoconstrictor actions of
the same dose of big ET-3 administered through the
brachial artery. Although a greater concentration of
infused big ET-3 will have been achieved in the hand
veins, it could be argued that infused big ET-3 is in con¬
tact with the hand vein under study (approximately 1
cm in length) for insufficient time to allow conversion
of big ET-3. However, the concentration of big ET-3
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achieved in the vein is sufficient to allow conversion to
the mature peptide, given the normal rates of conver¬
sion.15 Similar studies have shown that angiotensin I,
infused locally, constricts human hand veins in an
angiotensin converting enzyme-dependent manner.36-37
In contrast with the findings for ET-3 and big ET-3,
there is only a small difference in constrictor potency
between angiotensin I and angiotensin II in hand veins,
similar to the observations with angiotensin peptides in
the forearm resistance bed.36 The lack of conversion of
big ET-3 is consistent with the lack of response to big
ET-1 in human hand veins23 despite forearm vasocon¬
strictor actions of the same dose of big ET-1,3 Further¬
more, given the differences in flow between the forearm
circulation and the dorsal hand vein circulation,25 it
is likely that substantially higher concentrations of big
ET-1 and big ET-3 are reached in the dorsal hand vein.
Thus ECE activity for big ET-1 appears to have a simi¬
lar vessel distribution to ECE activity for big ET-3.
The endothelin system has been implicated in the
pathophysiology of several cardiovascular diseases.38
Although the major emphasis to date has been in the clin¬
ical development of endothelin receptor antagonists, the
search for a pathophysiologically relevant ECE and potent
ECE inhibitors to prevent endothelin production contin¬
ues.39-40 There is a current controversy as to whether com¬
bined ETa and ETB receptor antagonists are preferable
to selective ETA antagonists, which leave vasodilator ETB
receptors unblocked.38-41 Indeed, recent reports by our
group show that activation of the ETB receptor by endoge-
nously produced endothelin peptides produces vasodi¬
latation, at least in healthy subjects.13-14 ECE inhibitors,
by blocking generation of ET-1, will act as functional
antagonists at both ETA and ETB receptors, and so may
be less effective vasodilators, under some circumstances,
than selective ETA antagonists. Alternatively, given that
ET-1 is the major cardiovascular isoform and ET-3 is a
relatively selective agonist at ETB receptors, ET-1 selec¬
tive ECE inhibitors could be potentially useful therapeu¬
tic agents. The identification and further characterization
of the ECE responsible for big ET-1 conversion in vivo
may, therefore, be clinically important.
In conclusion, our results show that human forearm
resistance vessels have the capacity to convert exoge¬
nous big ET-3 to ET-3. In contrast, human hand veins
appear to lack this capacity, consistent with our ear¬
lier observations with big ET-1. These findings sug¬
gest that hand veins exhibit little or no functional ECE
activity.
We would like to acknowledge our gratitude to Helen MacCal-
luirt, MPH, BN, for her assistance in the completion of these studies.
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Constriction to ETB receptor agonists, BQ-3020 and sarafotoxin S6c,
in human resistance and capacitance vessels in vivo
Fiona E. Strachan, Thomas R. Crockett, Nicholas L. Mills, Gillian A. Gray' & David J. Webb
Clinical Pharmacology Unit & Research Centre, Department of Medical Sciences, University of Edinburgh, Western General Hospital, Edinburgh,
HH4 2XU and 1Department of Biomedical Sciences, University of Edinburgh, I Ceorge Square, Edinburgh, EHH 9J2
Aims The aim of the study was to examine the effects of the ETB receptor selective
agonists sarafotoxin S6c (SFTX6c) and BQ-3020 on the forearm resistance and
capacitance vessels in healthy subjects in vivo.
Methods The local response to intra-arterial or intravenous infusion of SFTX6c
(5 pmol min-1) or BQ-3020 (50 pmol min- ') was assessed, on separate occasions, in
eight healthy men (aged 20-28 years). Data (mean + s.e.mean) were examined by
anova. Results are expressed as percentage change from baseline at 90 min.
Results SFTX6c and BQ-3020 reduced forearm blood flow, following local intra¬
arterial infusion (— 25+7% and —27 +7%, respectively; P<0.001) and reduced hand
vein diameter, following local intravenous infusion ( — 30 + 8% and —16+7%,
respectively; P<0.001).
Conclusions We have shown that locally active infusions of the selective ETB receptor
agonists SFTX6c and BQ-3020 cause arterial constriction and venoconstriction in
healthy human blood vessels in vivo. These results indicate that ETB receptor
stimulation may mediate vasoconstriction in humans.
Keywords: endothelin-1, ETB receptor agonist, vasoconstriction
Introduction
The powerful vasoconstrictor and vasopressor effects of
endothelin-1 (ET-1) [1, 2j are mediated via the ET-1
selective, vascular smooth muscle cell ETA receptor [3],
while the predominant effect of the nonisopeptide
selective ETB receptor (4) would appear to be vasodilata¬
tion [5-7] mediated by the endothelial cell ETB receptor.
However, ETB receptors have also been described on
vascular smooth muscle cells [8] and may contribute to
vasoconstriction [9]. Indeed, we have previously demon¬
strated venoconstriction and vasoconstriction in response
to locally active doses of the ETB receptor selective agonist
sarafotoxin S6c (SFTX6c) [10] in healthy subjects 111—13]
and in patients with heart failure [14].
To address whether the vasoconstrictor effects of
SFTX6c [11-14] could also be demonstrated with
Correspondence: Fiona Strachan. Clinical Pharmacology Unit & Research Centre,
Department of Medical Sciences, University of Edinburgh. Western General
Hospital. Edinburgh, EH4 2XU, Tel.:+44 131332 1205, Fax:+44 131343 6017,
E-mail: f.strachan@ed.ac.
Received 9 August 1999, accepted 12 April 2000.
another, structurally distinct, ETB receptor agonist, we
investigated the response to infusion of locally active doses
of SFTX6c and BQ-3020, a selective ETB agonist [15,
16], in the forearm resistance and capacitance vessels of
healthy subjects in vivo. BQ-3020 is a linear analogue of




Eight healthy men, within the age range of 18-40 years,
were recruited to the study, which was conducted with
the approval of the local Research Ethics Committee and
with the written informed consent of each subject.
The effects of local intra-arterial and intravenous
infusion of BQ-3020 and SFTX6c were investigated in
eight healthy men in a single-blind, randomised, four way
crossover study. On separate occasions, each separated by
at least I week, each subject received either intra-arterial
infusion or intravenous infusion of SFTXbc or BQ-3020.
Subjects rested recumbent throughout each study in a
(c)2000 Blackwell Science Ltd Br J Clin Pharmacol. 50, 27-30 27
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Figure 1 Response of forearm blood flow and hand vein
diameter to local intra-arterial infusion and local intravenous
infusion of SFTX6c (5 pmol min ~ open circles) and BQ-3020
(50 pmol min 1; closed circles), respectively. Responses are
expressed as mean percentage change + s.e.mean.
quiet temperature-controlled room (23—25°C). Saline
(0.9%) was infused for at least 30 min before active drug
infusion to allow recording of baseline measurements.
Drugs, administration and measurements
Sarafotoxin S6c and BQ-3020 (both Calbiochem-Nova-
biochem, Nottingham, UK) were administered by
continuous infusion for 90 min. SFT'X6c was adminis¬
tered at an infusion rate of 5 pmol min ' as described
previously 11 1 — 141. BQ-3020 was administered at an
infusion rate of 50 pmol min , based on results from a
pilot study (data not shown).
The brachial artery of the nondominant arm was
cannulated under local anaesthetic (1% lignocaine; Astra
Pharmaceuticals, Kings Langley, England) with a 27 SWG
steel cannula (Cooper's Needle Works). The infusion
rate was kept constant at 1 ml min 1 throughout. The
response to intra-arterial infusion was assessed by
measurement of forearm blood flow using a standard
plethysmographic technique [17],
A 23-gauge butterfly needle was sited in a selected
dorsal hand vein in the direction ofblood flow without the
use of local anaesthetic. The same vein was cannulated for
each study in that individual. The infusion rate was kept
constant throughout at 0.25 ml min ' The response to
intravenous infusion was assessed by measurement of the
diameter of the cannulated dorsal hand vein using a
standard displacement technique [17, 18].
Blood pressure and heart rate were measured in the
noninfused arm using a well-validated semiautomated
method [19] at 30 min intervals throughout the infusions.
Statistical analysis
Analysis was performed as described previously [17]. All
results are expressed as mean + standard error of the mean
(s.e.mean) at 90 min. Blood pressure, heart rate and
baseline measurements were compared using the Student's
paired t-test. The forearm blood flow and vein diameter
responses were examined by repeated-measures analysis of
variance (anova) (Excel 5.0, Microsoft Ltd, Wokingham,
UK). Statistical significance was accepted at the 5% level.
Results
All subjects, aged 20—28 years, completed the study. There
was no significant difference between baseline measure¬
ments on each of the study visits. All drug effects were
confined to the infused ami [Table 1],
Sarafotoxin S6c and BQ-3020 reduced forearm blood
flow ( — 25+7% and —27 + 7%, respectively; P<0.001),
following intra-arterial infusion, indicating vasoconstric¬
tion in the infused arm (Figure 1). Both SFTX6c and BQ-
3020 caused a reduction in vein diameter following
intravenous infusion ( — 30 + 8% and —16 + 7%, respec¬
tively; P<0.001) (Figure 1).
Discussion
We have confirmed that infusion of a locally active dose of
the ETB receptor agonist SFTX6c causes arterial
constriction and venoconstriction in healthy human
blood vessels in vivo [11—13], We have also extended
these observations to show, for the first time, that similar
effects are seen with the structurally distinct ETB receptor
selective agonist, BQ-3020. These findings support the
view that vasoconstriction can occur in response to
stimulation ofETB receptors in vivo. It has been suggested
that this vasoconstriction results from displacement of
endogenous ET-1 onto unoccupied ETA receptors [6],
However, this seems unlikely, given that we have shown
28 (c) 2000 Blackwell Science Ltd Br J Clin Pharmacol, 50, 27-30
Vasoconstriction to 8Q-3020 and SFTX6c in vivo
Table 1 Mean artenal pressure (MAP), heart rate (HR), forearm blood flow (FBF) and vein diameter at baseline and at 90 mill following the start of
each infusion. Values are mean ± s.e.mean.
Inlra-arterial infusion
BQ-3020
(50 pmol min ')
SFIX6r
(5 pmol min ')
Intravenous infusion
BQ-3020 SFTX6c
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previously that the constrictor effects of SFTX6c could be
blocked by the selective ETB receptor antagonist BQ-788
[13] but not by the selective ETA receptor antagonist
BQ-123 (unpublished observations).
Although vasoconstriction does appear to occur with
ETB receptor selective agonists, the integrated role of
endothelial cell dilator and vascular smooth muscle
constrictor receptors only emerges from studies with
endothelin receptor antagonists. Indeed, we have recently
demonstrated local [7] and systemic [5] vasoconstriction in
response to the ETB receptor selective antagonist BQ-788
[20], indicating that the balance of effects of endogenous
ET-1 acting at vascular smooth muscle and endothelial
ETB receptors in healthy resistance vessels favours
vasodilatation. Further investigation of the role of the
ETB receptor in health and in cardiovascular disease is
important to distinguish whether combined ETA/ETB
antagonists or selective ETA antagonists will be more
effective as vasodilator treatments in the clinical setting.
Fiona Strachan was supported by a Wellcome Trust project grant
(PC! 048560). Professor David Webb is the recipient of a Research
Leave Fellowship from the Wellcome Trust (WT 0526330).
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Endothelin-1 does not contribute to
the release of tissue plasminogen
activator in vivo in man
D.E. Newby, F.E. Strachan, N.R. Johnston, D.J. Webb
Clinical Pharmacology Unit and Research Centre, University of Edinburgh, Western General Hospital, Edinburgh, UK
Summary Objectives: Endothelin-1 is a potent endothelium-derived vasoconstrictor peptide with autocrine and
paracrine actions. Tissue plasminogen activator (t-PA) and its inhibitor, plasminogen activator inhibitor type 1 (PAI-1),
are also released from the vascular endothelium and play a pivotal role in endogenous fibrinolysis. We, therefore,
examined the effects of exogenous and endogenous endothelin-1 on t-PA and PAI-1 release in vivo in man.
Design: Open investigative study.
Setting-. Clinical Research Centre, University of Edinburgh.
Subjects: Fourteen healthy male volunteers.
Interventions-. Unilateral brachial artery infusions of endothelin-1 at 2.5 and 10 pmol/min, and the selective endothelin
type B (ETb) receptor antagonist, BQ-788, at 1 nmol/min.
Main outcome measures: Blood flow and plasma fibrinolytic factors were measured in both forearms using venous
occlusion plethysmography and venous blood samples withdrawn from the antecubital fossae.
Results: Endothelin-1 caused a slow onset dose-dependent forearm vasoconstriction (P<0.001) with a maximal
reduction in blood flow of 40 ± 4% and 63 ± 3% at 2.5 and 10 pmol/min respectively. BQ-788 also caused a slow onset
reduction in forearm blood flow (P<0.001) reaching a maximum of 21 ± 3%. However, BQ-788 and endothelin-1 did not
affect plasma concentrations of t-PA or PAI-1 in the venous effluent of the infused forearm.
Conclusions: Despite sustaining significant vasoconstriction, neither endogenous nor exogenous endothelin-1
influences the release of t-PA or PAI-1 in the forearm vascular bed of man. This suggests that endothelin-1 does not
provide a major contribution to the regulation of endogenous fibrinolysis in man. © Harcourt Publishers Ltd 1999
INTRODUCTION
Endothelial cells in the precapillary arterioles and post¬
capillary venules' synthesize and release t-PA and PAI-1
both basally and in response to stimulation by various
coagulation factors and stimulants. The time course of t-
PA release is important since clot dissolution is much
more effective if t-PA is incorporated during clot forma¬
tion rather than following completion.2-3 The acute
release of t-PA results from the rapid translocation of a
dynamic intracellular storage pool4 and plays a pivotal
role in endogenous fibrinolysis.
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Endothelin-1 is a potent endothelium-derived vaso¬
constrictor peptide with autocrine and paracrine actions.
It is continuously released by the endothelium and con¬
tributes to the maintenance of basal vascular tone5 and
blood pressure.6 There are two main endothelin receptor
subtypes, ETA and ET^ but only the ETB receptors are pre¬
sent on the endothelium. Endothelin-1 causes vasocon¬
striction mainly through stimulation of the smooth
muscle cell ETA receptor, although smooth muscle ETB
receptors may also contribute in some vessel types. This
vasoconstrictor response is modulated by autocrine
endothelial cell ETB receptor-mediated generation of the
endothelium-derived vasodilators, nitric oxide and
prostacyclin.
The importance of endogenous t-PA release is exempli¬
fied by the high rate of spontaneous reperfusion in the
infarct-related artery after acute myocardial infarction,
occurring in around 30% of patients within the first 12 h.7-'
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Following an acute myocardial infarction, plasma endothe¬
lial concentrations are elevated and provide an important
prognostic marker of survival at 1 year.10 Furthermore, on
the basis of in vitro studies, it has been suggested that
endothelin-1 may contribute to the regulation of endoge¬
nous fibrinolysis and t-PA release.11"13 However, the evi¬
dence is contradictory, with endothelin-1 being found to
either inhibit13 or stimulate"12 endothelial cell t-PA release.
The role of endothelin-1 in the regulation of endogenous
fibrinolysis in man is currently unknown.
We,1415 and others,1617 have shown, using bilateral fore¬
arm venous occlusion plethysmography and unilateral
brachial artery infusions, that the forearm release of t-PA
and PAI-1 can be determined in vivo in man. Therefore,
the aim of the current study was, using synthetic
endothelin-1 peptide and the selective ETB receptor
antagonist, BQ-788, to determine whether endothelin-1,
of exogenous or endogenous origin, acts via the
endothelial ETB receptor to regulate the release of t-PA or
PAI-1 in vivo in man.
MATERIALS AND METHODS
Subjects
Fourteen healthy men aged between 20 and 33 years
participated in three studies which were undertaken with
the approval of the local research ethics committee and
in accordance with the Declaration of Helsinki. The writ¬
ten informed consent of each subject was obtained
before entry into the study. None of the subjects received
vasoactive or non-steroidal anti-inflammatory drugs in
the week before each phase of the study, and all
abstained from alcohol for 24 h, and from food, tobacco
and caffeine-containing drinks for at least 9 h, before
each study. All studies were performed in a quiet, tem¬
perature-controlled room maintained at 23.5-24.5°C.
Intra-arterial administration and drugs
The brachial artery of the non-dominant arm was cannu-
lated with a 27-standard wire gauge steel needle
(Cooper's Needle Works Ltd, Birmingham, UK) under 1%
lignocaine (Xylocaine; Astra Pharmaceuticals Ltd, Kings
Langley, UK) local anaesthesia. The cannula was attached
to a 16-gauge epidural catheter (Portex Ltd, Hythe, UK)
and patency maintained by infusion of saline (0.9%:
Baxter Healthcare Ltd, Thetford, UK) via an IVAC PI000
syringe pump (IVAC Ltd, Basingstoke, UK). The total rate
of intra-arterial infusions was kept constant throughout
all studies at 1 mL/min. Endothelin-1 (Clinalfa AG,
Laufelfingen, Switzerland) and BQ-788 (American Peptide
Company, Sunnyvale, USA) were administered following
dissolution in saline.
Forearm blood flow and blood pressure
Blood flow was measured in both forearms by venous
occlusion plethysmography using mercury-in-silastic
strain gauges applied to the widest part of the fore¬
arm.1819 During measurement periods the hands were
excluded from the circulation by rapid inflation of the
wrist cuffs to a pressure of 220 mmHg using E20 Rapid
Cuff Inflators (D.E. Hokanson Inc, Washington, USA).
Upper arm cuffs were inflated intermittently to 40 mmHg
for 10 s in every 15 s to achieve venous occlusion and
obtain plethysmography recordings. Analogue voltage
output from an EC-4 Strain Gauge Plethysmograph (D.E.
Hokanson) was processed by a MacLab® analogue-to-dig-
ital converter and Chart 1/3.3.8 software (AD Instruments
Ltd, Castle Hill, Australia) and recorded onto a Macintosh
Classic II computer (Apple Computers Inc, Cupertino,
USA). Calibration was achieved using the internal stan¬
dard of the plethysmograph.
Blood pressure was monitored in the non-infused arm
at intervals throughout each study using a semi-auto-
mated non-invasive oscillometry sphygmomanometer
(Takeda UA 751, Takeda Medical Inc, Tokyo, Japan).20
Venous sampling and assays
Venous cannulae (17G) were inserted into large subcuta¬
neous veins of the antecubital fossa in both arms. Ten mL
of blood was withdrawn simultaneously from each arm
and collected into acidified buffered citrate (Biopool*
Stabilyte™, Urned, Sweden; for t-PA assays) and citrate
(Monovette®, Sarstedt, Numbrecht, Germany; for PAI-1
assays) tubes, and kept on ice before being centrifuged at
2000 g for 30 min at 4°C. Platelet-free plasma was
decanted and stored at -80°C before assay.21
Plasma PAI-1 and t-PA antigen concentrations were
determined using an enzyme-linked immunosorbent
assay (ELISA); Coaliza* PAI-1 [22] and Coaliza® t-PA23
(Chromogenix AB, Molndal, Sweden) respectively. Plasma
t-PA activities were determined by a photometric method,
Coaset* t-PA24 (Chromogenix AB). Intra-assay coefficients
of variation were 7 and 5.5% for t-PA and PAI-1 antigen,
and 4% for t-PA activity respectively. Inter-assay coeffi¬
cients of variability were 4, 7.3 and 4% respectively. The
sensitivities of the assays were 2.5 ng/mL, 0.5 ng/mL and
0.10 IU/mL respectively. Haematocrit was determined by
capillary tube centrifugation of blood anticoagulated by
ethylene diamine tetraacetic acid and was obtained from
the infused forearm at baseline and at 120 min.
Study design
On each study day, subjects attended fasted and rested
recumbent throughout the study. Strain gauges and cuffs
Fibrinolysis & Proteolysis (1999) 13(4S5), 185-191 O Harcourt Publishers Lid 1999
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Time (min)
1 Absolute (mL/100 mL of tissue/min: upper panel) and
:entage (% relative to the non-infused forearm: lower panel)
nge of blood flow in the infused forearm during intra-arterial
sion of BQ-788 (1 nmol/min;0) and endothelin-1 (2.5
>l/min:0 and 10 pmol/min: •).
re applied and the brachial artery of the non-domi-
lt arm cannulated. Throughout each of the studies,
asurements of forearm blood flow were made every 10
i. Before drug administration, saline was infused for
min to allow time for equilibration and the final blood
v measurement during saline infusion was taken as
basal forearm blood flow.
Eight subjects received an intra-brachial infusion of
endothelin-1 at 2.5 and 10 pmol/min for 120 min, given
in random order, on two separate occasions, at least 1
week apart. Eight subjects (two had also attended for
endothelin-1 infusions) received an intra-brachial infu¬
sion of BQ-788 at 1 nmol/min for 120 min. Venous sam¬
ples were withdrawn from each arm at baseline and at 10,
20, 30, 50, 80 and 120 min after the start of endothelin-1
or BQ-788 infusion.
Data analysis and statistics
Plethysmography data were extracted from the Chart
data files and forearm blood flows were calculated for
individual venous occlusion cuff inflations by use of a
template spreadsheet (Excel v5; Microsoft Corporation,
Cambridge, USA). Recordings from the first 60 s after
wrist cuff inflation were not used because of the reflex
vasoconstriction this causes.18 '9 Usually, the last five flow
recordings in each 3 min measurement period were cal¬
culated and averaged for each arm. To reduce the vari¬
ability of blood flow data, the ratio of flows in the two
arms was calculated for each time point: in effect using
the non-infused arm as a contemporaneous control for
the infused arm.1819 Percentage changes in the infused
forearm blood flow were calculated1819 as follows:
% Change in blood flow =
100 x {I,/NIt—Ib/NIb} /
VNIb
Where Ib and NIb are the infused and non-infused fore¬
arm blood flows at baseline (time 0) respectively, and I,
and NI, are the infused and non-infused forearm blood
flows at a given time point respectively.
Estimated net release of t-PA activity and antigen was
defined previously1415 as the product of the infused fore¬
arm plasma flow (based on the mean haematocrit, HCt,
le 1 Systemic haemodynamics, forearm blood flow and haematocrit at baseline and after intra-arterial infusion for 120 min.
BQ-788 1 nmol/min
Basal Final
Endothelln-1 2.5 pmol/min Endothelln-1 10 pmol/min




















1.35 ±0.15 1.14 ± 0.061







3.4 ± 0.3 3.7 ± 0.5
4.0 ±0.4 2.5 ± 0.3'
1.13 ±0.03 0.42 ± 0.03t







3.1 ±0.3 4.1 ±0.3
3.6 ±0.4 1.6 ±0.1*
1.05 ±0.07 0.40 ± 0.03$
0.41 ±0.01 0.40 ±0.01$
3.001 (two-way ANOVA: infused vs non-infused)
0.001 (one-way ANOVA)
0.05 (paired t-test: basal vs final)
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and the infused forearm blood flow, FBF) and the con¬
centration difference between the infused ([t-PA],J and
non-infused arms ([t-PA]Non.J.
Estimated net t-PA release =
FBF x {1-HCt} x {[t-PAU - [t-PA]Non.J
Data were examined by two way analysis of variance
(ANOVA) with repeated measures and two-tailed paired
Student's t-test using Excel 16.O (Microsoft) where appro¬
priate. All results are expressed as mean ± SEM. Statistical
significance was taken at the 5% level. Based on previous
data,1415 the study had 90% power to detect a 20%
change in plasma t-PA concentrations between treatment
periods at the 5% level.
RESULTS
All subjects were normotensive and there were no signif¬
icant changes in blood pressure, heart rate or blood flow
in the contralateral arm throughout any of the studies
(Table 1). Haematocrit decreased slightly in each
endothelin study (Table 1). Between the 3 protocols there
were no significant differences in the baseline values of
blood pressure, heart rate, forearm blood flow, haemat¬
ocrit or plasma concentrations of t-PA and PAI-1.
Endothelin-1 infusions
Endothelin-1 decreased blood flow in the infused arm
(P<0.001) in a dose-dependent manner (Fig. 1) reaching a
minimum of 2.5 ± 0.3 mL/100 mL/min at 2.5 pmol/min
and 1.6 ±0.1 mL/100 mL/min at 10 pmol/min, after 120
min. This corresponds to a relative reduction in forearm
blood flow of 40 ± 4% and 63 ± 3% respectively. The
plasma concentrations of t-PA and PAI-1 did not change
in the infused arm (Fig. 2) during endothelin-1 infusion
at either concentration (P=NS; one-way ANOVA). In com¬
parison to the non-infused arm, there was a trend
(P=0.06; two-way ANOVA) for the infused forearm
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Fig. 2 Plasma concentrations of tissue plasminogen activator (t-
PA) antigen (ng/mL; solid lines) and activity (lU/mL; dashed lines)
in the infused (solid circles) and non-infused (open circles) forearm
during intra-arterial infusion of BQ-788 (1 nmol/min) and
endothelin-1 (2.5 and 10 pmol/min).
pmol/min of endothelin-1. However, there were no
significant differences in plasma concentrations of PAI-1
antigen (Table 2) or t-PA activity between the forearms.
Table 2 Plasma plasminogen activator inhibitor type 1 (PAI-1) concentrations (ng/mL) during endothelin-1 (ET-1) and BQ-788 infusion.
Mean ± SEM.
Time (min)
Baseline 10 20 30 50 80 120
BQ-788 (1 nmol/min)
infused arm 39 ± 15 37 ±13 43 ±15 41 + 13 37 ± 12 37 ± 12 29 ±9
non-infused arm 38 ± 13 40 ± 14 43 ± 14 41 + 13 37 ± 13 33 + 9 32 ±9
ET-1 (2.5 pmol/min)
infused arm 28 ±7 27 ±5 26 ±6 26 ±5 25 ±5 21 ±5 20 ±5
non-infused arm 27 ±5 29 ±6 29 ±6 27 ±5 28 + 7 25 ±5 23 ±4
ET-1 (10 pmol/min)
infused arm 25 ± 5 26 + 4 27 ±5 26 + 5 23 + 5 21+4 22 ±5
non-infused arm 27 ±5 27 + 5 26 ±5 25 ±4 24 ± 5 23 + 5 22 ±4
Fibrinolysis & Proteolysis (1999) 13(4/5). 185-191 O Harcourt Publishers Ltd 1999





























Fig. 3 Theoretical components of venous plasma t-PA
concentration under basal conditions and during increases (upper
panel) and decreases (lower panel) in blood flow with and without
direct stimulation of t-PA release. Open bars: circulating or arterial
t-PA; grey bars: basal 'constitutive' t-PA released from the tissue
bed: black bars: stimulated 'facultative' t-PA released from the
tissue bed
BQ-788 infusion
In comparison to the non-infused arm, BQ-788 decreased
blood flow in the infused forearm after 120 min (relative
reduction of 21 ± 3%) although the absolute blood flow
was unchanged (Fig. 1 and Table 1). The plasma concen¬
trations of t-PA and PAI-1 (Fig. 2 and Table 2) did not
change in the infused forearm (B=NS; one-way ANOVA)
or in comparison to the non-infused forearm (P=NS; two-
way ANOVA).
There was no significant net release of t-PA with infu¬
sions of either endothelin-1 or BQ-788 (Table 3).
DISCUSSION
We have demonstrated that, despite causing significant
reductions in blood flow, neither endogenous nor exoge¬
nous endothelin-1 influences the release of t-PA or PAI-1
in the forearm vascular bed of man. This suggests that
endothelin-1 does not contribute to the regulation of
endogenous fibrinolysis in man
Endothelial cell culture techniques have limitations in
the investigation of t-PA release and may not be truly
representative of the in vivo function of these cells. The
amount of t-PA released in culture is small and necessi¬
tates prolonged incubation periods and sensitive assays.
Moreover, the phenotype of endothelial cells in culture,
and the ability to release t-PA, changes with increasing
passages. This may account for the disparity of our find¬
ings with previous endothelial cell culture studies.13
Studies in intact whole animals have suggested that
systemic endothelin-1 infusion is associated with stimu¬
lation of t-PA release,12 although plasma t-PA concentra¬
tions are not increased by low sub-pressor doses of
endothelin-1 in man.25 Systemic endothelin-1 administra¬
tion, particularly at pressor doses, will induce changes in
cardiac function and regional blood flow as well as hav¬
ing widespread effects on disparate tissues. Thus, the
consequent changes in systemic fibrinolytic parameters
will be a combination of many factors, potentially includ¬
ing hepatic production and clearance of t-PA and PAI-1.
One approach, to avoid these confounding systemic
effects, has been to use the isolated perfused rat
hindlimb model. This ex vivo model has been reported to
demonstrate that endothelin-1 infusion stimulates mod¬
est amounts of t-PA release." However, this increased
'release' may, in part, reflect the concentrating effects of a
reduction in blood flow associated with endothelin-1
infusion and the concentrations of endothelin-1 adminis¬
tered. In studies conducted to date,11-13 endothelin-1 has
been administered in nanomolar concentrations.
Table 3 Estimated net release of tissue plasminogen activator (t-PA) antigen across the forearm during endothelin-1 (ET-1) and BQ-788
infusion. Mean (95% confidence intervals)
Time (mln)
Baseline 10 20 30 50 80 120
t-PA release (ng/100 mL/min)
BQ-788 (1 nmol/min) 1.1 0 0.4 0.3 -0.2 0.1 0.1
(-0.1 to 2.3) (-1.6 to 1.6) (-1.0 to 1.8) (-1.5 to 2.1) (-1.8 to 1.4) (-1.3 to 1.5) (-1.7 to 1.9)
ET-1 (2.5 pmol/min) 0.1 1.4 2.5 1 2 1.7 0
(-0.7 to 0.9) (-0.6 to 3.4) (0.5 to 4.5) (—0.8 to 2.6) (-1.0 to 5.0) (-1.1 to 4.5) (-0.2 to 0.2)
ET-1 (10 pmol/min) 1.3 0.5 0.9 0.3 0.9 0.1 0.8
(-0.3 to 2.9) (-0.4 to 1.9) (0.1 to 1.7) (-0.4 to 1.7) (-0.1 to 19) (-0.7 to 0.9) (0.0 tol .6)
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Although local abluminal concentrations may be high,
normal human plasma endothelin-1 concentrations are
in the femtomolar range. Indeed, in the present study,
assuming a total forearm blood flow of 30-50 mlVmin,
the forearm tissue concentration of endothelin-1 during
the 10 pmol/min infusion will be 200-300 fmol/mL The
previous ex vivo animal studies," therefore, represent
some 4-5 orders of magnitude higher concentrations
and the release of t-PA is likely to represent a pharmaco¬
logical rather than physiological effect.
We have not detected a significant release of t-PA from
the forearm with endothelin-1 infusion despite a 63%
reduction in blood flow at the higher dose. Basal t-PA
release is of the order of -0.9 ng/100 mL of tissue/min in
the forearm"5 and the apparent trend for an increase in t-
PA antigen concentrations may, in part, reflect the reduc¬
tion in blood flow associated with the marked forearm
vasoconstriction (see Fig. 3). This is borne out by the
unchanged t-PA activity, because it would be anticipated
that plasma PAI-1 and t-PA antigen concentrations would
increase proportionately with reductions in blood flow.
ETb receptor antagonism causes both inhibition of
endothelium-derived vasodilators such as nitric oxide,
and potential hyperstimulation of the unopposed ETA
receptor. However, as with endothelin-1, BQ-788 did not
affect plasma concentrations of t-PA or PAI-1 in the
infused forearm.
Forearm release of t-PA has been demonstrated using
various endothelial cell stimulants including metha-
choline,11,26 noradrenaline17 and desmopressin.27 Using
the same technique as in the present study, we have pre¬
viously demonstrated in vivo t-PA release of up to 80
ng/100 mL of tissue/min across the human forearm using
intrabrachial substance P infusion14 and this release is
sustained for at least 2h.15 In contrast, stimulation or
antagonism of the endothelial ET„ receptor, with
endothelin-1 and BQ-788 respectively, does not appear to
influence forearm t-PA release. It is, therefore, unlikely
that endothelin-1 provides a major contribution to the
regulation of t-PA release in man, although we cannot
exclude a small stimulatory effect.
Study limitations
In the forearm, typical resting arterio-venous differences
are only -10% of the total venous t-PA concentration
and the basal constitutive release of t-PA antigen is -0.9
ng/lOOmL of tissue/min.16 We have measured
venous-venous differences between the infused and
non-infused arms which, unlike the measurement of
arteno-venous differences of the infused arm, has the
disadvantage of not being able to correct for blood-flow-
dependent changes in venous plasma t-PA concentra¬
tions. Theoretically (see Fig. 3), in the absence of an
Fibrinolysis & Proteolysis (1999) 13(4/5). 185-191
alteration in t-PA release, a 60% reduction in blood flow
would be anticipated to increase total venous plasma
t-PA concentrations by only -7%, whereas a 200%
increase in flow would reduce t-PA concentrations to the
same degree (-7%). In the presence of stimulated t-PA
release, these small flow-dependent changes are propor¬
tionately reduced even further.
The measurement of arterio-venous differences neces¬
sitates arterial sampling and the insertion of large-bore
cannulae (19-20 gauge) which do not lend themselves to
multiple cannulations within the same subject.
Moreover, there is also the potential to introduce artefact
from the presence of a larger thrombogenic surface,
given that activated factor Xa is the most potent stimu¬
lant for t-PA release yet known.28 To minimize arterial
trauma and facilitate repeated studies in the same sub¬
jects, we have used 27-gauge arterial cannulae which
permit drug infusion but not arterial blood sampling.
However, we would suggest that flow-dependent
changes in venous t-PA concentrations are small, within
the variability of the t-PA assays (-5-7%) and are not of
practical importance. Interestingly, a significant fall in
the arterio-venous difference, or venous plasma concen¬
tration, of t-PA has not been detected during blood
flow increases of up to 600% with sodium nitroprusside
infusion.I4I6W
Measurement of venous-venous and arteno-venous
differences both have the potential limitation that they
can only estimate the net release of t-PA from the fore¬
arm and are unable to take account of clearance of t-PA
within the forearm. However, the majority of t-PA is
removed from the circulation by the liver"' and the con¬
tribution of forearm clearance of t-PA is, therefore, likely
to be very small.
During the present study, we did not see changes in
heart rate or blood pressure to suggest systemic effects of
endothelin-13' or BQ-788 infusion.32 However, measuring
venous concentrations bilaterally will control for any
potential systemic effects which may go unrecognized if
arterio-venous differences are measured in isolation.
Once a drug has a systemic rather than a local effect,
there is always the concern that subsequent t-PA release
may be influenced or mediated by the release of other
humoral factors, such as catecholamines. Moreover, if
the main mechanism of t-PA release is mediated by a sys-
temically released intermediate factor, then measuring
arterio-venous differences could fail to detect this since
arterial concentrations may remain unchanged and
venous concentrations will rise in both forearms.
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Systemic Blockade of the Endothelin-B Receptor Increases
Peripheral Vascular Resistance in Healthy Men
Fiona E. Strachan, James C. Spratt, Ian B. Wilkinson, Neil R. Johnston,
Gillian A. Gray, David J. Webb
Abstract—Endothelin-1 (ET-1) is an important mediator of vascular tone in humans, and a number of endothelin receptor
antagonists are currently in clinical development as vasodilator agents. While the vasoconstrictor role of the ETA
receptor is undisputed, the role of the ETB receptor remains unclear. Hemodynamic effects of systemic doses of the
ETB-selective antagonist BQ-788 were investigated in 5 healthy male volunteers (age range, 33 to 48 years) in a
placebo-controlled, four-way crossover study. After a 15-minute infusion of BQ-788 (3, 30, or 300 nmol/min) or
placebo, plasma ET-1 and big ET-1, blood pressure, heart rate, cardiac index, and stroke index were measured. Total
peripheral vascular resistance was calculated from cardiac index and mean arterial pressure. Hemodynamic data are
expressed as maximum, placebo-corrected, percentage change from baseline following BQ-788 (300 nmol/min) and
were examined by ANOVA. Plasma ET-1 increased by 3.7±1.2 pg/mL (maximum at 15 minutes, P=0.02), whereas
there was no significant change in plasma big ET-1. Although BQ-788 had no effect on mean arterial pressure, there
was a reduction in heart rate (13±7% at 50 minutes; P=0.002), cardiac index (17±5% at 40 minutes; PCO.OOOl), and
stroke index (8±4% at 40 minutes; P=0.002) and an increase in total peripheral vascular resistance (24±5% at 40
minutes; P<0.0001). The selective ETB receptor antagonist BQ-788 causes peripheral vasoconstriction in healthy
volunteers, suggesting that the overall balance of effects of endogenous ET-1 at the vascular ETB receptor favors
vasodilatation. Further investigation is now clearly required to address whether selective ETA or combined ETA/ETB
receptor blockade will be more effective in the clinical setting. (Hypertension. 1999;33[part II]:581-585.)
Key Words: endothelin ■ vasoconstriction ■ blood pressure ■ receptors, endothelin ■ endothelin receptor antagonist
The importance of endothelin-1 (ET-1) as a mediator ofbasal vascular t ne in vivo in humans has been demon¬
strated by local1 and systemic2 vasodilatation in response to
endothelin receptor antagonism. The potent vasoconstrictor
effects of ET-1,4-5 combined with the increased plasma
concentrations of ET-1 associated with cardiovascular dis¬
eases, including heart failure6 and renal failure,7 provide
strong evidence to support a functional role for ET-1 in the
development and maintenance of the increased peripheral
vascular resistance associated with these conditions.
The vascular effects of ET-1 are mediated by two distinct
receptors: the ET-1-selective ETA receptor* and the
nonisopeptide-selective ETB receptor.9 The sustained vaso¬
constrictor effects of ET-1 are predominantly mediated by the
ETa receptor, although vascular smooth muscle ETB receptors
have also been described"' and may, under some circum¬
stances, contribute to ET-1-mediated vasoconstriction in
animal models" and humans in vivo.12 ETB receptors were
first described on endothelial cells, where they act to modu¬
late the vasoconstrictor effects of ET-1 through generation of
nitric oxide11 and prostacyclin.14 The ET„ receptor also has a
role in the clearance of ET-1 from the circulation,15 although
the exact site of the clearance receptor remains to be
confirmed. The contribution of the vascular ETB receptor to
the recognized endogenous ET-1-mediated constrictor tone
depends on the balance between the ETB receptor-mediated
effects of vasodilatation, vasoconstriction, and ET-1
clearance.
Local vasoconstriction to ETB receptor agonists has been
described in healthy volunteers1216 and in patients with heart
failure.17 However, more recently, vasoconstriction after local
administration of the selective ETB receptor antagonist BQ-
788ls has been described in healthy volunteers5 and in
patients with heart failure.19 The results with antagonists are
particularly important as they indicate that the endogenous
effect of vascular ETB receptor stimulation in vivo favors
vasodilatation. Indeed, hypertension has been described after
administration of systemic doses of the selective ET„ receptor
antagonists A192621 in rats and BQ-788 in rabbits in vivo, as
well as in rescued ETB knockout mice.2"-21 The vasoconstric¬
tor effects of ETb antagonism may result directly from
blockade of an endothelial ET„ receptor-mediated dilator
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lone or indirectly from displacement of endogenously gener¬
ated ET-I to vasoconstrictor ETA receptors, or as a result of
reduced clearance of ET-I by vascular ET„ receptors. Con¬
firmation of the balance of the vascular effects mediated by
the ETb receptor in different circumstances is important in
understanding the physiology of the endothelin system and in
determining whether selective ETA receptor antagonists or
combined ETA/ET„ receptor antagonists are likely to be more
effective vasodilator agents in the clinical setting. Although
both selective and nonselective endothelin receptor antago¬
nists have demonstrated vasodilator effects in healthy sub¬
jects,1-2 in patients with heart failure22-2' and in patients with
hypertension,24-25 the question of whether selective ETA or
combined ETA/ETB receptor antagonism will be of more
benefit as vasodilator therapy remains to be clarified.
As a first step in understanding the contribution of the ETB
receptor to the maintenance of vascular tone in vivo, we




Five healthy male subjects between 18 and 50 years of age were
recruited to the study, which was performed in the Clinical Research
Center at the Western General Hospital, Edinburgh, with the ap¬
proval of the local research ethics committee and the written
informed consent of each subject. The investigations conformed with
the principles outlined in the Declaration of Helsinki. No subject
received vasoactive medication or nonsteroidal anti-inflammatory
drugs in the week before each phase of a study, and all subjects
abstained from alcohol for 24 hours and from food, caffeine-
containing drinks, and tobacco for at least 4 hours before any
measurements were made. All studies were performed in a quiet
room kept at a controlled temperature between 22°C to 24°C.
Drugs
BQ-788 (Clinalfa AG) was used as a selective ET„ receptor
antagonist on the basis of both a 1000-fold selectivity of BQ-788 for
the ETb receptor, in the nanomolar range, in human cell lines18 and
inhibition of ET-3 binding to recombinant human ETB receptors
expressed in Chinese hamster ovary cells, also in the nanomolar
range.2'' The dose range (3 to 300 nmol/min) used in the current
study was selected from previous work investigating the local effects
of BQ-788 in the forearm circulation1 and from a dose ranging pilot
study in which 2 volunteers were studied at each dose level (data not
shown) Selected doses (I to 300 nmol/min) were administered in the
pilot study to identify a no-effect dose and select an appropriate
maximum dose for the main study.
BQ-788 was dissolved in physiological saline (0.9%, Baxter
Healthcare, Ltd). Saline (0.9%, Baxter Healthcare, Ltd) was admin¬
istered as placebo. BQ-788 and placebo were administered in a
single-blind manner and infused intravenously at a constant rate for
1.5 minutes via an 18 standard wire gauge (SWG) cannula sited in the
left antecubital vein. All solutions were prepared from sterile stock
solutions on the day of the study.
Measurements
Plasma ET-I and Rig ET-I
Blood samples were obtained before dose and at 5, 15, 60. and 240
minutes after dose via an 18 SWG cannula sited in the noninlused
arm In brief, 10 nil. samples were collected into sterile F.I)I A tubes
(Kt EDTA, Vacutainer. Becton Dickinson Vaeulainer Systems),
centriluged immediately at 2000g for 20 minutes, and stored in plain
lubes at 80 ( helore assav HI I and big HI I (Peninsula
Laboratories Europe) were determined by standard radioimmunoas¬
say, as previously described.27 28
Blood samples were also taken on admission and before discharge
for routine biochemistry and hematology blood tests (sodium,
potassium, creatinine, urea, alkaline phosphatase, y-glutamyl
transpeptidase, hemoglobin, and white cell count).
Hemodynamic Recordings
Hemodynamic recordings were made at 10-minute intervals from 30
minutes before dose until I hour after the start of the infusion, with
an additional blood pressure measurement at 15 minutes correspond¬
ing with the end of the infusion. Recordings were again made at
30-minute intervals until 2 hours and hourly until 4 hours after the
start of the infusion.
Blood pressure and heart rate (HR) were recorded in duplicate at
each time point using a semiautomated noninvasive oscillometric
method in the noninfused arm (Takeda UA 751 sphygmomanometer,
Takeda Medical Inc)29; values were averaged for each time point.
Blood pressure is presented as mean arterial pressure (MAP; diastol¬
ic blood pressure+1/3 pulse pressure, in millimeters of mercury).
Cardiac output and stroke volume were recorded by a well
validated noninvasive bioimpedance technique (NCCOM3; BoMed
Medical Manufacturer Ltd).'0 These parameters were corrected for
body surface area and described as cardiac index (CI, liters per
minute per meters squared) and stroke index (SI, milliliters per meter
squared).2 Total peripheral vascular resistance index (TPVRI) was
calculated as MAP divided by CI and expressed in arbitrary units
(AU).
Study Design
Responses to BQ-788 (3, 30, and 300 nmol/min) and placebo were
investigated in a placebo-controlled, four-way crossover study.
Study drugs were administered in a single-blind manner. The order
of treatments was randomized. Five subjects attended for 4 separate
study visits, each separated by at least 5 days. Subjects were resident
in the research center for at least 6 hours. Subjects rested supine for
at least 20 minutes before hemodynamic measures, and baseline
measures were made in the 30 minutes before study drug
administration.
Analysis
Plasma ET-1 and big ET-1 are represented as absolute change from
predose (picograms per milliliter), with statistical significance as¬
sessed by paired t test. Hemodynamic results are expressed as
maximum placebo-corrected percentage changes from baseline
±SEM.2 Statistical analysis was performed on untransformed data.
Responses were examined by repeated-measures ANOVA. Statisti¬
cal significance was taken at the 5% level, and analysis was
performed using an Excel data analysis package (Excel 5.0,
Microsoft Ltd).
Results
All 5 healthy male subjects (age range, 33 to 48 years)
completed the study. No adverse events were reported, and
there were no clinically relevant changes in routine biochem¬
istry and hematology blood tests.
Plasma ET-1 and Big ET-1
Predose plasma ET-1 concentrations did not differ signifi¬
cantly for any of the treatments (range of baseline mean
values, 4.4 to 4.9 pg/mL). Plasma ET-I concentration in¬
creased significantly after administration of BQ-788 (from
4.6±0.8 to 8.4± 1.8 pg/mL at 15 minutes with .700 nmol/min,
/' 0.02) but not during treatment with the lower doses of
BQ-788 or placebo (Figure I). In contrast, concentrations of
big ET-I did not change significantly with iiealinciii.
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Figure 1. Change in plasma ET-1 concentrations after
15-minute intravenous infusion of BQ-788 or saline placebo in 5
subjects. Solid columns indicate BQ-788 at 300 nmol/min;
shaded columns, BQ-788 at 30 nmol/min; hatched columns,
BQ-788 at 3 nmol/min; and open columns, placebo. Plasma
ET-1 concentrations increased significantly after administration
of BQ-788 at 300 nmol/min.
Hemodynamic Parameters
Baseline measurements for hemodynamic parameters during
the placebo treatment period were as follows: MAP,
79±3 mm Hg; HR, 79±3 bpm; CI, 2.6±0.2 (L/min)/m2; SI,
49±3 mL/m2; and TPVRI, 31.1 ±1.8 AU. Baseline values
were similar for each of the other treatment periods. MAP did
not alter significantly after administration of BQ-788 at any
dose (3±2% at 90 minutes with 300 nmol/min; P=0.4)
(Figure 2). After administration of BQ-788, there were
changes in all other hemodynamic parameters when com¬
pared with placebo that appeared to be dose-related and that
were significant at 300 nmol/min; HR decreased (13±7% at
50 minutes after dose; P=0.002), CI decreased (17±5% at 40
minutes; P<0.0001), and there was a small reduction in SI
(8±4% at 40 minutes; P=0.002). TPVRI increased (24±5%
at 40 minutes; P<().()001).
Discussion
We have demonstrated substantial systemic vasoconstric¬
tion, associated with a reduction in HR and CI but no
change in MAP, in response to administration of the
selective ET„ receptor antagonist BQ-788 in healthy men.
Consistent with our earlier work in the forearm circula¬
tion,1 these observations are highly suggestive of the
overall effect of endogenous ETH receptor-mediated vas¬
cular tone favoring vasodilatation. An alternative explana¬
tion for the hemodynamic effects is that BQ-788 is directly
negatively chronotropic and that peripheral effects are
indirect. However, this is unlikely given our earlier work1
and the lack of evidence of an important positive chrono¬
tropic and inotropic role of the cardiac FT,, receptor.11
Although peripheral resistance was substantially in¬
creased, blood pressure was unaffected because of a
decrease in HR that was probably reflex in origin. We have
also demonstrated increases in plasma ET-1. bul not big




























Figure 2. Placebo-corrected mean percentage change in MAP,
HR, CI, SI, and TPVRI after 15-minute intravenous infusion of
BQ-788 or saline placebo in 5 subjects. Closed circles indicate
BQ-788 at 300 nmol/min; open circles, BQ-788 at 30 nmol/min;
and shaded diamonds, BQ-788 at 3 nmol/min. There was no
change in MAP, but there was a reduction in HR, CI, and SI and
an increase in TPVRI after administration of BQ-788 at 300
nmol/min.
tent with reduced clearance of ET-l by the ET„ receptor.1''
All of these effects were prominent with BQ-788 at the
highest dose but were not clearly seen at lower doses.
The vasoconstrictor effects of ET„ receptor antagonism
may result directly from blockade of the vasodilator effects of
the endothelial ET„ receptor or indirectly from displacement
of endogenously generated ET-1 from ETH receptors to
unoccupied ETA receptors. It is unlikely that these ellects are
mediated by nonselective ETA/ETB receptor blockade because
they are the opposite of those found with selective ETA
receptor antagonists in healthy subjects (unpublished data,
1998) and patients with heart failure22 and of those found
with combined ETA/ET„ receptor antagonists in healthy
subjects.2 Clearly, the indirect effects ol ET-1 on HIA
receptors are more relevant with administration ol selective
ET|, antagonists than with nonselective ETA/EIh receptor
antagonists, because in this latter situation the constrictor E I ,
receptor is also blocked. Indeed, vasodilator ellects have been
demonstrated with both selective' ' and nonselective
P < o.oooi
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endothelin receptor antagonists in humans, and the nonselec¬
tive ETA/ETB antagonist bosentan has recently been shown to
effectively lower blood pressure in patients with hyperten¬
sion. 21 However, direct comparison of the effects of selective
and nonselective endothelin receptor antagonism will be
important in assessing the relative contribution of each
receptor subtype to the vascular effects of ET-I.
We and others have previously demonstrated forearm
vasodilatation in response to local ETA receptor antagonism
with BQ-123.1112 In the presence of BQ-788 in healthy
volunteers, this effect was attenuated,1 suggesting that the
overall effect of vascular ETB receptor stimulation by endog¬
enous ET-1 is vasodilatation. This attenuation of BQ-123-
mediated vasodilatation by BQ-788 suggests that the vaso¬
constrictor effect of ETb receptor blockade is not mediated by
displacement of ET-1 onto the ETA receptor but is due to
direct blockade of ETB-mediated vasodilator tone. We have
also shown, using a "nitric oxide clamp" technique, that the
vasodilator response to BQ-123 is in part mediated by nitric
oxide1 and, therefore, probably mediated by the endothelial
ETb receptor. Loss of endothelial cell ETB-mediated vasodi¬
lator tone may occur in cardiovascular diseases, such as
essential hypertension and hypercholesterolemia, in which
there is associated endothelial dysfunction.33-14 Here, because
of a reduced capacity for ET„ receptor-mediated, nitric
oxide-dependent dilatation, selective ETA receptor antago¬
nists may be less effective.
In summary, we have demonstrated systemic vasocon¬
striction in response to acute ETB receptor blockade with
the selective ETB receptor antagonist BQ-788 in healthy
men in vivo, indicating that the predominant endogenous
effect of stimulating vascular ETB receptors is vasodilata¬
tion. One exciting possibility is that tonic endogenous
ET-1 release, acting via the endothelial ET„ receptor, is
responsible for the physiological basal release of nitric
oxide. This now needs to be addressed in clinical studies.
Further investigation of the influence of ETB receptor
antagonism on the sympathetic nervous system and renal
function are also warranted. In addition, direct comparison
of the effects of chronic administration of selective ETA
and combined ETA/ETB receptor antagonists is required in
patients with cardiovascular disease, with and without
endothelial dysfunction, in order to confirm which of these
approaches is likely to be more effective in the clinical
setting.
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Summary
Endothelin-l (ET-1) is a powerful vasoconstrictor peptide which is generated by the vascu¬
lar endothelium. It was first described in 1988 by Yanagisawa and colleagues and has since
become the focus of a great deal of research interest. As a result of its potent vasoconstrictor
effects, ET-1 has been implicated as an important mediator of the raised peripheral vascular
resistance associated with a number of cardiovascular conditions, notably heart failure, hy¬
pertension and renal failure. A number of endothelin receptor antagonists are currently in
development as novel treatments for cardiovascular disease. These compounds have vaso¬
dilator effects in healthy volunteers and in patients with cardiovascular disease both in the
presence and absence of existing treatments. Endothelin antagonists have also been shown
to have beneficial effects on renal function and may be of value in the treatment of both
chronic and acute renal failure.
Although current treatments have proven effective in limiting disease progression and mor¬
tality, cardiovascular disease remains a significant public healthcare problem. The endothe¬
lin system provides an exciting therapeutic target for the development of new treatments for
a number of cardiovascular diseases. The results from ongoing clinical trials are awaited
with interest.
Background
H I -1 is a potent vasoconstrictor peptide which is generated by the vascular endothelium [ 1 ].
ET-1 plays an important role in the regulation of vascular tone and blood pressure in vivo [2]
and, as a result of its powerful and sustained vasoconstrictor effects [3], has been implicated
as a mediator of the raised peripheral vascular resistance associated with a number of car¬
diovascular diseases, including essential (or primary) hypertension, chronic heart failure
and chronic renal failure. In addition to its direct vasoconstrictor actions, ET-1 can potentiate
the vasoconstrictor effects of other constrictor substances including noradrenaline and
angiotensin II [4], ET-1 has co-mitogenic effects [5], and thus may play a role in vascular
modelling and cell proliferation. The direct and indirect effects of ET-1 on vascular function
95
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Figure 1: Endothelin-1 (ET-1) is a 21 amino acid generated by a precursor pathway through the actions of endothelin converting
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Figure 2: Endothelin-1 is generated by endothelial cells and is secreted abluminally to act on both ETa and ETb receptors. ETa mediates
the potent vasoconstrictor effects of endothelin-1. The ETb receptor mediates vasodilatation through generation of nitric oxide and pros¬
tacyclin. The ETb receptor may also mediate vasoconstriction and acts as a clearance receptor for endothelin-1. The balance of effects at
the ETb receptor appears to favour dilatation [85],
COX: Cyclo-oxygenase; ET-1: Endothelin-1; NO: Nitric oxide; NOS: Nitric oxide synthase; PGh: Prostacyclin.
indicate its potential importance in the pathophysiology of the development and progres¬
sion of cardiovascular disease. Plasma concentrations of ET-1 are increased in a number of
cardiovascular diseases, including heart failure [6,7], renal failure [8,9], and myocardial in¬
farction (MI) [10], and, inmost cases, the increase in plasma endothelin concentrations corre¬
lates with markers of disease progression. Although it is unclear whether the increase in
plasma concentrations of ET-1 is merely amarker of disease progression, there is strong evi¬
dence to support a functional role for ET-1 in the pathophysiology of a number of cardiovas¬
cular diseases.
ET-1 is continuously generated from its precursor, big ET-1, through the actions of a specific
endothelin converting enzyme (ECE) (Figure 1). A number of factors stimulate the
generation of ET-1, including the vasoactive hormones, angiotensin II and arginine
vasopressin [11], inflammatory mediators and physicochemical factors, such as altered
vascular shear stress and hypoxia. ET-1 generation can also be inhibited by a number of
vasoactive factors, including nitric oxide [12]. Two endothelin receptors mediate the
vascular effects of ET-1 in humans, the ET^ [13] and ETg [14] receptors (Figure 2). The ET^
receptor situated on the vascular smooth muscle mediates the potent vasoconstrictor effects
of ET-1. The ETg receptor is present on endothelial cells where it mediates vasodilatation
through generation of nitric oxide and dilator prostanoids [15,16]. ETg receptors have also
been described on vascular smooth muscle cells [17] and these receptors appear, under some
circumstances, to mediate vasoconstriction [18,19], However, the contribution of the ETg
receptor to endogenous ET-1 mediated constrictor tone is currently unclear. From the results
of recent studies it would appear that, in healthy blood vessels [20] and in the blood vessels
of patients with chronic heart failure [21], the vasodilator effects of the ETg receptor
predominate. However, further clinical trials, in patientswith other forms of cardiovascular
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the overall balance of the vascular effects of ETg receptor stimulation, and effects on other
organs such as the kidney, will be crucial in determining whether combined ETa/b or
selective receptor blockade will be more beneficial in the treatment of cardiovascular
disease. A clearance role for the ETb receptor has also been proposed [22,23]. Although
clearance has been demonstrated from the lungs, liver and kidney [22], a specific site for the
clearance ETb receptor has not been identified. However, the clearance role of the ETg
receptor again provides a rationale for selective blockade of the ETa receptor, to allow
continuing clearance of endogenously generated ET-1 by the ETb receptor. The
development of ECE inhibitors and combined ETa/b and selective endothelin receptor
antagonists has been helpful in characterising the endothelin system. As yet there are no
selective ECE inhibitors in clinical development.
The potential value of endothelin antagonists as vasodilator treatments is currently being in¬
vestigated. Althoughmuch of the research interest is focused on the potential of endothelin
receptor antagonists in cardiovascular disease, endothelin receptor antagonistsmay also be
of value in the treatment of a number of conditions as diverse as bronchospasm [24], prostate
cancer [25], portal hypertension [26], and Gram-positive infection [27].
The focus of this review will be the development of endothelin antagonists as vasodilator
and antiproliferative treatments in cardiovascular disease.
Medical need
Cardiovascular disease is one of the main causes ofmorbidity and mortality in Western soci¬
ety. Despite the development of effective therapies, primary cardiovascular diseases com¬
monly progress to heart failure [28]. Recently successful therapies in chronic heart failure
focus on inhibiting neurohumoral pathways and other vasoconstrictors, thereby reducing
peripheral vascular resistance. Although this approach has proven successful in slowing
disease progression and in improving both morbidity and mortality, chronic heart failure
remains a significant cause of death and disability in the UK [29], The endothelin system has
emerged as an attractive new therapeutic target in cardiovascular medicine.Wewill discuss
the potential of endothelin antagonists in the context of essential hypertension, chronic heart
failure, acute and chronic renal failure, MI and subarachnoid haemorrhage.
Essential hypertension
Essential hvpertension is a condition in which arterial pressure is increased with no appar¬
ent primary cause. Peripheral vascular resistance is increased, and vascular and cardiac hy¬
pertrophy, which are associated with a worse prognosis, may develop. Hypertension is
commonlv seen in the middle-aged and elderly, affecting one in seven of the adult popula¬
tion, and is associated with an increased risk of stroke,MI, heart failure and renal failure. The
current aim of therapy is to reduce the degree of blood pressurewithin acceptable limits and
thereby prevent the risk of cardiovascular complications. Changes in lifestyle and dietary
habits can help reduce hypertension but drug intervention is required where thesemeasures
fail or where the degree of hypertension is more severe [30].
Plasma endothelin concentrations are not normally raised in essential hypertension but
have been described in patients with co-existing renal disease [8]. Nevertheless, the potent
vasoconstrictor and vasopressor actions of ET-1 may play a role in the development of in¬
creased blood pressure and in the pathophysiology of disease progression. The co-
mitogenic properties of ET-1 may be important in the hypertrophic and atherosclerotic pro¬
cess, again associated with an increasing cardiovascular risk. Early studies with endothelin
receptor antagonists in hypertension have been promising. Local vasodilatation has been
demonstrated in response to the ETa selective antagonist, BQ-123 [31 ], in healthy volunteers
(OAshley Publications Ltd. All rights reserv cJ Emerging Drugs 199X
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[32] and in patients with hypertension [33]. Systemic administration of the combined ETa/b
receptor antagonist, TAK-044 [34], lowered blood pressure and systemic vascular resistance
in healthy volunteers [2[. Interestingly, a single oral dose of the combined ETa/b antagonist,
bosentan, was effective in lowering blood pressure in patients with essential hypertension
[35]. Unpublished data suggest a chronic effect on blood pressure of endothelin receptor an¬
tagonism with bosentan that is equivalent to that associated with the ACE inhibitor, enala-
pril. In essential hypertension, endothelin antagonists may provide additional blood
pressure reduction in combination with existing therapies or may be useful in treating hy¬
pertension that has proven resistant to current methods of treatment. The combined vaso¬
constrictor and co-mitogenic properties of ET-1 provide an argument for the use of
endothelin antagonists in this condition and the results of further studies are awaited.
Heart failure
Heart failure is a common and disabling condition that results from impaired left ventricular
function. Cardiac output is lowered, sodium and water retention develop, and there is in¬
creased peripheral vascular resistance associated with activation of the sympathetic nerv¬
ous system and the renin-angiotensin system [36,37], A successful approach has been to
reduce peripheral vascular resistance in order to lessen the damaging effects of increased
vascular tone on cardiovascular function. Indeed, the use of ACE inhibitors [38], hydra¬
lazine or nitrates [39] has proven this approach to be effective in terms of both symptoms and
prognosis. However, despite the apparent success of ACE inhibitors,mortality remains high
[29]. The endothelin systemmay provide an additional therapeutic option in heart failure.
Plasma concentrations of ET-1 and its precursor, big ET-1, are elevated in heart failure and
correlatewith the likelihood of death and with the need for cardiac transplantation [6,7]. Al¬
though the increase in plasma ET-1 may result from reduced renal clearance, the increase in
big ET-1 concentrations indicates a likely increase in the generation of ET-1. Given the potent
vascular effects of ET-1, the correlation between measures of mortality and morbidity and
the increase in plasma levels of ET-1 and big ET-1, the endothelin system is likely to be of
functional importance in the pathophysiology of heart failure. Early clinical studies have
demonstrated benefits of endothelin antagonists in the presence and absence of existing
treatment with an ACE inhibitor. Local vasodilatation to selective ETa antagonism with
BQ-123 and to ECE inhibition with phosphoramidon, a non-selective ECE/NEP inhibitor
[40], was shown in patients with heart failure who were receiving treatmentwith an ACE in¬
hibitor [41]. Systemic administration of bosentan in patients with heart failure produced sig¬
nificant systemic and pulmonary vasodilatation; reducing mean arterial pressure,
pulmonary arterial pressure, right atrial pressure and pulmonary artery wedge pressure.
Cardiac index was also increased with no change in heart rate [42]. In healthy human vascu¬
lature it would appear that there is an endogenous ETR-mediated dilator tone [20]. Interest¬
ingly, in patients with heart failure, selective ETr receptor antagonism with BQ-788 [43]
resulted in local vasoconstriction [21], indicating that, despite increased plasma concentra¬
tions of ET-1, the endothelial ETb receptor provides sufficient vasodilator effects to balance
the constrictor effects of the vascular smooth muscle ETr receptor. Further investigation of
the systemic effects of combined ETa/b and selective endothelin receptor antagonism in
heart failure is required to confirm which approach will be ofmore benefit in the clinical set¬
ting. Phase II and III trials investigating selective and combined ETa/b endothelin antago¬
nists in the treatment of heart failure are in progress.
Given the increase in plasma concentrations of big ET-1 in heart failure [6,7] and the pro¬
posal that this indicates an increase in the generation of ET-1, ECE inhibitors may also be of
value in treating chronic heart failure. As yet there are no selective ECE inhibitors in clinical
development but non-selective ECE/NEP inhibitors are being investigated in this context.
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Chronic renal failure
Chronic renal failure results from a progressive loss of renal function, the two commonest
causes being hypertension and diabetes mellitus [44]. Continued loss of renal function de¬
spite the absence of underlying disease activity indicates that progressive damage results
from common mechanisms independent of the initial cause. Chronic renal vasoconstriction
contributes to the loss of functioning renal tissue and, although no specific mediator has
emerged as a clear therapeutic target, blood pressure control has proven to be of value in the
treatment of renal failure [45]. There is no clear evidence that one class of antihypertensive
agent is better than another [46], However, ACE inhibitors have demonstrated renoprotec-
tive effects in diabetes mellitus [47] and have proven useful in lowering blood pressure in
this context. There are a number of potential mediators involved in renal vasoconstriction
and long-term studies comparing the effects of ACE inhibitors with alternative therapeutic
measures are necessary.
Plasma concentrations of ET-1 are elevated in renal disease [8,9] and are likely to result from
a reduced renal clearance of ET-1 rather than increased production of the peptide. However,
it is also likely that ET-1 is involved in the progression of renal disease [48]. Indeed, in a rat
model of progressive renal disease, renal ET-1 gene expression correlated with disease pro¬
gression [49]. From animal studies, there is increasing evidence that ET-1 plays a role in the
progression of renal disease. Investigation of the role of ET-1 and the endothelin receptor
subtypes in renal function and the progression of renal disease in humans is ongoing.
Although the ETg receptor subtype predominates in the human kidney [50], a greater pro¬
portion of ETa receptors are localised to the vasculature and the ETa subtype is more likely
to be important in mediating renal vasoconstriction to ET-1 [51]. The selective ETa receptor
antagonist, FR139317, appeared to be successful in preventing disease progression in a rat
model of chronic renal disease; with a reduction in proteinuria, markers of cell proliferation
and evidence of protection against glomerular structural injury [52]. Tubular ETg receptors
may offer renoprotection through sodium and water excretion in ischaemic conditions [53].
Therefore, it may be more important to selectively block the ETa receptor and preserve ETg
mediated diuresis and natriuresis [53]. It is important to interpret the results of studies in
animalmodels with caution, due to species differences in renal physiology [45] and in endo¬
thelin receptor distribution [53]. Early clinical trials have been conducted in patients with
chronic renal failure. The results of such studies will help identify the potential of endothelin
antagonists in a clinical context.
Acute renal failure
Acute renal failure develops over a period of hours to days and can result from tubular is-
chaemia, obstruction or toxic insult, or from a marked reduction in renal perfusion [54],
Acute renal failure is associated with a high mortality [55] and is a common complication of
cardiac surgery and administration of radiocontrast agents. Renal vasoconstriction is
thought to be important in the pathophysiology of radiocontrast nephropathy, and this may
be mediated by ET-1 [56]. Indeed, plasma endothelin concentrations have been shown to in¬
crease following intravascular administration of a radiocontrast agent in rats [57], and selec¬
tive ETa antagonism reduced necrotic damage following radiocontrast administration in a
rat model [58]. The potent vasoconstrictor effects of ET-1, combined with its effects on renal
blood flow and glomerular filtration, suggest a role for endothelin in the pathophysiology of
ischaemic acute renal failure [59,60]. In addition to the beneficial effects described in chronic
renal failure, selective and combined ETa/b endothelin antagonists have also been shown to
limit disease progression in acute models of renal failure [48,59,61,62], Interestingly, ad¬
ministration of the ECE/NEP inhibitor, phosphoramidon [40], was more effective in restor¬
ing renal function and in minimising structural changes than selective ETa antagonism with
BMS-182874 in a model of ischaemic renal failure [63]. Again, further studies and direct
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comparison of selective and combined ETa/b antagonists are required to confirm the poten¬
tial of these compounds in the clinical setting.
Myocardial infarction
Plasma ET-1 concentrations are increased in MI and are strongly related to mortality [10].
The vascular effects of ET-1 indicate a potential role in the progression of myocardial dam¬
age to heart failure. However, it is not clear whether ET-1 plays a role in infarct development.
A number of studies have been carried out in animal models with conflicting results. In a
model of MI in pigs, the selective ETa receptor antagonist, PD 1567807, did not reduce in¬
farct size [64]. In contrast, the selective ETa receptor antagonist, BQ-123, improved survival
and lessened cardiac dysfunction in a rat model of MI [65]. These differences may be ex¬
plained by species difference in receptor distribution and function butmay also be related to
the timing of drug administration in relation to the myocardial event. The potential of endo-
thelin antagonists in the treatment ofMI and the prevention of the progression of cardiovas¬
cular disease remains to be confirmed.
Subarachnoid haemorrhage
Subarachnoid haemorrhage carries a risk of rebleeding and of cerebral ischaemia associated
with cerebral vasospasm. Although the mechanism involved in cerebral vasospasm is un¬
clear, ET-1 is a likely mediator of this effect [66], In support of this, combined ETa/b antago¬
nism with bosentan was effective in preventing [67] and reversing [66] cerebral vasospasm
in a rabbit model of subarachnoid haemorrhage. Selective ETa receptor antagonism, with
BQ-485 [68] andwith Ro 61-1790 [69], is also effective in limiting cerebral vasospasm in a dog
model of subarachnoid haemorrhage. Clinical trials investigating the effects of bosentan in
patients with subarachnoid haemorrhage are in progress and the results have so far been
promising [Breu, 1997 - personal communication]. ET-1 may also be involved in the devel¬
opment of cerebral ischaemia through cerebral vasoconstriction. Further investigation of se¬
lective and combined ETa/b endothelin antagonists in the treatment of subarachnoid
haemorrhage will reveal the true potential of these compounds in this context.
Existing treatment
Essential hypertension
Diuretics and beta-blockers are currently recommended as the treatments of first choice in
essential hypertension [30,70]. Clinical trials with diuretics and beta-blockers show they re¬
duce the risk of cardiovascular complications, including stroke, coronary heart disease and
renal disease [70], but these drugs have well documented limitations [30].
Although diuretics and beta-blockers are traditionally the first line of drug treatment in hy¬
pertension, additional classes of drugs are recommended for cases resistant to this ap¬
proach. These additional drugs include ACE inhibitors, angiotensin II receptor antagonists,
calcium antagonists and alpha-blockers [30,70]. It is common for drug treatments to be given
in combination, especially in cases that have only partially responded to initial treatment.
ACE inhibitors are indicated in patientswith heart failure orwith diabetic nephropathy [71 ]
and have been shown to reduce albuminuria in patients with hypertension [72], Although
ACE inhibitors have demonstrated renoprotective effects [47] through a lowering of intra-
glomerular pressure, this can unacceptably lower glomerular filtration rate in patients with
renal artery stenosis. Therefore, ACE inhibitors should be prescribed with caution in this
group. ACE inhibition leads to an increase in tissue kinin levels which may lead to symp¬
toms of cough, urticaria and angioneurotic oedema, and these adverse effects have obvious
effects on patient compliance and tolerance of this treatment.
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Angiotensin II receptor antagonists are a relatively new class of compounds that block the
effects of angiotensin IIwithout blocking its generation. There is no associated accumulation
of kinins and, consequently, the kinin mediated adverse effects associated with ACE inhibi¬
tion are absent. However, beneficial kinin-mediated dilatation may also be lost [70].
Calcium antagonists are also prescribed in the treatment of hypertension. Although admini¬
stration of these compounds has been associated with some disadvantages, results from the
SYST-EUR trial in elderly patients suggest that there is a reduction in the incidence of stroke
and in cardiovascular-related mortality with long-term administration of the calcium an¬
tagonist nitrendipine [73].
Despite increasing knowledge of the risk factors associated with the development of hyper¬
tension and the mechanisms underlying increased vascular tone, a considerable proportion
of hypertension remains resistant to current treatments [30,70]. One explanation for this
could be poor patient compliance. Also, it may be true that there are a number of different
mediators of hypertension and that the current range of therapies, although broad, is not ex¬
haustive and is not directed at causal influences. A number of genotypic variants have been
described which could identify individuals with differences inmetabolism or responses to a
given class of drug [74], If proven reliable, treatments could in future be prescribed accord¬
ing to specific genotypes.
Heartfailure
Treatment of heart failure should provide symptomatic relief, aim to prevent or delay the
progression of left ventricular dysfunction, and reducemortality [39], This requires a combi¬
nation of drugs, currently including: diuretics, vasodilators - nitrates, ACE inhibitors, hy¬
dralazine and isosorbide dinitrate - digoxin, anti-arrhythmic drugs and anticoagulants. Of
these drugs, ACE inhibitors have been the most effective in reducing both morbidity and
mortality in patients with heart failure [38]. The therapeutic benefits of ACE inhibition
probably result from a combination of vascular effects: prevention of the constrictor effects
of angiotensin 11, increased concentrations of the vasodilators bradykinin and nitric oxide,
and sympatholytic and parasympathomimetic effects. However, despite the success of ACE
inhibition, mortality remains high. Heart failure still represents a large public health prob¬
lem in the US, with approximately 400,000 new cases reported annually and annual health¬
care costs currently quoted at $17.8 billion [28]. Similarly, heart failure is a growing problem
in the UK with a reported annual cost to the NHS of £360 million [75].
Chronic renal failure
The aim of treatment in chronic renal failure is to slow its progression to prevent end-stage
renal disease. Current therapeutic approaches involve maintenance of blood pressure
within acceptable limits, renoprotection with ACE inhibitors, dietary restriction, close
monitoring of renal function and avoidance of further renal insult [44], Loop diuretics are ef¬
fective in reducing oedema associated with chronic renal failure [76]. There is a limited
range of effective therapies to prevent progression of chronic renal disease, and the health
cost is high. Although ACE inhibitors have proved useful in this context in terms of lowering
blood pressure and in reducing proteinuria, clinical studies comparing other treatments are
required to confirm that that their popularity matches their efficacy [46]. The limitations of
ACE inhibitor therapy described in the sections above illustrate the need for additional
therapies for use in combination with, or in place of, ACE inhibitors.
Acute renal failure
Initial treatment of acute renal failure focuses on treatment of the underlying condition and
correction of fluid and electrolyte imbalances. Haemodialysis is indicated in severe cases of
acute renal failure [54]. As yet, there is no clear drug of choice for acute renal failure and
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treatments are aimed at support and prevention of further renal damage. Loop diuretics
may be prescribed in acute renal failure. However, their benefits have not been confirmed
and long-term studies are in progress to evaluate their effects [76]. Dopamine has also been
indicated in the prevention and treatment of acute renal failure. However, as there is no clear
cut evidence to support its efficacy in this context, long-term trials are required [77]. The cost
of dialysis is considerable and the development of less expensive and more effective forms
of treatment for acute renal failure is of obvious advantage.
A number of vascular mediators are being investigated as potential therapeutic targets in
acute renal failure. Atrial natriuretic peptide (ANP) is an endogenous hormone that in¬
creases glomerular filtration rate, blocks tubular reabsorption of sodium and chloride, and
reverses endothelin-induced vasoconstriction. In a study of patients with renal dysfunction
following cardiac surgery, treatmentwith ANP improved renal function and reduced renal
vascular resistance [78]. However, acute treatment with anaritide, a synthetic form of ANP,
did not improve overall mortality rates in patients with acute tubular necrosis [79]. The
anti-inflammatory and antiproliferative effects of peptides isolated from matrix proteins
with the Arg-Gly-Asp sequence (RGD peptides) have generated interest in these com¬
pounds as potential new treatments for acute renal failure [80].
Myocardial infarction
Early reperfusion therapy in acute MI, through thrombolysis with pharmacological agents
or direct angioplasty, improves survival rates. However, reperfusion injury can occur and
complicate the recovery process. Clinical trials investigating the need to protect the myocar¬
dium against reperfusion injurywith agents such as adenosine are ongoing [81]. ACE inhibi¬
tors are also indicated followingMI, especially in patientswith left ventricular dysfunction.
In the SAVE trial [82], long-term treatment with the ACE inhibitor, captopril, within 3-16
days following MI improved survival and reduced the development of heart failure in pa¬
tients with asymptomatic left ventricular dysfunction. However, despite improvement in
mortality and delay in the progression of heart failure with current treatments, myocardial
infarction is still associated with significant morbidity and mortality. The timing of drug
treatment in myocardial infarction can have a marked effect on the success of the interven¬
tion as early initiation of ACE inhibition may lessen the associated therapeutic benefits [83].
Further investigation of the pathophysiology of the remodelling process is required.
Subarachnoid haemorrhage
The development of cerebral vasospasm following subarachnoid haemorrhage is associated
with much of its mortality and morbidity. However, there is no clear drug of choice recom¬
mended for the prevention of this event. Rebleeding and subsequent cerebral infarction is a
risk associated with subarachnoid haemorrhage. Treatment with the calcium antagonist, ni-
modipine, has been shown to reduce the incidence of cerebral infarction and improve out¬
come following subarachnoid haemorrhage [84], although to a limited degree.
Current research goals
The therapeutic potential of a number of orally active endothelin receptor antagonists is cur¬
rently under investigation in Phase II and Phase III clinical trials in heart failure and in hy¬
pertension. Demonstration of a vasodilator response to these compounds, especially in the
presence of existing therapies, will be vital if endothelin antagonists are to be indicated as al¬
ternative treatments in these chronic cardiovascular conditions. Once initial benefits have
been demonstrated, long-term trials will be necessary to confirm their benefits in terms of
prevention of disease progression. Phase II and III clinical trials investigating the long-term
administration of orally-active compounds in the treatment of patients with heart failure are
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in progress. Intravenous compounds are currently being investigated as potential treat¬
ments in acute renal failure. Studies in animal models have proven promising and clinical
trials are now required to confirm the potential of these compounds. The question of
whether combined ETa/b or selective receptor antagonism will be ofmore benefit as vasodi¬
lator treatments depends on the balance between the ETg receptor-mediated effects of vaso¬
dilatation, vasoconstriction and clearance [85]. Further investigation of the actionsmediated
by the ETg receptor in health and in specific disease states is necessary to answer this ques¬
tion. This issue is of particular relevance in cardiovascular diseases, such as essential hyper¬
tension and in hypercholesterolaemia, where there is associated endothelial dysfunction
[86,87], and there may be a reduced capacity for ETg receptor-mediated dilatation.
ECE inhibitionmay be a useful approach in limiting the vascular effects of ET-1 in conditions
where its generation is increased. ECE inhibitors are likely to have systemic vasodilator ef¬
fects: directly by inhibition of ET-1 generation and consequent removal of its constrictor
tone, and indirectly by removal of the inhibitory effects of ET-1 on nitric oxide generation
[12]. Indeed, local vasodilatation was demonstrated following local administration of the
non-selective ECE/NEP inhibitor, phosphoramidon [40], in humans in vivo [32]. At present
there are no selective ECE inhibitors in clinical development, although ECE inhibitors are
currently in preclinical development and are likely to progress towards studies in man.
Scientific rationale
ET-1 is a potent vasoconstrictor peptide generated by the endothelium [1]. It is one of a fam¬
ily of three related peptides: ET-1, ET-2 and ET-3, encoded from three distinct genes [88], As
ET-1 is the predominant isoform produced by the endothelium, it is likely to be themost im¬
portant in the regulation of vascular tone. ET-1 is generated from its precursor, big ET-1,
through the actions of an ECE. Generation of ET-1 is regulated at a transcriptional level and
is influenced by a number of factors (Figure 1). At least two ECE isoforms have been identi¬
fied [89,90], with a number of subtypes already described. It is not yet clear which of these
isoforms is involved in the pathophysiology of cardiovascular diseases [85,91].
ET-1 is secreted abluminally to act on the vascular smooth muscle in a paracrine and auto¬
crine manner. As a result, plasma concentrations of endothelin are not always an accurate re¬
flection of functional activity. Two human endothelin receptors have been characterised: the
ET-l-selective ETa receptor [13] and the non-isoform-selective ETg receptor [14] (Figure 2).
The characteristically sustained vasoconstriction to ET-1 [3] is primarily mediated by the
vascular smooth muscle ETa receptor. The endothelial ETg receptor stimulates generation
of nitric oxide and dilator prostaglandins [15,16] to mediate vasodilatation to modulate the
constrictor effects of the ETA receptor. The ETb receptor has also been described on the vas¬
cular smooth muscle [17], and, although the vascular smooth muscle ETg receptor appears
to mediate vasoconstriction under some circumstances [18,19], the physiological relevance
of this effect remains to be proven. Indeed, it would appear that selective ETb receptor an¬
tagonism results in systemic [92] and local [20,21] vasoconstriction, indicating that the bal¬
ance of effects at the ETg receptor favours vasodilatation [85]. The ETg receptor is also
thought to be involved in clearance of endothelin from the circulation [22]. In support of this,
plasma concentrations of ET-1 are dose-dependently increased following administration of
combined ETa/b [2,93,94] and selective ETb [22,95] receptor antagonists but not following
administration of a selective ETa receptor antagonist [95]. It could be that the vasoconstric¬
tor effects of selective ETb receptor antagonism result partly from inhibition of ETB-med-
iated clearance of ET-1, allowing the uncleared peptide to bind to unoccupied constrictor
ETa receptors [92].
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Figure 3: Trends in endothelin antagonist
patenting 1993-1997. Data derived from
MDL's ISlSBase.
1993 1994 1995 1996 1997
Year
The balance between the constrictor effects of ET-1,mediated by the vascular smoothmuscle
ETa and ETb receptors, and the dilator effects, mediated by the endothelial ETg receptor, is
important in determining the value of combined ETA/b and selective endothelin receptor
antagonists. As discussed earlier, there may be alterations in endothelin receptor function,
distribution and sensitivity in disease states that could lead to an imbalance between the ac¬
tions of ET-1 on the ETA and ETg receptors. Further investigation of the endogenous effects
of endothelin receptor stimulation in health, and in disease development and progression, is
required to identify the best approach to inhibit the damaging effects of chronic vasocon¬
striction or vasospasmwhile preserving the beneficial dilator effects and clearance actions of
the endothelial ETb receptor.
Competitive environment
There are currently a number of orally-active and intravenous endothelin antagonists in
clinical development. The first of these compoundswas bosentan, an orally active combined
ETA/b receptor antagonist, which is already in long-term Phase III clinical trials investigat¬
ingmorbidity andmortality in patientswith chronic heart failure. Although bosentan is cur¬
rently placed to be the first endothelin antagonist to reach the market, a number of
competitor compounds are also in Phase II and III trials. The orally active compoundswill be
valuable in the long-term treatment of chronic heart failure, hypertension and chronic renal
failure. Of these, chronic heart failure is currently the favoured indication. Intravenous an¬
tagonists are likely to be indicated in the initial treatment of acute renal failure, MI and, if
early clinical trials are encouraging, subarachnoid haemorrhage. Pulmonary hypertension,
migraine and prostatic hypertrophy are additional indications for which these compounds
may be considered.
Figure 3 illustrates the trends in pharmaceutical patenting of endothelin antagonists over
the period 1993 -1997. Table 1 provides details of selected lead endothelin antagonists that
have reached Phase II in their clinical development.
A number of pharmaceutical companies, including Abbott, Bristol-Myers Squibb, Knoll,
Merck, Parke-Davis, and Zeneca, are developing a range of selective and combined endo¬
thelin receptor antagonists. From the currently available literature, there is no indication
which of these compounds will be the company's lead compound or of the stage that they
have reached in their clinical development.
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Table 1: Competitive environment: selected lead endothelin antagonists in development.
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Comments Orally active, combined ETa/b receptor
antagonist.
Intravenous compound, combined ETa/b receptor
antagonist.
Table 1: Competitive environment: selected lead endothelin antagonists in development (continued).
Company SmithKline Beecham Texas Biotech















Comments Non-peptide compound, combined ETa/b receptor
antagonist.
Non-peptide, orally active selective ETA receptor
antagonist.
In addition to endothelin receptor antagonists, compounds that inhibit the activity of the
ECE are currently in preclinical development. As yet no selective compound is available for
clinical use but some have been described that are likely to proceed to clinical trials within
the next two years [96]. Also of interest are compounds with combined enzyme inhibitory
actions. A dual inhibitor of ECE and ACE, SCH-54470, is currently in preclinical develop¬
ment as a potential treatment for renal failure [97]. Dual ETA and angiotensin II receptor an¬
tagonists have also been described [98], Given the benefits of separate inhibition of the
endothelin and angiotensin systems, and the evidence that these systems are at least addi¬
tive in heart failure [99], combined inhibition of these systems offers an attractive therapeu¬
tic option.
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Potential development issues
The pharmaceutical market for the treatment of cardiovascular diseases has recently been
dominated by ACE inhibitors, particularly in chronic heart failure and chronic renal failure.
However, despite their success, there remain considerable mortality and morbidity associ¬
ated with the cardiovascular diseases discussed in this review. Endothelin antagonists ap¬
pear to offer additional vasodilatation in the presence of existing treatment with ACE
inhibitors in patients with chronic heart failure [41 ]. This, combined with the effects of endo¬
thelin antagonism on renal function, highlights the potential benefits of inhibition of the ac¬
tions of ET-1 in the treatment of the symptoms of cardiovascular disease and in slowing
disease progression.
Common adverse events experienced by subjects in clinical trials with endothelin antago¬
nists are consistent with systemic vasodilatation and include headaches, light-headedness
and nausea. The fact that much of the vasodilatation to selective ETa receptor antagonism is
caused by nitric oxide [20] could indicate that tolerance to these effects will develop. Inter¬
estingly, these headaches have been a less frequent occurrence in clinical trials in patient
groups than in healthy volunteer studies.
ECE inhibitors may prove useful in conditions where an increase in ET-1 generation is dem¬
onstrated and is of pathophysiological importance. These compounds would reduce the
damaging effects of ET-1 and have the same advantages and disadvantages of combined
ETa/b receptor antagonism. However, there are, as yet, no selective ECE inhibitors in clini¬
cal development and so these compounds are unlikely to be available for patient administra¬
tion within the next two years.
Editorial analysis
ET-1 is an endothelium-derived vasoconstrictor and co-mitogenic agentwhich acts as a local
paracrine and autocrine mediator, and is the most potent and sustained vasoconstrictor and
pressor substance yet identified. ET-1 is now known to play an important physiological role
in maintaining peripheral vascular tone and blood pressure [2,32]. ET-1 also has actions that
might influence the function of the heart, kidney and nervous system. However, its physio¬
logical importance in these systems remains to be determined.
Abnormalities of the endothelin system are now recognised to occur in a range of diseases
associated with vasoconstriction, vasospasm and vascular hypertrophy, and it appears that
ET-1 may be causal, or at least contributory, in some of these pathophysiological processes.
The use of endothelin receptor antagonists in experimental models of cardiovascular dis¬
ease and in human clinical pharmacology studies has indicated a number of conditions - in¬
cluding hypertension, heart failure, acute renal failure, subarachnoid haemorrhage and
pulmonary hypertension - in which further clinical studies would be worthwhile. A number
of peptide and orally-active non-peptide endothelin receptor antagonists are now under
clinical investigation and further studies are now required in specific diseases to determine
whether selective ETa or combined ETa/b receptor antagonists will be more effective.
Early clinical trials have demonstrated the potential therapeutic benefits of endothelin re¬
ceptor antagonists in a number of cardiovascular diseases. These compounds appear to be
well-tolerated, and effective, orally-active and intravenous formulations have been devel¬
oped. The fact that additional benefits have been seen in the presence of existing treatments
is encouraging for the future development of these compounds. Given the evidence in sup¬
port of an important role for ET-1 in the pathophysiology of cardiovascular disease and the
promising results of early clinical trials with endothelin receptor antagonists, treatments
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that inhibit the effects of the endothelin system are likely to be of great importance in this
clinical context.
Bibliography
Papers of special note have been highlighted as:
• of interest
•• of considerable interest
1. YANAGISAWA M, KURIHARA H, KIMURASef al.: A novel potent vasoconstrictor peptide
produced by vascular endothelial cells. Nature (1988) 332:411-415.
2. HAYNES WG, FERRO CJ, O'KANE KPJ et al.: Systemic endothelin receptor blockade
decreases peripheral vascular resistance and blood pressure in man. Circulation (1996)
93:1860-1870.
•• Demonstrates systemic vasodilator effects of combined ETA/B receptor antagonism.
3. CLARKE JG, BENJAMIN N, LARKIN SW et al.: Endothelin is a potent long-lasting
vasoconstrictor in men. Am. ]. Physiol. (1989) 257:H2033-2035.
4. YANG Z, RICHARD V, VON SEGESSER L: Threshold concentrations of endothelin-1
potentiate contractions to norepinephrine and serotonin in human arteries: a new
mechanism for vasospasm? Circulation (1990) 82:188-195.
5. WANG Y, ROSE MP, WEBB ML et al.: Endothelins stimulate mitogen-activated protein
kinase cascade through either ETA or ETB. Am. /. Physiol. (1994) 267:C1130-C1135.
6. PACHER R, BERGLER-KLEIN J, GLOBITS S et al.: Plasma big endothelin-1 concentrations
in congestive heart failure patients with or without systemic hypertension. Am. /. Cardiol.
(1993) 71:1293-1299.
7. WEI C-M, LERMAN A, RODEHEFFER R et al.: Endothelin in human congestive heart
failure. Circulation (1994) 89:1580-1586.
8. KOYAMA H, NISHIZAWA Y, MORII H et al.: Plasma endothelin levels in patients with
uraemia. Lancet (1989) 8645:991.
9. WARRENS AN, CASSIDY MJD, TAKAHASHI K et al.: Endothelin in renal failure. Nephrol.
Dial. Transplant. (1990) 5:418-422.
10. OMLAND T, LIE RT, AAKVAAG A: Plasma endothelin determination as a prognostic
indicator of 1-year mortality after acute myocardial infarction. Circulation (1994)
89:1573-1579.
11. EMORI T, HIRATA Y, OHTA K et al.: Cellular mechanism of endothelin-1 release by
angiotensin and vasopressin. Hypertension (1991) 18:165-170.
12. BOULANGERC, LUSCHERTF: Release of endothelin from the porcine aorta: inhibition by
endothelium-derived nitric oxide. ]. Clin. Invest. (1990) 85:587-590.
13. ARAI H, HORI S, ARAMOR1 1 et al.: Cloning and expression of a cDNA encoding an
endothelin receptor. Nature (1990) 348:730-732.
14. SAKURAI T, YANAGISAWA M, TAKUWA Y et al.: Cloning of a cDNA encoding a
non-isopeptide-selective subtype of the endothelin receptor. Nature (1990) 348:732-735.
15. DE NUCCI G, THOMAS R, D'ORLEANS JUSTE P et al.: Pressor effects of circulating
endothelin are limited by its removal in the pulmonary circulation and by the release of
prostacyclin and endothelium-derived relaxing factor. Proc. Natl. Acad. Sci. USA (1988)
85:9797-9800.
16. TSL'KAHARA H, ENDE H, MAGAZINE HI, BAHOU WF, GOLIGORSKY MS: Molecular
and functional characterization of the non-isopeptide-selective ETB receptor in
endothelial cells: receptor coupling to nitric oxide synthase. /. Biol. Cliem. (1994)
269:21778-21785.
17. DAVENPORT AP, O'REILLY G, MOLENAAR P et al.: Human endothelin receptors
characterized using reverse transcriptase-polymerase chain reaction, in situ hybridization,
and subtype-selective ligands BQ123 and BQ3020: evidence for expression of ETB
receptors in human vascular smooth muscle. /. Cardiovasc. Pharmacol. (1993) 22(Suppl.
8):S22-S25.
(OAshley Publications Ltd. All rights resetsed Emcrititifi Druids 1998
Strachan & Webb 109
18. CLOZEL M, GRAY GA, BREU V, LOFFLER B, OSTERWALDER R: The endothelin ETB
receptor mediates both vasodilatation and vasoconstriction in vivo. Biochem. Biophys. Res.
Commun. (1992) 186:867-873.
19. HAYNES WG, STRACHAN FE, WEBB DJ: Endothelin ETA and ETB receptors cause
vasoconstriction of human resistance and capacitance vessels in vivo. Circulation (1995)
92:357-363.
20. VERHAAR MC, STRACHAN FE, NEWBY DE et al.: Endothelin-A receptor antagonist
mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by
endothelin-B receptor blockade. Circulation (In press).
Important investigation of the mechanisms involved in ETA antagonist-mediated
vasodilatation and the role of the ETB receptor in healthy human vasculature.
21. LOVE MP, FERRO CJ, HAYNES WG, WEBB DJ, MCMURRAY JJ: Selective or non-selective
endothelin receptor blockade in chronic heart failure? Circulation (1996) 94(Suppl.
l):2899-2900.
22. FUKURODAT, FUJIKAWA T, OZAK1S etal.: Clearance of circulating endothelin-1 by ETB
receptors in rats. Biochem. Biophys. Res. Commun. (1994) 199:1461-1465.
23. DUPUIS J, STEWART DJ,CERNACEK P,GOSSELIN G: Human pulmonary circulation is an
important site for both clearance and production of endothelin-1. Circulation (1996)
94:1578-1584.
24. FUKURODA T, OZAKI M, IHARA K et al.: Necessity of dual blockade of endothelin ETA
and ETb receptor subtypes for antagonism of endothelin-1-induced contraction in human
bronchi. Br. /. Pharmacol. (1996) 117:995-999.
25. NELSON JB, HEDICAN SP, GEORGE DJ et al.: Identification of endothelin-1 in the
pathophysiology of metastatic adenocarcinoma of the prostate. Nature Med. (1995)
9:944-949.
26. GUNAL O, YEGEN C, AKTAN O, YALIN R, YEGEN B: Gastric functions in portal
hypertension: role of endothelin. Dig. Dis. Sci. (1996) 41:585-590.
27. UOSAKI Y, YOSHIDA M, OGAWA T, SAITOH YJ: RES 1149-1 and -2, novel non-peptidic
endothelin B receptor antagonists produced by Aspergillus sp. II. Structure derivation.
Antibiotics (1996) 49:6-12.
28. COHN J, BRISTOW M, CHIEN D et al.: Report of the National Heart, Lung and Blood
Institute Special Emphasis Panel on Heart Failure Research. Circulation (1997) 95:766-770.
29. DARGIE HJ, MCMURRAY JJV: Diagnosis and management of heart failure. Br. Med. ].
(1994) 308:321-328.
30. SEVER P, BEEVERSG, BULPITT C etal.: Management guidelines in essential hypertension:
report of the second working party of the British Hypertension Society. Br. Med. ]. (1993)
306:983-987.
31. IHARA M, NOGUCHI K, SAEKI T et al.: Biological profiles of highly potent novel
endothelin antagonists selective for the ETA receptor. Life Sci. (1992) 50:247-255.
32. HAYNES WG, WEBB DJ: Contribution of endogenous generation of endothelin-1 to basal
vascular tone. Lancet (1994) 344:852-854.
• Demonstrates vasodilatation to ECE inhibition and selective ETA antagonism in vivo.
33. FERRO CJ, HAYNES WG, HAND MF, WEBB DJ: The vascular endothelin and nitric oxide
systems in essential hypertension. /. Hypertens. (1996) 14(Suppl. 1):S50. Abstract.
34. WATANABE T, FUJINO M: TAK-044: an endothelin receptor antagonist. Cardiovasc. Drug
Rev. (1996) 14:36-46.
35. SCHMITT R, BELZ GG, FELL D et al.: Effects of the novel endothelin receptor antagonist
bosentan in hypertensive patients. Proceedings of the Seventh Meeting of the European
Hypertension Society. Milan, Italy (June 1995).
36. BENEDICT C: Neurohumoral aspects of heart failure. Cardiology Clinics (1994) 12:9-22.
37. NICHOLLS DP, ONUOHA GN, MCDOWELL G et al.: Neuroendocrine changes in chronic
cardiac failure. Basic Res. Cardiol. (1996) 91(Suppl. 1): 13-20.
38. THESOLVD INVESTIGATORS: Effect of enalapril on survival in patients with reduced left
ventricular ejection fractions and congestive heart failure. Neiv Engl. /. Med. (1991)
325:293-302.
39. COHN J: The management of chronic heart failure. New Engl. /. Med. (1996) 335:490-498.
OAshley Publications Ltd. All rights reserved Pmcr^ini' Drufi.s 1998
110 The endothelin system: a novel therapeutic target in cardiovascular disease
40. IKEGAWA R, MATSUMURA, TSUKAHARA Y, TAKAOKA M, MORIMOTO S:
Phosphoramidon inhibits the generation of endothelin-1 from exogenously applied big
endothelin-1 in cultured vascular endothelial cells and smooth muscle cells. FEBS Lett.
(1991) 293:45-48.
41. LOVE MP, HAYNES WG, GRAY GA, WEBB DJ, MCMURRAY JJV: Vasodilator effects of
endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in
chronic heart failure patients treated with ACE inhibitors. Circulation (1996) 94:2131-2137.
• Demonstrates local vasodilatation in response to ETA selective antagonism in heart failure
patients treated with ACE inhibitors.
42. KIOWSKI W, SUTSCH G, HUNZIKER P et al.: Evidence for endothelin-1 mediated
vasoconstriction in severe chronic heart failure. Lancet (1995) 346:732-736.
•• Demonstrates potential benefits of endothelin antagonism in chronic heart failure.
43. ISHIKAWA K, IHARA M, NOGUCHI Kef al.: Biochemical and pharmacological profile of a
potent and selective endothelin B-receptor antagonist, BQ-788. Proc. Natl. Acad. Sci. USA
(1994)91:4892-4896.
44. HOOD V, GENNAR1 F: End-stage renal disease: measures to prevent it or slow its
progression. Postgrad. Med. (1996) 100:163-176.
45. BECKER G, WHITWORTH J, IHLE B et al.: Prevention of progression in non-diabetic
chronic renal failure. Kidney Int. (1994) 45(Suppl. 45):S167-S170.
46. STRIKER GE: Report on a workshop to develop management recommendations for the
prevention of progression in chronic renal disease, Bethesda (MA) April 1994. Nephrol. Dial.
Transplant. (1995) 10:290-292.
47. HOLLENBERG N, RAIJ L: Angiotensin-converting enzyme inhibition and renal
protection: an assessment of implications for therapy. Arch. Int. Med. (1993) 8:2426-2435.
48. BENIGNI A: Defining the role of endothelins in renal pathophysiology on the basis of
selective and unselective endothelin receptor antagonist studies. Curr. Opin. Nephrol.
Hypertens. (1995) 4:349-353.
49. ORISIO S, BENIGNI A, BRUZZI I et al.: Renal endothelin gene expression is increased in
remnant kidney and correlates with disease progression. Kidney. Int. (1993) 43:354-358.
50. KARET FE, KUC RE, DAVENPORT AP: Novel ligands BQ123 and BQ3020 characterize
endothelin receptor subtypes ETA and ETB in human kidney. Kidney Int. (1993) 44:36-42.
51. DAVENPORT A, KUC R, HOSKINS S, KARET F, FITZGERALD F: [125I]-PD151242: a
selective ligand for endothelin ETA receptors in human kidney which localizes to renal
vasculature. Br. ]. Pharmacol. (1994) 113:1303-1310.
52. BENIGNI A, ZOJA C, CORNA D et al.: A specific endothelin subtype A receptor antagonist
protects against injury in renal disease progression. Kidney. Int. (1993) 44:440-444.
53. RABELINK TJ, KAASJAGER KA, STROES ES, KOOMANS HA: Endothelin in renal
pathophysiology: from experimental to therapeutic application. Kidney Int. (1996)
50:1827-1833.
• Review of potential of endothelin antagonists in renal disease.
54. THADHANI R, PASCUAL M, BONVENTRE JV: Acute renal failure. New Engl. /. Med. (1996)
332:1448-1459.
55. HUMES HD: Acute renal failure: the promise of new therapies. New Engl. J. Med. (1997)
336:870-871.
56. CANTLEY L, SPOKES K, CLARK B et al.: Role of endothelin and prostaglandins in
radiocontrast induced renal artery constriction. Kidney Int. (1993) 44:1217-1223.
57. HEYMAN S, CLARK B, KAISER N et al.: Radiocontrast agents induce endothelin release in
vivo and in vitro. J. Am. Soc. Nephrol. (1992) 3:58-65.
58. BIRD JE, GIANCARLI MR, MEGILl. JR, DURHAM SK: Effects of endothelin in
radiocontrast-induced nephropathy in rats are mediated through endothelin-A receptors.
/. Am. Soc. Nephrol. (1996) 7:1153-1157.
59. CLOZEL M, BREU V, BURRI K et al.: Pathophysiological role of endothelin revealed by the
first orally active endothelin receptor antagonist. Nature (1993) 365:759-761.
60. POLLOCK DM, OPGENORTH TJ: ETA receptor-mediated responses to endothelin-1 and
big endothelin-1 in the rat kidney. Br. j. Pharmacol. (1994) 111:729-732.
©Ashley Publications Ltd. All rights reserved Drills 1998
Strachan & Webb 111
61. MINO N, KOYABASHI M, NAKAJIMA A et al.: Protective effect of a selective endothelin
receptor antagonist, BQ-123, in ischemic acute renal failure in rats. Eur. /. Pharmacol. (1992)
221:77-83.
62. BROOKS D, DEPALMA P, GELLAI M et at.: Nonpeptide endothelin receptor antagonists.
III. Effect of SB209670 and BQ-123 on acute renal failure in anesthetized dogs. /. Pharmacol.
Exp. Ther. (1994) 271:769-775.
63. BIRD JE, WEBB ML,WASSERMAN AJ et a!. -. Comparison of a novel ETA receptor antagonist
and phosphoramidon in renal ischaemia. Pharmacology (1995) 50:9-23.
64. MERTZ TE, MCLANAHAN TB, FLYNN MA et ale. EndothelinA receptor antagonism by PD
156707 does not reduce infarct size after coronary artery occlusion/reperfusion in pigs. /.
Pharmacol. Exp. Ther. (1996) 278:42-49.
65. SAKAI S, MIYAUCHI T, KOBAYASHI M et al.: Inhibition of myocardial endothelin
pathway improves long-term survival in heart failure. Nature (1996) 384:353-355.
66. ROUX S, LOFFLER B-M, GRAY GA et al.: The role of endothelin in cerebral vasospasm.
Neurosurgery (1995) 37:78-86.
67. ZUCCARELLO M, SOATT1N GB, LEWIS Al et al.: Prevention of subarachnoid
hemorrhage-induced cerebral vasospasm by oral administration of endothelin receptor
antagonists. ]. Neurosurg. (1996) 84:503-507.
68. ITOH S, SASAKI T, IDE K et al.: A novel endothelin ETA receptor antgonist, BQ-485, and its
preventative effect on experimental cerebral vasospasm in dogs. Biochem. Biophys. Res.
Commun. (1993) 195:969-975.
69. BREU V, ROUX S, GILLER T et al.: Ro 61-1790, a new hydro soluble ET antagonist:
pharmacology and effects on cerebral vasospasm. Proceedings of the Fifth International
Conference on Endothelin. Kyoto, Japan (September 1997).
70. FREIS E, PAPADEMETRIOU V: Current drug treatment and treatment patterns with
antihypertensive drugs. Drugs (1996) 52:1-16.
71. LEWIS EL, HUNSICKER LG, PAIN RP et al.: The effect of converting enzyme inhibition on
diabetic nephropathy. New Engl. ]. Med. (1993) 329:1456-1462.
72. BIANCHI S, BIGAZZI R, BALDERI G et al.: Microalbuminuria in patients with essential
hypertension: effects of an angiotensin converting enzyme inhibitor and of a calcium
channel blocker. Am. J. Hypertens. (1991) 4:291-296.
73. STAESSON JA, FAGARD R, THIJS L et al.: Randomised double-blind comparison of
placebo and active treatment for older patients with isolated systolic hypertension. Lancet
(1997) 350:757-764.
74. BROWN M: The causes of essential hypertension. Br. ]. Clin. Pharmacol. (1996) 42:21-27.
75. MCMURRAY J, HARTW: The economic impact of heart failure on the UK National Health
Service. Eur. Heart. ]. (1993) 14(Suppl.):S133.
76. ALLISON M, SHILLIDAY I: Loop diuretic therapy in acute and chronic renal failure. /.
Cardiovasc. Pharmacol. (1993) 22:S59-S70.
77. DENTON M, CHERTOW G, BRADY H: 'Renal-dose' dopamine for the treatment of acute
renal failure: scientific rationale, experimental studies and clinical trials. Kidney Int. (1996)
49:4-14.
78. VALSSON F, RICKSTEN S-E, HEDNER, LUNCIN S: Effects of atrial natriuretic peptide on
acute renal impairment in patients with heart failure after cardiac surgery. Intensive Care
Med. (1996) 22:230-236.
79. ALLGREN R, MARBURY T, RAHMAN SN ct al.: Anaritide in acute tubular necrosis. New
Engl. /. Med. (1997) 336:828-834.
80. GOLIGORSKY M, NOIRI E, KESSLER H, ROMANOV V: Therapeutic potential of RGD
peptides in acute renal injury. Kidney Int. (1997) 51:1487-1492.
81. GRANGER CB: Adenosine for myocardial protection in acute myocardial infarction. Am. j.
Cardiol. (1997) 79(12A):44-48.
82. PFEFFER MA, BRAUNWALD E, MOYE LA ct al.: Effect of captopril on mortality and
morbidity in patients with left ventricular dysfunction after myocardial infarction. Results
of the survival and ventricular enlargement trial. New I'.ngl. /. Med. (1992) 327:669-677.
COAshley Publications Ltd All rights reser\ej l\rncri>ing l)rui>\ IWX
112 The endothelin system: a novel therapeutic target in cardiovascular disease
83. CLELAND JG: The clinical course of heart failure and its modification by ACE inhibitors:
insights from recent clinical trials. Eur. Heart ]. (1994) 15:125-130.
84. PICKARD JD, MURRAY GD, ILLINGWORTH Ret al.: Effect of oral nimodipine on cerebral
infarction and outcome after subarachnoid haemorrhage: British Aneurysm Nimodipine
Trial. Br. Med. J. (1989) 298:636-643.
85. WEBB DJ, MONGE JC, RABELINK TR, YANAG1SAWA M: Endothelin: new discoveries
and rapid progress in the clinic. Trends Pharmacol. Sci. (In press).
86. CASINO PR, KILCOYNE CM, CANNON RO, III, QUYYUMI AA, PANZA JA: Impaired
endothelium-dependent vascular relaxation in patients with hypercholesterolemia
extends beyond the muscarinic receptor. Am. /. Cardiol. (1995) 75:40-44.
87. PANZA JA, GARCIA CE, KILCOYNE CM, QUYYUMI AA, CANNON RO, III: Impaired
endothelium-dependent vasodilation in patients with essential hypertension: evidence
that nitric oxide abnormality is not localized to a single signal transduction pathway.
Circulation (1995) 91:1732-1738.
88. INOUE A, YANAGISAWA M, KIMURA S: The human endothelin family: three
structurally and pharmacologically distinct isopeptides predicted by three separate genes.
Proc. Natl. Acad. Sci. USA (1989) 86:2863-2867.
89. XU D, EMOTO N, GIAID A: ECE-1: a membrane-bound metalloprotease that catalyses the
proteolytic activation of big endothelin-1. Cell (1994) 78:473-485.
90. EMOTO N, YANAGISAWA M: Endothelin-converting enzyme-2 is a membrane-bound
phosphoramidon-sensitive metalloprotease with acidic pH optimum. /. Biol. Chem. (1995)
270:15262-15268.
91. TURNER AJ, MURPHY LJ: Molecular pharmacology of endothelin converting enzymes.
Biochem. Pharmacol. (1996) 51:91-102.
• Review of the molecular pharmacology of ECE.
92. GRATTON J-P, COURNOYER G, LOFFLER B-M, SIROIS P, D'ORLEANS-JUSTE P: ETB
receptor and nitric oxide synthase blockade induce BQ-123-sensitive pressor effects in the
rabbit. Circulation (1997) 30:1204-1209.
• Demonstrates systemic vasoconstriction to ETB receptor antagonism.
93. PLUMPTON C, FERRO CJ, HAYNES WG, WEBB DJ, DAVENPORT AP: The increase in
human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal
fragment induced by systemic administration of the endothelin antagonist TAK-044. Br. /.
Pharmacol. (1996) 119:311-314.
94. WEBER C, SCHMITT R, BIRNBOECK H et al.: Pharmacokinetics and pharmacodynamics of
the endothelin-receptor antagonist bosentan in healthy human subjects. Clin. Pharmacol.
Ther. (1996) 60:124-137.
• Review of the clinical pharmacology of bosentan, with results from Phase I clinical trials.
95. BRUNNER F, DOHERTY A: Role of ETB receptors in local clearance of endothelin-1 in rat
heart studies with the antagonists PD 155080 and BQ-788. FEBS Lett. (1996) 396:238-242.
96. DESCOMBES J-J, MENNECIER P, VERSLUYS Def al: S 17162 is a novel selective inhibitor
of Big ET-1 responses in the rat. /. Cardiovasc. Pharmacol. (1995) 26(Suppl. 3):S61-S64.
97. VEMULAPALLI S, FAWZI AB, CHINTALA M et al.: SCH-54470, a dual inhibitor of
endothelin- and angiotensin-converting enzymes attenuates chronic renal failure (CRF) in
remnant kidney rats. Pharmacologist (1997) 39:1-26.
98. WALSH TF, FITCH KJ, WILLIAMS DL et al.: Potent dual antagonists of endothelin and
angiotensin II receptors derived from alpha-phenoxyphenylacetic acids (Part 3). Bioorg.
Med. Chem. (1995) 511:1155-1158.
99. SUTSCH G, BERTEL O, KIOWSKI W: Acute and short-term effects of the nonpeptide
endothelin-1 receptor antagonist bosentan in humans. Cardiovasc. Drugs Ther. (1996)
10:717-725.
Fiona Strachar" & David J Webb
' Author for correspondence
Clinical Pharmacology Unit & Research Centre. The University of Edinburgh, Western General Hospital, Edinburgh, EH4
2XU, Scotland. UK
(Tel: +44 131 332 1205; Fax: +44 1 31 343 6017; Email: f.strachan(s>ed.ac.uk)
OAxhley Publications Ltd. All rights resers ed /-.'merging //rug.v 199K
Endothelin-A Receptor Antagonist-Mediated
Vasodilatation Is Attenuated by Inhibition ofNitric Oxide
Synthesis and by Endothelin-B Receptor Blockade
Marianne C. Verhaar, MI); Fiona E. Strachan, BN, RGN; David E. Newby, BSc, MB, MRCP;
Nicholas L. Cruden, BSc, MB, ChB; Hein A. Koomans, Ml), PhD;
Ton J. Rabelink, Ml), PhD; David J. Webb, Ml), FRCP
Background—The role of endothelin (ET)-l in maintenance of basal vascular tone has been demonstrated by local and
systemic vasodilatation to endothelin receptor antagonists in humans. Although the constrictor effects mediated by the
vascular smooth muscle ETA receptors are clear, the contribution from endothelial and vascular smooth muscle ET„
receptors remains to be defined. The present study, in human forearm resistance vessels in vivo, was designed to further
investigate the physiological function of ETA and ET„ receptor subtypes in human blood vessels and determine the
mechanism underlying the vasodilatation to the ETA-selective receptor antagonist BQ-123.
Methods and Results—Two studies were performed, each in groups of eight healthy subjects. Brachial artery infusion of
BQ-123 caused significant forearm vasodilatation in both studies. This vasodilatation was reduced by 95% (P=.006) with
inhibition of the endogenous generation of nitric oxide and by 38% (P<.0()1) with coinfusion of the ETU receptor
antagonist BQ-788. In contrast, inhibition of prostanoid generation did not affect the response to BQ-123. Infusion of
BQ-788 alone produced a 20% reduction in forearm blood flow (P<.0()1).
Conclusions—Selective ETA receptor antagonism causes vasodilatation of human forearm resistance vessels in vivo. This
response appears to result in major part from an increase in nitric oxide generation. ETU receptor antagonism either alone
or on a background of ETA antagonism causes local vasoconstriction, indicating that ETn receptors in blood vessels respond
to ET-1 predominantly by causing vasodilatation. (Circulation. 1998;97:752-756.)
Key Words: endothelin ■ nitric oxide ■ flow ■ receptors ■ prostaglandins
The endothelin (ET) family of peptides (ET 1, ET-2, ET-3)are generated in a variety of tissues and act primarily as
paracrine and autocrine factors. The major isoform in the
cardiovascular system, ET-1, is generated in the endothelium
from a precursor, big ET-1, through cleavage by a specific
endothelin-converting enzyme (ECE). Its actions are mediated
by two receptors, the ET, and the ETn receptor, which have
been characterized and cloned1 and are pharmacologically
distinct. The ETA receptor has a higher affinity for ET-1
(ET-15S> ET-3), whereas the ET,, receptor is nonisopeptidc
selective (ET-1 = ET-3). ETA receptors are expressed on vas¬
cular smooth muscle cells, and their activation by ET- I leads to
vasoconstriction. The physiological importance of endogenous
ET-1 in the maintenance of basal vascular tone and blood
pressure in humans lias been demonstrated by local' 1 and
systemic' vasodilatation in response to inhibitors of the endo¬
thelin system. An important role tor the ETA receptor in
mediating this response is suggested bv the substantial forearm
vasodilatation to local administration of the selective F.TA
receptor antagonist BQ-1231" in healthy subjects.
Initially, it was thought that ETj, receptors were present only
on endothelial cells, where they cause vasodilatation through
release of endothelium-derived vasodilators, including nitric
oxide (NO) and prostacyclin.''7 However, it is now recognized
that ET„ receptors are also present on the smooth muscle of
human arteries'' and can mediate vasoconstriction, ' " although
their contribution to ET-1-mediated constriction in humans
remains to be defined.1'' Therefore, although ETA receptor-
mediated vasoconstriction is undisputed, it is unclear whether
the balance of the effects of endogenous ET-1 on the endo¬
thelial and vascular smooth muscle ET„ receptors results
predominantly in a vasodilator or constrictor tone.
In addition to mediating vasodilator effects of endothelial
ET„ receptor activation, endothelium-dcrived dilators can in
turn modulate the production and actions of ET-1." " ' ' In the
short term NO inhibits production of ET-1 11 whereas chronic
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exposure causes upregulation of ETA receptors."' In addition,
endothelin receptor antagonists attenuate the pressor response
to NO inhibition,17 IK suggesting that this response may not
simply be due to loss of basal NO-mediated dilator tone. These
interactions indicate the existence of a complex relationship
between the endothelin and NO systems.
As a consequence of its potent vasoconstrictor1'' and growth-
promoting properties,2" ET-1 has also been implicated in the
pathophysiology of diseases such as hypertension, heart failure,
and renal failure.21 The recognition of the endothelin system as
a new therapeutic target in the treatment of cardiovascular
disease has lead to the rapid development of pharmacological
agents that inhibit either the production of ET-1 or its actions.
Recently, potent intravenous and orally active endothelin
receptor antagonists with different pharmacological profiles
have become available for clinical studies.2122 We are now in a
position where it would be valuable to explore the contribu¬
tion of the ET„ receptor to the vascular effects of ET-1.
The present study, in human forearm resistance vessels in
vivo, was designed to further investigate the physiological role
of ETa and ETU receptor subtypes and their possible interac¬
tions in mediating the vasodilator response to selective ETA
receptor antagonism. The first part of the study aimed to
investigate whether increased release of the endothelium-
dependent relaxant factors NO and prostacyclin contributes to
the vasodilator response to selective ETA receptor antagonism.
We therefore compared the response to the selective ETA
receptor antagonist BQ-123 during local inhibition of NO
synthase and during systemic inhibition of prostanoid genera¬
tion with the response to BQ-123 alone. In the second part of
the study, to investigate the role of the ETn receptor in
BQ-123-induced vasodilatation, we examined the effects of
simultaneous ETA and ET,{ receptor blockade compared with
ETa or ET|, receptor blockade alone.
Methods
Subjects
Twenty-two healthy subjects (1 woman) ranging in age from 20 to 43
years participated in two studies that were performed in the University
Hospital Utrecht (study 1) and the University Department of Medi¬
cine, Western General Hospital, Edinburgh (study 2), with the
approval of the local research ethics committees of each hospital and
the written informed consent of each subject. The investigations
conformed with the principles outlined in the Declaration of Helsinki.
No subjects had received vasoactive medication or nonsteroidal
anti-inflammatory drugs within the week before each phase of a study,
and all subjects abstained from alcohol for 24 hours and from food,
cafleine-containing drinks, and tobacco for at least 4 hours before any
measurements were made. All studies were performed in a quiet room
maintained at a controlled temperature between 22°C and 24.5°C.
Drug Administration
The brachial artery of the nondominant arm w as c.innulated with a 22
(study 1) or 27 SWG cannula (study 2) under lidocainc local anesthesia
(lidocaine 2%; Astra Pharmaceuticals Ltd). Drugs, with the exception
of aspirin, were dissolved in physiological saline (0.9%, Baxter
I lealtluare Ltd) and infused intra-arterially at locally active doses. The
infusion rate was kept constant at SO mL/h (study I) or 00 nil /h
(study 2). All solutions were prepared ascptuallv from sterile stock
solutions or ampules on the day of the study.
Drugs
BQ-123 (100 nniol/min, study 1; 10 nmol/min, study 2), was used as a
selective ETA receptor antagonist (study 1: American Peptide Co; study 2:
Clinalfa AG). We have demonstrated previously local forearm vasodila¬
tation to intra-arterial infusion of BQ-123 (100 nmol/min).4 In study 2,
we used a 10-fold lower dose of BQ-123 (10 nmol/min) because more
recent studies have shown that this causes vasodilatation of equal magni¬
tude to that seen with the higher dose.24 BQ-788 (1 nmol/min) was used
as a selective ET„ receptor antagonist24 (American Peptide Co). This dose
has been shown to completely inhibit venoconstriction to the selective
ETn receptor agonist sarafotoxin S6c.2s
The endogenous NO system in the forearm was inhibited by use of
an "NO clamp," as described previously.2<1 The NO synthase inhibitor
l-V' monomethyl-arginine (L-NMMA; Institut fur Pharmazie, Uni-
versitat Leipzig) was continuously infused at a rate of 200 fxg/100 mL
forearm volume per minute to achieve maximal inhibition of local
NO synthase.27 Sodium nitroprusside (SNP), an exogenous NO
donor (Merck) was then coinfused at titrated doses (12 to 30 ng/min).
After 8 minutes of L-NMMA infusion, when steady state forearm
blood flow was obtained, SNP was coinfused in incremental doses
and titrated until baseline forearm blood flow had been restored.
L-NMMA and SNP were then coinfused, at these rates, for the
remainder of the study. This allowed simulation of normal basal NO
activity during continuous inhibition of endogenous NO synthesis.
Aspirin (600 mg calcium acetylsalicylic acid; Carbasalatum Calcium,
Dagra Pharma BV) was administered orally 30 minutes before mea¬
surements in one phase of study 1. Aspirin irreversibly inhibits
cyclooxygenase (EC 1.14.99.1), which is responsible for the produc¬
tion of prostaglandins and thromboxanes. When given at a dose of 600
mg, aspirin inhibits bradykinin-stimulated endothelial production of




Forearm blood flow was measured simultaneously in both arms by
venous occlusion plethysmography using calibrated mercury-in-Silas-
tic strain-gauges applied to the widest part of the forearm.4,27 41 The
hands were excluded from the circulation during each measurement
period by inflation of a wrist cuff to 220 mm Hg. Upper arm cuffs
were intermittently inflated to 40 mm Hg for 10 seconds every 15
seconds to temporarily prevent venous outflow from the forearm and
thus obtain plethysmographies recordings. Recordings of forearm
blood flow were made over 2.5-minute periods at 5-minute intervals
(study 1) and over 3-minute periods at 10-minute intervals (study 2).
Venous occlusion plethysmography was performed using a dual-
channel strain-gauge plethysmograph (Hokanson), and calibration was
achieved using the internal standard of the Hokanson plethysmogra¬
phy unit. In study 1, a microcomputer-based R-wave-triggered
system for online semicontinuous monitoring was used,42 whereas in
study 2, voltage output was transferred to a Macintosh personal
computer (Classic II; Apple Computer) using a MacLab analog-digital
converter and Chart software (version 3.2.8; both from AD
Instruments).
Blood Pressure
Blood pressure was monitored during each study using either contin
nous nitra-arterial measurements in the infused arm (study I) or a
semiautomated noninvasive oscillometric method in the noninfused
arm (study 2).u Blood pressure in study 2 was measured immediately
after each forearm blood flow measurement, thereby avoiding any
effect of venous congestion caused by this procedure on blood flow.
General Study Design
Subjects rested recumbent throughout each study with both forearms
resting slightly above the level of the heart. Strain gauges and arm cuffs
were applied, and the left brachial artery cannula was sited. Before the
administration of drugs, saline was infused lor at least 30 minutes,
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Baseline Hemodynamic Values During Saline Infusion Before Infusion of Drugs
Study 1 Study 2
BQ-123 BQ-123+ BQ-123+ BQ-123 BQ-123+ BQ-788
Parameter (100 nmol/min) NO-Clamp Aspirin (10 nmol/min) BQ-788 (1 nmol/min)
Forearm blood How (mL/100 mL
per minute)
Infused arm 3.7±0.4 3 7±0.3 4.1 ±0.5 3.6±0.6 4.5±1.0 4.5±0.7
Control arm 4.6±0 5 3.4±0.2 3.4±0.5 3.4±0.6 3.3±0.8 3.1 ±0.4
Mean arterial pressure, mm Hg 78±2 82±3 79±2 83±5 90±3 93±4
Forearm blood flow in infused and control arm and mean arterial pressure in each phase of studies 1 and 2 at baseline before infusion of, respectively, BQ-123; BQ-123
SNP, and L-NMMA; BQ-123; BQ-123; BQ-123 and BQ-788; and BQ-788. there were no significant differences in baseline forearm blood flow or mean arterial pressure between
the phases of each study.
n=8 in each phase of studies 1 and 2.
during wtiicti baseline measurements of forearm blood flow were
made.
Study 1: Inhibition ofNO Synthase and
Prostanoid Generation With ETA
Receptor Blockade
Eight subjects were studied on three separate occasions, each separated
by at least 1 week. After baseline infusion of saline, BQ-123 was
infused for 90 minutes: on one occasion, during saline coinfusion; on
another, after stabilization of the NO-clamp; and on another, after
systemic inhibition of prostanoid generation. The effects of the
NO-clamp on forearm blood flow were studied during a 2-hour
period in 3 subjects (time control NO-clamp).
Study 2: Separate and Combined Blockade of ETA
and ETb Receptors
On 2 separate study days, in 8 subjects, the ETA receptor antagonist
BQ-123 was infused for 120 minutes alone or during coinfusion of
BQ-788, also for 120 minutes. On a separate occasion, BQ-788 was
infused alone for 120 minutes in 8 subjects (2 of whom also
participated in the earlier parts of study 2).
Analysis
Blood flow in both forearms was obtained from the mean of the last
five consecutive recordings of each measurement period. Because
wrist cuff inflation results in a transient forearm vasoconstriction,
recordings made in the first 60 seconds after w rist cuff inflation were
not used for analysis. The ratio of flows in the infused and noninfused
arms was calculated for each time point and expressed as percentage
change from baseline or, in the NO-clamp experiments, as percentage
change from the average of the last four recordings during NO-
clamping, before the administration of BQ-123. In both studies,
plethysmography data listings were extracted from data files, and
forearm blood flows were calculated for individual venous occlusion
cuff inflations using a template spreadsheet (Excel 5.0; Microsoft). All
results are expressed as mean±SEM. Data were examined by repeated
measures ANOVA (study 1, SigmaStat; Jandel Corp; study 2, Excel
5.0; Microsoft). Statistical significance was taken at the 5% level.
Results
There were no significant changes in hu-eline hemodynamics
between phases of each study ( Table) and no change in blood
pressure or blood flow m the noninfused forearm during the
course of the studies.
Study 1
Baseline forearm blood flow was restored during the NO-
clamp (basal infused forearm blood flow: 3.7 ±<1.3: during basal
NO clamp; 3.4±0 2; I'- IS) and kept stable lor .11 least -1(1
minutes before BQ-123 infusion was started. Blood flow in the
infused forearm in the time control NO clamp protocol varied
by <5% between baseline (pre-NO clamp) and with 120
minutes of NO clamping in 3 subjects.
BQ-123 caused progressive vasodilatation during coinfusion
of saline and after inhibition of prostanoid generation (P<.01
for both). The response appeared to plateau at 60 minutes, and
no differences were observed in these responses (38 ±9% versus
42±7% at 90 minutes; P=. 5). The vasodilator response to
BQ-123 was markedly reduced during NO-clamping (2±5%
at 90 minutes, P=.006 versus saline coinfusion) (Fig 1).
Study 2
Both BQ-123 alone and coadministration of BQ-123 and
BQ-788 caused progressive vasodilatation (P<.001) that ap¬
peared to plateau at 60 minutes (Fig 2). The vasodilatation to
BQ-123 alone was significantly greater than that during
coinfusion with BQ-788 (76±13% versus 47±14% at 120
minutes, P<.()01). BQ-788 alone caused a small but consistent
reduction in forearm blood flow (20±3% at 120 minutes,
P<.001) (Fig 2).
-HI 0 1(1 20 .10 4(1 50 60 HI HI! 90
lime (min)
Figure 1. Eight subjects received brachial artery infusion of
BQ-123 (100 nmol/min) during coinfusion of saline (•), BQ-123
(100 nmol/min) during inhibition of prostanoid generation (A), or
BQ-123 (100 nmol/min) during inhibition of NO generation (■).
Slow-onset vasodilatation occurred in response to BQ-123; this
response was attenuated during NO clamp but not during inhi¬
bition of prostanoid generation.
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Figure 2. Eight subjects received brachial artery infusion of
BQ-123 (10 nmol/min) alone (•), BQ-788 (1 nmol/min) alone (▲),
or BQ-123 (10 nmol/min) coinfused with BQ-788 (1 nmol/min)
(O). Slow-onset vasodilatation occurred in response to BQ-123;
this response was attenuated during coinfusion of BQ-788.
BQ-788 infusion alone caused a small but significant
vasoconstriction.
Discussion
In two centers, we have demonstrated slow-onset forearm
vasodilatation in response to local arterial infusion of the
selective ETA receptor antagonist BQ-123, confirming the
importance of endogenous ET-1 in the mediation of vascular
tone. From these data, it appears that this vasodilator response
is caused in large part by increased generation of NO, which
could he mediated by stimulation of the endothelial ET„
receptor. Indeed, our observation that the vasodilator response
to combined ETA and ET„ receptor antagonism was signifi¬
cantly less than that to selective ETA receptor antagonism alone
probably reflects the presence of an endogenous ETH-mediated
vasodilator tone. This is further supported by the local vaso¬
constrictor effect of ET„ receptor antagonism in the forearm
resistance vessels:
In the present study, to exclude the influence of the
endogenous NO system in mediation or modulation of the
effects of ET-I, I.-NMMA was infused to inhibit endogenous
local generation of NO. SNP was coinfused with L-NM.MA to
restore baseline blood flow " because local inhibition of NO
would otherwise result in vasoconstriction. In this situation,
endogenous NO is replaced with exogenous NO, in effect
applying a clamp to the local endogenous NO system. Using
this technique we have shown, lor the first time in humans in
vivo, that the vasodilatation to BQ-123 is m large part related
to NO generation. Inhibition of endogenous prostanoid gen ¬
eration by oral administration of aspirin has no effect 011 basal
forearm blood flow or systemic hemodvnamies and, more
importantly, had no effect on the response to BQ-123,
indicating that the dilator prostanoids do not provide an
important contribution to the vasodilator response to BQ-123.
Almost all of the response to BQ-123 appeared to be blocked
by NO clamping. However, on the basis of vasodilatation to
the EOF inhibitor phosphoramidon ' 111 previous studies,1 we
think it is likely that at least part of the response to lit) 123 is
directly due to withdrawal of endogenous I. 1 v mediated
vasoconstriction.
Selective ETA antagonism inhibits the actions of I I I at the
1 I A receptor while allowing its actions at the E l ,, receptor 10
be unopposed. El I can stimulate both the endothelial El),
receptor to cause dilatation and the vascular smooth muscle
FT 1, receptor to cause vasoconstriction. Therefore, the overall
effect depends on a balance between these two actions.
Unfortunately, there are 110 available pharmacological tools
that have been shown clearly to distinguish between the
endothelial and vascular smooth muscle ET„ receptors. We
have shown that coinfusion of the ET„ receptor antagonist
BQ-788 reduces the vasodilator response to BQ-123, suggest¬
ing that the balance of effects of ET-1 favors vasodilatation via
the endothelial ET,, receptor. This is further supported by the
vasoconstriction in these vessels to BQ-788 alone and by the
lesser degree of vasodilatation to the combined ETA/ET„
endothelin receptor antagonist TAK-044'1 than to the ETA-
selective agent BQ-123.1 It is possible that the predominant
effects of intra-luminal infusion of BQ-788 selectively affect
the endothelial ET„ receptor because the drug has better access
to the endothelial than to the smooth muscle receptors.
However, we believe this is unlikely because ET-1 and
BQ-123 find ready access to the smooth muscle. The response
to BQ-788 may indicate either displacement of ET-1 from, or
failure of clearance of ET-1 by, ET„ receptors.1'' However, our
present results cannot distinguish between these effects.
The observation that selective ETA receptor blockade not
only antagonizes direct F,TA receptor—mediated constriction
but also preserves beneficial ET„ receptor—mediated vasodila¬
tor tone and enhances endogenous NO generation may have
important implications in the use of endothelin antagonists as
treatments in cardiovascular disease. For example, the increased
NO generation caused by ETA receptor antagonists is poten¬
tially beneficial in ischemic heart disease. However, the clinical
relevance of our findings in various pathophysiological condi¬
tions cannot be fully determined from the present study
because endothelin receptors may be modified under these
circumstances. Indeed, in ischemic heart disease, there appears
to be upregulation ofhuman coronary ET„ receptors,"' and this
is associated, in heart failure, with enhanced vasoconstrictor
responses to sarafotoxin She in both the forearm 7 and coronary
circulation,1* whereas the response to BQ-788 appeared similar
to that of controls.1' Clearly, at some stage, it will be necessary
to examine the integrated physiology of systemic ETA and ET„
blockade in physiological and pathophysiological conditions to
fully understand the relative importance of the receptor
subtypes.
In summary, we have demonstrated that the local vasodilator
response to selective ETA receptor antagonism in human
forearm resistance vessels is derived 111 large part from increased
NO-mediated vasodilatation, most probably mediated by the
endothelial E I ,, receptor. Although our observations were
made 111 the forearm resistance vessels, these vessels are gener¬
ally representative of other vascular beds"1"1 and, importantly,
reflect the interaction of these systems > 1 vivo. Our results may
indicate new therapeutic uses for ETA receptor antagonists
because increased N() synthesis may be a desirable effect in, lor
example, isc hemic heart disease. One could also postulate that
enhanced endogenous NO generation may be responsible tor
the headac hes that are a recognized side effec t of I. I rec eptor
antagonists.
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Endogenous angiotensin II does not
contribute to sympathetic venoconstriction
in dorsal hand veins of healthy humans
Background: Sympathetically mediated venoconstriction is augmented by exogenously administered an¬
giotensin II. This study was designed to assess whether endogenous angiotensin II influences sympathet¬
ically mediated venous tone.
Methods: Responses of dorsal hand veins to local intravenous administration of subsystemic doses of
losartan, an angiotensin II type-1 receptor antagonist, were assessed with use of a well-validated displace¬
ment technique in eight healthy male volunteers. In a four-phase study, responses to local infusions of
angiotensin II (4 to 64 ng/min) and norepinephrine (1 to 128 ng/min) or to sympathetic venoconstric¬
tion produced by a single deep breath were compared in the presence ofeither saline placebo or 30 p.g/min
losartan. Each phase of the study was conducted on a separate day, in random order, and each phase was
separated by at least 1 week.
Results: Angiotensin II (p = 0.03) and norepinephrine (p < 0.001) caused dose-dependent venoconstric¬
tion. Losartan attenuated the venoconstriction induced by angiotensin II (p = 0.048) but had no effect on
the responses to norepinephrine or the venoconstriction induced by a single deep breath.
Conclusions: In contrast to exogenously administered angiotensin II, basal endogenous angiotensin II does
not influence sympathetically mediated venoconstriction in healthy humans. However, endogenous an¬
giotensin II may have a role in circumstances of renin-angiotensin system activation, such as salt depletion.
(Clin Pharmacol Ther 1997;62:327-33.)
Satoko Masumori, MB,ChB,a David E. Newby, BM, Fiona E. Strachan, BN,
Nicholas A. Boon, MD, FRCP, and David J. Webb, MD, FRCP
Edinburgh, Scotland
The renin-angiotensin system plays a key role in
the regulation of circulating blood volume and body
sodium balance1 through the generation of the po¬
tent vasoconstrictor peptide angiotensin II. In cir¬
cumstances of volume depletion, angiotensin II sus¬
tains blood pressure through elevation of peripheral
vascular resistance and reduction of central venous
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capacitance. These vasoconstrictor and venocon-
strictor effects are mediated by the vascular smooth
muscle angiotensin II type-1 (AT,) receptor. In ad¬
dition to producing vasoconstriction directly, angio¬
tensin II potentiates the activity of the sympathetic
nervous system. Administration of exogenous angio¬
tensin II at doses insufficient to cause vasoconstric¬
tion directly augments sympathetically mediated
constriction of dorsal hand veins2 and forearm re¬
sistance vessels1 of healthy subjects by a prejunc¬
tional effect.
Previous local vein studies that have assessed the
influence of the renin-angiotensin system in veins
have used angiotensin converting enzyme (ACE)
inhibitors.''' However, local ACE inhibition will po¬
tentially inhibit both the generation of angiotensin
II and the metabolism of bradykinin and is therefore
nonspecific in its action. Moreover, if locally active,
the drugs will not affect the circulating plasma con¬
centrations of angiotensin 11 to which the vessels are
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exposed. Losartan is a selective AT,-receptor antag¬
onist that has recently become available for clinical
use. In contrast to ACE inhibitors, AT,-receptor
antagonists are both specific and capable of directly
blocking the responses to angiotensin II. Previously,
we have shown that locally infused losartan inhibits
the vasoconstriction induced by angiotensin II in
human forearm resistance vessels.7
Capacitance vessels influence cardiac output and,
consequently, other hemodynamic parameters
through the regulation of cardiac preload. However,
when in vivo vascular responses in humans are ex¬
amined, systemic drug administration can cause
concomitant effects on many other tissues, as well as
influence neurohumoral reflexes through changes in
systemic hemodynamics. Therefore vascular re¬
sponses cannot be wholly attributed to a direct effect
of the drug.8 However, the assessment of venous
compliance in a single dorsal hand vein with use of
the Aellig displacement technique9,1" permits the
direct effect of locally active subsystemic doses of
infused drugs to be examined without these con¬
founding influences.8 Moreover, the cutaneous limb
veins, in contrast to the skeletal muscle veins, par¬
ticipate in the sympathetic venomotor reflexes.211
Thus responses in hand veins are representative of
the physiologic regulation of central venous capaci¬
tance and cardiac preload.12
The first aim of this study was to define a locally
active dose of losartan that would selectively and
effectively inhibit angiotensin II-mediated venocon-
striction. The second aim was to evaluate whether
basal endogenous angiotensin II contributes to sym¬
pathetically mediated venoconstriction through an
action at the AT,-receptor.
METHODS
Subjects. Eight healthy male subjects between 24
and 36 years old participated in four studies that
were undertaken in accordance with the Declaration
of Helsinki (1989) of the World Medical Association
and with the approval of the Lothian Research Eth¬
ics Committee. The written informed consent of
each subject was obtained before the study. None of
the subjects received vasoactive or nonsteroidal
anti-inflammatory drugs in the week before each
phase of the study, and all abstained from alcohol
for 24 hours and from food and caffeine-containing
drinks for at least 5 hours before each study. All
subjects were nonsmokers. Studies were performed
in a quiet temperature-controlled room maintained
at 23.5° to 24.5° C.
Drugs. Losartan (DuPont-Merck Inc., Wilming¬
ton, Del.), norepinephrine (Levophed; Sanofi
Winthrop Ltd., Guildford, England), and angioten¬
sin II (Clinalfa AG, Laufelfingen, Switzerland) were
dissolved in physiologic saline (0.9%; Baxter
Healthcare Ltd., Thetford, England) and adminis¬
tered into a dorsal hand vein. To prevent its oxida¬
tion, norepinephrine was dissolved in saline solution
that contained 0.1% ascorbic acid (Evans Medical
Ltd., Langhurst, England). The dose of losartan
used (30 |xg/min) was chosen to achieve an effective
subsystemic and locally active concentration and was
based on earlier pilot and published studies.7,13 Lo¬
cally administered losartan at 30 |xg/min is sufficient
to cause a 37-fold increase in the dose of angiotensin
II required to produce a 20% vasoconstriction in
forearm resistance vessels.7
Intravenous administration. A 23-gauge butterfly
cannula (Abbott Ireland, Sligo, Ireland) was in¬
serted into the dorsal hand vein in the direction of
flow and attached to a 16-gauge epidural catheter
(Portex Ltd., Hythe, England). Patency was main¬
tained by infusion of saline through an IVAC P1000
syringe pump (IVAC Ltd., Basingstoke, England).
The total rate of intravenous infusions was main¬
tained constant throughout all studies at 0.25 ml/
min, and the same hand vein was used for each
study.
Dorsal hand vein size. The left hand was supported
above the level of the heart by means of an arm rest.
The internal diameter of the dorsal hand vein, dis¬
tended by inflation of an upper arm cuff to 30 mm
Hg, was measured by the technique of Aellig9,10,14
with use of a linear variable differential transducer
(LVDT; model 025 MHR, Lucas Schaevitz Inc.,
Slough, Berkshire, England). In brief, the LVDT
was mounted on the dorsum of the hand with a small
tripod, and a magnetized rod was passed through
the core to rest on the summit of the vein approxi¬
mately 1 cm proximal to the tip of the infusion
cannula. Vertical displacement of the rod causes a
linear change in the voltage generated by the
LVDT, reflecting changes in the internal diameter
of the vein. Absolute changes in vein size were
determined by calibration with standard displace¬
ments.
The deep breath stimulus was performed as de¬
scribed previously.2,11 In brief, when vein size was
stable, subjects were asked to breathe out fully be¬
fore breathing in as deeply as possible. They were
asked to hold this inspiration for 10 seconds and to
avoid any tendency to breathe out. The technique
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was practiced before the study to ensure that sub¬
jects did not perform a Valsalva maneuver.
Blood pressure was monitored in the noninfused
arm at intervals throughout each study using a semi-
automated noninvasive oscillometric sphygmoma¬
nometer (Takeda UA 751, Takeda Medical Inc.,
Tokyo, Japan).15
Study design. This was a four-phase, single-blind
randomized study. Subjects rested semirecumbent
throughout each study, and the dorsal hand vein was
cannulated and the LVDT sited. Saline solution was
infused for the first 30 minutes and vein size was
measured every 5 minutes before subjects partici¬
pated in one of the following protocols:
• Protocol I—Effect of losartan on responses to an¬
giotensin II and norepinephrine: Six subjects at¬
tended each of 2 study days, at least 1 week apart,
and received infusion of saline placebo or losartan
at 30 p.g/min for 120 minutes, on separate occa¬
sions, in random order. After a 10-minute infu¬
sion of saline solution or losartan, angiotensin II
was coinfused at 4 and 64 ng/min for 7 minutes at
each dose.16 Vein size was measured at the end of
each infusion period. After a 15-minute saline
infusion, norepinephrine was coinfused at incre¬
mental doubling doses from 1 to 128 ng/min16 for
10 minutes at each dose. Vein size was measured
every 5 minutes during saline infusion and at the
end of the infusion of each dose of norepineph¬
rine.
® Protocol 2—Effect of losartan on venoconstriction
to a single deep breath: Six subjects attended each
of 2 study days, at least 1 week apart, and received
infusion of saline placebo or losartan at 30 g.g/min
for 60 minutes, on separate occasions, in random
order. Venoconstriction to a single deep breath
was measured 20 and 10 minutes before infusion
of losartan or saline solution, and the mean was
taken as the baseline response. The single deep
breath response was repeated at 20, 40, and 60
minutes during infusion of losartan or saline so¬
lution. Vein size was measured every 5 minutes
throughout the study.
l our subjects participated in both protocols.
Data analysis and statistics. Basal vein size was
calculated by taking the mean of the last three
measurements before receipt of the randomized
allocation of losartan or saline solution. Because
absolute basal vein size can vary greatly between
subjects, responses to angiotensin II, norepineph¬
rine, and a deep breath are expressed as the per¬
centage change in vein size from basal. All results
are expressed as mean values ± standard error of
the mean.
Data were examined by one- and two-way
ANOVA with repeated measures, and the Student
t test and distribution when appropriate, with Excel
4.0 (Microsoft Corp., Redmond, Wash.). Statistical
significance was taken at the 5% level. Confidence
intervals were obtained for the mean and area under
the curve (AUC) of the single deep breath re¬
sponses over 60 minutes of saline and losartan infu¬
sion. On the basis of the individual single deep
breath responses, the 90% power to detect a differ¬
ence between saline and losartan responses was cal¬
culated at a significance level of 5%.
RESULTS
There were no significant differences in blood
pressure or heart rate within and between the study
periods (Table I). Baseline vein sizes were similar
between study periods, with no significant differ¬
ences between the 4 study days.
• Protocol 1—Effect of losartan on venoconstriction
to angiotensin II and norepinephrine: Locally in¬
fused angiotensin II (p = 0.03; Fig. 1) and nor¬
epinephrine (p < 0.001; Fig. 2) caused dose-
dependent venoconstriction of the infused
superficial hand veins. Venoconstriction to angio¬
tensin II (p = 0.048 versus saline solution; Fig. 1)
but not norepinephrine (p = 0.48; Fig. 2) was
inhibited by coinfusion of losartan.
• Protocol 2—Effect of losartan on venoconstriction
to a single deep breath: Basal vein diameters were
unaffected by infusion of losartan at 30 p.g/min for
60 minutes. A single deep breath caused a -30%
reduction in vein diameter. There were no signif¬
icant differences in the venoconstriction to a sin¬
gle deep breath when performed in the presence
of losartan or saline infusion (Fig. 3), with an
overall mean venoconstriction of 24.9% (95%
confidence intervals [CI], 21.5% to 28.3%') and
24.5%, (95%. CI, 22.2% to 26.7%'). respectively,
f rom these responses, the study has a 90% power
of detecting an 8.1%. difference at each time point.
The difference between the AUC of the saline and
losartan responses was -1.4% (95% CI. -10.5%. to
• 7.8%-). Venoconstriction to a single deep breath
tended to diminish with time, although this effect
was not statistically significant (j> 0.71;
ANOVA).
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Fig. 1. Effects of losartan on venoconstriction induced by angiotensin II. Angiotensin II
coinfused with saline (open circles) or 30 p,g/min losartan (solid circles). *p = 0.048 versus
saline solution; ANOVA.
Table I. Hemodynamic characteristics and vein sizes on the 4 study days









Blood pressure (mm Hg)
Systolic 118 ±5 119 ±7 117 ±7 116 ±4 116 ±5 111 ±4 123 ± 9 111 ±3
Diastolic 71 ± 3 71 ± 2 76 ± 4 72 ± 3 69 ± 3 68 ± 2 67 ± I 67 ± 2
Mean 87 ± 4 87 ± 5 89 ± 6 87 ± 3 85 ± 4 82 ± 3 86 ± 5 82 ± 3
Heart rate (beats/min) 59 ± 4 58 ± 3 64 I 3 62 ± 3 66 ± 4 57 ± 3 63 ± 4 60 ± 2
Vein size (mm) 1.1 ±0.2 0.2 ±0.1 1.2 ±0.1 0.1 ±0.1 1.1 ±0.2 1.1 ±0.2 0.8 ± 0.1 0.9 ± 0.
Data are mean values ' SIM
DISCUSSION
In agreement with previous studies using angio¬
tensin II4"'' and norepinephrine''-1""' in the dorsal
hand veins, locally active subsystcmic infusions of
both agents caused dose-dependent venoconstric¬
tion. Losartan at a dose of .30 p,g/min, in keeping
with its pharmacologic actions as tin AT,-receptor
antagonist, inhibited the venoconstriction to exoge¬
nous angiotensin 11 but had no effect on the veno¬
constriction caused b\ the control venoconstrictor,
norepinephrine. There was no effect of losartan on
basal vein size because these vessels tire fully relaxed
in the basal state." 111 Swemic closes of losartan can
also inhibit venoconstriction to angiotensin II,17 but
here the response reflects the combined activity of
losartan and its long-acting active metabolite, E-
3174, and the effects of other influences associated
with systemic AT,-receptor antagonism.
The potential interaction between the sympa¬
thetic nervous and renin-angiotensin systems hits
been extensively reported. In vitro studies have-
shown that responses to sympathetic nerve stimula¬
tion are enhanced by angiotensin II in both animals
and humans.1"1'' This effect occurs predominantly
through the prejunctional release of norepineph¬
rine.1" Evidence supporting the physiologic role of
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Fig. 2. Effects of losartan on dose-response curves for norepinephrine. Norepinephrine was
coinfused with saline solution (open circles) or 30 p.g/min losartan (solid circles). There were
no significant differences (p = 0.48) between responses during saline and losartan infusions.
this interaction in vivo in humans with use of the
dorsal hand vein technique has been reported.2 Lo¬
cally infused angiotensin II, at doses insufficient to
cause venoconstriction directly, enhances sympa¬
thetically stimulated venoconstriction produced by a
single deep breath. If endogenous tissue or circulat¬
ing angiotensin 1118 maintains normal sympatheti¬
cally mediated venoconstriction, then losartan
should reduce the response to a single deep breath.
However, we have found no attenuation of the sin¬
gle deep breath response with losartan. The 95%
confidence intervals indicate that if angiotensin II
provides any contribution to sympathetically medi¬
ated venoconstriction. it is rather small. In addition,
this lack of overall effect cannot reflect a combina¬
tion of reduced prejunctional norepinephrine re¬
lease and increased postjunctional (^-adrenergic
receptor sensitivity because venoconstriction to nor¬
epinephrine was unaffected by losartan. This sug¬
gests that, under physiologic conditions, endoge¬
nous angiotensin II either has little or no influence
on sympathetically stimulated venous tone or, less
likely, its influence is through a mechanism that is
not mediated by an ATrreceptor. There was a trend
for the deep breath response to decrease with time,
consistent with previous studies that used repeated
single deep breath responses.14,20 This effect was
present during both saline and losartan infusions
and may represent a physiologic waning of the re¬
sponse (i.e., tachyphylaxis).
Unlike resistance vessels, dorsal hand veins have
very little resting tone and the effects of venodilators
are small and variable.8"1" Therefore hand veins are
generally preconstricted before assessment of re¬
sponses to venodilators. The absence of a venodila-
lory effect of losartan at rest, during sympathetic
stimulation, and during norepinephrine infusion
would suggest that endogenous angiotensin II does
not contribute to venous tone under physiologic
circumstances. By administering losartan through
the brachial artery, we' and others'* have shown
thiil angiotensin II, in healthy sodium-replete sub-
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Fig. 3. Effects of losartan on sympathetically mediated venoconstriction. Venoconstriction
resulting from single deep breath during infusion of saline solution (open squares) or 30
pg/min losartan (solid squares). There were no significant differences (/> = 0.80) between
responses during saline and losartan infusions.
jects on a Western diet, does not contribute to fore¬
arm resistance vessel tone, suggesting that physio¬
logic concentrations of angiotensin II are not active
in either peripheral resistance or capacitance ves¬
sels. Although angiotensin II clearly does contribute
to vascular tone under conditions of renin-
angiotensin system activation, such as sodium deple¬
tion or chronic heart failure, the mechanism by
which losartan and E3174 reduce blood pressure in
healthy sodium-replete humans is unlikely to be
peripheral venodilation or vasodilation. This docs
not preclude the possibility that a hypotensive effect
of angiotensin II antagonism might be mediated
through actions on the kidney2' 22 or central nervous
system.2'21 Interestingly, the evidence for a hypo¬
tensive action of losartan in sodium-replete humans
is contradictory.2x2'' Indeed, in the main study,25
which showed a hypotensive action of losartan, sub¬
jects had an elevated basal plasma renin activity,
suggesting that they had an activated renin-
angiotensin system, presumably secondary to mild
sodium depletion. Further studies arc required to
show whether endogenous angiotensin II contrib¬
utes to basal venous tone and sympathetic venocon ¬
striction under circumstances of renin-angiotensin
system activation.
In contrast to earlier findings,'1 ^ Xarnke and Fcld-
man27 reported a significant venodilation to ACF
inhibition in small or preconstricted dorsal hand
veins. However, we were unable to demonstrate any
significant venodilation to losartan in veins under
basal conditions or during norepinephrine venocon¬
striction. Our observations would therefore suggest
that this venodilation to ACE inhibition is not me¬
diated through a reduction in angiotensin II gener¬
ation but may result from the accumulation of veno-
dilator peptides such as bradykinin or substance P.
Alternatively, the findings of Zarnke and Feldman27
may represent a difference in responses between
larger and smaller hand veins or a nonspecific veno-
dilatory effect of high drug concentrations in small
low-flow veins.
In summary, when losartan is given at a locally
active and subsystemic dose of 30 p-g/min into the
dorsal hand vein, it inhibits the venoconstriction to
angiotensin II but not norepinephrine. Losartan
does not appear to have an effect on resting or
sympathetically stimulated venous tone. Therefore
it would appear that endogenous angiotensin II does
not contribute to the sympathetic venoconstrictor
rellex in hand veins of healthy humans. However,
endogenous angiotensin II may have a role in cir¬
cumstances of renin-angiotensin system activation,
such as salt depletion.
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Endothelin ETA and ETB Receptors Cause
Vasoconstriction of Human Resistance and
Capacitance Vessels In Vivo
William G. Haynes, BSc, MD, MRCP; Fiona E. Strachan, BN, RGN; David J. Webb, MD, FRCP, FFPM
Background The role of endothelin ET„ receptors in medi¬
ating vasoconstriction in humans is unclear. As yet, there have
been no in vivo studies in resistance vessels, and in vitro data
have been contradictory. We therefore investigated the func¬
tion of ETb receptors in vivo in human forearm resistance and
hand capacitance vessels using endothelin-1 as a nonselective
agonist at ETA and ETB receptors and endothelin-3 and
sarafotoxin S6c as selective agonists at the ETB receptor.
Methods and Results A series of single-blind studies were
performed, each in six healthy men. Brachial artery infusion of
endothelin-1 and endothelin-3 caused slow-onset dose-depen¬
dent forearm vasoconstriction. Although endothelin-3 caused
significantly less forearm vasoconstriction than endothelin-1 at
low doses, vasoconstriction was similar to the two isopeptides
at the highest dose (60 pmol/min). Endothelin-3 caused tran-
The endothelins are a family of 21-amino-acidpeptides with potent and characteristically sus¬taine vasoconstrictor and vasopressor actions.1
Endotheiin-1 is the predominant isopeptide generated
by the vascular endothelium.2 Endothelin-2 and endo¬
thelin-3 are more difficult to detect in humans and are
probably less important in their cardiovascular effects.
Two specific receptors for the endothelins have been
isolated by in vitro expression of cloned human cDNA.3-4
The ETa receptor has a high affinity for endothelin-1,
with a K, of 0.6 nmol/L for endothelin-1 compared with
140 nmol/L for endothelin-3.5 ETA receptor mRNA was
initially reported to be highly expressed in human aorta
but not cultured human endothelial cells, suggesting
selective vascular expression of this receptor in smooth
muscle cells.3 The ETB receptor has equal affinity for all
three endothelins, with K, values for endothelin-1 and
endothelin-3 of 0.12 and 0.06 nmol/L, respectively.5 The
ETB receptor has been reported to be highly expressed in
cultured endothelial cells4 but not vascular smooth mus¬
cle cells.6
On the basis of the greater vasoconstrictor potency of
endothelin-1 than endothelin-3 and the apparently ex¬
clusive expression of ETA receptors in vascular smooth
muscle, vasoconstriction to endothelin-1 was initially
thought to be mediated solely by vascular smooth muscle
cell ETa receptors. Vascular ETB receptors located on
endothelial cells were thought only to mediate generation
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sient forearm vasodilatation at this dose, whereas endothelin-1
showed only a nonsignificant trend toward causing early vaso¬
dilatation. Intra-arteriai sarafotoxin S6c caused a progressive
reduction in forearm blood flow, although less than that to
endothelin-1 (7'=.04). Dorsal hand vein infusion of sarafotoxin
S6c caused local venoconstriction that was also less than that to
endothelin-1 (P=.002).
Conclusions Selective ETB receptor agonists cause constric¬
tion of forearm resistance and hand capacitance vessels in vivo in
humans, suggesting that both ETA and ET0 receptors mediate
vasoconstriction. Hence, antagonists at both ETA and ETB recep¬
tors, or inhibitors of the generation of endotheiin-1, may be
necessary to completely prevent vasoconstriction to endogenously
generated endothelin-1. (Circulation. 1995;92:357-363.)
Key Words • endothelin • vasoconstriction • vessels
of endothelium-derived dilator substances. More recent
evidence suggests that ETB receptormRNA is expressed in
human vascular smooth muscle obtained from the aorta,
pulmonary artery, and coronary artery,7 consistent with a
potential vasoconstrictor role for this receptor. Indeed, in
animals, there is functional evidence for ETB receptor-
mediated vasoconstriction in vitro, particularly in venous
tissue.8"13 In addition, selective ETB receptor agonists have
pressor effects in animals in vivo.12-14-16 However, the
contribution of ETB receptors to vasoconstriction is vari¬
able and appears to depend markedly on species, vessel
type, and vessel size.17 Furthermore, the functional signifi¬
cance of such vascular smooth muscle ETB receptors in
humans is unclear, with in vitro studies reporting that ETB
receptors make either a minimal11-17"24 or, at most, a
moderate contribution25"27 to vasoconstriction, depending
on the types of vessel studied.
The relevance of this issue is emphasized by the recent
development of both selective and nonselective antago¬
nists at ETa and ETB receptors. For example, selective
ETA receptor antagonists will block vasoconstriction
mediated by ETA receptors but may not block all con¬
striction to endothelin-1 if there are also vasoconstrictor
ETa receptors. However, if the putative constrictor ETa
receptor is relatively unimportant in humans, then
blocking both ETA and ETB receptors may cause less
vasodilatation than blocking the ETA receptor alone,
because such receptor antagonists will also block the
endothelial dilator ETa receptor.
In view of the inconsistent results with and the poten¬
tial disadvantages of in vitro studies, we investigated the
function of endothelin ETA and ETB receptors in blood
vessels in vivo in humans. We used endothelin-1 as a
nonselective agonist at ETA and ETB receptors and
endothelin-3 and sarafotoxin S6c as selective ETB receptor
agonists; these peptides have about 2000- and 300 000-
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fold selectivity, respectively, for the ETB over the ETA
receptor.5-28 Using locally active doses of these agents,
we assessed responses both of resistance vessels, using
brachial artery administration,29 and of capacitance ves¬
sels, using dorsal hand vein administration.30-32 We used
local doses of peptides so that interpretation of the
results would not be confounded by direct effects of
systemic administration on kidney, heart, or brain or by
reflex effects consequent to changes in blood pressure.
Methods
Subjects
Twenty-four healthy male subjects between 22 and 38 years
of age participated in these studies, which were conducted with
the approval of the Lothian Medicine and Clinical Oncology
Ethics of Medical Research Subcommittee and with the written
informed consent of each subject. No subject received vasoac¬
tive or nonsteroidal anti-inflammatory drugs in the week before
each phase of the study, and all abstained from alcohol for 24
hours and from food, caffeine-containing drinks, and cigarettes
for at least 3 hours before any measurements were made. All
studies were performed in a quiet room maintained at a
constant temperature of between 22°C and 25°C.
Drugs
Pharmaceutical-grade endothelin-1 (Clinalfa, NovaBio-
chem), endothelin-3 (Qinalfa), and sarafotoxin S6c (Sigma
Chemical Co Ltd) were administered. A single dose of each
peptide was used in individual studies because the slow onset
and long-lasting action of the endothelin isopeptides preclude
the use of repeated doses in a single study to examine
conventional dose-response relations.33 The peptides were
dissolved in physiological saline (0.9%; Baxter Healthcare Ltd).
Intra-arterial Administration
The left brachial artery was cannulated under local anesthe¬
sia (1% lignocaine; Astra Pharmaceuticals) with a 27-standard
wire gauge steel needle (Coopers Needle Works) attached to a
16-gauge epidural catheter (Portex Ltd). Patency was main¬
tained by infusion of 0.9% physiological saline via a Weimed
P1000 syringe pump (Weimed Clinical Care Systems). The
total rate of intra-arterial infusion was maintained constant
throughout all intra-arterial studies at 1 mL/min.
Intravenous Administration
A vein on the dorsum of the left hand was cannulated in the
direction of flow with a 23-gauge butterfly needle (Abbott)
attached to a 16-gauge epidural catheter, without use of local
anesthesia. The same vein was used in each subject for each
individual study. Patency was maintained by infusion of 0.9%
physiological saline via a Weimed P1000 syringe pump. The
total rate of intravenous infusion was maintained constant
throughout all studies at 0.25 mL/min.
Measurements
Forearm Blood Flow
Blood flow was measured in the infused and noninfused
forearms by venous occlusion plethysmography34 using indium/
gallium-in-Silastic strain gauges2'' that were securely applied to
the widest part of each forearm. The hands were excluded from
the circulation during each measurement period by inflation of
a wrist cuff to 220 mm Hg. Upper-arm cuffs were intermittently
inflated to 40 mm Hg for 10 in every 15 seconds to temporarily
prevent venous outflow from the forearm and thus obtain
plethysmographic recordings. Recordings of forearm blood
flow were made repeatedly over 3-minute periods unless oth¬
erwise stated. Voltage output from a dual-channel Vasculab
SPG 16 strain-gauge plethvsmograph (Medasonics Inc) was
transferred to a Macintosh personal computer (Classic II,
Apple Computer Inc) with a MacLab analog-to-digital con¬
verter and chart software (v. 3.2.8; both from AD Instru¬
ments). Calibration was achieved by use of the internal stan¬
dard of the Vasculab plethysmography unit.
Dorsal Hand Vein Diameter
The left hand was supported above the level of the heart by
means of an arm rest. The ID of the dorsal hand vein,
distended by inflation of an upper arm cuff to 30 mm Hg, was
measured by the technique of Aellig.30 In brief, a magnetized
lightweight rod rested on the summit of the infused vein -»1 cm
downstream from the tip of the infusion cannula. This rod
passed through the core of a linear variable differential trans¬
former (LVDT; model 025 MHR, Lucas Schaevitz Inc) sup¬
ported above the hand by a small tripod, the legs of which
rested on areas of the dorsum of the hand free of veins. If
venoconstriction occurred while this cuff was inflated or if the
cuff was deflated with consequent emptying of the vein, there
was a downward displacement of the lightweight rod that
caused a linear change in the voltage generated by the LVDT.
The voltage output from the LVDT was transferred to a
Macintosh personal computer by use of a MacLab analog-to-
digitai converter and CHART software. Standard displacements
were used to calibrate the LVDT to determine the ID of the
vein.
Blood Pressure
A well-validated semiautomated noninvasive oscillometric
sphygmomanometer (Takeda UA 751, Takeda Medical Inc)
was used to make duplicate measurements of blood pressure in
the noninfused arm.35
Study Design
Four single-blind studies were performed, with the experi¬
mental subjects but not the investigators blinded to the peptide
and dose administered in each study.
Forearm Resistance Bed Protocols
Subjects rested recumbent throughout each study. Strain
gauges and arm cuffs were applied, and the left brachial artery
cannula was sited. Saline was infused for 30 minutes, during which
two measurements of forearm blood flow were made (at -20 and
-10 minutes). Blood pressure was measured immediately after
each forearm blood flow measurement, thereby avoiding any
effect on forearm blood flow measurements of the venous con¬
gestion caused by this procedure.36 Three protocols were then
followed, each in separate groups of subjects, as follows.
Protocol I: Low-dose intra-arterial endothelin-1 and endothe-
lin-3. On four separate occasions, in random order, six subjects
received brachial artery infusion of endothelin-1 and endothe¬
lin-3 at 1 and 5 pmol/min, each for 60 minutes. The choice of
doses was based on previous work showing, in vivo, that 5
pmol/min of endothelin-1 causes slow-onset vasoconstriction in
human forearm resistance vessels, reducing blood flow by
~40%.29J3 Forearm blood flow was recorded from 3 minutes
before to 5 minutes after the endothelin infusion was begun.
Thereafter, measurements were made at 5-minute intervals for
60 minutes. Blood pressure was measured 60 minutes after the
infusion was begun.
Protocol 2: High-dose intra-arterial endothelin-1 and endothe¬
lin-3. On two separate occasions, in random, balanced order,
six subjects received endothelin-1 and endothelin-3 via the
brachial artery at 60 pmol/min for 5 minutes, followed by
physiological saline for 55 minutes. Because no significant
vasodilatation had been observed in previous studies using
intra-arterial endothelin-1 at 5 pmol/min,29-33 we chose a dose
of 60 pmol/min with the intention of stimulating sufficient
endothelial generation of dilator substances to cause vasodila¬
tation before the development of vasoconstriction. Forearm
blood flow was recorded from 3 minutes before to 10 minutes
after the endothelin infusion was begun. Thereafter, measure¬
ments were made at 5-minute intervals for 60 minutes. Blood
pressure was measured 10 and 60 minutes after the infusion
was begun.
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Table 1. Mean Arterial Pressure, Heart Rate, and Forearm Blood Rows Before
and After Brachial Artery Administration of Peptides in the Two Study Protocols
(1 and 2) Comparing Endothelin-1 and Endothelin-3















Basal 89±5 882:6 90+5 88±4 87±5 83±4
10 min 89±6 87±3
60 min 91 ±6 892:7 89+4 86+ 4 89±6 90±4
HR, bpm
Basal 65±4 66+3 67±5 66±4 66 ±2 66±2
10 min 63±4 65±3




Basal 3.9+0.9 4.0+0.7 3.9±0.9 4.4+1.3 3.7±0.6 3.0±0.3




Basal 3.0+0.5 3.2±0.5 3.0±0.5 4.1 ±0.6 3.4±0.7 3.3±0.2
60 min 2.8+0.5 3.1 ±0.6 3.9±0.9 4.0±1.0 3.6±0.6 3.7±0.6
ET indicates endothelin; MAP, mean arterial pressure; HR, heart rate: bpm, beats per minute: and FBF,
forearm blood flow. Values are mean±SEM. There were no significant differences in basal MAP, HR, and FBF
between study days. MAP, HR, and FBF in the noninfused arm did not change significantly on any study day
after infusion of peptides.
Protocol 3: Intra-arterial endothelin-1 and sarafotoxin S6c. On
two separate occasions, in random, balanced order, six subjects
received endothelin-1 and sarafotoxin S6c via the brachial
artery at 5 pmol/min for 60 minutes. Forearm blood flow was
recorded from 3 minutes before to 5 minutes after peptide
infusion was begun. Thereafter, measurements were made at
5-minute intervals for 60 minutes. Blood pressure was mea¬
sured at 60 minutes, just before the infusion was terminated.
Hand Vein Studies
Protocol 4: Intravenous endothelin-1 and sarafotoxin S6c. Six
subjects were studied on two separate occasions, in random,
balanced order. Subjects rested semirecumbent throughout.
The dorsal hand vein cannula and the LVDT were sited. Saline
was infused for 30 minutes, during which vein diameter was
measured every 5 minutes. Endothelin-1 and sarafotoxin S6c
were infused at 5 pmol/min for 60 minutes, with measurements
of vein diameter every 5 minutes. The choice of this dose was
based on previous work that showed, in vivo, that endothelin-1
at 5 pmol/min causes slow-onset venoconstriction of *60% in
human skin capacitance vessels.29-31 Blood pressure was mea¬
sured twice before the dose was given and at 60 minutes, just
before the infusion was terminated.
Data Analysis and Statistics
Plethysmographic data listings were extracted from the
chart data files, and forearm blood flows were calculated for
individual venous occlusion cuff inflations by use of a template
spreadsheet (excel 4.0; Microsoft Ltd). Because wrist cuff
inflation results in a transient forearm vasoconstriction,37 re¬
cordings made in the first 60 seconds after wrist cuff inflation
were not used for analysis. Usually, the last five flow recordings
in each 3-minute measurement period were calculated and
averaged for the infused and noninfused arms. However, to
detect early transient changes in blood flow, every recording
made immediately before and after the start of peptide infusion
was analyzed. Basal blood flow was taken as the average of all
flow recordings made in the 2 minutes before infusion of
peptides was begun. The intersubject, intrasubject (interstudy),
and intrasubject (intrastudy) coefficients of variation for basal
forearm blood flow measurements in our laboratory are 51%,
33%, and 14%, respectively. The intersubject, intrasubject
(interstudy), and intrasubject (intrastudy) coefficients of varia¬
tion for the basal ratio of blood flow between infused and
noninfused arms in our laboratory are 22%, 15%, and 8%,
respectively. Therefore, to reduce the variability of blood flow
data, the ratio of flows in the two arms was calculated for each
time point, in effect using the noninfused arm as a contempo¬
raneous control for the infused arm.38 Forearm blood flow
results are shown as a percentage change from basal in the ratio
of blood flow between infused and noninfused arms.29
Basal vein diameter was calculated as the mean of the last
three measurements before the start of the peptide infusion,
expressed in millimeters. The intersubject, intrasubject (inter¬
study), and intrasubject (intrastudy) coefficients of variation for
basal hand vein diameter measurements in our laboratory are
43%, 26%, and 5%, respectively. Given the high intersubject
and interstudy variability in hand vein diameter, responses after
infusion of peptides are expressed as percentage change in vein
diameter from basal.32 Duplicate blood pressure measurements
were averaged at each time point. Basal blood pressure was
taken as the average of the second set of measurements made
before infusion of peptides.
To obtain an estimate of the contribution of ETB receptors to
vasoconstriction, the ratio of constriction to the ETa agonist
compared with constriction to endothelin-1 was calculated for
each subject at the 60-minute time point. Because these data
had a skewed distribution, ratios were logarithmically trans¬
formed for statistical analysis. Data are shown as mean values,
with 95% confidence intervals (CI) shown in the text and SEM
in the figures. Data were examined by a repeated-measures
ANOVA with statistical testing of overall significance by
Scheffe's F test (ANOVA) using statview 512* software
(Brainpower Inc) for the Apple Macintosh personal computer.
Results
Basal blood pressure, heart rate, forearm blood flow,
and vein diameter were similar on the different study
days, and there was no significant difference in basal
forearm blood flow between the infused and noninfused
arms (Tables 1 and 2). Blood pressure, heart rate, and
blood flow in the noninfuscd arm did not change signif¬
icantly after infusion of any study agent, confirming that
drug effects were confined to the infused arm (Tables 1
and 2).
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Table 2. Mean Arterial Pressure, Heart Rate, Forearm
Blood Flow, and Hand Vein Size Before and After
Administration of Peptides in the Two Study Protocols
(3 and 4) Comparing Endothelin-1 and Sarafotoxin S6c
Protocol 3 Protocol 4
ET-1 S6c ET-1 S6c
Parameter (5 pmol IA) (5 pmol IA) (5 pmol IV) (5 pmol IV)
MAP, mm Hg
Basal 82±3 82±3 8925 8423
60 min 852:3 852:4 892 4 8422
HR, bpm
Basal 62±8 632:3 702 4 6524










60 min 2.32:0.2 2.320.5
Vein size, mm
Basal 0.3720.08 0.44 20.08
IA indicates intra-arterial; IV, intravenous. Other abbreviations as in
Table 1. There were no significant differences in basal MAP, HR, FBF, and
hand vein diameter between study days. MAP, HR, and FBF in the
noninfused arm did not change significantly after infusion of peptides.
Protocol 1: Low-Dose Intra-arterial Endothelin-I
and Endothelin-3
Endothelin-I at 1 pmol/min caused a modest but
significant forearm vasoconstriction, with an 11% reduc¬
tion in forearm blood flow at 60 minutes (CI, -22% to
-1%; ANOVA, P=.02; Fig 1). Endothelin-3 at 1 pmol/
min tended to decrease forearm blood flow, with a 5%
reduction in blood flow at 60 minutes, but this was not
significant (CI, -14% to +3%; ANOVA, P=.163; Fig
1). There was no significant difference between the
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Fig 1. Graph. Six subjects received brachial artery infusion of
endothelin-3 (o, 1 pmol/min; a, 5 pmol/min) and on a separate
occasion, endothelin-1 (•, 1 pmol/min; a, 5 pmol/min), each for
60 minutes. Shaded bar indicates period of infusion of endothe-
lin isopeptides. Endothelin-1 caused significant forearm vaso¬
constriction at both doses, whereas the effect of endothelin-3
was significant only at 5 pmol/min. For clarity, error bars have
been removed from that part of the figure showing results for the
first 5 minutes of peptide infusion, ia indicates intra-arterial.
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Fig 2. Graph. Six subjects received brachial artery infusion of
endothelin-1 (■, 60 pmol/min) and on a separate occasion,
endothelin-3 (□, 60 pmol/min), each for 5 minutes. Shaded area
indicates period of infusion of endothelin isopeptides. Forearm
vasodilatation occurred initially with endothelin-3 but not with
endothelin-1. Both isopeptides then caused vasoconstriction of
similar degree, ia indicates intra-arterial.
min (ANOVA, P=.454). There was no significant vaso¬
dilatation early in the course of infusion of either
peptide. The average ratio of forearm vasoconstriction
to endothelin-3 and endothelin-1 was 0.16, although this
estimate had wide CIs (CI, 0.03 to 0.98).
Endothelin-1 at 5 pmol/min caused substantial fore¬
arm vasoconstriction, with a 40% reduction in forearm
blood flow at 60 minutes (CI, -52% to -28%; ANOVA,
P=.0002; Fig 1). The same dose of endothelin-3 also
significantly reduced forearm blood flow, with a 25%
reduction in blood flow at 60 minutes (CI. -36% to
—13%; ANOVA, .P=.001; Fig 1). There was significantly
greater vasoconstriction after endothelin-1 than endo¬
thelin-3 (ANOVA, P=.04). There was no significant
vasodilatation early in the course of infusion of either
peptide. The average ratio of forearm vasoconstriction
to endothelin-3 and endothelin-1 was 0.58 (CI, 0.39 to
0.87).
Protocol 2: High-Dose Intra-arterial Endothelin-1
and Endothelin-3
Endothelin-1, at 60 pmol/min for 5 minutes, caused a
trend to transient nonsignificant forearm vasodilatation
in the first 2 minutes of infusion, with a maximum
increase of 16% (CI, -7% to +23%; Fig 2) at 2 minutes.
Thereafter, vasoconstriction occurred, with the maxi¬
mum decrease in blood flow occurring at 10 minutes
(-28%; CI, —48% to -9%), although flow was still
reduced after 60 minutes (-17%; CI, -30% to -4%).
Endothelin-3 caused significant early forearm vasodila¬
tation, with a maximum increase in flow of 24% at 3
minutes (CI, +4% to +43%; Fig 2). Forearm vasocon¬
striction occurred after 10 minutes, with a maximum
reduction in blood flow of 24% at 60 minutes (CI, -43%
to -5%). There was a significant difference between the
overall responses to endothelin-1 and endothelin-3 over
the 60 minutes after bolus administration of isopeptide
(ANOVA, P=.04). However, maximum vasoconstriction
to the isopeptides was similar (Fig 2). The average ratio
of forearm vasoconstriction to endothelin-3 and endo¬
thelin- 1 was 0.82, although this estimate had wide CIs
(CI, 0.13 to 5.07).
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Fig 3. Graph. Six subjects received brachial artery infusion of
endothelin-1 (a, 5 pmol/min) and on a separate occasion,
sarafotoxin S6c (□, 5 pmol/min), each for 60 minutes. Shaded
bar indicates period of infusion of peptides. Both peptides
caused significant forearm vasoconstriction, although the effect
of sarafotoxin S6c was less than that of endothelin-1. ia indi¬
cates intra-arterial.
Protocol 3: Intra-arterial Endothelin-1 and
Sarafotoxin S6c
Endothelin-1 at 5 pmol/min did not cause early vaso¬
dilatation but did produce slow-onset forearm vasocon¬
striction, with a maximum reduction in forearm blood
flow of 48% at 60 minutes (CI, -60% to -37%;
ANOVA, P=.0001; Fig 3). There was no significant
vasodilatation to sarafotoxin S6c early in the course of
the infusion, although there may have been a trend for
this to occur (Fig 3). Like endothelin-1, sarafotoxin S6c
caused slow-onset forearm vasoconstriction (ANOVA
versus basal, P=.002; Fig 3). However, the maximum
change in blood flow with sarafotoxin S6c at 60 minutes
( — 25%; CI, —37% to -13%) was significantly less than
that to endothelin-1 (ANOVA, P = .04). The average
ratio of forearm vasoconstriction to sarafotoxin S6c and
endothelin-1 was 0.48 (CI, 0.30 to 0.75).
Protocol 4; Intravenous Endothelin-1 and
Sarafotoxin S6c
Endothelin-1 caused a slow-onset and marked de¬
crease in hand vein diameter, with a maximal reduction
at 60 minutes (-68%; CI, -84% to -52%; ANOVA,
P=,001; Fig 4). Sarafotoxin S6c also caused venocon-
striction, although the maximum decrease in hand vein
size at 60 minutes (-19%; CI, -29% to -9%; ANOVA
versus basal, P=.003; Fig 4) was significantly less than
that to endothelin-1 (ANOVA, P=.002). The average
ratio of venoconstriction to sarafotoxin S6c and endo-
thelin-1 was 0.25 (CI, 0.14 to 0.44).
Discussion
These studies show that selective agonists at endothe-
lin ETu receptors constrict forearm resistance and hand
capacitance vessels in vivo in humans. In addition, high
doses of endothelin-3, and perhaps of endothelin-1,
cause transient forearm vasodilatation. These results
suggest an important role for ETU receptors in mediating
the vascular effects of endothelin-1. It is possible that
different findings might have been obtained if other
vascular beds had been studied. However, responses in
lothdin-l/Swr»fotoxm S6c (1t)J
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Fig 4. Graph. Six subjects received dorsal hand vein infusion of
endothelin-1 (■, 5 pmol/min) and on a separate occasion,
sarafotoxin S6c (□, 5 pmol/min), each for 60 minutes. Shaded
bar indicates period of infusion of peptides. Both peptides
caused significant venoconstriction, although the effect of
sarafotoxin S6c was less than that of endothelin-1. iv indicates
intravenous.
human forearm resistance vessels and dorsal hand veins
are thought to be broadly representative of responses in
other resistance and capacitance beds.39 Given that
resting forearm blood flow is =50 mlVmin,39 doses of 1,
5, and 60 pmol/min of peptide should achieve local
concentrations of =0.02, =0.1, and =1 nmol/L, respec¬
tively. Endothelin-1 would be expected to act equally on
both ETa and ETB receptors at these concentrations,
while endothelin-3 would be expected to be relatively
selective for the ETB receptor, because this isopeptide
has a Kj at ETA receptors of about 140 nmol/L.5 Sarafo¬
toxin S6c at 5 pmol/min should have been highly selec¬
tive for the ETB receptor, because the calculated con¬
centration in forearm blood (0.1 nmol/L) is at least
70 000-fold lower than its at ETA receptors (>7300
nmol/L).s
Administration of endothelin-3 at 60 pmol/min caused
significant early forearm vasodilatation, and there was
also a tendency for similar transient vasodilatation to
occur with endothelin-1, although this was not statisti¬
cally significant. Vasodilatation is likely to have been due
to activation of ETB receptors on endothelial cells,
causing generation of endothelium-derived dilator sub¬
stances.31 The apparent absence of significant vasodila¬
tation to high-dose endothelin-1 may have been due to
additional early vasoconstriction mediated by ETA re¬
ceptors masking dilatation, although it should be noted
that the CIs at these time points were sufficiently wide
for an =20% vasodilatation to endothelin-1 to have
been missed by chance. Lower doses of endothelin-1 and
sarafotoxin S6c failed to cause early vasodilatation. The
lack of vasodilatation to endothelin-1 contrasts with
previous findings,4" possibly because of differences in
doses used and experimental design. In view of the
relatively high doses required to cause vasodilatation, it
is likely that vasodilatation to the endothelins represents
a pharmacological rather than a physiological phenom¬
enon. Because human dorsal hand veins have no basal
tone, it is not possible to demonstrate whether endothe¬
lin-1 or sarafotoxin S6c causes venodilatation without
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preconstriction of the vein. Previous work has shown no
venodilatation to endothelin-1 or endothelin-3 in pre-
constricted dorsal hand veins.41 Nonetheless, inhibition
of prostaglandin but not nitric oxide generation poten¬
tiates venoconstriction to endothelin-1 in vivo in hu-'
mans.31 Thus, the venous endothelium may generate
vasodilator substances in response to endothelin, but the
vasodilator effects of such substances appear to be
masked by the simultaneous direct venoconstriction
caused by the peptide and serve only to modulate
venoconstriction.
Given that both endotheiin-3 and sarafotoxin S6c
caused vasoconstriction, our results suggest the presence
of vasoconstrictor ETB receptors. However, constriction
to the ETb agonists was almost always less than that to
the nonselective ETA and ETB agonist endotheiin-1,
implying that both ETA and ETB receptors contribute to
vasoconstriction. The 95% CIs of the ratio of forearm
vasoconstriction to sarafotoxin S6c and endothelin-1 are
consistent with ET0 receptors contributing substantially
to constriction, accounting for between 30% and 75% of
the response to endothelin-1. Although the magnitude
of the ETb contribution in vitro appears to differ be¬
tween vessels,17 the similarity of responses in forearm
resistance vessels and cutaneous capacitance vessels of
the hand suggests that ETB receptors may be of wide¬
spread functional importance in human blood vessels.
Our finding of ETB receptor-mediated vasoconstric¬
tion of resistance vessels contrasts with some in vitro
studies that suggest little contribution of ETB receptors
to constriction of human arteries.u-17-24 This difference
may reflect the fact that we examined responses in an
intact resistance bed, because ETB receptor-mediated
vasoconstriction appears to play a relatively greater role
in smaller vessels, particularly those responsible for
determining resistance.17-42 All of the in vitro studies in
which human vessels exhibited little or no ETB-mediated
arterial vasoconstriction examined vessels >400 i±m in
diameter.u-17"24 In addition to the influence of vessel size
on the contribution of ETB receptors, there may be
regional differences. Local injection of the ETA antago¬
nist PD147953 has been shown to completely prevent
vasoconstriction of human skin vessels caused by intra¬
dermal injection of endothelin-1, suggesting that vaso¬
constriction is mediated mainly by ETA receptors in this
microvascular bed.43 The effects of sarafotoxin S6c,
compared with those of endothelin-1, were less in hand
veins than in forearm resistance vessels, despite in vitro
evidence from animal vessels that responses to ETa
agonists are greater in veins than arteries.8-9-12-13 This
may reflect a true species difference, because endothe¬
lin-1 is about eightfold more potent as a venoconstrictor
than endothelin-3 in human hand veins,41 which also
suggests that ETA receptors predominate in these
vessels.
Although vasoconstriction to the ETB agonists endo¬
thelin-3 and sarafotoxin S6c is most likely to be caused
by stimulation of vascular smooth muscle ETn receptors,
there are alternative explanations. First, ETU receptors
may be confined to endothelial cells but cause late-onset
vasoconstriction through stimulation of the generation
of endothelium-derived vasoconstrictor agents. These
substances might include constrictor prostanoids or even
endothelin-1, because endothelin-3 is known to stimu¬
late production of endothelin-1 in vitro.44 Second, some
of the effects of endothelin-3 could have been mediated
by a putative ETC (endothelin-3-selective) receptor sit¬
uated on endothelial cells. However, although there is
evidence from binding44 and functional43 studies to
support the existence of an endothelin-3-selective re¬
ceptor in the vasculature, and a potential candidate has
been identified in Xenopus laevts melanophores.46 this
receptor has not been identified in humans. Any contri¬
bution from the putative ETC receptor will depend on its
isolation and pharmacological characterization. Third,
there may be receptor-mediated clearance of endoge-
nously generated endothelin-1 by ETB receptors, as has
been shown in animals.47 If this were the case, ETB
agonists might prevent local clearance of endothelin-1,
which would then act on ETA receptors to cause vaso¬
constriction. However, this possibility appears highly
unlikely, given that ETA antagonists do not influence
vasoconstriction to sarafotoxin S6c in vitro.8-10-13-26-48 In
future, studies with selective ETB receptor antagonists
should clarify this issue, because such agents would be
expected to potentiate responses to endothelin-1 if ETB
receptor-mediated clearance of endothelin-1 does
occur.
Thus, the most likely explanation for our results is that
there are functionally active ETA and ETB receptors on
vascular smooth muscle cells causing vasoconstriction, to
both of which endothelin-1 would have access. These
findings have implications for the future development of
antiendothelin therapies, because they suggest that full
inhibition of vasoconstriction to endogenously gener¬
ated endothelin-1 may be obtained only by use of either
combined ET^b endothelin receptor antagonists44 or
inhibitors of endothelin generation.29
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Forearm Vasoconstriction to Endothelin-1 Is Mediated by
ETa and ETB Receptors In Vivo in Humans
William G. Haynes, Fiona E. Strachan, Gillian A. Gray, and David J. Webb
University of Edinburgh, Department of Medicine, Western General Hospital, Edinburgh, Scotland
Summary: The role of endothelin (ET)-B (ETB) receptors
in mediating vasoconstriction in humans is unclear. As
yet, in vitro data have been contradictory, and there have
been no in vivo studies in resistance vessels. We inves¬
tigated the function of ETB receptors in vivo in human
forearm resistance vessels using ET-1 as a nonselective
agonist at ETA and ETB receptors and ET-3 and sarafo-
toxin S6c as ETB receptor agonists. Brachial artery infu¬
sion of ET-1 and ET-3 caused slow-onset, dose-
dependent forearm vasoconstriction. Although ET-3
caused significantly less forearm vasoconstriction than
ET-1 at low doses, vasoconstriction to the two isopep-
tides was similar at the highest dose (60 pmol/min). ET-3
caused initial transient forearm vasodilatation at this
dose, whereas ET-1 showed only a nonsignificant trend
toward causing early vasodilatation. Intra-arterial sarafo-
toxin S6c caused a progressive reduction in forearm
blood flow, although less than that to ET-1. Therefore,
ETb receptor agonists contract human resistance vessels
in vivo. The effects of ET-3 and sarafotoxin S6c, com¬
pared with ET-1, suggest that both ETA and ETB recep¬
tors mediate vasoconstriction. Antagonists at both ETA
and ETb receptors, or inhibitors of the generation of ET-
1, may be necessary to completely prevent vasoconstric¬
tion to endogenously generated ET-1. Key Words: Endo-
thelins—Sarafotoxin S6c—Vasoconstriction—Vasodila¬
tation.
Endothelin (ET)-l was initially believed to medi¬
ate vasoconstriction solely through vascular
smooth-muscle cell ETA receptors, and ETB recep¬
tors were believed to mediate only endothelium-
dependent dilation (1,2). More recent evidence sug¬
gests that ETB receptor mRNA is expressed in hu¬
man vascular smooth muscle obtained from the
aorta, pulmonary artery, and coronary artery (3),
consistent with a vasoconstrictor role for this recep¬
tor. Indeed, in animals there is functional evidence
for ETb receptor-mediated vasoconstriction in
vitro and in vivo (4-6), although the contribution is
variable and appears to depend markedly on spe¬
cies, vessel type, and vessel size (3). Furthermore,
the functional significance of such vascular smooth
muscle ETB receptors in humans is unclear, with
apparently contradictory results being obtained
from in vitro studies (7,8).
In view of the inconsistent results with in vitro
studies, we have investigated the function of ETA
and ETb receptors in blood vessels in vivo in human
subjects. We used ET-1 as a nonselective agonist at
ETa and ETB receptors, and ET-3 and sarafotoxin
S6c as selective ETB receptor agonists, these pep¬
tides having respectively about 2,000- and >30,000-
fold selectivity for the ETB over the ETA receptor
(9). These agents were administered via the brachial
artery and forearm resistance vessel responses
were assessed by plethysmography. We used local
doses of peptides so that interpretation of the re¬
sults would not be confounded by direct effects of
systemic administration on kidney, heart, or brain,




Eighteen healthy male subjects between 22 and 38
years of age participated in these studies, which were
conducted with the approval of the local Ethics Commit¬
tee and with the written informed consent of each subject.
All studies were performed in a quiet room maintained at
a constant temperature of 22-25°C.
Address correspondence and reprint requests to Prof. D. J. Webb at University Department of Medicine, Western General Hospital,
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Procedures
All drugs were administered via a brachial artery as
previously described (10). Blood flow was measured in
both forearms by venous occlusion plethysmography us¬
ing indium/gallium-in-silastic strain gauges and blood
pressure measured in duplicate in the noninfused arm as
before (10).
Study design
Subjects rested recumbent throughout each study.
Strain gauges and arm cuffs were applied and the left
brachial artery cannula sited. Saline was infused for 30
min, during which two measurements of forearm blood
flow were made (at -20 and - 10 min). Three protocols
were then followed, each in separate groups of subjects.
Protocol 1: low-dose intra-arterial ET-I and ET-3. On
four separate occasions, in random order, six subjects
received ET-1 (Clinalfa, NovaBiochem, Nottingham,
U.K.) and ET-3 (Clinalfa) at 1 and 5 pmol/min, each for 60
min. Forearm blood flow was recorded from 3 min before
to 5 min after starting ET. Thereafter, measurements
were made at 5-min intervals for 60 min. Blood pressure
was measured 60 min after starting the infusion.
Protocol 2: high-dose intra-arterial ET-1 and ET-3. On
two separate occasions, in random order, six subjects
received ET-1 and ET-3 at 60 pmol/min for 5 min, fol¬
lowed by saline for 55 min. Forearm blood flow was re¬
corded from 3 min before to 10 min after starting ET.
Thereafter, measurements were made at 5-min intervals
for 60 min. Blood pressure was measured 10 and 60 min
after starting the infusion.
Protocol 3: intra-arterial ET-I and sarafotoxin S6c. On
two separate occasions, in random, balanced order, six
subjects received ET-1 and sarafotoxin S6c (Sigma
Chemical Co., Ltd., Poole, Dorset, U.K.) at 5 pmol/min
for 60 min. Forearm blood flow was recorded from 3 min
before to 5 min after starting peptide infusion. Thereafter,
measurements were made at 5-min intervals for 60 min.
Blood pressure was measured at 60 min, just before halt¬
ing the infusion.
Data analysis and statistics
Basal blood flow was taken as the average of all flow
recordings made in the 2 min before starting infusion of
peptides. Forearm blood flow results are shown as a per¬
centage change from basal in the ratio of blood flow be¬
tween infused and noninfused arms (10). Duplicate blood
pressure measurements were averaged at each timepoint.
To obtain an estimate of the contribution of ETB recep¬
tors to vasoconstriction, the ratio of constriction to the
ETb agonist compared with constriction to ET-1 was cal¬
culated for each subject at the 60-min time point. Because
these data had a skewed distribution, ratios were log
transformed for statistical analysis and are expressed as
means with 95% confidence intervals (CI). Other data are
shown as mean values with SEM. Data were examined
statistically by a repeated measures analysis of variance
combined with Scheffe's F test.
RESULTS
Protocol 1: low-dose intra-arterial ET-1 and ET-3
ET-I at 1 pmol/min caused modest but significant
forearm vasoconstriction, with a 11 ± 4% reduction
in forearm blood flow at 60 min (p = 0.02). ET-3 at
1 pmol/min tended to decrease forearm blood flow,
with a 5 ± 3% reduction in blood flow at 60 min, but
this was not significant (p = 0.163). The average
ratio of forearm vasoconstriction to ET-3 and ET-1
at 1 pmol/min was 0.16, although this estimate had
wide confidence intervals (CI 0.03-0.98). ET-1 at 5
pmol/min caused substantial forearm vasoconstric¬
tion, with a 40 ± 5% reduction in forearm blood
flow at 60 min (p = 0.0002). The same dose of ET-3
also significantly reduced forearm blood flow, with
a 25 ± 5% reduction in blood flow at 60 min (p =
0.001). The average ratio of forearm vasoconstric¬
tion to ET-3 and ET-1 at 5 pmol/min was 0.58 (CI
0.39-0.87). There was no significant vasodilation
early in the course of infusion of either peptide, at
either dose.
Protocol 2: high-dose intra-arterial ET-1 and ET-3
ET-1 at 60 pmol/min for 5 min caused transient
nonsignificant forearm vasodilatation in the first 2
min of infusion, followed by vasoconstriction, with
the maximal decrease in blood flow occurring at 10
min, although flow was still reduced after 60 min
(Fig. 1). ET-3 caused significant early forearm va¬
sodilatation, followed by slow-onset vasoconstric¬
tion. There was a significant difference between the
overall responses to ET-1 and ET-3 over the 60 min
after bolus administration of isopeptide (p = 0.04),
although maximum vasoconstriction to the isopep-
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FIG. 1. Six subjects received brachial artery infusion of ET-1
(■, 60 pmol/min), and, on a separate occasion, ET-3 (□, 60
pmol/min), each for 5 min. The shaded area indicates the
period of infusion of endothelin isopeptides. Forearm vasodi¬
latation occurred initially with ET-3 but not with ET-1. Both
isopeptides then caused vasoconstriction of similar degree.
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arm vasoconstriction to ET-3 and ET-1 was 0.82 (CI
0.13-5.07).
Protocol 3: intra-arterial ET-1 and sarafotoxin S6c
ET-1 produced slow-onset forearm vasoconstric¬
tion (p = 0.0001) (Fig. 2). There was no significant
vasodilation to sarafotoxin S6c early in the course
of the infusion, although there may have been a
trend for this to occur (Fig. 2). Like ET-1, sarafo¬
toxin S6c caused slow-onset forearm vasoconstric¬
tion (p = 0.002). However, the maximum change in
blood flow with sarafotoxin S6c at 60 min was sig¬
nificantly less than that to ET-1 (p = 0.04). The
average ratio of forearm vasoconstriction to sarafo¬
toxin S6c and ET-1 was 0.48 (CI 0.30-0.75).
Basal blood pressure, heart rate, and forearm
blood flow were similar on the different study days,
and there was no significant difference in basal fore¬
arm blood flow between the infused and noninfused
arms. Blood pressure, heart rate, and blood flow in
the noninfused arm did not change significantly af¬
ter infusion of any study agent, confirming that drug
effects were confined to the infused arm.
DISCUSSION
These studies show that selective agonists at ETB
receptors constrict forearm resistance vessels in
vivo in humans. In addition, high doses of ET-3,
-20 -10 0 10 20 30 40 50 60
Time (min)
FIG. 2. Six subjects received brachial artery infusion of en-
dothelin-1 (■, 5 pmol/min), and, on a separate occasion, sa¬
rafotoxin S6c (□, 5 pmol/min), each for 60 min. The shaded
bar indicates the period of infusion of peptides. Both pep¬
tides caused significant forearm vasoconstriction, although
the effect of sarafotoxin S6c was less than that of ET-1 (ia,
intra-arterial).
and perhaps of ET-1, cause transient forearm va¬
sodilatation. These findings suggest a potentially
important role for ETB receptors in mediating the
vascular effects of ET-1. Given that resting forearm
blood flow is —50 ml/min, doses of 1, 5, and 60
pmol/min of peptide should achieve local concen¬
trations of—0.02, —0.1, and —1 nM, respectively.
ET-1 would be expected to act equally on both ETA
and ETb receptors at these concentrations, whereas
ET-3 would be expected to be relatively selective
for the ETb receptor, because this isopeptide has a
K; at ETa receptors of approximately 140 nAf (9).
Sarafotoxin S6c at 5 pmol/min should have been
highly selective for the ETB receptor because the
calculated concentration in forearm blood (0.1 nM)
is at least 70,000-fold lower than its K{ at ETA re¬
ceptors (>7,300 nM) (9).
Administration of ET-3 at 60 pmol/min caused
significant early forearm vasodilation, and there
was also a tendency for similar transient vasodila¬
tion to occur with ET-1, though it was not statisti¬
cally significant. Vasodilation is likely to have been
due to activation of ETB receptors on endothelial
cells, causing generation of ET-derived dilator sub¬
stances (2). The apparent absence of significant va¬
sodilation to high-dose ET-1 may have been due to
additional early vasoconstriction mediated by ETA
receptors, thus masking dilation. Lower doses of
ET-1 and sarafotoxin S6c failed to cause early va¬
sodilation. In view of the relatively high doses re¬
quired to cause vasodilation, it is likely that vasodi¬
lation to the endothelins represents a pharmaco¬
logic rather than a physiologic phenomenon.
Given that both ET-3 and sarafotoxin S6c caused
vasoconstriction, our results indicate the presence
of vasoconstrictor ETB receptors. However, this
constriction was less than that to ET-1, implying
that both ETa and ETB receptors contribute to the
vasoconstriction. The 95% confidence intervals of
the ratio of forearm vasoconstriction to sarafotoxin
S6c and ET-1 are consistent with ETB receptors
contributing 30-75% of the response to ET-1. Our
finding of vasoconstrictor ETB receptors in human
resistance vessels contrasts with some in vitro stud¬
ies (3). This difference may reflect the fact that we
examined responses in an intact resistance bed, be¬
cause ETb receptor-mediated vasoconstriction ap¬
pears to play a relatively greater role in the smaller
vessels that determine resistance (3,11).
Although the vasoconstriction to ETB agonists is
most likely caused by stimulation of vascular
smooth muscle ETB receptors, there are alternative
explanations. First, ETB receptors may be confined
to endothelial cells but cause late-onset vasocon¬
striction through stimulation of the generation of
endothelium-derived vasoconstrictor agents. These
substances might include constrictor prostanoids or
even ET-1, because ET-3 is known to stimulate pro¬
duction of ET-1 in vitro (12). Second, some of the
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effects of ET-3 could have been mediated by a pu¬
tative ETC (ET-3-selective) receptor, although as
yet this has been identified only in Xenopus laevis
melanophores (13). Third, there may be receptor-
mediated clearance of endogenously generated
ET-1 by ETb receptors, as has been shown in ani¬
mals (14). If this were the case, ETB agonists might
prevent local clearance of ET-1, which would then
act on ETa receptors to cause vasoconstriction.
However, this possibility appears highly unlikely
because ETA antagonists do not influence vasocon¬
striction to S6c in vitro (8). In the future, studies
with selective ETB receptor antagonists should clar¬
ify this issue, because if ETB receptor-mediated
clearance of ET-1 does occur, such agents would be
expected to potentiate response to ET-1.
In conclusion, the most likely explanation for our
results is that there are functionally active ETA and
ETb receptors on vascular smooth muscle cells
causing vasoconstriction, to both of which ET-1
would have access. These findings have implica¬
tions for the future development of anti-endothelin
therapies, because they suggest that full inhibition
of vasoconstriction to endogenously generated
ET-1 can be obtained only with either combined
ETa/b receptor antagonists or inhibitors of endothe-
lin generation.
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Endothelium-Dependent Modulation of Venoconstriction
to Sarafotoxin S6c in Human Veins In Vivo
Fiona E. Strachan, William G. Haynes, and David J. Webb
University- of Edinburgh, Department of Medicine, Western General Hospital, Edinburgh, Scotland
Summary: We investigated the vascular effects mediated
by ETa and ETB receptors in human dorsal hand veins in
vivo, using sarafotoxin S6c (SFTX6c) as a selective ago¬
nist of ETB receptors and endothelin-1 (ET-1) as a non¬
selective agonist of ETA and ETB receptors. The cvclo-
oxygenase inhibitor aspirin and the nitric oxide synthase
inhibitor L-NMMA were used to examine the modulating
role of endothelial vasodilators on the response to
SFTX6c. Drugs were all infused into the hand veins, at
locally but not svstemically active doses, via a 23 SW'G
butterfly cannula, with the exception of aspirin, which
was administered orally. Hand vein size was measured by
the Aeliig technique. The study was performed in six
healtht male subjects. Data (mean - SEND were exam¬
ined by ANOVA. Results are expressed as percent
change from baseline at 60 mm. ET-1 (5 pmol/min for 60
mini caused venoconsiriction of 68 - 6% (p = 0.00011.
SFTX6c at the same dose caused venoconsiriction of 19
i 45c (p = 0.003). The response to SFTX6c was signifi¬
cantly less than to ET-1 (p = 0.002). Constriction to
SFTX6c tended to increase when this agent was co¬
administered with aspirin (25 - 79E) or L-NMMA (24 ±
10%) and was significantly potentiated when these agents
were co-administered (45 = 49c: p = 0.01 vs. SFTX6c
alone). We have demonstrated that the selective ETB ag¬
onist SFTX6c produces venoconsiriction in human hand
veins in vivo and that this venoconstnction is modulated
by the generation of endothelium-derived vasodilators. In
this vascular bed. venoconstriction rather than venodila-
tation appears to be the predominant effect of stimulation
of ETb receptors with SFTX6c. Key Words: Human—
Venoconstriction—Endotheiin-1—Sarafotoxin S6c—
Endothelium.
The endothelins are a family of 21-amino-acid
peptides with potent and characteristically sus¬
tained vasoconstrictor and vasopressor actions (1).
Endothelin-1 (ET-1) is the predominant isopeptide
generated by the vascular endothelium (2) and
therefore appears to be the most important isoform
mediating cardiovascular effects. Two specific re¬
ceptors for the endothelins have been isolated by in
vitro expression of cloned human cDNA (3.4). The
ETa receptor has a high affinity for ET-1 compared
with endothelin-3 (ET-3). whereas the ETB receptor
has equal affinity for both endothelins.
Vasoconstriction to ET-1 was initially believed to
be mediated solely by vascular smooth-muscle cell
ETa receptors, and endothelial cell ETB receptors
were believed only to mediate generation of endo¬
thelium-derived dilator substances. Indeed, there is
considerable evidence that stimulation of endothe¬
lial ETb receptors can cause production of nitric
oxide and dilator prostanoids, both to cause the ini¬
tial depressor effect of systemic bolus administra¬
tion of ET-1 and to modulate the sustained vaso¬
constriction associated with ET-1 (5). More re¬
cently. it has been shown that ETB receptor mRNA
is expressed in human vascular smooth muscle (6).
consistent with a potential vasoconstrictor role for
the ETb receptor. Indeed, in animals and in hu¬
mans. there is functional evidence for ETB recep¬
tor-mediated vasoconstriction in vitro, particularly
in veins (7-9). However, the contribution of ETB
receptors to ET-l-mediated constriction can vary
depending on species, vessel type, and vessel size.
In human hand veins, venoconstriction to ET-1 is
attenuated by dilator prostanoids but not by nitric
oxide (10). Here, we have examined the role of the
endothelium-derived dilators nitric oxide and pros¬
tacyclin in modulating venoconstriction to locally
but not syslemically active doses of sarafotoxin S6c
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(SFTX6c), an endothelin receptor agonist with




Six healthy men (age range 25-39 years) participated in
the study, with local Ethics Review Committee approval.
Subjects rested semirecumbent in a quiet room main¬
tained at a constant temperature for each study (25-27°C).
Drugs were infused via a 23 SWG cannula (Abbott) sited
in a selected dorsal hand vein in the direction of flow, as
described previously (10). Local anesthesia was not em¬
ployed. The same dorsal hand vein was used in each
study. Internal diameter of the dorsal hand vein was mea¬
sured by the Aellig displacement technique (12) at 5-min
intervals throughout each study period. Blood pressure
was measured in the noninfused arm at 30-min intervals.
Drugs
On separate occasions. ET-1 (NovaBiochem. Notting¬
ham. U.K.) and SFTXS6c (Sigma Chemical Co Ltd..
Nottingham. U.K.) were administered for 60 min at a
constant rate of 5 pmol/'min. based on results from previ¬
ous studies (10.13). A single dose was used because the
slow onset and long-lasting action of the endotheiins pre¬
cludes the use of repeated doses in a single study to ex¬
amine conventional dose-response relationships. l-.V1'-
monomethyl-arginine (L-NMMA: NovaBiochem. Not¬
tingham. U.K.). a specific substrate analogue inhibitor of
nitric oxide synthase in humans (14). was administered in
a dose of 100 nmol/min (10). This dose of L-NMMA has
no effect on basal hand vein size (15). Aspirin 1600 mg.
soluble: Reckitt & Coleman. Hull. U.K.) was dissolved in
200 ml water and administered 30 min before local peptide
infusions. Aspirin irreversibly inhibits cyclo-oxygenase
(EC 1.14.99.1) and. when given at this dose, inhibits
bradykinin-stimulated endothelial production of prosta¬
cyclin by at least 859e. with recovery developing over the
next 6 h (16). All drugs, with the exception of aspirin,
were dissolved in saline (0.9%: Travenoi). In each study,
saline was infused for 30 min before infusion of the study
agent. The total rate of infusion was maintained constant
throughout all studies at 0.25 ml/min.
Study design
The study involved five separate study periods in the
same subjects, each study period separated by at least I
week. Responses to ET-1 and SFTX6c alone were exam¬
ined. In addition, responses to SFTX6c were investigated
in the presence of aspirin and L-NMMA, administered
both independently and together. The order of the study
periods was randomized, with the exception of the sarafo-
toxin and combined L-NMMA and aspirin study, which
was the final study period for each subject.
Data presentation and statistics
Basal vein size was calculated in millimeters as the
mean of the last two measurements taken during saline
infusion. Vein size during drug administration was ex¬
pressed as percentage change in vein size from basal, at
60 min. All results are expressed as mean ± SEM. Data
were examined by repeated measures analysis of vari¬
ance. Statistical significance was accepted at the 5%
level.
RESULTS
In the six subjects, basal vein size was similar for
each study and blood pressure did not alter signifi¬
cantly throughout any of the study periods. ET-1
alone caused a slowly developing venoconstriction.
with a maximum 68 = reduction of basal inter¬
nal vein diameter at 60 min (p = 0.0001 vs. basal).
SFTX6c also caused significant venoconstriction
(19 ± 4%: p = 0.00? vs. basai). The response to
ET-l was substantially greater than that to SFTX6c
(p = 0.002) (Fig. I). Venoconstriction to SFTX6c
tended to increase after administration of aspirin (25
r 7%) and during co-infusion of L-NMMA (24 i
109r). but was not significantly different than that to
SFTX6c alone (Fig. 2). Venoconstriction to
SFTX6c was substantially and significantly in¬
creased in the presence of aspirin and L-NMMA
together (46 := 9%: p - 0.01 vs. SFTX6c: p =
0.0001 vs. basal). Venoconstriction to SFTX6c in
the presence of both aspirin and L-NMMA was less
prominent than, but did not differ significantly
from, that to ET-1 when infused alone (p = ().!)
( Figs. 1 and 2).
DISCUSSION
In these studies we have investigated the veno-
constrictor effects of SFTX6c and their modulation
by the endothelium-derived dilators nitric oxide and
prostacyclin. We have confirmed the earlier find¬
ings that ET-1 (10) and SFTX6c (13) constrict hu¬
man hand veins. As before (13). an equivalent dose
of SFTX6c causes less venoconstriction than ET-1.
I i i I I I I
a 10 20 30 40 50 60
Time (min)
FIG. 1. Endothelin-1 (5 pmol/min; open circles), sarafotoxin
S6c (5 pmol/min alone; closed circles), and sarafotoxin S6c
(5 pmol/min with L-NMMA 100 nmol/min and after aspirin 600
mg; closed squares).
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FIG. 2. Sarafotoxin S6c (5 pmol/min alone; closed circles),
co-infused with L-NMMA (open triangles), after aspirin 600
mg (closed triangles), and with both L-NMMA and aspirin
(closed squares).
These findings suggest that ETB receptors contrib¬
ute to but do not wholly account for ET-l-mediated
venoconstriction.
In addition, we have demonstrated that the veno¬
constriction to SFTX6c is significantly and substan¬
tially increased when generation of both nitric oxide
and dilator prostanoids, most likely prostacyclin, is
blocked. Combined inhibition of nitric oxide and
prostacyclin appeared to produce a greater effect on
venoconstriction to SFTX6c than the addition of
the individual effects of inhibition of generation of
either nitric oxide or prostacyclin alone. This may
reflect a capacity for the endothelium to compen¬
sate for inhibition of one dilator mediator by in¬
creased production of another. We have shown pre¬
viously that responses to ET-1 are potentiated by
aspirin administration but not by co-infusion of
L-NMMA (10). It would be important to further
investigate responses to ET-1 in human hand veins
in vivo in the presence of L-NMMA and aspirin,
both alone and given together. It appears from our
results with SFTX6c that the endothelial ETB re¬
ceptor modulates the constrictor effects produced
by stimulation of the vascular smooth muscle ETB
receptors, through generation of vasodilator sub¬
stances by the endothelium. However, in these ex¬
periments the vasoconstrictor action predominates.
In diseases such as chronic heart failure, in which
endo'helium-dependent vasodilatation is impaired,
vem :onstrictor effects of ET -1 may be enhanced as
a ret It of unopposed vasoconstrictor effects medi¬
ated 3v both ETa and ETB receptors on vascular
smooth muscle. Given that the overall effect of
combined stimulation of the vascular smooth mus¬
cle and endothelial cell ETB receptors is venocon¬
striction. it may be necessary to block both ETA
and ETb receptors to completely block venocon¬
striction to ET-1. Drugs that would act specifically
on the vascular smooth-muscle receptors (17) may
be more effective vasodilators, because they would
fully block ET-1 mediated vasoconstriction while
allowing the potentially desirable effects of the en¬
dothelial ETb receptors to be preserved.
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